{"PMC7108439": [["IntroductionIntensive investigations over the last 6 years have led to the discovery of a number of new or emerging putative respiratory viruses, including human metapneumovirus (HMPV) (van den Hoogen et al., 2001), human coronaviruses, SARS (Ksiazek et al., 2003), NL63 (van der Hoek et al., 2004) and HKU1 (Woo et al., 2005), human bocavirus (HBoV) (Allander et al., 2005) and very recently, two new human polyomaviruses, KI virus (KIV) (Allander et al., 2007) and WU virus (WUV) (Gaynor et al., 2007).", [["respiratory viruses", "DISEASE", 125, 144], ["human metapneumovirus", "DISEASE", 156, 177], ["human coronaviruses", "DISEASE", 216, 235], ["SARS", "DISEASE", 237, 241], ["human", "ORGANISM", 156, 161], ["metapneumovirus", "ORGANISM", 162, 177], ["HMPV", "ORGANISM", 179, 183], ["human", "ORGANISM", 216, 221], ["human", "ORGANISM", 328, 333], ["bocavirus", "ORGANISM", 334, 343], ["HBoV", "ORGANISM", 345, 349], ["human", "ORGANISM", 402, 407], ["polyomaviruses", "ORGANISM", 408, 422], ["KI virus", "ORGANISM", 424, 432], ["KIV", "ORGANISM", 434, 437], ["WU virus", "ORGANISM", 467, 475], ["human", "SPECIES", 156, 161], ["metapneumovirus", "SPECIES", 162, 177], ["human", "SPECIES", 216, 221], ["human", "SPECIES", 328, 333], ["human", "SPECIES", 402, 407], ["human metapneumovirus", "SPECIES", 156, 177], ["HMPV", "SPECIES", 179, 183], ["human coronaviruses", "SPECIES", 216, 235], ["human bocavirus", "SPECIES", 328, 343], ["HBoV", "SPECIES", 345, 349], ["human polyomaviruses", "SPECIES", 402, 422], ["KI virus", "SPECIES", 424, 432], ["KIV", "SPECIES", 434, 437], ["WU virus", "SPECIES", 467, 475], ["WUV", "SPECIES", 477, 480], ["emerging putative respiratory viruses", "PROBLEM", 107, 144], ["human metapneumovirus", "PROBLEM", 156, 177], ["human coronaviruses", "PROBLEM", 216, 235], ["SARS", "PROBLEM", 237, 241], ["human bocavirus (HBoV", "PROBLEM", 328, 349], ["KI virus", "PROBLEM", 424, 432], ["new", "OBSERVATION_MODIFIER", 100, 103], ["respiratory viruses", "OBSERVATION", 125, 144]]], ["Their role as causative agents of respiratory disease has been conclusively demonstrated for some of these (HMPV, SARS, NL63), but for others their classification as a respiratory pathogen remains highly speculative in the absence of fulfilling Koch's postulates.", [["respiratory", "ANATOMY", 34, 45], ["respiratory disease", "DISEASE", 34, 53], ["SARS", "DISEASE", 114, 118], ["respiratory pathogen", "DISEASE", 168, 188], ["HMPV", "ORGANISM", 108, 112], ["HMPV", "SPECIES", 108, 112], ["respiratory disease", "PROBLEM", 34, 53], ["HMPV", "PROBLEM", 108, 112], ["SARS", "PROBLEM", 114, 118], ["a respiratory pathogen", "PROBLEM", 166, 188], ["respiratory disease", "OBSERVATION", 34, 53]]], ["This is particularly so for the newly discovered human KIV and WUV.IntroductionKIV and WUV were discovered independently in Sweden and the USA within months of each other.", [["human", "ORGANISM", 49, 54], ["KIV", "CANCER", 55, 58], ["WUV", "CANCER", 63, 66], ["WUV", "CANCER", 87, 90], ["human KIV", "PROTEIN", 49, 58], ["human", "SPECIES", 49, 54], ["human", "SPECIES", 49, 54]]], ["Allander et al. (2007) showed that KIV is phylogenetically related to other primate polyomaviruses in the early region of the genome, but had little homology in the late region.", [["KIV", "GENE_OR_GENE_PRODUCT", 35, 38], ["primate polyomaviruses", "ORGANISM", 76, 98], ["KIV", "PROTEIN", 35, 38], ["other primate polyomaviruses", "PROBLEM", 70, 98], ["polyomaviruses", "OBSERVATION", 84, 98], ["early", "OBSERVATION_MODIFIER", 106, 111], ["genome", "ANATOMY", 126, 132]]], ["Similarly, by multiple sequence alignments of the predicted STAg, LTAg, VP1 and VP2 open reading frames, Gaynor et al. (2007) confirmed that WUV was clearly another novel polyomavirus that is most closely related to KIV.", [["STAg", "GENE_OR_GENE_PRODUCT", 60, 64], ["LTAg", "GENE_OR_GENE_PRODUCT", 66, 70], ["VP1", "GENE_OR_GENE_PRODUCT", 72, 75], ["WUV", "GENE_OR_GENE_PRODUCT", 141, 144], ["polyomavirus", "ORGANISM", 171, 183], ["KIV", "CANCER", 216, 219], ["STAg, LTAg, VP1 and VP2 open reading frames", "DNA", 60, 103], ["WUV", "DNA", 141, 144], ["KIV", "DNA", 216, 219], ["the predicted STAg", "TEST", 46, 64], ["LTAg", "TEST", 66, 70], ["VP1", "TEST", 72, 75], ["another novel polyomavirus", "PROBLEM", 157, 183], ["polyomavirus", "OBSERVATION", 171, 183]]], ["They also showed that WUV differed significantly from the other human polyomaviruses BK (BKV) and JC (JCV) in genome sequence and suggested that it is likely to have unique biological properties.IntroductionAs a first step in elucidating the distribution and a possible role in human disease of KIV and WUV, we sought to determine the presence of these viruses in the population and their association with the respiratory tract.", [["respiratory tract", "ANATOMY", 410, 427], ["human", "ORGANISM", 64, 69], ["polyomaviruses BK (BKV", "ORGANISM", 70, 92], ["JC (JCV", "ORGANISM", 98, 105], ["human", "ORGANISM", 278, 283], ["KIV", "CANCER", 295, 298], ["WUV", "CANCER", 303, 306], ["respiratory tract", "ORGANISM_SUBDIVISION", 410, 427], ["genome sequence", "DNA", 110, 125], ["human", "SPECIES", 64, 69], ["human", "SPECIES", 278, 283], ["human polyomaviruses", "SPECIES", 64, 84], ["BKV", "SPECIES", 89, 92], ["JCV", "SPECIES", 102, 105], ["human", "SPECIES", 278, 283], ["KIV", "SPECIES", 295, 298], ["WUV", "SPECIES", 303, 306], ["JC (JCV) in genome sequence", "PROBLEM", 98, 125], ["human disease of KIV", "PROBLEM", 278, 298], ["these viruses", "PROBLEM", 347, 360], ["viruses", "OBSERVATION", 353, 360], ["respiratory tract", "ANATOMY", 410, 427]]], ["For this purpose we had at our disposal respiratory samples collected during 2003 from patients with acute respiratory tract infection (ARTI) that had been extensively tested for other known respiratory viruses.", [["respiratory samples", "ANATOMY", 40, 59], ["respiratory tract", "ANATOMY", 107, 124], ["acute respiratory tract infection", "DISEASE", 101, 134], ["ARTI", "DISEASE", 136, 140], ["respiratory viruses", "DISEASE", 191, 210], ["patients", "ORGANISM", 87, 95], ["tract", "ORGANISM_SUBDIVISION", 119, 124], ["patients", "SPECIES", 87, 95], ["acute respiratory tract infection", "PROBLEM", 101, 134], ["other known respiratory viruses", "PROBLEM", 179, 210], ["acute", "OBSERVATION_MODIFIER", 101, 106], ["respiratory tract", "ANATOMY", 107, 124], ["infection", "OBSERVATION", 125, 134], ["respiratory viruses", "OBSERVATION", 191, 210]]], ["This sample cohort was investigated for the presence of KIV and WUV, seasonality, and rate of co-infection with each other or other common respiratory viruses.Respiratory specimens and nucleic acid extraction ::: Materials and methodsWe examined 2866 respiratory samples consisting of 2733 nasopharyngeal aspirates (NPAs), 91 bronchoalveolar lavage (BAL), 33 bronchial washings (BW) and 9 endotracheal aspirates (ETA) for the presence of KIV and WUV.", [["Respiratory specimens", "ANATOMY", 159, 180], ["respiratory samples", "ANATOMY", 251, 270], ["nasopharyngeal aspirates", "ANATOMY", 290, 314], ["NPAs", "ANATOMY", 316, 320], ["bronchoalveolar lavage", "ANATOMY", 326, 348], ["BAL", "ANATOMY", 350, 353], ["bronchial", "ANATOMY", 359, 368], ["endotracheal aspirates", "ANATOMY", 389, 411], ["co-infection", "DISEASE", 94, 106], ["respiratory viruses", "DISEASE", 139, 158], ["nucleic acid", "CHEMICAL", 185, 197], ["KIV", "GENE_OR_GENE_PRODUCT", 56, 59], ["nucleic acid", "SIMPLE_CHEMICAL", 185, 197], ["nasopharyngeal aspirates", "MULTI-TISSUE_STRUCTURE", 290, 314], ["NPAs", "CANCER", 316, 320], ["bronchoalveolar lavage", "MULTI-TISSUE_STRUCTURE", 326, 348], ["BAL", "MULTI-TISSUE_STRUCTURE", 350, 353], ["endotracheal aspirates", "MULTI-TISSUE_STRUCTURE", 389, 411], ["KIV", "SPECIES", 56, 59], ["KIV", "SPECIES", 438, 441], ["KIV", "PROBLEM", 56, 59], ["WUV", "PROBLEM", 64, 67], ["seasonality", "PROBLEM", 69, 80], ["co-infection", "PROBLEM", 94, 106], ["other common respiratory viruses", "PROBLEM", 126, 158], ["Respiratory specimens", "TEST", 159, 180], ["nucleic acid extraction", "TEST", 185, 208], ["respiratory samples", "TEST", 251, 270], ["nasopharyngeal aspirates", "TEST", 290, 314], ["NPAs", "TEST", 316, 320], ["bronchoalveolar lavage", "TEST", 326, 348], ["BAL)", "TEST", 350, 354], ["bronchial washings", "TEST", 359, 377], ["endotracheal aspirates", "TEST", 389, 411], ["KIV and WUV", "TREATMENT", 438, 449], ["co-infection", "OBSERVATION", 94, 106], ["respiratory viruses", "OBSERVATION", 139, 158], ["nasopharyngeal", "ANATOMY", 290, 304], ["aspirates", "OBSERVATION", 305, 314], ["bronchoalveolar lavage", "OBSERVATION", 326, 348], ["bronchial", "ANATOMY", 359, 368], ["endotracheal", "ANATOMY", 389, 401]]], ["Also, in consideration of the fact that BKV and JCV may be frequently found in urine and blood, we examined 215 urine samples, and 102 blood samples.Respiratory specimens and nucleic acid extraction ::: Materials and methodsNPAs were collected from January 2003 until January 2004, from hospitalized patients or patients presenting for assessment at hospital emergency departments in Queensland, Australia, with ARTI.", [["urine", "ANATOMY", 79, 84], ["blood", "ANATOMY", 89, 94], ["urine samples", "ANATOMY", 112, 125], ["blood samples", "ANATOMY", 135, 148], ["Respiratory specimens", "ANATOMY", 149, 170], ["nucleic acid", "CHEMICAL", 175, 187], ["ARTI", "DISEASE", 412, 416], ["BKV", "ORGANISM", 40, 43], ["JCV", "ORGANISM", 48, 51], ["urine", "ORGANISM_SUBSTANCE", 79, 84], ["blood", "ORGANISM_SUBSTANCE", 89, 94], ["urine samples", "ORGANISM_SUBSTANCE", 112, 125], ["blood samples", "ORGANISM_SUBSTANCE", 135, 148], ["nucleic acid", "SIMPLE_CHEMICAL", 175, 187], ["patients", "ORGANISM", 300, 308], ["patients", "ORGANISM", 312, 320], ["patients", "SPECIES", 300, 308], ["patients", "SPECIES", 312, 320], ["BKV", "SPECIES", 40, 43], ["JCV", "SPECIES", 48, 51], ["BKV and JCV", "PROBLEM", 40, 51], ["urine samples", "TEST", 112, 125], ["blood samples", "TEST", 135, 148], ["Respiratory specimens", "TEST", 149, 170], ["nucleic acid extraction", "TEST", 175, 198], ["ARTI", "PROBLEM", 412, 416], ["BKV", "OBSERVATION", 40, 43]]], ["Patients ranged in age from 3 days to 95 years (mean = 9.2 years; median age = 1.38 years), and 76.5% of specimens were from children 5 years of age or younger.", [["specimens", "ANATOMY", 105, 114], ["Patients", "ORGANISM", 0, 8], ["specimens", "CANCER", 105, 114], ["children", "ORGANISM", 125, 133], ["Patients", "SPECIES", 0, 8], ["children", "SPECIES", 125, 133]]], ["Nucleic acids were extracted from 0.2 mL of each NPA specimen using the High Pure Viral Nucleic Acid kit (Roche Diagnostics, Australia), according to the manufacturer's instructions.Respiratory specimens and nucleic acid extraction ::: Materials and methodsTo ensure that a diverse urine sample population was tested in this study, we included specimens that were obtained from a general hospital population and submitted for routine investigation of micro-organisms.", [["specimen", "ANATOMY", 53, 61], ["Respiratory specimens", "ANATOMY", 182, 203], ["urine sample", "ANATOMY", 282, 294], ["specimens", "ANATOMY", 344, 353], ["nucleic acid", "CHEMICAL", 208, 220], ["NPA", "CHEMICAL", 49, 52], ["Nucleic acids", "SIMPLE_CHEMICAL", 0, 13], ["nucleic acid", "SIMPLE_CHEMICAL", 208, 220], ["urine", "ORGANISM_SUBSTANCE", 282, 287], ["Nucleic acids", "TREATMENT", 0, 13], ["NPA specimen", "TEST", 49, 61], ["Respiratory specimens", "TEST", 182, 203], ["nucleic acid extraction", "TEST", 208, 231], ["a diverse urine sample population", "TEST", 272, 305], ["this study", "TEST", 320, 330], ["specimens", "TEST", 344, 353], ["routine investigation", "TEST", 426, 447], ["micro-organisms", "PROBLEM", 451, 466], ["acids", "OBSERVATION_MODIFIER", 8, 13]]], ["Urine samples were collected between October 1999 and August 2005 from pediatric and adult patients ranging in age from 1 day to 76 years (mean = 16.9 years; median age = 24.6 years).", [["Urine samples", "ANATOMY", 0, 13], ["Urine samples", "ORGANISM_SUBSTANCE", 0, 13], ["patients", "ORGANISM", 91, 99], ["patients", "SPECIES", 91, 99], ["Urine samples", "TEST", 0, 13]]], ["Fifty-five samples were included from adult immunocompromised (bone marrow transplant) patients.", [["samples", "ANATOMY", 11, 18], ["bone marrow", "ANATOMY", 63, 74], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 63, 74], ["patients", "ORGANISM", 87, 95], ["patients", "SPECIES", 87, 95], ["adult immunocompromised (bone marrow transplant", "TREATMENT", 38, 85], ["immunocompromised", "OBSERVATION", 44, 61], ["bone", "ANATOMY", 63, 67], ["marrow transplant", "OBSERVATION", 68, 85]]], ["Nucleic acids were extracted from 0.2 mL of each urine specimen with a QIAamp DNA blood mini kit (Qiagen, Clifton Hill, Australia).", [["urine specimen", "ANATOMY", 49, 63], ["blood", "ANATOMY", 82, 87], ["Nucleic acids", "SIMPLE_CHEMICAL", 0, 13], ["urine specimen", "ORGANISM_SUBSTANCE", 49, 63], ["blood", "ORGANISM_SUBSTANCE", 82, 87], ["Nucleic acids", "TREATMENT", 0, 13], ["urine specimen", "TEST", 49, 63]]], ["This procedure has been shown to be suitable for the extraction of viral DNA from urine specimens because of the high DNA yield and the removal of PCR inhibitors (Echavarria et al., 1998).", [["urine specimens", "ANATOMY", 82, 97], ["DNA", "CELLULAR_COMPONENT", 73, 76], ["urine specimens", "ORGANISM_SUBSTANCE", 82, 97], ["DNA", "CELLULAR_COMPONENT", 118, 121], ["viral DNA", "DNA", 67, 76], ["This procedure", "TREATMENT", 0, 14], ["the extraction", "TREATMENT", 49, 63], ["viral DNA", "PROBLEM", 67, 76], ["urine specimens", "TEST", 82, 97], ["the high DNA yield", "PROBLEM", 109, 127], ["the removal of PCR inhibitors", "TREATMENT", 132, 161], ["viral", "OBSERVATION", 67, 72]]], ["Similarly, 102 blood samples collected between October 2004 and June 2005 for the monitoring of aspergillosis in 27 children with leukemia ranging in age from 2 to 16 years (mean = 7.6 years; median age = 6.0 years) were tested for KIV and WUV.", [["blood samples", "ANATOMY", 15, 28], ["leukemia", "ANATOMY", 130, 138], ["aspergillosis", "DISEASE", 96, 109], ["leukemia", "DISEASE", 130, 138], ["blood samples", "ORGANISM_SUBSTANCE", 15, 28], ["aspergillosis", "CANCER", 96, 109], ["children", "ORGANISM", 116, 124], ["leukemia", "CANCER", 130, 138], ["KIV", "PROTEIN", 232, 235], ["children", "SPECIES", 116, 124], ["KIV", "SPECIES", 232, 235], ["blood samples", "TEST", 15, 28], ["aspergillosis", "PROBLEM", 96, 109], ["leukemia", "PROBLEM", 130, 138], ["KIV and WUV", "TREATMENT", 232, 243], ["aspergillosis", "OBSERVATION", 96, 109]]], ["A 200 \u03bcL volume of each blood sample was extracted as described for urine samples above.Detection of KIV and WUV by PCR ::: Materials and methodsExtracts were analyzed for the presence of KIV and WUV sequences by conventional PCR.", [["blood sample", "ANATOMY", 24, 36], ["urine samples", "ANATOMY", 68, 81], ["blood", "ORGANISM_SUBSTANCE", 24, 29], ["urine samples", "ORGANISM_SUBSTANCE", 68, 81], ["KIV", "GENE_OR_GENE_PRODUCT", 101, 104], ["KIV", "GENE_OR_GENE_PRODUCT", 188, 191], ["KIV", "DNA", 101, 104], ["WUV", "DNA", 109, 112], ["KIV and WUV sequences", "DNA", 188, 209], ["KIV", "SPECIES", 101, 104], ["KIV", "SPECIES", 188, 191], ["A 200 \u03bcL volume of each blood sample", "TREATMENT", 0, 36], ["urine samples", "TEST", 68, 81], ["methodsExtracts", "TREATMENT", 138, 153], ["KIV and WUV sequences", "TEST", 188, 209], ["conventional PCR", "TEST", 213, 229]]], ["A common PCR reaction mix was used for all conventional assays consisting of 1.25 units of QIAGEN HotStart Taq (Qiagen), 2.5 pmol of each primer, 0.625 \u03bcL of 10 mM dNTPs, 0.5 \u03bcL of 25 mM MgCl2, 2.5 \u03bcL of 10\u00d7 QIAGEN PCR buffer (Qiagen) and 2.5 \u03bcL of nucleotide extract made up to a 25 \u03bcL volume.", [["dNTPs", "CHEMICAL", 164, 169], ["MgCl2", "CHEMICAL", 187, 192], ["nucleotide extract", "CHEMICAL", 249, 267], ["dNTPs", "CHEMICAL", 164, 169], ["MgCl2", "CHEMICAL", 187, 192], ["nucleotide", "CHEMICAL", 249, 259], ["A common PCR reaction mix", "TREATMENT", 0, 25], ["QIAGEN HotStart Taq (Qiagen)", "TREATMENT", 91, 119], ["25 mM MgCl2", "TREATMENT", 181, 192], ["QIAGEN PCR buffer (Qiagen)", "TREATMENT", 208, 234], ["nucleotide extract", "TREATMENT", 249, 267]]], ["For KIV, specimens were screened using primers POLVP1-39F and POLVP1-363R and positive results were confirmed with a second set of primers (POLVP1-118F and POLVP1-324R) as originally described by Allander et al. (2007).", [["specimens", "ANATOMY", 9, 18], ["specimens", "CANCER", 9, 18], ["POLVP1-39F", "GENE_OR_GENE_PRODUCT", 47, 57], ["POLVP1-363R", "GENE_OR_GENE_PRODUCT", 62, 73], ["POLVP1-118F", "GENE_OR_GENE_PRODUCT", 140, 151], ["POLVP1-324R", "GENE_OR_GENE_PRODUCT", 156, 167], ["primers POLVP1-39F and POLVP1-363R", "DNA", 39, 73], ["POLVP1", "DNA", 140, 146], ["POLVP1", "DNA", 156, 162], ["specimens", "TEST", 9, 18], ["primers POLVP1", "TEST", 39, 53], ["POLVP1", "TEST", 62, 68], ["primers", "TEST", 131, 138], ["POLVP1", "TEST", 140, 146], ["POLVP1", "TEST", 156, 162]]], ["The KIV PCR assays utilized cycling conditions of 15 min incubation at 95 \u00b0C, followed by 40 cycles of 95 \u00b0C for 30 s, 54 \u00b0C for 30 s and 72 \u00b0C for 1 min, followed by a final extension of 10 min at 72 \u00b0C. WUV was initially detected by conventional PCR using primers AG0044 and AG0045, as described by Gaynor et al. (2007), utilizing 15 min incubation at 95 \u00b0C, followed by 40 cycles of 95 \u00b0C for 30 s, 56 \u00b0C for 30 s and 72 \u00b0C for 1 min, and a final extension of 10 min at 72 \u00b0C. PCR amplification products were realized by electrophoresis on 2% agarose gels and visualized with ethidium bromide staining.", [["ethidium bromide", "CHEMICAL", 579, 595], ["ethidium bromide", "CHEMICAL", 579, 595], ["WUV", "GENE_OR_GENE_PRODUCT", 205, 208], ["ethidium bromide", "SIMPLE_CHEMICAL", 579, 595], ["WUV", "SPECIES", 205, 208], ["The KIV PCR assays", "TEST", 0, 18], ["cycling conditions", "TREATMENT", 28, 46], ["PCR amplification products", "TREATMENT", 480, 506], ["electrophoresis", "TEST", 524, 539], ["2% agarose gels", "TREATMENT", 543, 558], ["ethidium bromide staining", "TREATMENT", 579, 604]]], ["Positive results were confirmed using a WUV-specific real-time PCR assay, which was recently developed in our laboratory, incorporating a hydrolysis (TaqMan) probe (Bialasiewicz et al., 2007).PCR analysis for other respiratory viruses ::: Materials and methodsSamples had been previously tested for the presence of other significant respiratory viruses (respiratory syncytial virus (RSV), influenza virus A and B (INF A & B), parainfluenza viruses 1,2,3 (PIV 1,2,3), adenoviruses (ADV), HMPV) as previously described (Syrmis et al., 2004, Maertzdorf et al., 2004).", [["respiratory viruses", "DISEASE", 215, 234], ["respiratory viruses", "DISEASE", 333, 352], ["respiratory syncytial virus (RSV)", "DISEASE", 354, 387], ["influenza", "DISEASE", 389, 398], ["parainfluenza viruses", "DISEASE", 426, 447], ["respiratory viruses", "ORGANISM", 333, 352], ["respiratory syncytial virus", "ORGANISM", 354, 381], ["RSV", "ORGANISM", 383, 386], ["influenza virus A", "ORGANISM", 389, 406], ["B", "GENE_OR_GENE_PRODUCT", 411, 412], ["INF A & B", "ORGANISM", 414, 423], ["parainfluenza viruses", "ORGANISM", 426, 447], ["adenoviruses", "ORGANISM", 467, 479], ["ADV", "ORGANISM", 481, 484], ["HMPV", "ORGANISM", 487, 491], ["respiratory syncytial virus", "SPECIES", 354, 381], ["influenza virus", "SPECIES", 389, 404], ["parainfluenza", "SPECIES", 426, 439], ["respiratory syncytial virus", "SPECIES", 354, 381], ["RSV", "SPECIES", 383, 386], ["ADV", "SPECIES", 481, 484], ["HMPV", "SPECIES", 487, 491], ["a WUV", "TEST", 38, 43], ["a hydrolysis (TaqMan) probe", "TREATMENT", 136, 163], ["PCR analysis", "TEST", 192, 204], ["methodsSamples", "TEST", 253, 267], ["other significant respiratory viruses (respiratory syncytial virus", "PROBLEM", 315, 381], ["RSV", "TEST", 383, 386], ["influenza virus A", "PROBLEM", 389, 406], ["B (INF A & B", "TEST", 411, 423], ["parainfluenza viruses", "PROBLEM", 426, 447], ["PIV", "TEST", 455, 458], ["adenoviruses", "PROBLEM", 467, 479], ["HMPV", "PROBLEM", 487, 491], ["respiratory viruses", "OBSERVATION", 215, 234], ["significant", "OBSERVATION_MODIFIER", 321, 332], ["respiratory viruses", "OBSERVATION", 333, 352], ["respiratory syncytial", "ANATOMY", 354, 375], ["parainfluenza viruses", "OBSERVATION", 426, 447]]], ["All KIV and WUV positive specimens were further tested to determine the simultaneous presence of human rhinoviruses (HRV), human coronaviruses (HCoV) OC43, 229E, NL63 and HKU1 (Arden et al., 2006, Sloots et al., 2006) and HBoV.", [["KIV", "ANATOMY", 4, 7], ["specimens", "ANATOMY", 25, 34], ["KIV", "GENE_OR_GENE_PRODUCT", 4, 7], ["human", "ORGANISM", 97, 102], ["rhinoviruses", "ORGANISM", 103, 115], ["HRV", "ORGANISM", 117, 120], ["human", "ORGANISM", 123, 128], ["coronaviruses", "ORGANISM", 129, 142], ["HCoV", "CELL", 144, 148], ["HBoV", "ORGANISM", 222, 226], ["human", "SPECIES", 97, 102], ["human", "SPECIES", 123, 128], ["KIV", "SPECIES", 4, 7], ["human rhinoviruses", "SPECIES", 97, 115], ["HRV", "SPECIES", 117, 120], ["human coronaviruses", "SPECIES", 123, 142], ["HCoV", "SPECIES", 144, 148], ["All KIV and WUV positive specimens", "TEST", 0, 34], ["human rhinoviruses", "PROBLEM", 97, 115], ["OC43", "TEST", 150, 154], ["NL63", "TEST", 162, 166], ["HBoV", "PROBLEM", 222, 226], ["rhinoviruses", "OBSERVATION", 103, 115], ["HBoV", "OBSERVATION", 222, 226]]], ["The presence of HBoV was determined by real-time PCR using primers STBoVP-1f (GGCAGAATTCAGCCATACTCAAA) and STBoVP-1r (TCTGGGTTAGTGCAAACCATGA) and a hydrolysis probe STBoVP-1probe (AGAGTAGGACCACAGTCATCAGACACTGCTCC-Yakima) targeting the HBoV VP-1 gene.", [["HBoV", "ORGANISM", 16, 20], ["STBoVP-1f", "GENE_OR_GENE_PRODUCT", 67, 76], ["STBoVP-1r", "GENE_OR_GENE_PRODUCT", 107, 116], ["STBoVP-1probe", "SIMPLE_CHEMICAL", 165, 178], ["HBoV", "ORGANISM", 235, 239], ["VP-1", "GENE_OR_GENE_PRODUCT", 240, 244], ["primers STBoVP-1f", "DNA", 59, 76], ["STBoVP", "DNA", 107, 113], ["1r", "DNA", 114, 116], ["hydrolysis probe STBoVP-1probe", "DNA", 148, 178], ["Yakima", "DNA", 213, 219], ["HBoV VP-1 gene", "DNA", 235, 249], ["HBoV", "SPECIES", 16, 20], ["HBoV VP-1", "SPECIES", 235, 244], ["HBoV", "PROBLEM", 16, 20], ["primers STBoVP", "TEST", 59, 73], ["STBoVP", "TEST", 107, 113], ["a hydrolysis probe STBoVP", "TEST", 146, 171], ["the HBoV VP", "TREATMENT", 231, 242], ["HBoV", "OBSERVATION", 16, 20]]], ["All HBoV-positive results were confirmed by a second real-time PCR assay developed in our laboratory targeting the NP-1 gene (unpublished data).Sequencing of KIV and WUV genomes ::: Materials and methodsWe sequenced the complete genomes of KIV detected in three patients in this study, and compared those sequences to KIV sequences available for the Swedish isolates (Allander et al., 2007).", [["HBoV", "ORGANISM", 4, 8], ["NP-1", "GENE_OR_GENE_PRODUCT", 115, 119], ["KIV", "GENE_OR_GENE_PRODUCT", 158, 161], ["KIV", "GENE_OR_GENE_PRODUCT", 240, 243], ["patients", "ORGANISM", 262, 270], ["NP-1 gene", "DNA", 115, 124], ["KIV and WUV genomes", "DNA", 158, 177], ["KIV", "DNA", 240, 243], ["KIV sequences", "DNA", 318, 331], ["patients", "SPECIES", 262, 270], ["All HBoV", "TEST", 0, 8], ["PCR assay", "TEST", 63, 72], ["the NP", "TEST", 111, 117], ["this study", "TEST", 274, 284], ["KIV sequences", "TEST", 318, 331]]], ["Similarly we sequenced six complete WUV genomes using previously described protocols (Gaynor et al., 2007) and sought to determine the genetic relationship of WUV with each other and compared to the other human polyomaviruses BKV and JCV.", [["WUV", "CANCER", 159, 162], ["human", "ORGANISM", 205, 210], ["polyomaviruses", "ORGANISM", 211, 225], ["BKV", "ORGANISM", 226, 229], ["JCV", "ORGANISM", 234, 237], ["WUV genomes", "DNA", 36, 47], ["human", "SPECIES", 205, 210], ["human polyomaviruses BKV", "SPECIES", 205, 229], ["JCV", "SPECIES", 234, 237], ["BKV", "OBSERVATION", 226, 229], ["JCV", "OBSERVATION", 234, 237]]], ["Raw KIV and WUV sequence data were aligned together with JCV, BKV and SV40 sequences using BioEdit version 7.0.5.3.", [["JCV", "ORGANISM", 57, 60], ["BKV", "ORGANISM", 62, 65], ["SV40", "ORGANISM", 70, 74], ["Raw KIV and WUV sequence", "DNA", 0, 24], ["JCV, BKV and SV40 sequences", "DNA", 57, 84], ["KIV", "SPECIES", 4, 7], ["JCV", "SPECIES", 57, 60], ["BKV", "SPECIES", 62, 65], ["WUV sequence data", "TEST", 12, 29], ["JCV", "TEST", 57, 60], ["BKV", "TEST", 62, 65], ["BioEdit version", "TEST", 91, 106]]], ["Fractional nucleotide sequence identity matrices were used to examine the relationship between KIV, WUV, JCV, and BKV, with SV40 being utilized as the rooting out-group.Prevalence and temporal distribution of KIV and WUV ::: ResultsOf 2866 specimens tested, 75 (2.6%) NPA were positive for KIV and 128 (4.5%) NPA were positive for WUV.", [["specimens", "ANATOMY", 240, 249], ["nucleotide", "CHEMICAL", 11, 21], ["KIV", "GENE_OR_GENE_PRODUCT", 95, 98], ["WUV", "GENE_OR_GENE_PRODUCT", 100, 103], ["JCV", "ORGANISM", 105, 108], ["BKV", "ORGANISM", 114, 117], ["SV40", "ORGANISM", 124, 128], ["NPA", "CANCER", 268, 271], ["NPA", "CANCER", 309, 312], ["KIV", "SPECIES", 95, 98], ["WUV", "SPECIES", 100, 103], ["JCV", "SPECIES", 105, 108], ["BKV", "SPECIES", 114, 117], ["KIV", "SPECIES", 290, 293], ["Fractional nucleotide sequence identity matrices", "PROBLEM", 0, 48], ["KIV", "TEST", 95, 98], ["JCV", "TEST", 105, 108], ["SV40", "TREATMENT", 124, 128], ["specimens", "TEST", 240, 249], ["NPA", "TEST", 268, 271], ["KIV", "TEST", 290, 293], ["NPA", "TEST", 309, 312], ["WUV", "PROBLEM", 331, 334]]], ["The youngest KIV positive subject was 4 months of age, and the oldest 69 years, and for WUV, 19 days and 52 years, respectively.", [["KIV", "CANCER", 13, 16]]], ["78.6% of KIV-positive results were from children 5 years of age or younger and 93.0% of WUV-positive results fell in this age group.", [["KIV", "GENE_OR_GENE_PRODUCT", 9, 12], ["children", "ORGANISM", 40, 48], ["children", "SPECIES", 40, 48], ["KIV", "TEST", 9, 12], ["WUV", "TEST", 88, 91]]], ["Although both viruses had a consistent presence during 2003, there appeared to be no seasonal pattern of peak infection associated with KIV in our sample population.", [["infection", "DISEASE", 110, 119], ["KIV", "SPECIES", 136, 139], ["peak infection", "PROBLEM", 105, 119], ["viruses", "OBSERVATION", 14, 21], ["peak", "OBSERVATION_MODIFIER", 105, 109], ["infection", "OBSERVATION", 110, 119]]], ["However, there appeared to be a predominance of infection with WUV in Queensland patients during the period from late winter to early summer, peaking in December (Fig. 1).", [["infection", "DISEASE", 48, 57], ["patients", "ORGANISM", 81, 89], ["patients", "SPECIES", 81, 89], ["infection", "PROBLEM", 48, 57], ["appeared to be", "UNCERTAINTY", 15, 29], ["predominance", "OBSERVATION_MODIFIER", 32, 44], ["infection", "OBSERVATION", 48, 57]]], ["In contrast, the prevalence of KIV for this period was 2.9% compared to 2.5% for the remaining year.", [["KIV", "CANCER", 31, 34], ["KIV", "SPECIES", 31, 34]]], ["However, this distribution across different seasons proved not to be statistically significant for either virus.", [["virus", "PROBLEM", 106, 111], ["virus", "OBSERVATION", 106, 111]]], ["In this specimen set for 2003, complete annual prevalence data were only available for those respiratory viruses considered to be of most clinical significance.", [["respiratory viruses", "DISEASE", 93, 112], ["complete annual prevalence data", "TEST", 31, 62], ["those respiratory viruses", "PROBLEM", 87, 112]]], ["Of these the predominant viral pathogen detected was RSV (9.2%), followed by HMPV (7.1%); INF A (3.5%); PIV 3 (2.3%); and ADV (1.3%).", [["ADV", "CHEMICAL", 122, 125], ["RSV", "ORGANISM", 53, 56], ["RSV", "SPECIES", 53, 56], ["HMPV", "SPECIES", 77, 81], ["ADV", "SPECIES", 122, 125], ["these the predominant viral pathogen", "PROBLEM", 3, 39], ["RSV", "TEST", 53, 56], ["HMPV", "TEST", 77, 81], ["INF A", "TEST", 90, 95], ["PIV", "TEST", 104, 107], ["ADV", "TEST", 122, 125], ["predominant", "OBSERVATION_MODIFIER", 13, 24], ["viral", "OBSERVATION_MODIFIER", 25, 30], ["pathogen", "OBSERVATION", 31, 39]]], ["Examination of the urine and blood samples failed to detect the presence of either KIV or WUV in any samples.Co-detection of KIV and WUV with other respiratory viruses ::: ResultsKIV and WUV were associated with the co-detection of another respiratory virus in 56 of 75 (74.7%) and 102 of 128 (79.7%) cases, respectively.", [["urine", "ANATOMY", 19, 24], ["blood samples", "ANATOMY", 29, 42], ["samples", "ANATOMY", 101, 108], ["respiratory viruses", "DISEASE", 148, 167], ["urine", "ORGANISM_SUBSTANCE", 19, 24], ["blood samples", "ORGANISM_SUBSTANCE", 29, 42], ["KIV", "GENE_OR_GENE_PRODUCT", 83, 86], ["KIV", "GENE_OR_GENE_PRODUCT", 125, 128], ["WUV", "CANCER", 187, 190], ["KIV", "PROTEIN", 125, 128], ["KIV", "SPECIES", 125, 128], ["Examination of the urine", "TEST", 0, 24], ["blood samples", "TEST", 29, 42], ["either KIV or WUV", "PROBLEM", 76, 93], ["another respiratory virus", "PROBLEM", 232, 257], ["respiratory viruses", "OBSERVATION", 148, 167]]], ["Both were most commonly co-detected with HRV, followed by HBoV as the second most frequently detected virus (Table 1).", [["HBoV", "ORGANISM", 58, 62], ["HBoV", "SPECIES", 58, 62], ["HBoV", "PROBLEM", 58, 62]]], ["Interestingly, in 14 patients, KIV was co-detected with WUV and in only one of these no other respiratory virus was present.Clinical presentation of KIV and WUV infected patients ::: ResultsThe clinical signs at presentation to hospital from 51 of 75 KIV-positive and 98 of 128 WUV-positive patients were scrutinized, and presenting clinical features were recorded.", [["WUV infected", "DISEASE", 157, 169], ["patients", "ORGANISM", 21, 29], ["KIV", "GENE_OR_GENE_PRODUCT", 31, 34], ["WUV", "CANCER", 56, 59], ["KIV", "CANCER", 149, 152], ["patients", "ORGANISM", 170, 178], ["WUV", "CANCER", 278, 281], ["patients", "ORGANISM", 291, 299], ["KIV", "PROTEIN", 31, 34], ["patients", "SPECIES", 21, 29], ["patients", "SPECIES", 170, 178], ["patients", "SPECIES", 291, 299], ["KIV", "SPECIES", 31, 34], ["KIV", "SPECIES", 149, 152], ["WUV", "TREATMENT", 56, 59], ["other respiratory virus", "PROBLEM", 88, 111], ["KIV", "TEST", 251, 254], ["WUV", "TEST", 278, 281], ["respiratory virus", "OBSERVATION", 94, 111]]], ["There was no observable difference in presenting signs between patients infected with KIV and those infected with WUV, and these were consistent with ARTI.", [["ARTI", "DISEASE", 150, 154], ["patients", "ORGANISM", 63, 71], ["WUV", "CANCER", 114, 117], ["patients", "SPECIES", 63, 71], ["KIV", "SPECIES", 86, 89], ["WUV", "SPECIES", 114, 117], ["observable difference", "PROBLEM", 13, 34], ["KIV", "TREATMENT", 86, 89], ["WUV", "TREATMENT", 114, 117], ["ARTI", "PROBLEM", 150, 154], ["no observable", "UNCERTAINTY", 10, 23], ["difference", "OBSERVATION_MODIFIER", 24, 34], ["consistent with", "UNCERTAINTY", 134, 149], ["ARTI", "OBSERVATION", 150, 154]]], ["These signs also did not differ from those observed in patients with ARTI attributed to other respiratory viruses, or in fact those patients for whom a cause of infection could not be identified.", [["ARTI", "DISEASE", 69, 73], ["respiratory viruses", "DISEASE", 94, 113], ["infection", "DISEASE", 161, 170], ["patients", "ORGANISM", 55, 63], ["patients", "ORGANISM", 132, 140], ["patients", "SPECIES", 55, 63], ["patients", "SPECIES", 132, 140], ["ARTI", "PROBLEM", 69, 73], ["other respiratory viruses", "PROBLEM", 88, 113], ["infection", "PROBLEM", 161, 170], ["respiratory", "ANATOMY", 94, 105], ["viruses", "OBSERVATION", 106, 113], ["infection", "OBSERVATION", 161, 170]]], ["Clinical presentation for these patients was comprised predominantly of cough, fever and malaise (Table 2).Phylogenetic analysis of KIV and WUV ::: ResultsThe results of phylogenetic analysis showed a high level of genome conservation for KIV, with 99.4\u2013100% similarity at a nucleotide level between the strains detected in Australia (GenBank accession numbers EF520287\u2013EF520289) compared to KIV sequences reported by the Swedish group.", [["cough", "DISEASE", 72, 77], ["fever", "DISEASE", 79, 84], ["nucleotide", "CHEMICAL", 275, 285], ["nucleotide", "CHEMICAL", 275, 285], ["patients", "ORGANISM", 32, 40], ["KIV", "GENE_OR_GENE_PRODUCT", 239, 242], ["KIV", "DNA", 132, 135], ["KIV", "DNA", 239, 242], ["KIV sequences", "DNA", 392, 405], ["patients", "SPECIES", 32, 40], ["cough", "PROBLEM", 72, 77], ["fever", "PROBLEM", 79, 84], ["malaise", "PROBLEM", 89, 96], ["Phylogenetic analysis", "TEST", 107, 128], ["phylogenetic analysis", "TEST", 170, 191], ["KIV", "TEST", 239, 242], ["a nucleotide level", "TEST", 273, 291], ["the strains", "PROBLEM", 300, 311], ["KIV sequences", "TEST", 392, 405], ["cough", "OBSERVATION", 72, 77]]], ["Detailed analysis of the viral DNA sequence confirmed that KIV and WUV were closely related genetically, but were clearly divergent from BKV and JCV (Fig. 2).DiscussionThis is the first study examining the association of two newly described human polyomaviruses, KIV and WUV, with illness in the human respiratory tract.", [["respiratory tract", "ANATOMY", 302, 319], ["illness in the human respiratory tract", "DISEASE", 281, 319], ["DNA", "CELLULAR_COMPONENT", 31, 34], ["KIV", "GENE_OR_GENE_PRODUCT", 59, 62], ["WUV", "GENE_OR_GENE_PRODUCT", 67, 70], ["BKV", "ORGANISM", 137, 140], ["JCV", "ORGANISM", 145, 148], ["human", "ORGANISM", 241, 246], ["polyomaviruses", "ORGANISM", 247, 261], ["human", "ORGANISM", 296, 301], ["respiratory tract", "ORGANISM_SUBDIVISION", 302, 319], ["viral DNA sequence", "DNA", 25, 43], ["KIV", "DNA", 59, 62], ["WUV", "DNA", 67, 70], ["human", "SPECIES", 241, 246], ["human", "SPECIES", 296, 301], ["KIV", "SPECIES", 59, 62], ["WUV", "SPECIES", 67, 70], ["BKV", "SPECIES", 137, 140], ["JCV", "SPECIES", 145, 148], ["human polyomaviruses", "SPECIES", 241, 261], ["KIV", "SPECIES", 263, 266], ["WUV", "SPECIES", 271, 274], ["human", "SPECIES", 296, 301], ["Detailed analysis", "TEST", 0, 17], ["the viral DNA sequence", "TEST", 21, 43], ["KIV and WUV", "PROBLEM", 59, 70], ["BKV", "PROBLEM", 137, 140], ["the first study", "TEST", 176, 191], ["human polyomaviruses", "TREATMENT", 241, 261], ["KIV", "TREATMENT", 263, 266], ["WUV", "TREATMENT", 271, 274], ["illness in the human respiratory tract", "PROBLEM", 281, 319], ["BKV", "OBSERVATION", 137, 140], ["polyomaviruses", "OBSERVATION", 247, 261], ["human", "ANATOMY_MODIFIER", 296, 301], ["respiratory tract", "ANATOMY", 302, 319]]], ["In our sample of respiratory specimens collected from individuals presenting to a hospital emergency department for assessment or admission, KIV and WUV were found at a prevalence of 2.6% and 4.5%, respectively.", [["respiratory specimens", "ANATOMY", 17, 38], ["respiratory specimens", "CANCER", 17, 38], ["KIV", "SPECIES", 141, 144], ["respiratory specimens", "TEST", 17, 38], ["assessment", "TEST", 116, 126], ["respiratory", "ANATOMY", 17, 28]]], ["It is not possible to prove a causal relationship between the detection of KIV and WUV and respiratory disease from these findings; this will require further more comprehensive studies, ideally involving those that satisfy Koch's postulates.DiscussionHowever, a number of features in the detection of these newly discovered viruses mean further exploration of a causal role in respiratory disease is warranted.", [["respiratory", "ANATOMY", 377, 388], ["respiratory disease", "DISEASE", 91, 110], ["respiratory disease", "DISEASE", 377, 396], ["KIV", "CANCER", 75, 78], ["KIV", "SPECIES", 75, 78], ["KIV", "PROBLEM", 75, 78], ["WUV", "PROBLEM", 83, 86], ["respiratory disease", "PROBLEM", 91, 110], ["comprehensive studies", "TEST", 163, 184], ["these newly discovered viruses", "PROBLEM", 301, 331], ["respiratory disease", "PROBLEM", 377, 396], ["not possible", "UNCERTAINTY", 6, 18], ["respiratory disease", "OBSERVATION", 91, 110], ["viruses", "OBSERVATION", 324, 331], ["respiratory disease", "OBSERVATION", 377, 396]]], ["KIV and WUV were present in respiratory secretions from patients with ARTI at rates similar to those reported for the recently described respiratory viruses, human coronavirus HKU1, NL63 (Lau et al., 2006), and HBoV (Kesebir et al., 2006).", [["respiratory secretions", "ANATOMY", 28, 50], ["respiratory viruses", "DISEASE", 137, 156], ["KIV", "GENE_OR_GENE_PRODUCT", 0, 3], ["WUV", "GENE_OR_GENE_PRODUCT", 8, 11], ["secretions", "ORGANISM_SUBSTANCE", 40, 50], ["patients", "ORGANISM", 56, 64], ["human", "ORGANISM", 158, 163], ["coronavirus HKU1", "ORGANISM", 164, 180], ["HBoV", "ORGANISM", 211, 215], ["KIV", "PROTEIN", 0, 3], ["WUV", "PROTEIN", 8, 11], ["patients", "SPECIES", 56, 64], ["human", "SPECIES", 158, 163], ["coronavirus", "SPECIES", 164, 175], ["KIV", "SPECIES", 0, 3], ["human coronavirus", "SPECIES", 158, 175], ["respiratory secretions", "PROBLEM", 28, 50], ["ARTI at rates", "PROBLEM", 70, 83], ["the recently described respiratory viruses", "PROBLEM", 114, 156], ["human coronavirus HKU1", "TEST", 158, 180], ["HBoV", "TEST", 211, 215], ["respiratory secretions", "OBSERVATION", 28, 50], ["respiratory viruses", "OBSERVATION", 137, 156]]], ["Neither of the viruses were detected in other sample sets consisting of urine from a variety of sources, and blood from immunocompromised children.", [["sample", "ANATOMY", 46, 52], ["urine", "ANATOMY", 72, 77], ["blood", "ANATOMY", 109, 114], ["urine", "ORGANISM_SUBSTANCE", 72, 77], ["blood", "ORGANISM_SUBSTANCE", 109, 114], ["children", "ORGANISM", 138, 146], ["children", "SPECIES", 138, 146], ["the viruses", "PROBLEM", 11, 22], ["viruses", "OBSERVATION", 15, 22], ["urine", "OBSERVATION", 72, 77]]], ["This was contrary to observations for the other human polyomaviruses BKV and JCV, which are commonly present in clinical urine samples and blood specimens, particularly from immunocompromised patients (Rossi et al., 2007, Polo et al., 2004, Azzi et al., 1996).", [["urine samples", "ANATOMY", 121, 134], ["blood specimens", "ANATOMY", 139, 154], ["human", "ORGANISM", 48, 53], ["polyomaviruses BKV", "ORGANISM", 54, 72], ["JCV", "ORGANISM", 77, 80], ["urine samples", "ORGANISM_SUBSTANCE", 121, 134], ["blood specimens", "ORGANISM_SUBSTANCE", 139, 154], ["patients", "ORGANISM", 192, 200], ["human", "SPECIES", 48, 53], ["patients", "SPECIES", 192, 200], ["human polyomaviruses BKV", "SPECIES", 48, 72], ["JCV", "SPECIES", 77, 80], ["the other human polyomaviruses BKV and JCV", "PROBLEM", 38, 80], ["clinical urine samples", "TEST", 112, 134], ["blood specimens", "TEST", 139, 154], ["BKV", "OBSERVATION", 69, 72]]], ["These results would suggest that the biology of KIV and WUV may be similar to each other, but quite different from BKV and JCV.DiscussionDetermining the role of KIV and WUV as human respiratory pathogens is confounded by the high level of co-detection of these viruses with other respiratory agents, particularly HRV.", [["respiratory", "ANATOMY", 280, 291], ["respiratory pathogens", "DISEASE", 182, 203], ["KIV", "GENE_OR_GENE_PRODUCT", 48, 51], ["WUV", "GENE_OR_GENE_PRODUCT", 56, 59], ["BKV", "ORGANISM", 115, 118], ["JCV", "ORGANISM", 123, 126], ["KIV", "GENE_OR_GENE_PRODUCT", 161, 164], ["WUV", "GENE_OR_GENE_PRODUCT", 169, 172], ["human", "ORGANISM", 176, 181], ["human", "SPECIES", 176, 181], ["BKV", "SPECIES", 115, 118], ["JCV", "SPECIES", 123, 126], ["human", "SPECIES", 176, 181], ["KIV", "TREATMENT", 161, 164], ["WUV", "TREATMENT", 169, 172], ["human respiratory pathogens", "PROBLEM", 176, 203], ["these viruses", "PROBLEM", 255, 268], ["other respiratory agents", "TREATMENT", 274, 298], ["BKV", "OBSERVATION", 115, 118], ["JCV", "OBSERVATION", 123, 126], ["viruses", "OBSERVATION", 261, 268]]], ["This feature is very similar to observations reported for HBoV where the rates of co-detection have ranged from 33.3% (Naghipour et al., 2007) to 83.7% (Fry et al., 2007), and, although epidemiologically the virus is associated with pneumonia, it is postulated that infection and illness of HBoV may be dependent on co-infection with other viruses (Fry et al., 2007).", [["pneumonia", "DISEASE", 233, 242], ["infection", "DISEASE", 266, 275], ["HBoV", "DISEASE", 291, 295], ["HBoV", "ORGANISM", 58, 62], ["HBoV", "ORGANISM", 291, 295], ["HBoV", "SPECIES", 58, 62], ["HBoV", "SPECIES", 291, 295], ["HBoV", "PROBLEM", 58, 62], ["co-detection", "TEST", 82, 94], ["the virus", "PROBLEM", 204, 213], ["pneumonia", "PROBLEM", 233, 242], ["infection", "PROBLEM", 266, 275], ["HBoV", "PROBLEM", 291, 295], ["co-infection", "PROBLEM", 316, 328], ["other viruses", "PROBLEM", 334, 347], ["virus", "OBSERVATION", 208, 213], ["associated with", "UNCERTAINTY", 217, 232], ["pneumonia", "OBSERVATION", 233, 242], ["infection", "OBSERVATION", 266, 275], ["co-infection", "OBSERVATION", 316, 328]]], ["Similarly, this may be true for infection and disease involving KIV and WUV.DiscussionThe clinical features associated with KIV and WUV infection in our study population were not sufficiently distinctive to differentiate them from other respiratory viral infections in children.", [["infection", "DISEASE", 32, 41], ["infection", "DISEASE", 136, 145], ["respiratory viral infections", "DISEASE", 237, 265], ["KIV", "CANCER", 64, 67], ["children", "ORGANISM", 269, 277], ["children", "SPECIES", 269, 277], ["KIV", "SPECIES", 64, 67], ["KIV", "SPECIES", 124, 127], ["WUV", "SPECIES", 132, 135], ["infection", "PROBLEM", 32, 41], ["disease", "PROBLEM", 46, 53], ["KIV", "TREATMENT", 124, 127], ["WUV infection", "PROBLEM", 132, 145], ["our study population", "TEST", 149, 169], ["other respiratory viral infections", "PROBLEM", 231, 265], ["may be true for", "UNCERTAINTY", 16, 31], ["infection", "OBSERVATION", 32, 41], ["infection", "OBSERVATION", 136, 145], ["respiratory", "ANATOMY", 237, 248], ["viral infections", "OBSERVATION", 249, 265]]], ["However, the majority of these patients, including those in whom KIV (25.3%) or WUV (20.3%) were the only pathogen detected, were sufficiently sick to require medical attention, thereby representing a significant burden on the health care system.DiscussionPhylogenetic analysis of KIV and WUV sequences confirmed that these viruses are genetically distinct.", [["patients", "ORGANISM", 31, 39], ["KIV", "GENE_OR_GENE_PRODUCT", 281, 284], ["KIV and WUV sequences", "DNA", 281, 302], ["patients", "SPECIES", 31, 39], ["KIV", "TEST", 65, 68], ["WUV", "TEST", 80, 83], ["a significant burden on the health care system", "PROBLEM", 199, 245], ["Phylogenetic analysis", "TEST", 256, 277], ["KIV and WUV sequences", "TEST", 281, 302], ["these viruses", "PROBLEM", 318, 331], ["significant", "OBSERVATION_MODIFIER", 201, 212], ["burden", "OBSERVATION", 213, 219], ["viruses", "OBSERVATION", 324, 331]]], ["No evidence for the existence of viral genetic subtypes was found, but these observations are limited by the small number of specimens examined in this study.", [["specimens", "ANATOMY", 125, 134], ["specimens", "CANCER", 125, 134], ["viral genetic subtypes", "PROBLEM", 33, 55], ["these observations", "TEST", 71, 89], ["the small number of specimens", "PROBLEM", 105, 134], ["this study", "TEST", 147, 157], ["evidence for", "UNCERTAINTY", 3, 15], ["viral", "OBSERVATION_MODIFIER", 33, 38], ["small", "OBSERVATION_MODIFIER", 109, 114]]], ["Given this, it would be prudent to perform phylogenetic analysis on a larger population of KIV and WUV before firm conclusions on circulating viral (sub) types may be proposed.", [["KIV", "CANCER", 91, 94], ["WUV", "CANCER", 99, 102], ["KIV", "SPECIES", 91, 94], ["phylogenetic analysis", "TEST", 43, 64], ["a larger population of KIV", "TREATMENT", 68, 94], ["firm conclusions", "PROBLEM", 110, 126], ["circulating viral (sub) types", "TREATMENT", 130, 159]]], ["Such studies are currently proceeding in our laboratory.DiscussionThis preliminary study examines the presence of two newly described human polyomaviruses, KIV and WUV, in respiratory samples from patients with ARTI.", [["respiratory samples", "ANATOMY", 172, 191], ["ARTI", "DISEASE", 211, 215], ["human", "ORGANISM", 134, 139], ["polyomaviruses", "ORGANISM", 140, 154], ["KIV", "CELL", 156, 159], ["WUV", "GENE_OR_GENE_PRODUCT", 164, 167], ["respiratory samples", "CANCER", 172, 191], ["patients", "ORGANISM", 197, 205], ["human", "SPECIES", 134, 139], ["patients", "SPECIES", 197, 205], ["human polyomaviruses", "SPECIES", 134, 154], ["KIV", "SPECIES", 156, 159], ["Such studies", "TEST", 0, 12], ["This preliminary study", "TEST", 66, 88], ["two newly described human polyomaviruses", "PROBLEM", 114, 154], ["WUV", "TREATMENT", 164, 167], ["ARTI", "PROBLEM", 211, 215], ["polyomaviruses", "OBSERVATION", 140, 154], ["respiratory", "ANATOMY", 172, 183]]], ["Through more comprehensive studies, further data will need to be obtained before the role of these viruses as respiratory pathogens can be firmly established.", [["respiratory pathogens", "DISEASE", 110, 131], ["comprehensive studies", "TEST", 13, 34], ["further data", "TEST", 36, 48], ["these viruses", "PROBLEM", 93, 106], ["respiratory pathogens", "PROBLEM", 110, 131]]], ["It remains possible that KIV and WUV are not involved in respiratory disease and their presence in the respiratory tract simply reflects their mode of transmission.", [["respiratory", "ANATOMY", 57, 68], ["respiratory tract", "ANATOMY", 103, 120], ["respiratory disease", "DISEASE", 57, 76], ["KIV", "GENE_OR_GENE_PRODUCT", 25, 28], ["WUV", "GENE_OR_GENE_PRODUCT", 33, 36], ["respiratory tract", "ORGANISM_SUBDIVISION", 103, 120], ["KIV", "SPECIES", 25, 28], ["KIV and WUV", "PROBLEM", 25, 36], ["respiratory disease", "PROBLEM", 57, 76], ["not involved", "UNCERTAINTY", 41, 53], ["respiratory disease", "OBSERVATION", 57, 76], ["respiratory tract", "ANATOMY", 103, 120]]], ["Establishing the association of these viruses with a particular disease will be challenging, but considering the oncogenic potential of polyomaviruses in mammals, the results of such studies may have important medical implications.", [["polyomaviruses", "ORGANISM", 136, 150], ["these viruses", "PROBLEM", 32, 45], ["a particular disease", "PROBLEM", 51, 71], ["polyomaviruses", "PROBLEM", 136, 150], ["such studies", "TEST", 178, 190], ["viruses", "OBSERVATION", 38, 45], ["polyomaviruses", "OBSERVATION", 136, 150]]]], "64eb0b568710d1e316b9c001d00443dadaee3105": [["IntroductionThe discovery of COVID-19 has led to global panic and substantial challenges in rapidly and systematically identifying suitable interventions for this unpredictable disease.", [["COVID-19", "CHEMICAL", 29, 37], ["panic", "DISEASE", 56, 61], ["COVID-19", "DNA", 29, 37], ["COVID", "TEST", 29, 34], ["global panic", "PROBLEM", 49, 61], ["suitable interventions", "TREATMENT", 131, 153], ["this unpredictable disease", "PROBLEM", 158, 184], ["global", "OBSERVATION_MODIFIER", 49, 55], ["panic", "OBSERVATION", 56, 61], ["substantial", "OBSERVATION_MODIFIER", 66, 77], ["challenges", "OBSERVATION", 78, 88]]], ["[1] Similar challenges have been associated with severe acute respiratory syndrome (SARS), [2] H1N1, [3] H7N9, [4] Middle East Respiratory Syndrome (MERS), [5] and Ebola Virus Disease (EVD), [6] among others.", [["acute respiratory syndrome", "DISEASE", 56, 82], ["SARS", "DISEASE", 84, 88], ["Middle East Respiratory Syndrome", "DISEASE", 115, 147], ["MERS", "DISEASE", 149, 153], ["Ebola Virus Disease", "DISEASE", 164, 183], ["EVD", "DISEASE", 185, 188], ["[3] H7N9", "SIMPLE_CHEMICAL", 101, 109], ["Ebola Virus", "ORGANISM", 164, 175], ["Ebola Virus", "SPECIES", 164, 175], ["Ebola Virus", "SPECIES", 164, 175], ["severe acute respiratory syndrome (SARS)", "PROBLEM", 49, 89], ["H1N1", "PROBLEM", 95, 99], ["H7N9", "PROBLEM", 105, 109], ["Middle East Respiratory Syndrome (MERS)", "PROBLEM", 115, 154], ["Ebola Virus Disease (EVD)", "PROBLEM", 164, 189], ["associated with", "UNCERTAINTY", 33, 48], ["severe", "OBSERVATION_MODIFIER", 49, 55], ["acute", "OBSERVATION_MODIFIER", 56, 61], ["respiratory syndrome", "OBSERVATION", 62, 82], ["Respiratory Syndrome", "OBSERVATION", 127, 147], ["Ebola Virus", "OBSERVATION", 164, 175]]], ["When addressing infectious diseases that are not well understood, and capable of exhibiting aggressive clinical courses with subsequent patient mortality, rapid intervention that is optimally suited to target the pathogen is critical.", [["infectious diseases", "DISEASE", 16, 35], ["patient", "ORGANISM", 136, 143], ["patient", "SPECIES", 136, 143], ["infectious diseases", "PROBLEM", 16, 35], ["rapid intervention", "TREATMENT", 155, 173]]], ["Due to the unpredictability and severity of these pathogens, combination therapy based on drug repurposing is often indicated due to the urgency of intervention and the requirement of previously established drug safety in humans.", [["humans", "ORGANISM", 222, 228], ["humans", "SPECIES", 222, 228], ["humans", "SPECIES", 222, 228], ["these pathogens", "PROBLEM", 44, 59], ["combination therapy", "TREATMENT", 61, 80], ["drug repurposing", "TREATMENT", 90, 106], ["intervention", "TREATMENT", 148, 160], ["pathogens", "OBSERVATION", 50, 59]]], ["Unfortunately, these drug combinations are often designed using trial-and-error strategies.", [["these drug combinations", "TREATMENT", 15, 38]]], ["Specifically, drugs are selected based on their targets or mechanism of action, and they are administered using clinical standard dosing guidelines.", [["drugs", "TREATMENT", 14, 19], ["clinical standard dosing guidelines", "TREATMENT", 112, 147]]], ["Dose adjustments are made when toxicity is observed.", [["toxicity", "DISEASE", 31, 39], ["Dose adjustments", "TREATMENT", 0, 16], ["toxicity", "PROBLEM", 31, 39]]], ["Unfortunately, these approaches likely preclude optimal treatment outcomes.IntroductionPreviously, a broad spectrum of methodologies have been used as part of multiple important studies to develop combination therapies to address multiple disease indications.", [["combination therapies", "TREATMENT", 197, 218], ["multiple disease indications", "PROBLEM", 230, 258]]], ["When confronted with a novel pathogen strain with high virulence, a potential capacity for rapid and continuous mutation, and poor patient outcomes, the global community often requires rapidly actionable responses due to patient mortality that may quickly follow initial diagnosis.", [["patient", "ORGANISM", 131, 138], ["patient", "ORGANISM", 221, 228], ["patient", "SPECIES", 131, 138], ["patient", "SPECIES", 221, 228], ["a novel pathogen strain", "PROBLEM", 21, 44], ["high virulence", "PROBLEM", 50, 64], ["rapid and continuous mutation", "PROBLEM", 91, 120]]], ["To address the COVID-19 crisis, a substantial number of clinical trials have been initiated.", [["the COVID", "TEST", 11, 20], ["clinical trials", "TREATMENT", 56, 71]]], ["[8] Treatment options explored to address COVID-19 have included repurposed human immunodeficiency virus (HIV) and influenza-related monotherapies and drug cocktails, trials of investigational therapies such as remdesivir (Gilead Sciences), and has sparked a worldwide effort to develop a vaccine.", [["human immunodeficiency virus (HIV) and influenza", "DISEASE", 76, 124], ["remdesivir", "CHEMICAL", 211, 221], ["COVID-19", "CHEMICAL", 42, 50], ["remdesivir", "CHEMICAL", 211, 221], ["human immunodeficiency virus", "ORGANISM", 76, 104], ["HIV", "ORGANISM", 106, 109], ["remdesivir", "SIMPLE_CHEMICAL", 211, 221], ["human immunodeficiency virus", "SPECIES", 76, 104], ["human immunodeficiency virus", "SPECIES", 76, 104], ["HIV", "SPECIES", 106, 109], ["Treatment options", "TREATMENT", 4, 21], ["COVID", "TEST", 42, 47], ["repurposed human immunodeficiency virus", "PROBLEM", 65, 104], ["influenza", "PROBLEM", 115, 124], ["monotherapies", "TREATMENT", 133, 146], ["drug cocktails", "TREATMENT", 151, 165], ["investigational therapies", "TREATMENT", 177, 202], ["a vaccine", "TREATMENT", 287, 296]]], ["Among large sets of candidate therapies for drug repurposing in combination therapy, standard approaches involve drug selection based on mechanism of action.", [["candidate therapies", "TREATMENT", 20, 39], ["drug repurposing", "TREATMENT", 44, 60], ["combination therapy", "TREATMENT", 64, 83], ["standard approaches", "TREATMENT", 85, 104], ["drug selection", "TREATMENT", 113, 127]]], ["Drug dosing is subsequently determined by established clinical guidelines.", [["Drug dosing", "TREATMENT", 0, 11]]], ["Traditional design approaches are based on trial-and-error, and barriers include sub-optimal efficacy and dose-limiting toxicities.", [["toxicities", "DISEASE", 120, 130], ["Traditional design approaches", "TREATMENT", 0, 29], ["limiting toxicities", "PROBLEM", 111, 130]]], ["In sum, the lack of a systematic way to interrogate the massive drug-dose parameter space created by these pools of candidate therapies preclude the ability to optimize treatment outcomes.IntroductionTo address this challenge, this work reports the outcomes of Project IDentif.AI, which harnesses an AI-based platform to interrogate drug and dose parameter spaces that are insurmountably large for brute-force testing of all possible combinations.", [["the massive drug-dose parameter space", "TREATMENT", 52, 89], ["candidate therapies", "TREATMENT", 116, 135], ["treatment outcomes", "TREATMENT", 169, 187], ["AI", "PROBLEM", 277, 279], ["drug and dose parameter spaces", "TREATMENT", 333, 363], ["force testing", "TEST", 404, 417], ["massive", "OBSERVATION_MODIFIER", 56, 63], ["large", "OBSERVATION_MODIFIER", 388, 393]]], ["Project IDentif.AI sought to determine the duration of time required to simultaneously identify the best drugs and doses from a pool of 12 candidate therapies that optimally inhibited the infection of the A549 lung cell line by VSV (efficacy) while maintaining A549 (efficacy).", [["A549 lung cell line", "ANATOMY", 205, 224], ["A549", "ANATOMY", 261, 265], ["infection", "DISEASE", 188, 197], ["A549 lung cell line", "CELL", 205, 224], ["VSV", "ORGANISM", 228, 231], ["A549", "CELL", 261, 265], ["A549 lung cell line", "CELL_LINE", 205, 224], ["A549", "CELL_LINE", 261, 265], ["VSV", "SPECIES", 228, 231], ["a pool of 12 candidate therapies", "TREATMENT", 126, 158], ["the infection", "PROBLEM", 184, 197], ["the A549 lung cell line", "TREATMENT", 201, 224], ["infection", "OBSERVATION", 188, 197], ["A549 lung cell line", "OBSERVATION", 205, 224]]], ["These therapies included amantadine HCl, dexamethasone, azithromycin, chloroquine diphosphate, naproxen sodium, fluoxetine HCl, loratadine, omeprazole sodium, ritonavir, lopinavir, doxycycline and ribavirin.", [["amantadine HCl", "CHEMICAL", 25, 39], ["dexamethasone", "CHEMICAL", 41, 54], ["azithromycin", "CHEMICAL", 56, 68], ["chloroquine diphosphate", "CHEMICAL", 70, 93], ["naproxen sodium", "CHEMICAL", 95, 110], ["fluoxetine HCl", "CHEMICAL", 112, 126], ["loratadine", "CHEMICAL", 128, 138], ["omeprazole sodium", "CHEMICAL", 140, 157], ["ritonavir", "CHEMICAL", 159, 168], ["lopinavir", "CHEMICAL", 170, 179], ["doxycycline", "CHEMICAL", 181, 192], ["ribavirin", "CHEMICAL", 197, 206], ["amantadine HCl", "CHEMICAL", 25, 39], ["dexamethasone", "CHEMICAL", 41, 54], ["azithromycin", "CHEMICAL", 56, 68], ["chloroquine diphosphate", "CHEMICAL", 70, 93], ["naproxen sodium", "CHEMICAL", 95, 110], ["fluoxetine", "CHEMICAL", 112, 122], ["HCl", "CHEMICAL", 123, 126], ["loratadine", "CHEMICAL", 128, 138], ["omeprazole sodium", "CHEMICAL", 140, 157], ["ritonavir", "CHEMICAL", 159, 168], ["lopinavir", "CHEMICAL", 170, 179], ["doxycycline", "CHEMICAL", 181, 192], ["ribavirin", "CHEMICAL", 197, 206], ["amantadine", "SIMPLE_CHEMICAL", 25, 35], ["HCl", "SIMPLE_CHEMICAL", 36, 39], ["dexamethasone", "SIMPLE_CHEMICAL", 41, 54], ["azithromycin", "SIMPLE_CHEMICAL", 56, 68], ["chloroquine diphosphate", "SIMPLE_CHEMICAL", 70, 93], ["naproxen", "SIMPLE_CHEMICAL", 95, 103], ["sodium", "SIMPLE_CHEMICAL", 104, 110], ["fluoxetine", "SIMPLE_CHEMICAL", 112, 122], ["HCl", "SIMPLE_CHEMICAL", 123, 126], ["loratadine", "SIMPLE_CHEMICAL", 128, 138], ["omeprazole", "SIMPLE_CHEMICAL", 140, 150], ["sodium", "SIMPLE_CHEMICAL", 151, 157], ["ritonavir", "SIMPLE_CHEMICAL", 159, 168], ["lopinavir", "SIMPLE_CHEMICAL", 170, 179], ["doxycycline", "SIMPLE_CHEMICAL", 181, 192], ["ribavirin", "SIMPLE_CHEMICAL", 197, 206], ["These therapies", "TREATMENT", 0, 15], ["amantadine HCl", "TREATMENT", 25, 39], ["dexamethasone", "TREATMENT", 41, 54], ["azithromycin", "TREATMENT", 56, 68], ["chloroquine diphosphate", "TREATMENT", 70, 93], ["naproxen sodium", "TREATMENT", 95, 110], ["fluoxetine HCl", "TREATMENT", 112, 126], ["loratadine", "TREATMENT", 128, 138], ["omeprazole sodium", "TREATMENT", 140, 157], ["ritonavir", "TREATMENT", 159, 168], ["lopinavir", "TREATMENT", 170, 179], ["doxycycline", "TREATMENT", 181, 192], ["ribavirin", "TREATMENT", 197, 206]]], ["The 12 candidate therapies were selected based on multiple factors that may be considered during pandemics, including prior studies examining their role as repurposed monotherapies in addressing a diverse range of viral pathogens, global adoption and availability of the therapies, as well as tolerability by broad classes of patients, among others.", [["patients", "ORGANISM", 326, 334], ["patients", "SPECIES", 326, 334], ["The 12 candidate therapies", "TREATMENT", 0, 26], ["prior studies", "TEST", 118, 131], ["monotherapies", "TREATMENT", 167, 180], ["viral pathogens", "PROBLEM", 214, 229], ["the therapies", "TREATMENT", 267, 280]]], ["Specifically, Amantadine HCl is an organic compound that was developed to address influenza infections.", [["Amantadine HCl", "CHEMICAL", 14, 28], ["influenza infections", "DISEASE", 82, 102], ["Amantadine HCl", "CHEMICAL", 14, 28], ["Amantadine HCl", "SIMPLE_CHEMICAL", 14, 28], ["Amantadine HCl", "TREATMENT", 14, 28], ["an organic compound", "PROBLEM", 32, 51], ["influenza infections", "PROBLEM", 82, 102]]], ["[9] It has been repurposed for treatment of motor impairment in Parkinson's disease, [10] and explored for improvement of fatigue in patients with multiple sclerosis.", [["motor impairment", "DISEASE", 44, 60], ["Parkinson's disease", "DISEASE", 64, 83], ["fatigue", "DISEASE", 122, 129], ["multiple sclerosis", "DISEASE", 147, 165], ["patients", "ORGANISM", 133, 141], ["patients", "SPECIES", 133, 141], ["motor impairment", "PROBLEM", 44, 60], ["Parkinson's disease", "PROBLEM", 64, 83], ["fatigue", "PROBLEM", 122, 129], ["multiple sclerosis", "PROBLEM", 147, 165], ["multiple", "OBSERVATION_MODIFIER", 147, 155], ["sclerosis", "OBSERVATION", 156, 165]]], ["[11] Dexamethasone is a potent anti-inflammatory and immunosuppressant glucocorticoid.", [["Dexamethasone", "CHEMICAL", 5, 18], ["[11] Dexamethasone", "CHEMICAL", 0, 18], ["[11] Dexamethasone", "SIMPLE_CHEMICAL", 0, 18], ["glucocorticoid", "SIMPLE_CHEMICAL", 71, 85], ["Dexamethasone", "TREATMENT", 5, 18], ["a potent anti-inflammatory", "TREATMENT", 22, 48], ["immunosuppressant glucocorticoid", "TREATMENT", 53, 85], ["immunosuppressant glucocorticoid", "OBSERVATION", 53, 85]]], ["It is used in therapies against a wide range of indications, including oncology and bacterial infections.", [["bacterial infections", "DISEASE", 84, 104], ["therapies", "TREATMENT", 14, 23], ["a wide range of indications", "TREATMENT", 32, 59], ["bacterial infections", "PROBLEM", 84, 104], ["bacterial", "OBSERVATION_MODIFIER", 84, 93], ["infections", "OBSERVATION", 94, 104]]], ["[12] It has been successfully used to treat denguerelated hemophagocytic syndrome.", [["hemophagocytic syndrome", "DISEASE", 58, 81], ["denguerelated hemophagocytic syndrome", "PROBLEM", 44, 81], ["hemophagocytic syndrome", "OBSERVATION", 58, 81]]], ["[13] Azithromycin is an antibiotic given to patients with bacterial infections of lower respiratory tract, [14] including community-acquired pneumonia.", [["lower respiratory tract", "ANATOMY", 82, 105], ["Azithromycin", "CHEMICAL", 5, 17], ["bacterial infections of lower respiratory tract", "DISEASE", 58, 105], ["pneumonia", "DISEASE", 141, 150], ["[13] Azithromycin", "CHEMICAL", 0, 17], ["[13] Azithromycin", "SIMPLE_CHEMICAL", 0, 17], ["patients", "ORGANISM", 44, 52], ["lower", "ORGANISM_SUBDIVISION", 82, 87], ["respiratory tract", "ORGANISM_SUBDIVISION", 88, 105], ["patients", "SPECIES", 44, 52], ["Azithromycin", "TREATMENT", 5, 17], ["an antibiotic", "TREATMENT", 21, 34], ["bacterial infections of lower respiratory tract", "PROBLEM", 58, 105], ["community-acquired pneumonia", "PROBLEM", 122, 150], ["bacterial", "OBSERVATION_MODIFIER", 58, 67], ["infections", "OBSERVATION", 68, 78], ["lower", "ANATOMY_MODIFIER", 82, 87], ["respiratory tract", "ANATOMY", 88, 105], ["pneumonia", "OBSERVATION", 141, 150]]], ["[15] It has been explored as a novel antimalarial agent.", [["a novel antimalarial agent", "TREATMENT", 29, 55]]], ["[16] Chloroquine disphosphate is the most widely used drug against malaria.", [["Chloroquine", "CHEMICAL", 5, 16], ["malaria", "DISEASE", 67, 74], ["[16] Chloroquine disphosphate", "CHEMICAL", 0, 29], ["[16] Chloroquine disphosphate", "SIMPLE_CHEMICAL", 0, 29], ["Chloroquine disphosphate", "TREATMENT", 5, 29], ["malaria", "PROBLEM", 67, 74]]], ["In recent years it has been found to target other infectious diseases, including HIV and fungal infections.", [["infectious diseases", "DISEASE", 50, 69], ["HIV and fungal infections", "DISEASE", 81, 106], ["HIV", "ORGANISM", 81, 84], ["HIV", "SPECIES", 81, 84], ["HIV", "SPECIES", 81, 84], ["other infectious diseases", "PROBLEM", 44, 69], ["HIV", "PROBLEM", 81, 84], ["fungal infections", "PROBLEM", 89, 106], ["infectious", "OBSERVATION", 50, 60], ["fungal", "OBSERVATION_MODIFIER", 89, 95], ["infections", "OBSERVATION", 96, 106]]], ["[17] Naproxen sodium is an established nonselective, nonsteroidal anti-inflammatory drug (NSAID) commonly used for treating mild and moderate pain and inflammation.", [["[17] Naproxen sodium", "CHEMICAL", 0, 20], ["pain", "DISEASE", 142, 146], ["inflammation", "DISEASE", 151, 163], ["[17] Naproxen sodium", "CHEMICAL", 0, 20], ["[17] Naproxen sodium", "SIMPLE_CHEMICAL", 0, 20], ["NSAID", "SIMPLE_CHEMICAL", 90, 95], ["Naproxen sodium", "TREATMENT", 5, 20], ["nonsteroidal anti-inflammatory drug (NSAID)", "TREATMENT", 53, 96], ["mild and moderate pain", "PROBLEM", 124, 146], ["inflammation", "PROBLEM", 151, 163], ["mild", "OBSERVATION_MODIFIER", 124, 128], ["moderate", "OBSERVATION_MODIFIER", 133, 141], ["pain", "OBSERVATION", 142, 146], ["inflammation", "OBSERVATION", 151, 163]]], ["[18] Recently, It has been shown to act against influenza A and B viruses.", [["influenza A and B viruses", "DISEASE", 48, 73], ["influenza A and B viruses", "ORGANISM", 48, 73], ["influenza A", "SPECIES", 48, 59], ["B viruses", "SPECIES", 64, 73], ["influenza A and B viruses", "PROBLEM", 48, 73]]], ["[19] Fluoxetine HCL, widely known as Prozac, is an antidepressant used to treat a range of depressive disorders.", [["Fluoxetine", "CHEMICAL", 5, 15], ["HCL", "CHEMICAL", 16, 19], ["Prozac", "CHEMICAL", 37, 43], ["antidepressant", "CHEMICAL", 51, 65], ["depressive disorders", "DISEASE", 91, 111], ["[19] Fluoxetine", "CHEMICAL", 0, 15], ["[19] Fluoxetine HCL", "SIMPLE_CHEMICAL", 0, 19], ["Prozac", "SIMPLE_CHEMICAL", 37, 43], ["Fluoxetine HCL", "TREATMENT", 5, 19], ["Prozac", "TREATMENT", 37, 43], ["an antidepressant", "TREATMENT", 48, 65], ["depressive disorders", "PROBLEM", 91, 111]]], ["[20] Its antiviral properties have been explored for treating coxsackievirus.", [["coxsackievirus", "ORGANISM", 62, 76], ["Its antiviral properties", "TREATMENT", 5, 29], ["coxsackievirus", "PROBLEM", 62, 76]]], ["[21] Loratadine is a secondgeneration nonsedating antihistamine used for allergies.", [["Loratadine", "CHEMICAL", 5, 15], ["allergies", "DISEASE", 73, 82], ["[21] Loratadine", "CHEMICAL", 0, 15], ["[21] Loratadine", "SIMPLE_CHEMICAL", 0, 15], ["Loratadine", "TREATMENT", 5, 15], ["a secondgeneration nonsedating antihistamine", "TREATMENT", 19, 63], ["allergies", "PROBLEM", 73, 82]]], ["[22] Recent clinical trials have evaluated its use as abortive therapy in pegfilgrastim-associated bone pain.", [["bone", "ANATOMY", 99, 103], ["pegfilgrastim", "CHEMICAL", 74, 87], ["bone pain", "DISEASE", 99, 108], ["pegfilgrastim", "SIMPLE_CHEMICAL", 74, 87], ["bone", "TISSUE", 99, 103], ["abortive therapy", "TREATMENT", 54, 70], ["pegfilgrastim", "TREATMENT", 74, 87], ["bone pain", "PROBLEM", 99, 108], ["bone", "ANATOMY", 99, 103], ["pain", "OBSERVATION", 104, 108]]], ["[23] Omeprazole sodium is a proton pump inhibitor (PPI) used to treat gastrointestinal reflux disease and in Helicobacter pylori eradication therapy for gastritis and peptic ulcers.", [["gastrointestinal", "ANATOMY", 70, 86], ["peptic", "ANATOMY", 167, 173], ["Omeprazole sodium", "CHEMICAL", 5, 22], ["PPI", "CHEMICAL", 51, 54], ["gastrointestinal reflux disease", "DISEASE", 70, 101], ["Helicobacter pylori", "DISEASE", 109, 128], ["gastritis", "DISEASE", 153, 162], ["peptic ulcers", "DISEASE", 167, 180], ["[23] Omeprazole sodium", "CHEMICAL", 0, 22], ["[23] Omeprazole sodium", "SIMPLE_CHEMICAL", 0, 22], ["Helicobacter pylori", "ORGANISM", 109, 128], ["gastritis", "PATHOLOGICAL_FORMATION", 153, 162], ["peptic ulcers", "PATHOLOGICAL_FORMATION", 167, 180], ["Helicobacter pylori", "SPECIES", 109, 128], ["Helicobacter pylori", "SPECIES", 109, 128], ["Omeprazole sodium", "TREATMENT", 5, 22], ["a proton pump inhibitor", "TREATMENT", 26, 49], ["PPI)", "TREATMENT", 51, 55], ["gastrointestinal reflux disease", "PROBLEM", 70, 101], ["Helicobacter pylori eradication therapy", "TREATMENT", 109, 148], ["gastritis", "PROBLEM", 153, 162], ["peptic ulcers", "PROBLEM", 167, 180], ["gastrointestinal", "ANATOMY", 70, 86], ["reflux", "OBSERVATION", 87, 93], ["Helicobacter pylori", "OBSERVATION", 109, 128], ["peptic", "OBSERVATION_MODIFIER", 167, 173], ["ulcers", "OBSERVATION", 174, 180]]], ["[24] Omeprazole and other PPIs have recently been investigated for and demonstrated antitumor activity and anti-inflammatory effects.", [["antitumor", "ANATOMY", 84, 93], ["Omeprazole", "CHEMICAL", 5, 15], ["[24] Omeprazole", "CHEMICAL", 0, 15], ["[24] Omeprazole", "SIMPLE_CHEMICAL", 0, 15], ["antitumor", "CANCER", 84, 93], ["Omeprazole", "TREATMENT", 5, 15], ["other PPIs", "TREATMENT", 20, 30], ["antitumor activity", "TREATMENT", 84, 102], ["anti-inflammatory effects", "TREATMENT", 107, 132]]], ["[25] Ritonavir and lopinavir are antiretroviral medications commonly used in combination treatment for patients infected with (HIV), with ritonavir used as a booster with other protease inhibitors like lopinavir.", [["Ritonavir", "CHEMICAL", 5, 14], ["lopinavir", "CHEMICAL", 19, 28], ["ritonavir", "CHEMICAL", 138, 147], ["lopinavir", "CHEMICAL", 202, 211], ["[25] Ritonavir", "CHEMICAL", 0, 14], ["lopinavir", "CHEMICAL", 19, 28], ["ritonavir", "CHEMICAL", 138, 147], ["lopinavir", "CHEMICAL", 202, 211], ["[25] Ritonavir", "SIMPLE_CHEMICAL", 0, 14], ["lopinavir", "SIMPLE_CHEMICAL", 19, 28], ["patients", "ORGANISM", 103, 111], ["ritonavir", "SIMPLE_CHEMICAL", 138, 147], ["lopinavir", "SIMPLE_CHEMICAL", 202, 211], ["patients", "SPECIES", 103, 111], ["HIV", "SPECIES", 127, 130], ["Ritonavir", "TREATMENT", 5, 14], ["lopinavir", "TREATMENT", 19, 28], ["antiretroviral medications", "TREATMENT", 33, 59], ["ritonavir", "TREATMENT", 138, 147], ["other protease inhibitors", "TREATMENT", 171, 196], ["lopinavir", "TREATMENT", 202, 211]]], ["[26] Lopinavir and ritonavir combination has demonstrated in vitro antiviral www.advancedsciencenews.com www.advtherap.com activity against SARS and favorable clinical response in patients with SARS.", [["Lopinavir", "CHEMICAL", 5, 14], ["ritonavir", "CHEMICAL", 19, 28], ["SARS", "DISEASE", 140, 144], ["SARS", "DISEASE", 194, 198], ["[26] Lopinavir", "CHEMICAL", 0, 14], ["ritonavir", "CHEMICAL", 19, 28], ["[26] Lopinavir", "SIMPLE_CHEMICAL", 0, 14], ["ritonavir", "SIMPLE_CHEMICAL", 19, 28], ["patients", "ORGANISM", 180, 188], ["patients", "SPECIES", 180, 188], ["Lopinavir", "TREATMENT", 5, 14], ["ritonavir combination", "TREATMENT", 19, 40], ["vitro antiviral", "TREATMENT", 61, 76], ["SARS", "PROBLEM", 140, 144], ["SARS", "PROBLEM", 194, 198]]], ["[27] Ritonavir has also been explored and shown to be highly effective as a booster in fixed-dose combinations for patients with Hepatitis C. [27] Doxycycline is a tetracycline antibiotic with a broad antimicrobial spectrum of activity.", [["Ritonavir", "CHEMICAL", 5, 14], ["Hepatitis C. [27]", "CHEMICAL", 129, 146], ["Doxycycline", "CHEMICAL", 147, 158], ["tetracycline", "CHEMICAL", 164, 176], ["[27] Ritonavir", "CHEMICAL", 0, 14], ["[27] Doxycycline", "CHEMICAL", 142, 158], ["tetracycline", "CHEMICAL", 164, 176], ["[27] Ritonavir", "SIMPLE_CHEMICAL", 0, 14], ["patients", "ORGANISM", 115, 123], ["[27] Doxycycline", "SIMPLE_CHEMICAL", 142, 158], ["tetracycline", "SIMPLE_CHEMICAL", 164, 176], ["patients", "SPECIES", 115, 123], ["Ritonavir", "TREATMENT", 5, 14], ["a booster in fixed-dose combinations", "TREATMENT", 74, 110], ["Hepatitis C.", "PROBLEM", 129, 141], ["Doxycycline", "TREATMENT", 147, 158], ["a tetracycline antibiotic", "TREATMENT", 162, 187], ["a broad antimicrobial spectrum of activity", "TREATMENT", 193, 235]]], ["[28] In recent clinical trials, doxycycline has been shown to treat nasal polyps and rosacea, as an anti-inflammatory.", [["nasal polyps", "ANATOMY", 68, 80], ["doxycycline", "CHEMICAL", 32, 43], ["nasal polyps", "DISEASE", 68, 80], ["rosacea", "DISEASE", 85, 92], ["doxycycline", "CHEMICAL", 32, 43], ["doxycycline", "SIMPLE_CHEMICAL", 32, 43], ["nasal polyps", "PATHOLOGICAL_FORMATION", 68, 80], ["doxycycline", "TREATMENT", 32, 43], ["nasal polyps", "PROBLEM", 68, 80], ["rosacea", "PROBLEM", 85, 92], ["an anti-inflammatory", "TREATMENT", 97, 117], ["nasal", "ANATOMY", 68, 73], ["polyps", "OBSERVATION", 74, 80], ["rosacea", "OBSERVATION", 85, 92]]], ["[29] Ribavirin is an antiviral medication often administered in combination with interferon-based therapies for patients with chronic Hepatitis C. [30] Additionally, Ribavirin has been shown to be an effective treatment for respiratory syncytial virus and hemorrhagic fevers.", [["Ribavirin", "CHEMICAL", 5, 14], ["chronic Hepatitis C.", "DISEASE", 126, 146], ["Ribavirin", "CHEMICAL", 166, 175], ["respiratory syncytial virus", "DISEASE", 224, 251], ["hemorrhagic fevers", "DISEASE", 256, 274], ["[29] Ribavirin", "CHEMICAL", 0, 14], ["Ribavirin", "CHEMICAL", 166, 175], ["[29] Ribavirin", "SIMPLE_CHEMICAL", 0, 14], ["patients", "ORGANISM", 112, 120], ["Ribavirin", "SIMPLE_CHEMICAL", 166, 175], ["respiratory syncytial virus", "ORGANISM", 224, 251], ["interferon", "PROTEIN", 81, 91], ["patients", "SPECIES", 112, 120], ["respiratory syncytial virus", "SPECIES", 224, 251], ["Ribavirin", "TREATMENT", 5, 14], ["an antiviral medication", "TREATMENT", 18, 41], ["interferon-based therapies", "TREATMENT", 81, 107], ["chronic Hepatitis C.", "PROBLEM", 126, 146], ["Ribavirin", "TREATMENT", 166, 175], ["an effective treatment", "TREATMENT", 197, 219], ["respiratory syncytial virus", "PROBLEM", 224, 251], ["hemorrhagic fevers", "PROBLEM", 256, 274], ["chronic", "OBSERVATION_MODIFIER", 126, 133], ["Hepatitis", "OBSERVATION", 134, 143], ["syncytial virus", "OBSERVATION", 236, 251], ["hemorrhagic", "OBSERVATION_MODIFIER", 256, 267], ["fevers", "OBSERVATION", 268, 274]]], ["[31] Within 3 days, our studies successfully identified and repeatedly validated multiple drug combinations that simultaneously reduced VSV infection to 1.5% with no apparent adverse impact on A549 viability.", [["A549", "ANATOMY", 193, 197], ["infection", "DISEASE", 140, 149], ["VSV", "ORGANISM", 136, 139], ["A549", "CELL", 193, 197], ["VSV", "SPECIES", 136, 139], ["our studies", "TEST", 20, 31], ["multiple drug combinations", "TREATMENT", 81, 107], ["simultaneously reduced VSV infection", "PROBLEM", 113, 149], ["apparent adverse impact", "PROBLEM", 166, 189], ["VSV infection", "OBSERVATION", 136, 149], ["A549 viability", "OBSERVATION", 193, 207]]], ["In addition, this platform identified multiple highly efficacious and tolerable regimens, presenting the potential of multiple options for treatment.", [["tolerable regimens", "TREATMENT", 70, 88], ["treatment", "TREATMENT", 139, 148], ["multiple", "OBSERVATION_MODIFIER", 38, 46], ["highly", "OBSERVATION_MODIFIER", 47, 53], ["efficacious", "OBSERVATION", 54, 65]]], ["This study demonstrated that Project IDentif.AI can potentially be used for patientspecific or population-wide development of actionable combination therapy.", [["AI", "SIMPLE_CHEMICAL", 45, 47], ["This study", "TEST", 0, 10], ["actionable combination therapy", "TREATMENT", 126, 156]]], ["It's implementation also does not require complex disease mechanism or drug target information for implementation.", [["complex disease mechanism", "PROBLEM", 42, 67]]], ["This may enable its immediate application toward dynamically-optimized drug repurposing and novel combination therapy development against high priority pathogens such as COVID-19 and others.IntroductionIn addition to reporting rapid experimentally identified and validated combination therapies against VSV infection of A549, this work also discusses key further studies needed, and provides global health and healthcare economics policy perspectives that may provide a roadmap toward the broader clinical deployment of Project IDentif.AI. Collectively, these analyses demonstrate that technology and innovative policy considerations are needed to drive advances in clinical practice in addressing pre-pandemic and pandemic challenges.Optimization of Cell Density, VSV Incubation Time and Multiplicity of Infection (MOI)The VSV model used for this study was encoded with green fluorescent protein (GFP) to monitor cell infection, with GFP intensity corresponding to viral infection efficiency.", [["A549", "ANATOMY", 320, 324], ["Cell", "ANATOMY", 751, 755], ["cell", "ANATOMY", 914, 918], ["COVID-19", "CHEMICAL", 170, 178], ["VSV infection", "DISEASE", 303, 316], ["infection", "DISEASE", 919, 928], ["infection", "DISEASE", 972, 981], ["VSV", "ORGANISM", 303, 306], ["A549", "CELL", 320, 324], ["Cell", "CELL", 751, 755], ["VSV", "ORGANISM", 765, 768], ["VSV", "ORGANISM", 824, 827], ["green fluorescent protein", "GENE_OR_GENE_PRODUCT", 871, 896], ["GFP", "GENE_OR_GENE_PRODUCT", 898, 901], ["cell", "CELL", 914, 918], ["GFP", "GENE_OR_GENE_PRODUCT", 935, 938], ["A549", "CELL_LINE", 320, 324], ["green fluorescent protein", "PROTEIN", 871, 896], ["GFP", "PROTEIN", 898, 901], ["VSV", "SPECIES", 303, 306], ["VSV", "SPECIES", 765, 768], ["VSV", "SPECIES", 824, 827], ["optimized drug repurposing", "TREATMENT", 61, 87], ["novel combination therapy", "TREATMENT", 92, 117], ["high priority pathogens", "PROBLEM", 138, 161], ["COVID", "TEST", 170, 175], ["combination therapies", "TREATMENT", 273, 294], ["VSV infection of A549", "PROBLEM", 303, 324], ["further studies", "TEST", 355, 370], ["AI", "PROBLEM", 536, 538], ["these analyses", "TEST", 554, 568], ["pre-pandemic and pandemic challenges", "TREATMENT", 698, 734], ["Cell Density", "PROBLEM", 751, 763], ["VSV Incubation", "TREATMENT", 765, 779], ["Infection", "PROBLEM", 805, 814], ["The VSV model", "TEST", 820, 833], ["this study", "TEST", 843, 853], ["green fluorescent protein (GFP", "PROBLEM", 871, 901], ["cell infection", "PROBLEM", 914, 928], ["GFP intensity", "PROBLEM", 935, 948], ["viral infection efficiency", "PROBLEM", 966, 992], ["Cell Density", "OBSERVATION", 751, 763], ["Infection", "OBSERVATION", 805, 814], ["viral", "OBSERVATION_MODIFIER", 966, 971], ["infection", "OBSERVATION", 972, 981]]], ["The GFP intensity of VSV-infected cells under different MOI parameters (0.125, 0.25, 0.5, 1) were assessed.", [["cells", "ANATOMY", 34, 39], ["GFP", "GENE_OR_GENE_PRODUCT", 4, 7], ["VSV", "ORGANISM", 21, 24], ["cells", "CELL", 34, 39], ["VSV-infected cells", "CELL_LINE", 21, 39], ["VSV", "SPECIES", 21, 24], ["The GFP intensity", "TEST", 0, 17], ["VSV", "TEST", 21, 24], ["infected cells", "PROBLEM", 25, 39], ["different MOI parameters", "TEST", 46, 70], ["intensity", "OBSERVATION_MODIFIER", 8, 17], ["infected cells", "OBSERVATION", 25, 39]]], ["Cell densities for each well of 96 well plate varied between 4000 (4k), 8000 (8k) and 12 000 (12k) per well.", [["Cell", "ANATOMY", 0, 4], ["Cell", "CELL", 0, 4], ["Cell densities", "TEST", 0, 14]]], ["Infection was allowed for 24 and 30 h (Figure 1A,B) .", [["Infection", "PROBLEM", 0, 9]]], ["As indicated in the figure and microscopic images, MOI as low as 0.125 was sufficient to mediate nearly 100% cell infection after 24 h for 12k per well initial cell density.", [["cell", "ANATOMY", 109, 113], ["cell", "ANATOMY", 160, 164], ["infection", "DISEASE", 114, 123], ["cell", "CELL", 109, 113], ["cell", "CELL", 160, 164], ["microscopic images", "TEST", 31, 49], ["MOI", "PROBLEM", 51, 54], ["cell density", "OBSERVATION", 160, 172]]], ["We therefore utilized 12k per well as the initial cell density throughout the study.", [["cell", "ANATOMY", 50, 54], ["cell", "CELL", 50, 54], ["the study", "TEST", 74, 83], ["cell density", "OBSERVATION", 50, 62]]], ["Microscope images of bright field and fluorescence are merged for visualization under different MOI parameters (0.001, 0.01, 0.1) after VSV infection occurred for 12 h ( Figure 1C ) and 24 h ( Figure 1D ).", [["infection", "DISEASE", 140, 149], ["VSV", "ORGANISM", 136, 139], ["VSV", "SPECIES", 136, 139], ["Microscope images", "TEST", 0, 17], ["visualization", "TEST", 66, 79], ["VSV infection", "PROBLEM", 136, 149]]], ["Of note, as indicated in the Figure 1C and ImageJ cell counting results, only 9.56 \u00b1 2.55% (n = 3) cells were infected under MOI = 0.001 during 12 h.", [["cell", "ANATOMY", 50, 54], ["cells", "ANATOMY", 99, 104], ["cell", "CELL", 50, 54], ["cells", "CELL", 99, 104], ["ImageJ cell counting", "TEST", 43, 63], ["MOI", "TEST", 125, 128]]], ["A MOI = 0.01 infected a majority of the cells after a 12 h incubation and the overall GFP intensity continued to increase at the 24 h checkpoint, indicating that the virus continued its reproduction inside the cells during this period of time.Single Drug Dose Response Curves for Cell Viability and Viral InfectionIn order to assess single drug toxicity and antiviral efficacy, single drug-dose response curves were acquired.", [["cells", "ANATOMY", 40, 45], ["cells", "ANATOMY", 210, 215], ["Cell", "ANATOMY", 280, 284], ["toxicity", "DISEASE", 345, 353], ["cells", "CELL", 40, 45], ["GFP", "GENE_OR_GENE_PRODUCT", 86, 89], ["cells", "CELL", 210, 215], ["Cell", "CELL", 280, 284], ["A MOI", "TEST", 0, 5], ["a 12 h incubation", "TREATMENT", 52, 69], ["the overall GFP intensity", "TEST", 74, 99], ["the virus", "PROBLEM", 162, 171], ["Cell Viability", "TEST", 280, 294], ["Viral InfectionIn order", "TREATMENT", 299, 322], ["single drug toxicity", "PROBLEM", 333, 353], ["antiviral efficacy", "TREATMENT", 358, 376], ["single drug-dose response curves", "TEST", 378, 410], ["increase", "OBSERVATION_MODIFIER", 113, 121], ["virus", "OBSERVATION", 166, 171]]], ["Cell viability was assessed at 24 h and VSV infection was recorded at 12 and 24 h at an initial cell density of 12k per well.", [["Cell", "ANATOMY", 0, 4], ["cell", "ANATOMY", 96, 100], ["infection", "DISEASE", 44, 53], ["Cell", "CELL", 0, 4], ["VSV", "ORGANISM", 40, 43], ["cell", "CELL", 96, 100], ["VSV", "SPECIES", 40, 43], ["Cell viability", "TEST", 0, 14], ["VSV infection", "PROBLEM", 40, 53], ["infection", "OBSERVATION", 44, 53]]], ["The MOI was maintained at 0.01.", [["The MOI", "TREATMENT", 0, 7]]], ["The VSV and drugs were simultaneously added to the host cells for co-incubation.", [["cells", "ANATOMY", 56, 61], ["VSV", "ORGANISM", 4, 7], ["cells", "CELL", 56, 61], ["host cells", "CELL_TYPE", 51, 61], ["VSV", "SPECIES", 4, 7], ["The VSV", "TREATMENT", 0, 7], ["drugs", "TREATMENT", 12, 17], ["co-incubation", "TREATMENT", 66, 79], ["VSV", "OBSERVATION", 4, 7]]], ["Dose response curves for Amantadine HCl (AMT); Dexamethasone (DEX); Azithromycin (AZT); Chloroquine Diphosphate (CLR); NPX, Naproxen Sodium (NPX); Fluoxetine HCl (FLX); LRT, Loratadine (LRT); Omeprazole Sodium (OMP); Ritonavir (RTN); Lopinavir (LPN); Doxycycline (DOX); Ribavirin (RBV) (Figure 2) .", [["Amantadine HCl", "CHEMICAL", 25, 39], ["AMT", "CHEMICAL", 41, 44], ["Dexamethasone", "CHEMICAL", 47, 60], ["DEX", "CHEMICAL", 62, 65], ["Azithromycin", "CHEMICAL", 68, 80], ["AZT", "CHEMICAL", 82, 85], ["Chloroquine Diphosphate", "CHEMICAL", 88, 111], ["CLR", "CHEMICAL", 113, 116], ["NPX", "CHEMICAL", 119, 122], ["Naproxen Sodium", "CHEMICAL", 124, 139], ["NPX", "CHEMICAL", 141, 144], ["Fluoxetine HCl", "CHEMICAL", 147, 161], ["FLX", "CHEMICAL", 163, 166], ["Loratadine", "CHEMICAL", 174, 184], ["Omeprazole Sodium", "CHEMICAL", 192, 209], ["OMP", "CHEMICAL", 211, 214], ["Ritonavir", "CHEMICAL", 217, 226], ["Lopinavir", "CHEMICAL", 234, 243], ["Doxycycline", "CHEMICAL", 251, 262], ["DOX", "CHEMICAL", 264, 267], ["Ribavirin", "CHEMICAL", 270, 279], ["RBV", "CHEMICAL", 281, 284], ["Amantadine HCl", "CHEMICAL", 25, 39], ["AMT", "CHEMICAL", 41, 44], ["Dexamethasone", "CHEMICAL", 47, 60], ["DEX", "CHEMICAL", 62, 65], ["Azithromycin", "CHEMICAL", 68, 80], ["AZT", "CHEMICAL", 82, 85], ["Chloroquine Diphosphate", "CHEMICAL", 88, 111], ["CLR", "CHEMICAL", 113, 116], ["NPX", "CHEMICAL", 119, 122], ["Naproxen Sodium", "CHEMICAL", 124, 139], ["NPX", "CHEMICAL", 141, 144], ["Fluoxetine HCl", "CHEMICAL", 147, 161], ["FLX", "CHEMICAL", 163, 166], ["Loratadine", "CHEMICAL", 174, 184], ["Omeprazole Sodium", "CHEMICAL", 192, 209], ["Ritonavir", "CHEMICAL", 217, 226], ["Lopinavir", "CHEMICAL", 234, 243], ["Doxycycline", "CHEMICAL", 251, 262], ["DOX", "CHEMICAL", 264, 267], ["Ribavirin", "CHEMICAL", 270, 279], ["RBV", "CHEMICAL", 281, 284], ["Amantadine HCl", "SIMPLE_CHEMICAL", 25, 39], ["AMT", "SIMPLE_CHEMICAL", 41, 44], ["Dexamethasone", "SIMPLE_CHEMICAL", 47, 60], ["DEX", "SIMPLE_CHEMICAL", 62, 65], ["Azithromycin", "SIMPLE_CHEMICAL", 68, 80], ["AZT", "SIMPLE_CHEMICAL", 82, 85], ["Chloroquine Diphosphate", "SIMPLE_CHEMICAL", 88, 111], ["CLR", "SIMPLE_CHEMICAL", 113, 116], ["NPX", "SIMPLE_CHEMICAL", 119, 122], ["Naproxen Sodium", "SIMPLE_CHEMICAL", 124, 139], ["NPX", "SIMPLE_CHEMICAL", 141, 144], ["Fluoxetine HCl", "SIMPLE_CHEMICAL", 147, 161], ["FLX", "SIMPLE_CHEMICAL", 163, 166], ["LRT", "SIMPLE_CHEMICAL", 169, 172], ["Loratadine", "SIMPLE_CHEMICAL", 174, 184], ["LRT", "SIMPLE_CHEMICAL", 186, 189], ["Omeprazole Sodium", "SIMPLE_CHEMICAL", 192, 209], ["OMP", "SIMPLE_CHEMICAL", 211, 214], ["Ritonavir", "SIMPLE_CHEMICAL", 217, 226], ["RTN", "SIMPLE_CHEMICAL", 228, 231], ["Lopinavir", "SIMPLE_CHEMICAL", 234, 243], ["LPN", "SIMPLE_CHEMICAL", 245, 248], ["Doxycycline", "SIMPLE_CHEMICAL", 251, 262], ["DOX", "SIMPLE_CHEMICAL", 264, 267], ["Ribavirin", "SIMPLE_CHEMICAL", 270, 279], ["RBV", "SIMPLE_CHEMICAL", 281, 284], ["Amantadine HCl (AMT)", "TREATMENT", 25, 45], ["Dexamethasone (DEX)", "TREATMENT", 47, 66], ["Azithromycin (AZT)", "TREATMENT", 68, 86], ["Chloroquine Diphosphate (CLR)", "TREATMENT", 88, 117], ["NPX", "TREATMENT", 119, 122], ["Naproxen Sodium (NPX)", "TREATMENT", 124, 145], ["Fluoxetine HCl (FLX)", "TREATMENT", 147, 167], ["LRT, Loratadine (LRT)", "TREATMENT", 169, 190], ["Omeprazole Sodium (OMP)", "TREATMENT", 192, 215], ["Ritonavir (RTN)", "TREATMENT", 217, 232], ["Lopinavir (LPN)", "TREATMENT", 234, 249], ["Doxycycline (DOX)", "TREATMENT", 251, 268], ["Ribavirin (RBV)", "TREATMENT", 270, 285]]], ["NPX and RBV were tested at concentrations of 0.5, 5, 50, and 500 \u00d7 10 \u22126 m while all the remaining drugs were tested at concentrations of 0.1, 1, 10, and 100 \u00d7 10 \u22126 m (Table S1, Supporting Information).", [["NPX", "CHEMICAL", 0, 3], ["RBV", "CHEMICAL", 8, 11], ["NPX", "CHEMICAL", 0, 3], ["RBV", "CHEMICAL", 8, 11], ["NPX", "SIMPLE_CHEMICAL", 0, 3], ["RBV", "SIMPLE_CHEMICAL", 8, 11], ["NPX", "TREATMENT", 0, 3], ["RBV", "TREATMENT", 8, 11]]], ["As monotherapies, none of the drugs were able to mediate viral infection levels below 5%.", [["infection", "DISEASE", 63, 72], ["monotherapies", "TREATMENT", 3, 16], ["the drugs", "TREATMENT", 26, 35], ["viral infection levels", "PROBLEM", 57, 79]]], ["With the exception of AZT, FLX, LRT, LPN and DOX, which mediated observable toxicity at high concentrations, the candidate monotherapies and their studied concentration ranges appeared tolerable (over 75% cell viability).", [["cell", "ANATOMY", 205, 209], ["AZT", "CHEMICAL", 22, 25], ["FLX", "CHEMICAL", 27, 30], ["DOX", "CHEMICAL", 45, 48], ["toxicity", "DISEASE", 76, 84], ["AZT", "CHEMICAL", 22, 25], ["FLX", "CHEMICAL", 27, 30], ["LRT", "CHEMICAL", 32, 35], ["LPN", "CHEMICAL", 37, 40], ["DOX", "CHEMICAL", 45, 48], ["AZT", "SIMPLE_CHEMICAL", 22, 25], ["FLX", "SIMPLE_CHEMICAL", 27, 30], ["LRT", "SIMPLE_CHEMICAL", 32, 35], ["LPN", "SIMPLE_CHEMICAL", 37, 40], ["DOX", "SIMPLE_CHEMICAL", 45, 48], ["cell", "CELL", 205, 209], ["AZT", "TREATMENT", 22, 25], ["FLX", "TREATMENT", 27, 30], ["LRT", "TREATMENT", 32, 35], ["LPN", "TREATMENT", 37, 40], ["DOX", "TREATMENT", 45, 48], ["observable toxicity", "PROBLEM", 65, 84], ["the candidate monotherapies", "TREATMENT", 109, 136], ["AZT", "OBSERVATION", 22, 25]]], ["Of note, the final DMSO concentration for all the tests did not exceed 0.3% to ensure the cell viability can be attributed to drug treatments.Artificial Intelligence-Based Optimization of Combination Therapy from a 12-Drug PoolThe core aim of Project IDentif.AI was to simultaneously identify the combinatorial drugs and doses that optimally inhibited VSV infection of A549 while maximizing A549 viability.", [["cell", "ANATOMY", 90, 94], ["A549", "ANATOMY", 369, 373], ["A549", "ANATOMY", 391, 395], ["DMSO", "CHEMICAL", 19, 23], ["infection", "DISEASE", 356, 365], ["DMSO", "CHEMICAL", 19, 23], ["DMSO", "SIMPLE_CHEMICAL", 19, 23], ["cell", "CELL", 90, 94], ["VSV", "ORGANISM", 352, 355], ["A549", "CELL", 369, 373], ["A549", "CELL", 391, 395], ["A549", "CELL_LINE", 369, 373], ["A549", "CELL_LINE", 391, 395], ["VSV", "SPECIES", 352, 355], ["the final DMSO concentration", "TREATMENT", 9, 37], ["all the tests", "TEST", 42, 55], ["the cell viability", "PROBLEM", 86, 104], ["drug treatments", "TREATMENT", 126, 141], ["Artificial Intelligence", "TREATMENT", 142, 165], ["Combination Therapy", "TREATMENT", 188, 207], ["the combinatorial drugs", "TREATMENT", 293, 316], ["VSV infection of A549", "PROBLEM", 352, 373], ["cell viability", "OBSERVATION", 90, 104], ["A549 viability", "OBSERVATION", 391, 405]]], ["In lieu of using prior information pertaining to the synergistic affects among the 12 candidate drugs to identify suitable drug combinations, Project IDentif.AI harnessed a quadratic relationship between drug/dose inputs and efficacy/safety outputs to effectively identify the drug-dose parameter space from which the optimal drug combinations could be pinpointed, and drug synergy was identified after the optimization process was completed.", [["the 12 candidate drugs", "TREATMENT", 79, 101], ["AI", "PROBLEM", 158, 160], ["drug/dose inputs", "TREATMENT", 204, 220], ["efficacy/safety outputs", "TREATMENT", 225, 248], ["the drug-dose parameter space", "TREATMENT", 273, 302], ["the optimal drug combinations", "TREATMENT", 314, 343], ["drug synergy", "PROBLEM", 369, 381]]], ["The viral infection outcomes from each drug treatment were recorded at 12 and 24 h.", [["viral infection", "DISEASE", 4, 19], ["The viral infection", "PROBLEM", 0, 19], ["each drug treatment", "TREATMENT", 34, 53], ["viral", "OBSERVATION_MODIFIER", 4, 9], ["infection", "OBSERVATION", 10, 19]]], ["For the purposes of evaluating the speed of optimization that would also yield experimentally validated VSV inhibition from a 12-drug set, a minimum threshold of 72 drug combinations with a broad range of corresponding dose levels were initially assessed (MOI = 0.1, Table S2 , Supporting Information).", [["VSV", "ORGANISM", 104, 107], ["VSV", "SPECIES", 104, 107], ["MOI", "TEST", 256, 259]]], ["Viral infection and drug treatment was simultaneously applied to host cells.", [["cells", "ANATOMY", 70, 75], ["Viral infection", "DISEASE", 0, 15], ["Viral", "ORGANISM", 0, 5], ["host cells", "CELL", 65, 75], ["host cells", "CELL_TYPE", 65, 75], ["Viral infection", "PROBLEM", 0, 15], ["drug treatment", "TREATMENT", 20, 34], ["infection", "OBSERVATION", 6, 15], ["drug treatment", "OBSERVATION", 20, 34]]], ["The efficacy and corresponding accumulative equivalent dose of the 72 drug combinations revealed a broad spectrum of VSV infection rates ( Figure 3A ).", [["infection", "DISEASE", 121, 130], ["VSV", "ORGANISM", 117, 120], ["VSV", "SPECIES", 117, 120], ["VSV infection rates", "PROBLEM", 117, 136], ["accumulative", "OBSERVATION_MODIFIER", 31, 43], ["equivalent", "OBSERVATION_MODIFIER", 44, 54], ["VSV infection", "OBSERVATION", 117, 130]]], ["The capacity for infection inhibition of each drug, as well as the quantitative interaction with the other drugs in the 12-drug pool were evaluated with the STRICT algorithm at 12 h ( Figure 3B ) and 24 h ( Figure 3C ).", [["infection", "DISEASE", 17, 26], ["infection", "PROBLEM", 17, 26], ["the other drugs", "TREATMENT", 97, 112], ["the STRICT algorithm", "TEST", 153, 173], ["infection", "OBSERVATION", 17, 26]]], ["Of note, the key therapies that were shown to contribute toward viral inhibition when delivered in combination with other candidates, and merit further optimization included amantadine HCl, azithromycin, chloroquine diphosphate, omeprazole sodium, and ribavirin.Artificial Intelligence-Based Optimization of Combination Therapy from a 12-Drug PoolOf note, some of the candidate drugs performed well as monotherapies.", [["amantadine HCl", "CHEMICAL", 174, 188], ["azithromycin", "CHEMICAL", 190, 202], ["chloroquine diphosphate", "CHEMICAL", 204, 227], ["omeprazole sodium", "CHEMICAL", 229, 246], ["ribavirin", "CHEMICAL", 252, 261], ["amantadine HCl", "CHEMICAL", 174, 188], ["azithromycin", "CHEMICAL", 190, 202], ["chloroquine diphosphate", "CHEMICAL", 204, 227], ["omeprazole sodium", "CHEMICAL", 229, 246], ["ribavirin", "CHEMICAL", 252, 261], ["amantadine", "SIMPLE_CHEMICAL", 174, 184], ["HCl", "SIMPLE_CHEMICAL", 185, 188], ["azithromycin", "SIMPLE_CHEMICAL", 190, 202], ["chloroquine diphosphate", "SIMPLE_CHEMICAL", 204, 227], ["omeprazole", "SIMPLE_CHEMICAL", 229, 239], ["sodium", "SIMPLE_CHEMICAL", 240, 246], ["ribavirin", "SIMPLE_CHEMICAL", 252, 261], ["viral inhibition", "PROBLEM", 64, 80], ["amantadine HCl", "TREATMENT", 174, 188], ["azithromycin", "TREATMENT", 190, 202], ["chloroquine diphosphate", "TREATMENT", 204, 227], ["omeprazole sodium", "TREATMENT", 229, 246], ["ribavirin", "TREATMENT", 252, 261], ["Artificial Intelligence", "TREATMENT", 262, 285], ["Combination Therapy", "TREATMENT", 308, 327], ["the candidate drugs", "TREATMENT", 364, 383], ["monotherapies", "TREATMENT", 402, 415]]], ["However, this is a common observation in in vitro platforms, and there is a subsequent need to ultimately incorporate these drugs into clinically actionable combination therapy regimens in order to optimize their use against a pathogen in question, despite their promising single drug activity.", [["these drugs", "TREATMENT", 118, 129], ["actionable combination therapy regimens", "TREATMENT", 146, 185], ["a pathogen", "PROBLEM", 225, 235]]], ["Importantly, sufficient testing of the drug-dose parameter space may also reveal that drugs with promising monotherapy activity do not belong in the optimal combination therapy regimens, which has been commonly observed using our platform.", [["drugs", "TREATMENT", 86, 91], ["promising monotherapy activity", "TREATMENT", 97, 127], ["therapy regimens", "TREATMENT", 169, 185]]], ["[32]Systematic Validation of Optimized Combination Regimens from a 5-Drug PoolTo validate the combination regimens of the 5 candidate drugs that were advanced for further consideration, we conducted a subsequent round of experiments with 30 combinations consisting of these 5 drugs (MOI = 0.1, Table S3 , Supporting Information).", [["Optimized Combination Regimens", "TREATMENT", 29, 59], ["a 5-Drug PoolTo", "TREATMENT", 65, 80], ["the combination regimens", "TREATMENT", 90, 114], ["the 5 candidate drugs", "TREATMENT", 118, 139], ["these 5 drugs", "TREATMENT", 268, 281]]], ["Viral infection and drug treatment was simultaneously applied to host cells.", [["cells", "ANATOMY", 70, 75], ["Viral infection", "DISEASE", 0, 15], ["Viral", "ORGANISM", 0, 5], ["host cells", "CELL", 65, 75], ["host cells", "CELL_TYPE", 65, 75], ["Viral infection", "PROBLEM", 0, 15], ["drug treatment", "TREATMENT", 20, 34], ["infection", "OBSERVATION", 6, 15], ["drug treatment", "OBSERVATION", 20, 34]]], ["The viral infection from each drug treatment was recorded at 12 h ( Figure 4A) .", [["viral infection", "DISEASE", 4, 19], ["The viral infection", "PROBLEM", 0, 19], ["each drug treatment", "TREATMENT", 25, 44], ["viral", "OBSERVATION_MODIFIER", 4, 9], ["infection", "OBSERVATION", 10, 19]]], ["A parabolic polynomial model was built with stepwise regression following the combinatorial optimization studies.", [["A parabolic polynomial model", "PROBLEM", 0, 28], ["stepwise regression", "PROBLEM", 44, 63], ["the combinatorial optimization studies", "TEST", 74, 112], ["parabolic", "OBSERVATION", 2, 11], ["polynomial model", "OBSERVATION", 12, 28]]], ["When assessing the drug interaction coefficients as well as the parabolic response surfaces, broad synergy was subsequently observed (Figure 4B-D; Equation S1, Supporting Information).", [["broad synergy", "PROBLEM", 93, 106]]], ["The optimal combination (Optimal Combo 1) mediated a 1.5% VSV infection rate compared to no drug treatment and was comprised of Amantadine HCl (5 \u00d7 10 \u22126 m), Azithromycin (5 \u00d7 10 \u22126 m), Chloroquine Diphosphate (0.5 \u00d7 10 \u22126 m), and Ribavirin (2.5 \u00d7 10 \u22126 m).", [["infection", "DISEASE", 62, 71], ["Amantadine HCl", "CHEMICAL", 128, 142], ["Azithromycin", "CHEMICAL", 158, 170], ["Chloroquine Diphosphate", "CHEMICAL", 186, 209], ["Ribavirin", "CHEMICAL", 231, 240], ["Amantadine HCl", "CHEMICAL", 128, 142], ["Azithromycin", "CHEMICAL", 158, 170], ["Chloroquine Diphosphate", "CHEMICAL", 186, 209], ["Ribavirin", "CHEMICAL", 231, 240], ["VSV", "ORGANISM", 58, 61], ["Amantadine HCl", "SIMPLE_CHEMICAL", 128, 142], ["Azithromycin", "SIMPLE_CHEMICAL", 158, 170], ["Chloroquine Diphosphate", "SIMPLE_CHEMICAL", 186, 209], ["Ribavirin", "SIMPLE_CHEMICAL", 231, 240], ["VSV", "SPECIES", 58, 61], ["a 1.5% VSV infection rate", "TREATMENT", 51, 76], ["drug treatment", "TREATMENT", 92, 106], ["Amantadine HCl", "TREATMENT", 128, 142], ["Azithromycin", "TREATMENT", 158, 170], ["Chloroquine Diphosphate", "TREATMENT", 186, 209], ["Ribavirin", "TREATMENT", 231, 240]]], ["Optimal Combo 2 mediated an infection rate of 1.6% compared to no drug treatment and was comprised of Amantadine HCl (5 \u00d7 10 \u22126 m), Azithromycin (5 \u00d7 10 \u22126 m), Chloroquine Diphosphate (0.5 \u00d7 10 \u22126 m), and Omeprazole Sodium (0.5 \u00d7 10 \u22126 m) ( Table 1) .", [["infection", "DISEASE", 28, 37], ["Amantadine HCl", "CHEMICAL", 102, 116], ["Azithromycin", "CHEMICAL", 132, 144], ["Chloroquine", "CHEMICAL", 160, 171], ["Diphosphate", "CHEMICAL", 172, 183], ["Omeprazole Sodium", "CHEMICAL", 205, 222], ["Amantadine HCl", "CHEMICAL", 102, 116], ["Azithromycin", "CHEMICAL", 132, 144], ["Chloroquine Diphosphate", "CHEMICAL", 160, 183], ["Omeprazole Sodium", "CHEMICAL", 205, 222], ["Amantadine HCl", "SIMPLE_CHEMICAL", 102, 116], ["Azithromycin", "SIMPLE_CHEMICAL", 132, 144], ["Chloroquine Diphosphate", "SIMPLE_CHEMICAL", 160, 183], ["Omeprazole", "SIMPLE_CHEMICAL", 205, 215], ["Sodium", "SIMPLE_CHEMICAL", 216, 222], ["an infection rate", "TEST", 25, 42], ["drug treatment", "TREATMENT", 66, 80], ["Amantadine HCl", "TREATMENT", 102, 116], ["Azithromycin", "TREATMENT", 132, 144], ["Chloroquine Diphosphate", "TREATMENT", 160, 183], ["Omeprazole Sodium", "TREATMENT", 205, 222], ["infection", "OBSERVATION", 28, 37]]], ["Of note, both of these combinations were based on individual drug doses that were lower than the high doses needed to Adv. Therap.", [["individual drug doses", "TREATMENT", 50, 71]]], ["2020, 2000034 achieve sufficient efficacy as monotherapies.", [["monotherapies", "TREATMENT", 45, 58]]], ["It is important to note that for many of the top-ranked combinations, the component therapies exhibited unfavorable efficacy when delivered as monotherapies, but played a key role in mediating optimal efficacy when co-administered.", [["the component therapies", "TREATMENT", 70, 93], ["monotherapies", "TREATMENT", 143, 156]]], ["As an example, for Amantadine HCl, Chloroquine Diphosphate, and Omeprazole Sodium, monotherapy was shown to be relatively ineffective at high doses.", [["Amantadine HCl", "CHEMICAL", 19, 33], ["Chloroquine Diphosphate", "CHEMICAL", 35, 58], ["Omeprazole Sodium", "CHEMICAL", 64, 81], ["Amantadine HCl", "CHEMICAL", 19, 33], ["Chloroquine Diphosphate", "CHEMICAL", 35, 58], ["Omeprazole Sodium", "CHEMICAL", 64, 81], ["Amantadine HCl", "SIMPLE_CHEMICAL", 19, 33], ["Chloroquine Diphosphate", "SIMPLE_CHEMICAL", 35, 58], ["Omeprazole", "SIMPLE_CHEMICAL", 64, 74], ["Sodium", "SIMPLE_CHEMICAL", 75, 81], ["Amantadine HCl", "TREATMENT", 19, 33], ["Chloroquine Diphosphate", "TREATMENT", 35, 58], ["Omeprazole Sodium", "TREATMENT", 64, 81], ["monotherapy", "TREATMENT", 83, 94]]], ["Compared to no drug treatment, Amantadine (HCl) treatment exhibited infection rates of \u224875%.", [["Amantadine", "CHEMICAL", 31, 41], ["HCl", "CHEMICAL", 43, 46], ["infection", "DISEASE", 68, 77], ["Amantadine", "CHEMICAL", 31, 41], ["HCl", "CHEMICAL", 43, 46], ["Amantadine", "SIMPLE_CHEMICAL", 31, 41], ["HCl", "SIMPLE_CHEMICAL", 43, 46], ["drug treatment", "TREATMENT", 15, 29], ["Amantadine (HCl) treatment", "TREATMENT", 31, 57], ["infection rates", "TEST", 68, 83], ["infection", "OBSERVATION", 68, 77]]], ["Chloroquine Diphosphate treatment exhibited infection rates of \u224825%, and Omeprazole Sodium treatment exhibited infection rates of \u224850%.", [["Chloroquine", "CHEMICAL", 0, 11], ["Diphosphate", "CHEMICAL", 12, 23], ["infection", "DISEASE", 44, 53], ["Omeprazole Sodium", "CHEMICAL", 73, 90], ["infection", "DISEASE", 111, 120], ["Chloroquine Diphosphate", "CHEMICAL", 0, 23], ["Omeprazole Sodium", "CHEMICAL", 73, 90], ["Chloroquine", "SIMPLE_CHEMICAL", 0, 11], ["Diphosphate", "SIMPLE_CHEMICAL", 12, 23], ["Omeprazole", "SIMPLE_CHEMICAL", 73, 83], ["Sodium", "SIMPLE_CHEMICAL", 84, 90], ["Chloroquine Diphosphate treatment", "TREATMENT", 0, 33], ["infection rates", "TEST", 44, 59], ["Omeprazole Sodium treatment", "TREATMENT", 73, 100], ["infection rates", "TEST", 111, 126], ["infection", "OBSERVATION", 111, 120]]], ["To further evaluate the importance of drug and dose optimization in system-atic combination therapy design, it is important to note that Optimal Combo 1 and Sub-Optimal Combo 2 were comprised of the same therapies, but at different doses.", [["drug and dose optimization in system", "TREATMENT", 38, 74], ["atic combination therapy", "TREATMENT", 75, 99], ["Sub-Optimal Combo 2", "TREATMENT", 157, 176], ["the same therapies", "TREATMENT", 195, 213]]], ["This alone resulted in infection rates of 1.5% and 10.7%, an approximately sevenfold difference in efficacy and demonstrating the importance of simultaneous drug and dose optimization.", [["infection", "DISEASE", 23, 32], ["infection rates", "TEST", 23, 38], ["simultaneous drug and dose optimization", "TREATMENT", 144, 183], ["infection", "OBSERVATION", 23, 32], ["sevenfold", "OBSERVATION_MODIFIER", 75, 84], ["difference", "OBSERVATION_MODIFIER", 85, 95]]], ["This is further confirmed by the scenario where replacing Amantadine HCl with Omeprazole Sodium and administering this combination at a sub-optimal dose results in a 21.6% infection rate.", [["Amantadine HCl", "CHEMICAL", 58, 72], ["Omeprazole Sodium", "CHEMICAL", 78, 95], ["infection", "DISEASE", 172, 181], ["Amantadine HCl", "CHEMICAL", 58, 72], ["Omeprazole Sodium", "CHEMICAL", 78, 95], ["Amantadine HCl", "SIMPLE_CHEMICAL", 58, 72], ["Omeprazole", "SIMPLE_CHEMICAL", 78, 88], ["Sodium", "SIMPLE_CHEMICAL", 89, 95], ["Amantadine HCl", "TREATMENT", 58, 72], ["Omeprazole Sodium", "TREATMENT", 78, 95], ["a 21.6% infection rate", "PROBLEM", 164, 186]]], ["This represents a 14-fold difference in efficacy compared to Optimal Combo 1.", [["a 14-fold difference in efficacy", "PROBLEM", 16, 48], ["14-fold", "OBSERVATION_MODIFIER", 18, 25]]], ["With regards to the factors contributing toward the optimal treatment outcomes, analysis of the interaction terms showed that the effects were primarily due to single-drug contributions, drug quadratic effects, 2-drug interaction synergy as well as 3drug interaction synergy ( Figure 4E ; Equation S2-S4, Supporting Information).Systematic Validation of Optimized Combination Regimens from a 5-Drug PoolFluorescence microscopy was also used to further evaluate the viral infection rate for optimal drug combinations and the nonoptimal drug combinations ( Figure 5 ).", [["infection", "DISEASE", 471, 480], ["3drug", "SIMPLE_CHEMICAL", 249, 254], ["drug quadratic effects", "PROBLEM", 187, 209], ["Optimized Combination Regimens", "TREATMENT", 354, 384], ["Drug PoolFluorescence microscopy", "TEST", 394, 426], ["the viral infection rate", "PROBLEM", 461, 485], ["optimal drug combinations", "TREATMENT", 490, 515], ["the nonoptimal drug combinations", "TREATMENT", 520, 552], ["viral", "OBSERVATION_MODIFIER", 465, 470], ["infection", "OBSERVATION", 471, 480]]], ["Of note, no apparent adverse effects cell density for Optimal Combo 1 and 2 were observed.", [["cell", "ANATOMY", 37, 41], ["cell", "CELL", 37, 41], ["apparent adverse effects cell density", "PROBLEM", 12, 49], ["Optimal Combo", "TREATMENT", 54, 67], ["no apparent", "UNCERTAINTY", 9, 20], ["cell density", "OBSERVATION", 37, 49]]], ["The identification and validation process implemented during Project IDentif.AI demonstrated that rapid optimization of the combination therapy development roadmap could be completed within 3 days (Figure 6 ).The Role of AI toward Optimizing Combinatorial Drug RepurposingDuring the COVID-19 outbreak, immediately deployable combination therapies based on drug repurposing were used in the clinic.", [["The identification", "TEST", 0, 18], ["validation process", "TREATMENT", 23, 41], ["the combination therapy", "TREATMENT", 120, 143], ["Optimizing Combinatorial Drug RepurposingDuring the COVID", "TREATMENT", 231, 288], ["deployable combination therapies", "TREATMENT", 314, 346], ["drug repurposing", "TREATMENT", 356, 372], ["rapid", "OBSERVATION_MODIFIER", 98, 103]]], ["These included Kaletra (ritonavir/lopinavir) in combination with oseltamivir.", [["Kaletra", "CHEMICAL", 15, 22], ["ritonavir", "CHEMICAL", 24, 33], ["lopinavir", "CHEMICAL", 34, 43], ["oseltamivir", "CHEMICAL", 65, 76], ["ritonavir", "CHEMICAL", 24, 33], ["lopinavir", "CHEMICAL", 34, 43], ["oseltamivir", "CHEMICAL", 65, 76], ["Kaletra", "SIMPLE_CHEMICAL", 15, 22], ["ritonavir", "SIMPLE_CHEMICAL", 24, 33], ["lopinavir", "SIMPLE_CHEMICAL", 34, 43], ["oseltamivir", "SIMPLE_CHEMICAL", 65, 76], ["Kaletra (ritonavir/lopinavir)", "TREATMENT", 15, 44], ["oseltamivir", "TREATMENT", 65, 76]]], ["(Tamiflu \u00ae ), and other regimens.", [["Tamiflu \u00ae", "SIMPLE_CHEMICAL", 1, 10], ["Tamiflu", "TREATMENT", 1, 8], ["other regimens", "TREATMENT", 18, 32]]], ["Repurposed monotherapies and combination therapies carry the benefit of previously demonstrated safety in patients and threshold efficacy for other indications.", [["patients", "ORGANISM", 106, 114], ["patients", "SPECIES", 106, 114], ["Repurposed monotherapies", "TREATMENT", 0, 24], ["combination therapies", "TREATMENT", 29, 50]]], ["Therefore, it is common in these scenarios to select a small pool of established therapies to coadminister, and to adjust drug doses accordingly if toxicity issues ensue.", [["toxicity", "DISEASE", 148, 156], ["drug doses", "TREATMENT", 122, 132], ["toxicity issues", "PROBLEM", 148, 163], ["small", "OBSERVATION_MODIFIER", 55, 60]]], ["While shown to be potentially clinically effective for some patients, this is largely a trial-and-error strategy.", [["patients", "ORGANISM", 60, 68], ["patients", "SPECIES", 60, 68]]], ["Globally optimizing drug repurposing is a starkly different approach, and can yield combinations comprised of unexpected therapies that far outperform traditional drug combination development, which is based on target/mechanism-based drug selection followed by dose finding.The Role of AI toward Optimizing Combinatorial Drug RepurposingWhen not constrained by drug selection based on targets and mechanism of action, the pool of candidate therapies can be enlarged to include a broader diversity of compounds for repurposing.", [["unexpected therapies", "TREATMENT", 110, 130], ["based drug selection", "TREATMENT", 228, 248], ["Optimizing Combinatorial Drug RepurposingWhen", "TREATMENT", 296, 341], ["drug selection", "TREATMENT", 361, 375], ["therapies", "TREATMENT", 440, 449], ["drug repurposing", "OBSERVATION", 20, 36]]], ["Unfortunately, it should also be noted that drug dosing not only impacts single drug efficacy and safety.", [["drug dosing", "TREATMENT", 44, 55]]], ["In the context of drug combination design, dosing considerations will also impact the drugs that ultimately comprise the best combinations.", [["the drugs", "TREATMENT", 82, 91]]], ["This effectively creates a parameter space that is too large to interrogate using brute-force testing of all possible combinations.The Role of AI toward Optimizing Combinatorial Drug RepurposingProject IDentif.AI sought to overcome this barrier that is pervasive across the drug development roadmap for virtually all indications, and demonstrate that the rapid interrogation of a 12drug parameter space could be completed within a timespan of days.", [["a parameter space", "PROBLEM", 25, 42], ["brute-force testing", "TEST", 82, 101], ["AI", "PROBLEM", 210, 212], ["the rapid interrogation", "TEST", 351, 374], ["a 12drug parameter space", "TREATMENT", 378, 402]]], ["In lieu of drug selection followed by dose finding, we used a previously established quadratic correlation between the 12-drug Table 1 .", [["drug selection", "TREATMENT", 11, 25]]], ["AI-optimized regimens.", [["AI", "SIMPLE_CHEMICAL", 0, 2], ["AI", "TEST", 0, 2], ["optimized regimens", "TREATMENT", 3, 21]]], ["Two optimal, sub-optimal, and non-optimal combinations from those experimentally tested during the AI optimization process are shown (units = micromolar). pool and drug doses (input) as well as inhibition of A549 infection by VSV and A549 viability (outputs) to systematically identify the top drug combinations.", [["A549", "ANATOMY", 208, 212], ["A549", "ANATOMY", 234, 238], ["infection", "DISEASE", 213, 222], ["A549", "CELL", 208, 212], ["VSV", "ORGANISM", 226, 229], ["A549", "CELL", 234, 238], ["VSV", "SPECIES", 226, 229], ["the AI optimization process", "TREATMENT", 95, 122], ["pool and drug doses", "TREATMENT", 155, 174], ["A549 infection", "PROBLEM", 208, 222], ["sub-optimal", "OBSERVATION_MODIFIER", 13, 24]]], ["This was achieved independent of any prior knowledge of drug targets, mechanism-of-action, or complex disease biology.", [["complex disease biology", "PROBLEM", 94, 117]]], ["Furthermore, the implementation of our platform does not require training based on existing data sets or big data.", [["existing data sets", "TEST", 83, 101], ["big data", "TEST", 105, 113]]], ["Instead, a specified set of experiments based on a broad spectrum of drug-dose combinations that sufficiently rep-resents the parameter space that is created by the 12-drug set is prospectively conducted.", [["drug-dose combinations", "TREATMENT", 69, 91]]], ["As such, the optimization process is driven completely by prospectively validated data on a cell line or patient sample.", [["cell line", "ANATOMY", 92, 101], ["sample", "ANATOMY", 113, 119], ["cell line", "CELL", 92, 101], ["patient", "ORGANISM", 105, 112], ["cell line", "CELL_LINE", 92, 101], ["patient", "SPECIES", 105, 112], ["a cell line", "TREATMENT", 90, 101]]], ["Many efforts to evaluate drug sets for single drug treatment or sampled combinations have been conducted.", [["drug sets", "TREATMENT", 25, 34], ["single drug treatment", "TREATMENT", 39, 60]]], ["Global optimization of combination therapy design from a large drug set opens up the doors to a broader spectrum of actionable regimens.", [["combination therapy", "TREATMENT", 23, 42], ["a large drug", "TREATMENT", 55, 67], ["actionable regimens", "TREATMENT", 116, 135], ["large", "OBSERVATION_MODIFIER", 57, 62]]], ["As our study has shown, even when combinations comprised of the same drugs are administered at varying doses, a sevenfold difference in efficacy was observed, and even greater differences (14fold) were observed when one drug was substituted (omeprazole sodium) for another (amantadine HCl, yielding a combination of azithromycin-chloroquine diphosphate-omeprazole sodiumribavirin) under sub-optimal dosing conditions.", [["omeprazole sodium", "CHEMICAL", 242, 259], ["amantadine HCl", "CHEMICAL", 274, 288], ["azithromycin-chloroquine diphosphate-omeprazole sodiumribavirin", "CHEMICAL", 316, 379], ["omeprazole sodium", "CHEMICAL", 242, 259], ["amantadine HCl", "CHEMICAL", 274, 288], ["azithromycin", "CHEMICAL", 316, 328], ["chloroquine diphosphate", "CHEMICAL", 329, 352], ["omeprazole sodiumribavirin", "CHEMICAL", 353, 379], ["omeprazole", "SIMPLE_CHEMICAL", 242, 252], ["sodium", "SIMPLE_CHEMICAL", 253, 259], ["amantadine", "SIMPLE_CHEMICAL", 274, 284], ["HCl", "SIMPLE_CHEMICAL", 285, 288], ["azithromycin", "SIMPLE_CHEMICAL", 316, 328], ["chloroquine diphosphate-omeprazole", "SIMPLE_CHEMICAL", 329, 363], ["sodiumribavirin", "SIMPLE_CHEMICAL", 364, 379], ["our study", "TEST", 3, 12], ["the same drugs", "TREATMENT", 60, 74], ["a sevenfold difference in efficacy", "PROBLEM", 110, 144], ["omeprazole sodium", "TREATMENT", 242, 259], ["another (amantadine HCl", "TREATMENT", 265, 288], ["azithromycin", "TREATMENT", 316, 328], ["chloroquine diphosphate", "TREATMENT", 329, 352], ["omeprazole sodiumribavirin", "TREATMENT", 353, 379], ["sub-optimal dosing conditions", "TREATMENT", 387, 416], ["sevenfold", "OBSERVATION_MODIFIER", 112, 121], ["difference", "OBSERVATION_MODIFIER", 122, 132], ["greater", "OBSERVATION_MODIFIER", 168, 175]]], ["This is an interesting finding considering the single drug substitution resulted in such a profound disparity in treatment outcomes, even if all of the drugs considered comprised the top 2 optimal combinations.", [["the single drug substitution", "TREATMENT", 43, 71], ["treatment outcomes", "TREATMENT", 113, 131], ["the drugs", "TREATMENT", 148, 157], ["profound", "OBSERVATION_MODIFIER", 91, 99], ["disparity", "OBSERVATION_MODIFIER", 100, 109]]], ["This further demonstrated the importance of simultaneous drug/dose optimization.", [["simultaneous drug/dose optimization", "TREATMENT", 44, 79]]], ["Importantly, this process produced multiple drug/dose-optimized combinations within 3 days.", [["multiple drug/dose", "TREATMENT", 35, 53], ["multiple", "OBSERVATION_MODIFIER", 35, 43]]], ["This approach has the potential of providing a pipeline of alternatives for patients if issues such as drug resistance are encountered.", [["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 76, 84], ["a pipeline of alternatives", "TREATMENT", 45, 71], ["drug resistance", "PROBLEM", 103, 118]]], ["It is important to emphasize that this study was conducted using an in vitro VSV model, and the top ranked drug combination has not been subsequently clinically validated.", [["VSV", "ORGANISM", 77, 80], ["VSV", "SPECIES", 77, 80], ["this study", "TEST", 34, 44], ["an in vitro VSV model", "TREATMENT", 65, 86]]], ["In addition, the VSV model was selected primarily due to it being a well-characterized and readily available platform.", [["VSV", "ORGANISM", 17, 20], ["VSV", "SPECIES", 17, 20], ["the VSV model", "TEST", 13, 26]]], ["If a different disease platform and/or host model are used, it is highly probable that the ranking, drugs that comprise the combinations, and the number of drugs that mediate optimal performance will change.", [["a different disease platform", "PROBLEM", 3, 31], ["drugs", "TREATMENT", 100, 105], ["drugs", "TREATMENT", 156, 161], ["highly probable", "UNCERTAINTY", 66, 81]]], ["Also, this study was conducted with a diverse range of potential drug candidates.", [["this study", "TEST", 6, 16]]], ["In a clinical setting, especially to address COVID-19 or other clinically relevant pathogens, the pool of drug candidates, which should be developed in consultation with the treating clinical team, is likely to differ substantially from the pool used in this study.", [["COVID", "TEST", 45, 50], ["other clinically relevant pathogens", "PROBLEM", 57, 92], ["this study", "TEST", 254, 264]]], ["Furthermore, if this approach is applied toward clinical samples, patient-specific rankings of optimal combinations can potentially emerge.", [["samples", "ANATOMY", 57, 64], ["patient", "ORGANISM", 66, 73], ["patient", "SPECIES", 66, 73], ["clinical samples", "TEST", 48, 64]]], ["The importance of the findings of this study are centered on the ability to rapidly interrogate massive parameter spaces that are created when both the right drugs and their right respective doses have to simultaneously reconciled.", [["this study", "TEST", 34, 44], ["massive parameter spaces", "PROBLEM", 96, 120], ["the right drugs", "TREATMENT", 148, 163], ["their right respective doses", "TREATMENT", 168, 196], ["massive", "OBSERVATION", 96, 103], ["right", "ANATOMY_MODIFIER", 152, 157], ["right", "ANATOMY_MODIFIER", 174, 179]]], ["The ability to reconcile this extraordinarily large set of possible combinations in a timely fashion into actionable and globally optimized combinations may be effective www.advancedsciencenews.com www.advtherap.com for scenarios where the prevention of community spread of novel and aggressive pathogens is critical.", [["scenarios", "PROBLEM", 220, 229], ["community spread of novel and aggressive pathogens", "PROBLEM", 254, 304]]], ["While additional further clinical validation at the point-of-care is required, several key factors pertaining to the broad clinical relevance and prior validation of technologies related to Project IDentif.AI should be noted.", [["further clinical validation", "TEST", 17, 44], ["AI", "PROBLEM", 206, 208]]], ["Firstly, previous oncology studies using the quadratic phenotypic optimization platform (QPOP) and CURATE.AI, which are foundational to Project IDentif.AI, have demonstrated that benchtop-based implementation of this approach have directly led to markedly enhanced patient outcomes compared to traditionally observed results.", [["patient", "ORGANISM", 265, 272], ["patient", "SPECIES", 265, 272], ["previous oncology studies", "TEST", 9, 34], ["AI", "PROBLEM", 106, 108], ["this approach", "TREATMENT", 212, 225], ["markedly enhanced patient outcomes", "PROBLEM", 247, 281]]], ["[33, 34] Additional clinical validation studies, including one study that harnessed a related AI-guided dosing platform against HIV in humans have further demonstrated the critical importance of drug dosage in mediating optimal treatment efficacy and tolerability.", [["HIV", "ORGANISM", 128, 131], ["humans", "ORGANISM", 135, 141], ["HIV", "SPECIES", 128, 131], ["humans", "SPECIES", 135, 141], ["HIV", "SPECIES", 128, 131], ["humans", "SPECIES", 135, 141], ["Additional clinical validation studies", "TEST", 9, 47], ["one study", "TEST", 59, 68], ["a related AI", "TREATMENT", 84, 96], ["guided dosing platform", "TREATMENT", 97, 119], ["HIV in humans", "PROBLEM", 128, 141], ["drug dosage", "TREATMENT", 195, 206]]], ["[34, 35] Of note, doses that are lower than expected, as well as dosages that were dynamically modulated were commonly used to optimize patient outcomes.Harnessing AI toward Global Health: Impact on Healthcare Infrastructure, Policy, Surveillance, and EconomicsDeploying AI-optimized infectious disease intervention may result in impact beyond technical and clinical innovation.", [["infectious disease", "DISEASE", 284, 302], ["patient", "ORGANISM", 136, 143], ["patient", "SPECIES", 136, 143], ["Surveillance", "TEST", 234, 246], ["infectious disease intervention", "TREATMENT", 284, 315], ["lower", "OBSERVATION_MODIFIER", 33, 38], ["infectious", "OBSERVATION", 284, 294]]], ["To scale these platforms toward broader use, healthcare policy, economics, and infrastructure implications as they apply to the patient, payer, and system should be considered.", [["patient", "ORGANISM", 128, 135], ["patient", "SPECIES", 128, 135], ["infrastructure implications", "TREATMENT", 79, 106]]], ["This platform in many ways simultaneously serves as a diagnostic and intervention, because it identifies actionable intervention by calibrating prospectively-obtained patient or population-based data.", [["patient", "ORGANISM", 167, 174], ["patient", "SPECIES", 167, 174], ["intervention", "TREATMENT", 69, 81]]], ["Added possible benefits include the fact that optimizing drug repurposing to use well-established and potentially cost-effective therapies to manage unpredictable clinical courses, and reductions in treatment complications associated with dose-limiting toxicities and lack of efficacy that may be encountered with trial-anderror/nonoptimized repurposing.", [["toxicities", "DISEASE", 253, 263], ["cost-effective therapies", "TREATMENT", 114, 138], ["unpredictable clinical courses", "TREATMENT", 149, 179], ["treatment complications", "TREATMENT", 199, 222], ["limiting toxicities", "PROBLEM", 244, 263]]], ["These outcomes may lead to reduced healthcare cost burden, which opens up important discussions on how these platforms can be scaled and efficiently integrated into healthcare workflows to enable better informed healthcare spending decisions by patients.", [["patients", "ORGANISM", 245, 253], ["patients", "SPECIES", 245, 253], ["reduced healthcare cost burden", "PROBLEM", 27, 57]]], ["[36] These outcomes may also serve as a foundation for broader clinical deployment of AI to intervene effectively at the earlier stages of an epidemic.Harnessing AI toward Global Health: Impact on Healthcare Infrastructure, Policy, Surveillance, and EconomicsEffective tailoring of treatment to both populations and individuals may also increase healthcare quality and efficiency, enabling an opportunity to personalize healthcare costs via qualitybased pricing.", [["broader clinical deployment of AI", "TREATMENT", 55, 88], ["an epidemic", "PROBLEM", 139, 150], ["treatment", "TREATMENT", 282, 291], ["qualitybased pricing", "TREATMENT", 441, 461], ["epidemic", "OBSERVATION", 142, 150]]], ["Specifically, technologies that realize actionable data on patient-specific drug/dose profiles will play a key role in establishing the relationship between individualizing treatment with improved quality of care.", [["patient", "ORGANISM", 59, 66], ["patient", "SPECIES", 59, 66], ["specific drug/dose profiles", "TREATMENT", 67, 94], ["individualizing treatment", "TREATMENT", 157, 182]]], ["This relationship will also be driven by the emergence of quality variation, as some patients, hospital systems, and payers will be more willing than others to make available and/or pay for the testing that may generate more, or better data on patient-specific drug/dose profiles.", [["patients", "ORGANISM", 85, 93], ["patient", "ORGANISM", 244, 251], ["patients", "SPECIES", 85, 93], ["patient", "SPECIES", 244, 251], ["the testing", "TEST", 190, 201]]], ["[37] This concept led to a proposed personalized treatment plan for diabetes patients by using the patients' dose-effect characteristics.", [["diabetes", "DISEASE", 68, 76], ["patients", "ORGANISM", 77, 85], ["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 77, 85], ["patients", "SPECIES", 99, 107], ["a proposed personalized treatment plan", "TREATMENT", 25, 63], ["diabetes patients", "PROBLEM", 68, 85]]], ["They subsequently reported substantial cost reductions and improvements in health outcomes.", [["substantial cost reductions", "PROBLEM", 27, 54], ["substantial", "OBSERVATION_MODIFIER", 27, 38], ["cost", "OBSERVATION_MODIFIER", 39, 43], ["reductions", "OBSERVATION_MODIFIER", 44, 54]]], ["For example, this approach in the U.S. is implemented under the name of \"pay for performance\" or \"payment by results\" in the U.K. These strategies have shown that performance-based contracting can improve social welfare, [39] an important consideration considering that pandemic mortality rates have been linked to social inequality, with higher mortality rates being observed with lower socioeconomic status patients.", [["patients", "ORGANISM", 409, 417], ["patients", "SPECIES", 409, 417]]], ["[40] Therefore, in the context of global health and addressing epidemics and pandemics, the impact of AI-guided healthcare will likely expand beyond technical advances and also influence the broader domains of healthcare economics and equality.Harnessing AI toward Global Health: Impact on Healthcare Infrastructure, Policy, Surveillance, and EconomicsIn addition to considering patient-centric healthcare coverage of emerging AI platforms to tailor their treatment, as the latest circumstances show on a larger scale, global health emergencies can substantially impact economies.", [["patient", "ORGANISM", 379, 386], ["patient", "SPECIES", 379, 386], ["epidemics", "PROBLEM", 63, 72], ["pandemics", "PROBLEM", 77, 86], ["AI-guided healthcare", "TREATMENT", 102, 122], ["centric healthcare coverage", "TREATMENT", 387, 414], ["emerging AI platforms", "TREATMENT", 418, 439], ["their treatment", "TREATMENT", 450, 465]]], ["For example, prolonged overburdening of providers, patients, payers and policymakers due to pandemics, coupled with ageing populations can lead to unsustainable healthcare infrastructures.", [["pandemics", "DISEASE", 92, 101], ["patients", "ORGANISM", 51, 59], ["patients", "SPECIES", 51, 59], ["pandemics", "PROBLEM", 92, 101]]], ["When considering the core disease areas that receive the most attention, such as cancer, diabetes, and cardiovascular, the reality is that communicable infection remains a formidable healthcare infrastructural burden.", [["cancer", "ANATOMY", 81, 87], ["cardiovascular", "ANATOMY", 103, 117], ["cancer", "DISEASE", 81, 87], ["diabetes", "DISEASE", 89, 97], ["communicable infection", "DISEASE", 139, 161], ["cancer", "CANCER", 81, 87], ["the core disease areas", "PROBLEM", 17, 39], ["cancer", "PROBLEM", 81, 87], ["diabetes", "PROBLEM", 89, 97], ["communicable infection", "PROBLEM", 139, 161], ["cancer", "OBSERVATION", 81, 87], ["diabetes", "OBSERVATION", 89, 97], ["infection", "OBSERVATION", 152, 161]]], ["[41] For example, in many parts of the world, there remains a need to develop better infectious disease interventions to fight the overuse of antibiotics (positioned to consume 10 million lives annually by 2050).", [["infectious disease interventions", "TREATMENT", 85, 117], ["antibiotics", "TREATMENT", 142, 153], ["infectious", "OBSERVATION", 85, 95]]], ["[42] This challenge alone could have dramatic economic consequences.", [["dramatic economic consequences", "PROBLEM", 37, 67]]], ["Considering the regional relevance of this problem, \u224880% of the malaria parasites in parts of Thailand and Vietnam were resistant to artemisinin and piperaquine, and that the failure rates of the among the most potent frontline combination therapy regimens comprised of dihydroartemisinin-piperaquine (DHA-PPQ) had reached as high as 87% in Northern Thailand.", [["malaria parasites", "DISEASE", 64, 81], ["artemisinin", "CHEMICAL", 133, 144], ["piperaquine", "CHEMICAL", 149, 160], ["dihydroartemisinin-piperaquine", "CHEMICAL", 270, 300], ["DHA-PPQ", "CHEMICAL", 302, 309], ["artemisinin", "CHEMICAL", 133, 144], ["piperaquine", "CHEMICAL", 149, 160], ["dihydroartemisinin", "CHEMICAL", 270, 288], ["piperaquine", "CHEMICAL", 289, 300], ["DHA-PPQ", "CHEMICAL", 302, 309], ["artemisinin", "SIMPLE_CHEMICAL", 133, 144], ["piperaquine", "SIMPLE_CHEMICAL", 149, 160], ["dihydroartemisinin-piperaquine", "SIMPLE_CHEMICAL", 270, 300], ["DHA", "SIMPLE_CHEMICAL", 302, 305], ["-PPQ", "SIMPLE_CHEMICAL", 305, 309], ["this problem", "PROBLEM", 38, 50], ["the malaria parasites", "PROBLEM", 60, 81], ["artemisinin", "TREATMENT", 133, 144], ["piperaquine", "TREATMENT", 149, 160], ["the failure rates", "PROBLEM", 171, 188], ["potent frontline combination therapy regimens", "TREATMENT", 211, 256], ["dihydroartemisinin", "TREATMENT", 270, 288], ["piperaquine (DHA-PPQ", "TREATMENT", 289, 309], ["malaria", "OBSERVATION", 64, 71]]], ["[43] Many solutions ranging from vaccines to novel drug designs are being proposed to address the COVID-19 situation.", [["Many solutions", "TREATMENT", 5, 19], ["vaccines", "TREATMENT", 33, 41], ["novel drug designs", "TREATMENT", 45, 63], ["the COVID", "TEST", 94, 103]]], ["However, maintaining agility in modulating drug regimens to account for potentially rapid viral mutation or other factors that could dynamically predict patient responses and identify corresponding optimized interventions will be critical.", [["patient", "ORGANISM", 153, 160], ["patient", "SPECIES", 153, 160], ["modulating drug regimens", "TREATMENT", 32, 56], ["rapid viral mutation", "PROBLEM", 84, 104]]], ["Dengue, which affects more than 400 million people each year, is highly-dynamic based on variables such as geographical climate.", [["Dengue", "DISEASE", 0, 6], ["Dengue", "ORGANISM", 0, 6], ["people", "SPECIES", 44, 50], ["Dengue", "PROBLEM", 0, 6]]], ["A recent study has suggested that 8000 cases of TB could be prevented each year solely through the use of more advanced analytics.", [["TB", "DISEASE", 48, 50], ["A recent study", "TEST", 0, 14], ["TB", "PROBLEM", 48, 50]]], ["[44] The economic evaluation of interventions may become increasingly important as extraordinary circumstances strain healthcare system-wide operations as well as industry operations.", [["The economic evaluation", "TEST", 5, 28], ["interventions", "TREATMENT", 32, 45], ["wide operations", "TREATMENT", 136, 151], ["industry operations", "TREATMENT", 163, 182]]], ["Therefore, governments and healthcare systems may be under pressure to substantially impact their quality-adjusted-life-years (QALY) and disability-adjusted-lifeyears (DALY).", [["healthcare systems", "TREATMENT", 27, 45]]], ["It should also be noted that the compound annual growth rate (CAGR) in global spend on drug research and development was 3.6% between 2010 and 2017, outpacing global sales of prescription drugs, which grew at a CAGR of 2.0% during the same period.", [["the compound annual growth rate", "PROBLEM", 29, 60], ["prescription drugs", "TREATMENT", 175, 193], ["a CAGR", "TEST", 209, 215], ["growth", "OBSERVATION_MODIFIER", 49, 55]]], ["[45] Further analysis has shown that the www.advancedsciencenews.com www.advtherap.com same life expectancy in countries could be achieved at 30% of current healthcare expenditures.", [["Further analysis", "TEST", 5, 21]]], ["[46] Therefore, the importance of accomplishing more while using less resources, making healthcare systems more economically-viable, and maximizing the potential of deploying AI into the agile and dynamic deployment of therapeutic regimens cannot be overstated.Harnessing AI toward Global Health: Impact on Healthcare Infrastructure, Policy, Surveillance, and EconomicsFrom a global health surveillance perspective, merging and re-emerging infectious diseases will continue to pose a threat to mankind, and it is necessary to develop an arsenal of tools that can be utilized in combatting these pathogens with epidemic/pandemic potential.", [["infectious diseases", "DISEASE", 440, 459], ["therapeutic regimens", "TREATMENT", 219, 239], ["re-emerging infectious diseases", "PROBLEM", 428, 459]]], ["In February 2018, The World Health Organization (WHO) added to the R&D Blueprint list of priority of diseases, Disease X. [47] Clade X was previously considered a hypothetical variant of an existing family of organisms that evolved to cause human disease.", [["human", "ORGANISM", 241, 246], ["human", "SPECIES", 241, 246], ["human", "SPECIES", 241, 246], ["diseases", "PROBLEM", 101, 109], ["Disease X.", "PROBLEM", 111, 121], ["organisms", "PROBLEM", 209, 218], ["human disease", "PROBLEM", 241, 254]]], ["A preparedness exercise using this modelled pandemic-causing pathogen demonstrated that a lack of actionable interventions could cause devastating global outcomes.", [["A preparedness exercise", "TREATMENT", 0, 23], ["pathogen", "PROBLEM", 61, 69], ["actionable interventions", "TREATMENT", 98, 122], ["devastating global outcomes", "PROBLEM", 135, 162]]], ["[48] As exhibited with the recent emergence of COVID-19, there are adequate tools to rapidly identify and obtain genomic details in near real time through modern sequencing techniques that often enable the swift development of effective diagnostics.", [["[48] As", "CHEMICAL", 0, 7], ["COVID", "TEST", 47, 52], ["modern sequencing techniques", "TREATMENT", 155, 183]]], ["[49] However, the ability to develop medical therapeutics that are both effective and easily deployable remains a critical gap in epidemic response efforts.", [["medical therapeutics", "TREATMENT", 37, 57]]], ["Vaccines and therapeutics for the past two outbreaks have benefited from greater than 20 years of development efforts that allowed for rapid advancement to human use clinical studies.", [["human", "ORGANISM", 156, 161], ["human", "SPECIES", 156, 161], ["human", "SPECIES", 156, 161], ["Vaccines", "TREATMENT", 0, 8], ["therapeutics", "TREATMENT", 13, 25], ["clinical studies", "TEST", 166, 182]]], ["In epidemic situations interventions that address both individual patient illness and control/prevention of continued transmission are necessary.", [["patient", "ORGANISM", 66, 73], ["patient", "SPECIES", 66, 73], ["interventions", "TREATMENT", 23, 36]]], ["The spectrum of disease caused by emerging/re-emerging infectious diseases can vary considerably including severe symptomatic disease, moderate/mild symptomatic disease, and asymptomatic spreaders.", [["infectious diseases", "DISEASE", 55, 74], ["disease", "PROBLEM", 16, 23], ["emerging infectious diseases", "PROBLEM", 46, 74], ["severe symptomatic disease", "PROBLEM", 107, 133], ["moderate/mild symptomatic disease", "PROBLEM", 135, 168], ["asymptomatic spreaders", "PROBLEM", 174, 196], ["disease", "OBSERVATION", 16, 23], ["infectious", "OBSERVATION", 55, 65], ["severe", "OBSERVATION_MODIFIER", 107, 113], ["symptomatic", "OBSERVATION_MODIFIER", 114, 125], ["disease", "OBSERVATION", 126, 133], ["moderate", "OBSERVATION_MODIFIER", 135, 143], ["mild", "OBSERVATION_MODIFIER", 144, 148], ["symptomatic", "OBSERVATION_MODIFIER", 149, 160], ["disease", "OBSERVATION", 161, 168]]], ["Moreover, convalescence remains a challenge as recovering patients may continue to shed virus, sometimes for extended periods of time after initial infection.", [["infection", "DISEASE", 148, 157], ["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 58, 66], ["initial infection", "PROBLEM", 140, 157], ["infection", "OBSERVATION", 148, 157]]], ["Therefore, effective therapeutics and interventions must have the ability to address the full spectrum of disease and contribute to controlling transmission and spread of the pathogen.Harnessing AI toward Global Health: Impact on Healthcare Infrastructure, Policy, Surveillance, and EconomicsRecently, efforts around monoclonal antibodies (Mabs) have been proposed as a possible solution.", [["monoclonal antibodies", "PROTEIN", 317, 338], ["Mabs", "PROTEIN", 340, 344], ["effective therapeutics", "TREATMENT", 11, 33], ["interventions", "TREATMENT", 38, 51], ["disease", "PROBLEM", 106, 113], ["the pathogen", "PROBLEM", 171, 183], ["monoclonal antibodies (Mabs", "TREATMENT", 317, 344], ["disease", "OBSERVATION", 106, 113]]], ["[50] While traditional development times for Mabs frame (6 months to years), overall costs (\u2265$100 per gram), [51] and laborious clinical administration (intravenous), has previously limited their utility in emergency situations, especially in austere and resource-limited clinical settings, substantial efforts have been directed to overcome these challenges.", [["intravenous", "ANATOMY", 153, 164], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 153, 164]]], ["Numerous efforts have considered drug repurposing for infectious disease indications as an approach to quickly respond to an outbreak.", [["infectious disease", "DISEASE", 54, 72], ["infectious disease indications", "PROBLEM", 54, 84]]], ["Small molecule therapeutics are ideal for rapid deployment in response to an epidemic because they are often stable at room temperature, easily available and have known human pharmacokinetic and safety profiles.", [["human", "ORGANISM", 169, 174], ["human", "SPECIES", 169, 174], ["human", "SPECIES", 169, 174], ["Small molecule therapeutics", "TREATMENT", 0, 27], ["rapid deployment", "TREATMENT", 42, 58], ["molecule", "OBSERVATION_MODIFIER", 6, 14], ["therapeutics", "OBSERVATION_MODIFIER", 15, 27]]], ["[53] Most successful cases of drug repurposing have been largely serendipitous clinical discoveries, however tremendous effort has also been focused on rational drug repurposing through pathogenic phenotypic in silico and in vitro screening efforts.", [["drug repurposing", "TREATMENT", 30, 46], ["rational drug repurposing", "TREATMENT", 152, 177], ["pathogenic phenotypic in silico", "PROBLEM", 186, 217]]], ["On-target mechanisms of action(s) (MOAs) are often useful targets to block pathogen attachment, entry, and replication within the host.", [["block pathogen attachment", "PROBLEM", 69, 94]]], ["Existing viral drugs are usually the first to be applied to novel viral threats.", [["Existing viral drugs", "TREATMENT", 0, 20], ["viral drugs", "OBSERVATION", 9, 20]]], ["An additional benefit with repurposed molecules is their potential off-target impacts on a pathogen.", [["repurposed molecules", "TREATMENT", 27, 47], ["a pathogen", "PROBLEM", 89, 99]]], ["These off-target effects are usually harder to define during development.Harnessing AI toward Global Health: Impact on Healthcare Infrastructure, Policy, Surveillance, and EconomicsA major challenge in drug repurposing efforts is that few drugs demonstrate the safety and potency alone to achieve therapeutic antiviral activity.", [["therapeutic antiviral activity", "TREATMENT", 297, 327]]], ["Therefore, studies have focused on combinational strategies to meet the potency and safety dose requirements to be considered in response to a new threat.", [["studies", "TEST", 11, 18], ["combinational strategies", "TREATMENT", 35, 59], ["safety dose requirements", "TREATMENT", 84, 108]]], ["[54] These efforts rely on in vitro and in vivo testing to evaluate and can be considerably difficult to demonstrate, even with two drug combinations.", [["vivo testing", "TEST", 43, 55]]], ["[55] In vitro and especially in vivo testing of single drugs or combinations can be a lengthy process (months to years).", [["single drugs", "TREATMENT", 48, 60]]], ["[56] Higher complexity combinational approaches offer the greatest benefit, but traditional methods developing higher-order combinations .", [["traditional methods", "TREATMENT", 80, 99]]], ["Emerging in silico modelling and AI approaches that are driven by prospective experimental validation are converging to allow for potentially rapid responses to outbreak and pandemic events.", [["AI approaches", "TREATMENT", 33, 46], ["pandemic events", "PROBLEM", 174, 189]]], ["[7,32,57] The approach described here, and other recently reported methods are key steps to higher order combinational treatment formulations that overcomes past limitations with repurposing and will allow for disease specific and likely personalized antivirals.", [["combinational treatment formulations", "TREATMENT", 105, 141], ["disease", "PROBLEM", 210, 217], ["personalized antivirals", "TREATMENT", 238, 261]]], ["[58] The optimized combinations in Table 1 were derived and identified from those experimentally tested, and thus further studies using the optimized combinations as determined from IDentif.AI will be required.ConclusionThis work has provided a foundation toward the rapid identification of dynamically optimized and actionable combination therapies to address a broad spectrum of infectious disease applications while also accounting for new strains that may eventually circulate.", [["further studies", "TEST", 114, 129], ["AI", "TREATMENT", 190, 192], ["actionable combination therapies", "TREATMENT", 317, 349], ["infectious disease applications", "TREATMENT", 381, 412], ["new strains", "PROBLEM", 439, 450], ["infectious", "OBSERVATION", 381, 391]]], ["Given the mechanism-and disease-agnostic foundation of Project IDentif.AI, further studies will evaluate this platform for rapid COVID-19 intervention, and establish its readiness to pinpoint regimens toward downstream pathogens with aggressive clinical courses.", [["disease", "PROBLEM", 24, 31], ["further studies", "TEST", 75, 90], ["rapid COVID-19 intervention", "TREATMENT", 123, 150], ["pinpoint regimens", "TREATMENT", 183, 200], ["downstream pathogens", "PROBLEM", 208, 228], ["aggressive clinical courses", "TREATMENT", 234, 261]]], ["Pairing the technical capabilities of AI-driven drug development platforms with important policybased considerations and lessons learned from the global response to SARS, H1N1, EVD, and other epidemics/pandemics may ultimately lead to expedited intervention at scale.Experimental SectionCell Culture: The lung cancer cell line (A549, ATCC, USA) was cultured in high-glucose Dulbecco's modified Eagle's medium (DMEM) (Invitrogen, USA) that was supplemented with 10% fetal bovine serum (FBS) (Invitrogen, USA) and 1% penicillin-streptomycin (Invitrogen, USA).", [["lung cancer cell line", "ANATOMY", 305, 326], ["A549", "ANATOMY", 328, 332], ["ATCC", "ANATOMY", 334, 338], ["fetal bovine serum", "ANATOMY", 465, 483], ["FBS", "ANATOMY", 485, 488], ["SARS", "DISEASE", 165, 169], ["H1N1", "DISEASE", 171, 175], ["EVD", "DISEASE", 177, 180], ["lung cancer", "DISEASE", 305, 316], ["glucose", "CHEMICAL", 366, 373], ["penicillin", "CHEMICAL", 515, 525], ["streptomycin", "CHEMICAL", 526, 538], ["glucose", "CHEMICAL", 366, 373], ["penicillin", "CHEMICAL", 515, 525], ["streptomycin", "CHEMICAL", 526, 538], ["lung cancer cell line", "CELL", 305, 326], ["A549, ATCC, USA", "CELL", 328, 343], ["bovine", "ORGANISM", 471, 477], ["serum", "ORGANISM_SUBSTANCE", 478, 483], ["FBS", "ORGANISM_SUBSTANCE", 485, 488], ["penicillin-streptomycin", "SIMPLE_CHEMICAL", 515, 538], ["lung cancer cell line", "CELL_LINE", 305, 326], ["A549", "CELL_LINE", 328, 332], ["ATCC", "CELL_LINE", 334, 338], ["USA", "CELL_LINE", 340, 343], ["bovine", "SPECIES", 471, 477], ["ATCC", "SPECIES", 334, 338], ["bovine", "SPECIES", 471, 477], ["AI", "PROBLEM", 38, 40], ["SARS", "PROBLEM", 165, 169], ["H1N1", "PROBLEM", 171, 175], ["EVD", "TREATMENT", 177, 180], ["pandemics", "PROBLEM", 202, 211], ["intervention at scale", "TREATMENT", 245, 266], ["Experimental SectionCell Culture", "TEST", 267, 299], ["The lung cancer", "PROBLEM", 301, 316], ["ATCC", "TEST", 334, 338], ["10% fetal bovine serum (FBS", "TREATMENT", 461, 488], ["Invitrogen", "TEST", 491, 501], ["1% penicillin", "TREATMENT", 512, 525], ["streptomycin", "TREATMENT", 526, 538], ["lung", "ANATOMY", 305, 309], ["cancer cell line", "OBSERVATION", 310, 326]]], ["The culture was maintained at 37\u00b0C containing 5% v/v CO 2 and the cells were harvested upon reaching 80% confluence.", [["cells", "ANATOMY", 66, 71], ["CO", "CHEMICAL", 53, 55], ["cells", "CELL", 66, 71], ["The culture", "TEST", 0, 11], ["5% v/v CO", "TREATMENT", 46, 55]]], ["100 \u00b5L of cell suspension (4-12k cells per well) was seeded in 96-well plates and pre-incubated for 12 h for treatment with the candidate drugs and viral platform.", [["cell", "ANATOMY", 10, 14], ["cells", "ANATOMY", 33, 38], ["cell", "CELL", 10, 14], ["cells", "CELL", 33, 38], ["cell suspension", "TREATMENT", 10, 25], ["treatment", "TREATMENT", 109, 118], ["the candidate drugs", "TREATMENT", 124, 143], ["viral platform", "TREATMENT", 148, 162]]], ["Cells without any drug treatment and without viral infection served as a control.", [["Cells", "ANATOMY", 0, 5], ["viral infection", "DISEASE", 45, 60], ["Cells", "CELL", 0, 5], ["any drug treatment", "TREATMENT", 14, 32], ["viral infection", "PROBLEM", 45, 60], ["without", "UNCERTAINTY", 37, 44], ["viral", "OBSERVATION_MODIFIER", 45, 50], ["infection", "OBSERVATION", 51, 60]]], ["Drug-induced cytotoxicity was measured using a cell counting kit-8 (CCK8, DOJINDO, Japan).", [["cell", "ANATOMY", 47, 51], ["Drug", "SIMPLE_CHEMICAL", 0, 4], ["cell", "CELL", 47, 51], ["Drug-induced cytotoxicity", "PROBLEM", 0, 25], ["a cell counting kit", "TEST", 45, 64], ["CCK8", "TEST", 68, 72]]], ["Briefly, 15 \u00b5L of CCK8 solution was added to each well containing 150 \u00b5L solution and then incubated for 2 h at 37\u00b0C in order to conduct the cytotoxicity assay.", [["CCK8", "CHEMICAL", 18, 22], ["CCK8", "CHEMICAL", 18, 22], ["CCK8", "SIMPLE_CHEMICAL", 18, 22], ["CCK8 solution", "TREATMENT", 18, 31], ["the cytotoxicity assay", "TEST", 137, 159]]], ["The cell viability was assessed by measuring the absorbance (450 nm) via a microplate reader (BioTek, Synergy HT, USA).Experimental SectionViral Infection and Plate Reader: Vesicular stomatitis virus (VSV), a RNA virus, was used as the pathogen model in this work.", [["cell", "ANATOMY", 4, 8], ["Vesicular stomatitis", "DISEASE", 173, 193], ["cell", "CELL", 4, 8], ["Vesicular stomatitis virus", "ORGANISM", 173, 199], ["VSV", "ORGANISM", 201, 204], ["Vesicular stomatitis virus", "SPECIES", 173, 199], ["Vesicular stomatitis virus", "SPECIES", 173, 199], ["VSV", "SPECIES", 201, 204], ["The cell viability", "TEST", 0, 18], ["the absorbance", "TEST", 45, 59], ["a microplate reader (BioTek", "TREATMENT", 73, 100], ["Experimental SectionViral Infection", "PROBLEM", 119, 154], ["Vesicular stomatitis virus (VSV", "PROBLEM", 173, 204], ["a RNA virus", "PROBLEM", 207, 218], ["cell viability", "OBSERVATION", 4, 18], ["Infection", "OBSERVATION", 145, 154], ["Vesicular stomatitis virus", "OBSERVATION", 173, 199]]], ["VSV was engineered and encoded with green fluorescent protein (GFP).", [["VSV", "ORGANISM", 0, 3], ["green fluorescent protein", "GENE_OR_GENE_PRODUCT", 36, 61], ["GFP", "GENE_OR_GENE_PRODUCT", 63, 66], ["green fluorescent protein", "PROTEIN", 36, 61], ["GFP", "PROTEIN", 63, 66], ["VSV", "SPECIES", 0, 3], ["VSV", "PROBLEM", 0, 3], ["green fluorescent protein", "TEST", 36, 61]]], ["The concentration of VSV stock was 1 \u00d7 10 4 pfu \u00b5L \u22121 , and different multiplicity of infection (MOI) parameters were used to optimize the final MOI for cell infection.", [["cell", "ANATOMY", 153, 157], ["infection", "DISEASE", 86, 95], ["infection", "DISEASE", 158, 167], ["VSV", "ORGANISM", 21, 24], ["cell", "CELL", 153, 157], ["VSV", "SPECIES", 21, 24], ["The concentration of VSV stock", "TREATMENT", 0, 30], ["infection (MOI) parameters", "TREATMENT", 86, 112], ["cell infection", "PROBLEM", 153, 167], ["infection", "OBSERVATION", 86, 95], ["cell infection", "OBSERVATION", 153, 167]]], ["The MOI used for the optimization process included 1, 0.5, 0.25, 0.125, 0.1, 0.01, and 0.001 and 0 (control).", [["The MOI", "TREATMENT", 0, 7]]], ["Cells were infected by VSV under different MOI parameters for 12, 24, and 30 h during the optimization process.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["VSV", "ORGANISM", 23, 26], ["VSV", "SPECIES", 23, 26]]], ["100 \u00b5L of cell suspension (12k cells per well) was seeded in a 96 well-plate and pre-incubated for 12 h to be infected by VSV.", [["cell", "ANATOMY", 10, 14], ["cells", "ANATOMY", 31, 36], ["cell", "CELL", 10, 14], ["cells", "CELL", 31, 36], ["VSV", "ORGANISM", 122, 125], ["VSV", "SPECIES", 122, 125], ["cell suspension (12k cells", "TREATMENT", 10, 36], ["infected", "OBSERVATION", 110, 118]]], ["Following viral infection, the GFP fluorescence intensity of the cells induced by VSV reproduction was measured with a microplate reader (BioTek, Synergy HT, USA) using the top-reading mode, with excitation wavelength of 483 nm, and emission wavelength of 535 nm).Experimental SectionDilution of Candidate Therapies: 12 drugs purchased from Selleckchem (TX, USA) were included in this study.", [["cells", "ANATOMY", 65, 70], ["viral infection", "DISEASE", 10, 25], ["GFP", "GENE_OR_GENE_PRODUCT", 31, 34], ["cells", "CELL", 65, 70], ["VSV", "ORGANISM", 82, 85], ["VSV", "SPECIES", 82, 85], ["viral infection", "PROBLEM", 10, 25], ["the GFP fluorescence", "TEST", 27, 47], ["the cells", "PROBLEM", 61, 70], ["a microplate reader (BioTek", "TREATMENT", 117, 144], ["emission wavelength", "TEST", 233, 252], ["12 drugs", "TREATMENT", 317, 325], ["this study", "TEST", 380, 390], ["viral", "OBSERVATION_MODIFIER", 10, 15], ["infection", "OBSERVATION", 16, 25]]], ["These included amantadine HCl, dexamethasone, azithromycin, chloroquine diphosphate, naproxen sodium, fluoxetine HCl, loratadine, omeprazole sodium, ritonavir, lopinavir, doxycycline and ribavirin.", [["amantadine HCl", "CHEMICAL", 15, 29], ["dexamethasone", "CHEMICAL", 31, 44], ["azithromycin", "CHEMICAL", 46, 58], ["chloroquine diphosphate", "CHEMICAL", 60, 83], ["naproxen sodium", "CHEMICAL", 85, 100], ["fluoxetine HCl", "CHEMICAL", 102, 116], ["loratadine", "CHEMICAL", 118, 128], ["omeprazole sodium", "CHEMICAL", 130, 147], ["ritonavir", "CHEMICAL", 149, 158], ["lopinavir", "CHEMICAL", 160, 169], ["doxycycline", "CHEMICAL", 171, 182], ["ribavirin", "CHEMICAL", 187, 196], ["amantadine HCl", "CHEMICAL", 15, 29], ["dexamethasone", "CHEMICAL", 31, 44], ["azithromycin", "CHEMICAL", 46, 58], ["chloroquine diphosphate", "CHEMICAL", 60, 83], ["naproxen sodium", "CHEMICAL", 85, 100], ["fluoxetine", "CHEMICAL", 102, 112], ["HCl", "CHEMICAL", 113, 116], ["loratadine", "CHEMICAL", 118, 128], ["omeprazole sodium", "CHEMICAL", 130, 147], ["ritonavir", "CHEMICAL", 149, 158], ["lopinavir", "CHEMICAL", 160, 169], ["doxycycline", "CHEMICAL", 171, 182], ["ribavirin", "CHEMICAL", 187, 196], ["amantadine HCl", "SIMPLE_CHEMICAL", 15, 29], ["dexamethasone", "SIMPLE_CHEMICAL", 31, 44], ["azithromycin", "SIMPLE_CHEMICAL", 46, 58], ["chloroquine diphosphate", "SIMPLE_CHEMICAL", 60, 83], ["naproxen", "SIMPLE_CHEMICAL", 85, 93], ["sodium", "SIMPLE_CHEMICAL", 94, 100], ["fluoxetine", "SIMPLE_CHEMICAL", 102, 112], ["HCl", "SIMPLE_CHEMICAL", 113, 116], ["loratadine", "SIMPLE_CHEMICAL", 118, 128], ["omeprazole", "SIMPLE_CHEMICAL", 130, 140], ["sodium", "SIMPLE_CHEMICAL", 141, 147], ["ritonavir", "SIMPLE_CHEMICAL", 149, 158], ["lopinavir", "SIMPLE_CHEMICAL", 160, 169], ["doxycycline", "SIMPLE_CHEMICAL", 171, 182], ["ribavirin", "SIMPLE_CHEMICAL", 187, 196], ["amantadine HCl", "TREATMENT", 15, 29], ["dexamethasone", "TREATMENT", 31, 44], ["azithromycin", "TREATMENT", 46, 58], ["chloroquine diphosphate", "TREATMENT", 60, 83], ["naproxen sodium", "TREATMENT", 85, 100], ["fluoxetine HCl", "TREATMENT", 102, 116], ["loratadine", "TREATMENT", 118, 128], ["omeprazole sodium", "TREATMENT", 130, 147], ["ritonavir", "TREATMENT", 149, 158], ["lopinavir", "TREATMENT", 160, 169], ["doxycycline", "TREATMENT", 171, 182], ["ribavirin", "TREATMENT", 187, 196]]], ["Amantadine HCl, chloroquine diphosphate, naproxen sodium, fluoxetine HCl, omeprazole sodium, doxycycline and ribavirin were diluted using complete cell culture medium, while dexamethasone, azithromycin, loratadine, ritonavir, and lopinavir were diluted in DMSO.", [["cell", "ANATOMY", 147, 151], ["Amantadine HCl", "CHEMICAL", 0, 14], ["chloroquine diphosphate", "CHEMICAL", 16, 39], ["naproxen sodium", "CHEMICAL", 41, 56], ["fluoxetine HCl", "CHEMICAL", 58, 72], ["omeprazole sodium", "CHEMICAL", 74, 91], ["doxycycline", "CHEMICAL", 93, 104], ["ribavirin", "CHEMICAL", 109, 118], ["dexamethasone", "CHEMICAL", 174, 187], ["azithromycin", "CHEMICAL", 189, 201], ["loratadine", "CHEMICAL", 203, 213], ["ritonavir", "CHEMICAL", 215, 224], ["lopinavir", "CHEMICAL", 230, 239], ["DMSO", "CHEMICAL", 256, 260], ["Amantadine HCl", "CHEMICAL", 0, 14], ["chloroquine diphosphate", "CHEMICAL", 16, 39], ["naproxen sodium", "CHEMICAL", 41, 56], ["fluoxetine HCl", "CHEMICAL", 58, 72], ["omeprazole sodium", "CHEMICAL", 74, 91], ["doxycycline", "CHEMICAL", 93, 104], ["ribavirin", "CHEMICAL", 109, 118], ["dexamethasone", "CHEMICAL", 174, 187], ["azithromycin", "CHEMICAL", 189, 201], ["loratadine", "CHEMICAL", 203, 213], ["ritonavir", "CHEMICAL", 215, 224], ["lopinavir", "CHEMICAL", 230, 239], ["DMSO", "CHEMICAL", 256, 260], ["Amantadine", "SIMPLE_CHEMICAL", 0, 10], ["HCl", "SIMPLE_CHEMICAL", 11, 14], ["chloroquine diphosphate", "SIMPLE_CHEMICAL", 16, 39], ["naproxen", "SIMPLE_CHEMICAL", 41, 49], ["sodium", "SIMPLE_CHEMICAL", 50, 56], ["fluoxetine", "SIMPLE_CHEMICAL", 58, 68], ["HCl", "SIMPLE_CHEMICAL", 69, 72], ["omeprazole", "SIMPLE_CHEMICAL", 74, 84], ["sodium", "SIMPLE_CHEMICAL", 85, 91], ["doxycycline", "SIMPLE_CHEMICAL", 93, 104], ["ribavirin", "SIMPLE_CHEMICAL", 109, 118], ["cell", "CELL", 147, 151], ["dexamethasone", "SIMPLE_CHEMICAL", 174, 187], ["azithromycin", "SIMPLE_CHEMICAL", 189, 201], ["loratadine", "SIMPLE_CHEMICAL", 203, 213], ["ritonavir", "SIMPLE_CHEMICAL", 215, 224], ["lopinavir", "SIMPLE_CHEMICAL", 230, 239], ["DMSO", "SIMPLE_CHEMICAL", 256, 260], ["Amantadine HCl", "TREATMENT", 0, 14], ["chloroquine diphosphate", "TREATMENT", 16, 39], ["naproxen sodium", "TREATMENT", 41, 56], ["fluoxetine HCl", "TREATMENT", 58, 72], ["omeprazole sodium", "TREATMENT", 74, 91], ["doxycycline", "TREATMENT", 93, 104], ["ribavirin", "TREATMENT", 109, 118], ["complete cell culture medium", "TREATMENT", 138, 166], ["dexamethasone", "TREATMENT", 174, 187], ["azithromycin", "TREATMENT", 189, 201], ["loratadine", "TREATMENT", 203, 213], ["ritonavir", "TREATMENT", 215, 224], ["lopinavir", "TREATMENT", 230, 239]]], ["The final stock concentration of all the drugs was 100 \u00d7 10 \u22123 m.", [["all the drugs", "TREATMENT", 33, 46]]], ["With the exception of naproxen sodium and ribavirin, the other 10 drugs were further diluted for four concentrations including 0.1, 1, 10, and 100 \u00d7 10 \u22126 m during the drug optimization process.", [["naproxen sodium", "CHEMICAL", 22, 37], ["ribavirin", "CHEMICAL", 42, 51], ["naproxen sodium", "CHEMICAL", 22, 37], ["ribavirin", "CHEMICAL", 42, 51], ["naproxen", "SIMPLE_CHEMICAL", 22, 30], ["sodium", "SIMPLE_CHEMICAL", 31, 37], ["ribavirin", "SIMPLE_CHEMICAL", 42, 51], ["naproxen sodium", "TREATMENT", 22, 37], ["ribavirin", "TREATMENT", 42, 51], ["the other 10 drugs", "TREATMENT", 53, 71], ["the drug optimization process", "TREATMENT", 164, 193]]], ["The concentrations of naproxen sodium and ribavirin during the drug optimization process were 0.5, 5, 50, and 500 \u00d7 10 \u22126 m.", [["naproxen sodium", "CHEMICAL", 22, 37], ["ribavirin", "CHEMICAL", 42, 51], ["naproxen sodium", "CHEMICAL", 22, 37], ["ribavirin", "CHEMICAL", 42, 51], ["naproxen", "SIMPLE_CHEMICAL", 22, 30], ["sodium", "SIMPLE_CHEMICAL", 31, 37], ["ribavirin", "SIMPLE_CHEMICAL", 42, 51], ["naproxen sodium", "TREATMENT", 22, 37], ["ribavirin", "TREATMENT", 42, 51], ["the drug optimization process", "TREATMENT", 59, 88]]], ["The maximum possible final concentration of DMSO added to the cells for monotherapies and combination therapies was 0.3% for both.", [["cells", "ANATOMY", 62, 67], ["DMSO", "CHEMICAL", 44, 48], ["DMSO", "CHEMICAL", 44, 48], ["DMSO", "SIMPLE_CHEMICAL", 44, 48], ["cells", "CELL", 62, 67], ["DMSO", "TREATMENT", 44, 48], ["the cells", "TREATMENT", 58, 67], ["monotherapies", "TREATMENT", 72, 85], ["combination therapies", "TREATMENT", 90, 111], ["maximum", "OBSERVATION_MODIFIER", 4, 11]]], ["During the drug optimization process, triplicates were run per treatment condition.Experimental SectionDesign-Of-Experiment (DOE): The experimental design of the first stage of testing was generated according to uniform design theory.", [["the drug optimization process", "TREATMENT", 7, 36]]], ["[59] 72 combinations were chosen with the largest sum of multi-drug interaction distances and smallest variance of accumulative doses from trillions of randomly generated experiment designs.", [["accumulative doses", "TREATMENT", 115, 133], ["accumulative doses", "OBSERVATION", 115, 133]]], ["The design of the second stage of validation was generated according to orthogonal array design (OAD).Experimental SectionAccumulative Equivalent Dose: To cancel the disparity of the therapeutic concentration ranges between drugs, as well as to facilitate the expression of dose concentrations, the concept of equivalent dose was adopted.", [["drugs", "TREATMENT", 224, 229], ["dose concentrations", "TREATMENT", 274, 293]]], ["1 equivalent dose refers to 5 \u00d7 10 \u22126 m for naproxen sodium and ribavirin, and 1 \u00d7 10 \u22126 m for the others.", [["naproxen sodium", "CHEMICAL", 44, 59], ["ribavirin", "CHEMICAL", 64, 73], ["naproxen sodium", "CHEMICAL", 44, 59], ["ribavirin", "CHEMICAL", 64, 73], ["naproxen", "SIMPLE_CHEMICAL", 44, 52], ["sodium", "SIMPLE_CHEMICAL", 53, 59], ["ribavirin", "SIMPLE_CHEMICAL", 64, 73], ["naproxen sodium", "TREATMENT", 44, 59], ["ribavirin", "TREATMENT", 64, 73]]], ["Thus, the accumulative equivalent dose of a combination therapy was defined as the sum of the equivalent doses of its constituents.Experimental SectionData Analysis: The parabolic response surface analysis and multi-drug interaction regression analysis were conducted via the build-in function \"stepwiselm\" in MATLAB 2018a with self-written code.", [["a combination therapy", "TREATMENT", 42, 63], ["The parabolic response surface analysis", "TEST", 166, 205], ["multi-drug interaction regression analysis", "TEST", 210, 252], ["accumulative", "OBSERVATION_MODIFIER", 10, 22], ["equivalent", "OBSERVATION_MODIFIER", 23, 33]]], ["STRICT is a scoring algorithm based on projection distance, which assesses the capacity of infection inhibition by giving an anti-viral score to each drug and pairwise interaction in this study.", [["infection", "DISEASE", 91, 100], ["STRICT", "DNA", 0, 6], ["a scoring algorithm", "TEST", 10, 29], ["infection inhibition", "PROBLEM", 91, 111], ["an anti-viral score", "TREATMENT", 122, 141], ["this study", "TEST", 183, 193], ["infection", "OBSERVATION", 91, 100]]], ["[60] Consider a combination k = (x k,1 , x k,2 , \u2026 , x k, n ), the normalized Euclidean distance from point k to the projection p on axis i isExperimental SectionWhere D k, i is normalized to [0,1], and mapped with a decreasing function:Experimental SectionThe single drug STRICT score is then defined as the sum of the productions of the outputs, projections, and the function of the distance, which can be denoted asExperimental SectionUsing this definition, the STRICT score can be easily expanded to multidrug interactions, if point k is projected to plane i, j instead of axis i.", [["a combination k", "TEST", 14, 29], ["k", "TEST", 35, 36], ["k", "TEST", 43, 44], ["k", "TEST", 55, 56], ["the normalized Euclidean distance", "PROBLEM", 63, 96], ["Experimental Section", "TREATMENT", 237, 257], ["The single drug STRICT score", "TEST", 257, 285]]]], "9735c289f323e4edefb7532889f9fa56d35a52cf": [["IntroductionCOVID-19 constitutes a new major global health challenge.", [["IntroductionCOVID-19", "CHEMICAL", 0, 20], ["IntroductionCOVID", "TEST", 0, 17]]], ["The socioeconomic and health care impacts of this pandemic are unprecedented, with worldwide economic loss, travel restrictions, closure of business activities, social distancing, isolation and quarantine, fear of shortage of basic needs, and rapid spread of mental health problems [1] [2] [3] .", [["worldwide economic loss", "PROBLEM", 83, 106]]], ["The unpredictable nature of and its associated individual, societal, and global repercussions not only threaten one's physical health but also affects their mental health.", [["unpredictable", "OBSERVATION_MODIFIER", 4, 17]]], ["Data from a cross-sectional study in China revealed that more than half of the surveyed participants experienced moderate-to-severe psychological distress secondary to the outbreak 4 .", [["psychological distress", "DISEASE", 132, 154], ["participants", "ORGANISM", 88, 100], ["participants", "SPECIES", 88, 100], ["a cross-sectional study", "TEST", 10, 33], ["moderate-to-severe psychological distress", "PROBLEM", 113, 154], ["the outbreak 4", "PROBLEM", 168, 182], ["moderate", "OBSERVATION_MODIFIER", 113, 121]]], ["The distress stems from the constant fear of contracting the virus, contracting it, losing loved ones to the illness, and being socially isolated or quarantined.IntroductionThese factors can precipitate mental illness in those with no previous psychiatric history or exacerbate symptoms in those with a pre-existing mental illness 5 .IntroductionOne of the core features of COVID-19 is its predilection for infecting older adults and those with chronic underlying health conditions, resulting in higher mortality 6 .", [["illness", "DISEASE", 109, 116], ["illness", "DISEASE", 210, 217], ["psychiatric", "DISEASE", 244, 255], ["COVID-19", "CHEMICAL", 374, 382], ["The distress stems", "PROBLEM", 0, 18], ["contracting the virus", "PROBLEM", 45, 66], ["mental illness", "PROBLEM", 203, 217], ["exacerbate symptoms", "PROBLEM", 267, 286], ["a pre-existing mental illness", "PROBLEM", 301, 330], ["COVID", "TEST", 374, 379], ["chronic underlying health conditions", "PROBLEM", 445, 481], ["distress stems", "OBSERVATION", 4, 18], ["virus", "OBSERVATION", 61, 66], ["chronic", "OBSERVATION_MODIFIER", 445, 452]]], ["Given that older adults generally suffer a greater number and higher severity of chronic diseases as compared to the younger population 7 , one can expect that the COVID-19 outbreak will disproportionately affect the geriatric population.IntroductionIn this respect, the subspecialty of geriatric psychiatry is uncharted territory.", [["chronic diseases", "DISEASE", 81, 97], ["adults", "ORGANISM", 17, 23], ["chronic diseases", "PROBLEM", 81, 97], ["the COVID", "TEST", 160, 169], ["higher severity", "OBSERVATION_MODIFIER", 62, 77], ["chronic", "OBSERVATION_MODIFIER", 81, 88], ["diseases", "OBSERVATION", 89, 97]]], ["Scarce literature exists about the psychiatry of old age during pandemics.", [["pandemics", "PROBLEM", 64, 73]]], ["During the severe acute respiratory distress syndrome (SARS) outbreak, which occurred between 2002 and 2004, a mental health toll particularly affected the geriatric population.", [["acute respiratory distress syndrome", "DISEASE", 18, 53], ["SARS", "DISEASE", 55, 59], ["the severe acute respiratory distress syndrome", "PROBLEM", 7, 53], ["SARS", "PROBLEM", 55, 59], ["severe", "OBSERVATION_MODIFIER", 11, 17], ["acute", "OBSERVATION_MODIFIER", 18, 23], ["respiratory distress", "OBSERVATION", 24, 44]]], ["A case study conducted in Hong Kong in 2003 attributed 22 suicide events to be \"SARS-related\", with the mean age of attempters being 74.9Introductionyears.", [["SARS", "DISEASE", 80, 84], ["A case study", "TEST", 0, 12], ["SARS", "PROBLEM", 80, 84]]], ["Disease burden among the elderly with long-term illness contributed as a significant factor for suicide 8 .", [["illness", "DISEASE", 48, 55], ["Disease burden", "PROBLEM", 0, 14], ["long-term illness", "PROBLEM", 38, 55]]], ["Another cross-sectional study, also conducted in Hong Kong, showed an increase in suicide rates in older adults during the year of the outbreak; this was particularly significant in females above the age of 65 years 9 .", [["Another cross-sectional study", "TEST", 0, 29], ["an increase in suicide rates", "PROBLEM", 67, 95], ["increase", "OBSERVATION_MODIFIER", 70, 78], ["significant", "OBSERVATION_MODIFIER", 167, 178]]], ["A lingering elevation in rates of elderly suicide was observed until 2004 10 .IntroductionIt is essential to recognize how the impact of the COVID-19 outbreak on mental health varies around the world, particularly in low-and middle-income countries 11 .", [["A lingering elevation", "PROBLEM", 0, 21], ["elderly suicide", "PROBLEM", 34, 49], ["the COVID", "TREATMENT", 137, 146], ["lingering", "OBSERVATION_MODIFIER", 2, 11], ["elevation", "OBSERVATION_MODIFIER", 12, 21]]], ["In the Arab countries of the Middle East and North Africa (MENA) region, the percentage of the population over the age of 65 is estimated at 5.1% (of a total population of 449 million) 12 .", [["Middle", "ANATOMY_MODIFIER", 29, 35], ["North", "ANATOMY_MODIFIER", 45, 50], ["Africa", "ANATOMY_MODIFIER", 51, 57], ["percentage", "OBSERVATION_MODIFIER", 77, 87], ["population", "OBSERVATION_MODIFIER", 95, 105]]], ["Few programs in the Arab countries of the MENA region, governmental, communitybased, or initiated by private sectors, have tried to meet the needs and overcome the challenges of the geriatric population 14, 15 .IntroductionGeriatric mental health, on the other hand, is frequently overlooked 16 .", [["MENA", "ANATOMY", 42, 46], ["region", "ANATOMY_MODIFIER", 47, 53]]], ["This stems from a lack of awareness about the symptoms of mental illness in the elderly and a dismissive belief that affected mental health constitutes a normal part of the aging process 17 .", [["illness", "DISEASE", 65, 72], ["the symptoms", "PROBLEM", 42, 54], ["mental illness", "PROBLEM", 58, 72]]], ["Even though psychiatry of the old age constitutes one of the priority areas for health interventions in the Arab countries of the MENA region 17 , little is known about the state of geriatric mental health during the COVID-19 outbreak in this part of the world.", [["health interventions", "TREATMENT", 80, 100]]], ["Therefore, throughout this evolving situation, and as a group of Arab early-career psychiatrists, we provide a state-of-the-art review of the status of geriatric psychiatry in the Arab region during the COVID-19 outbreak.", [["the COVID", "TEST", 199, 208]]], ["We then shed light on the general and targeted mental health interventions implemented during the COVID-19 outbreak.", [["the COVID", "TEST", 94, 103]]], ["Finally, we derive targeted interventions for implementation in the Arab countries of the MENA region.MethodsWe invited thirteen early-career psychiatrists from the Arab countries of the MENA region to share information related to geriatric psychiatry and COVID-19 in their respective nations.", [["MENA region", "DNA", 90, 101], ["implementation", "TREATMENT", 46, 60], ["COVID", "TEST", 256, 261], ["MENA", "ANATOMY", 90, 94], ["region", "ANATOMY_MODIFIER", 95, 101]]], ["We elected for early-career rather than mid-career or late-career psychiatrists to provide a new perspective about the situation of geriatric psychiatry in this part of the world and to add emphasis on the importance of early-careers, the torchbearer of future psychiatry 18 To complement this search, we also checked different search engines (PubMed, Medline, and Scopus), from inception until April 5, 2020, for references about the status of the COVID-19 outbreak and geriatric psychiatry in the MENA region.", [["MENA region", "DNA", 499, 510], ["the COVID", "TEST", 445, 454]]], ["Terms used in the search included \"COVID-19\", \"coronavirus\", \"SARS-COV-2\", \"geriatrics\", \"elderly\", \"aging\", \"mental health\", \"psychological distress\", \"coping style\", \"social support\", and \"psychiatric disorders\".", [["coronavirus", "DISEASE", 47, 58], ["SARS", "DISEASE", 62, 66], ["psychological distress", "DISEASE", 127, 149], ["psychiatric disorders", "DISEASE", 191, 212], ["psychological distress", "PROBLEM", 127, 149]]], ["Ethical permission was not sought as there was no direct involvement of human participants and data used were already available in the public domain.Status of geriatric mental health in the Arab countries of the MENA regionFew studies assessed the mental health status of the geriatric population in the Arab countries of the MENA region.", [["human", "ORGANISM", 72, 77], ["MENA region", "DNA", 326, 337], ["human", "SPECIES", 72, 77], ["participants", "SPECIES", 78, 90], ["human", "SPECIES", 72, 77], ["the MENA regionFew studies", "TEST", 208, 234], ["MENA", "ANATOMY", 326, 330], ["region", "ANATOMY_MODIFIER", 331, 337]]], ["These studies are mainly clustered in Egypt, Lebanon, Kingdom of Saudi Arabia (KSA), and the United Arab Emirates (UAE), and mostly tackle old age depression.Status of geriatric mental health in the Arab countries of the MENA regionOverall, research in this part of the world indicates a high prevalence of depression among the geriatric population, with prevalence numbers varying between 18% and 46% [19] [20] [21] [22] [23] [24] [25] .", [["depression", "DISEASE", 147, 157], ["depression", "DISEASE", 307, 317], ["[19] [20] [21] [22] [23] [24] [25]", "CHEMICAL", 402, 436], ["20] [21] [22] [23] [24", "SIMPLE_CHEMICAL", 408, 430], ["These studies", "TEST", 0, 13], ["depression", "PROBLEM", 147, 157], ["depression", "PROBLEM", 307, 317], ["prevalence numbers", "TEST", 355, 373], ["depression", "OBSERVATION", 147, 157]]], ["Depressive symptoms are also common within sub-populations of older adults, reaching a prevalence of 46% in those with Parkinson's disease 26 and 57% to 86% in dementia of Alzheimer's type and vascular dementia, respectively 27 .", [["vascular", "ANATOMY", 193, 201], ["Depressive symptoms", "DISEASE", 0, 19], ["Parkinson's disease", "DISEASE", 119, 138], ["dementia", "DISEASE", 160, 168], ["Alzheimer's type and vascular dementia", "DISEASE", 172, 210], ["vascular", "MULTI-TISSUE_STRUCTURE", 193, 201], ["Depressive symptoms", "PROBLEM", 0, 19], ["Parkinson's disease", "PROBLEM", 119, 138], ["dementia", "PROBLEM", 160, 168], ["Alzheimer's type", "PROBLEM", 172, 188], ["vascular dementia", "PROBLEM", 193, 210], ["dementia", "OBSERVATION", 160, 168], ["Alzheimer", "OBSERVATION", 172, 181], ["vascular", "ANATOMY", 193, 201], ["dementia", "OBSERVATION", 202, 210]]], ["Most studies identified living alone [22] [23] [24] [25] , living in a nursing home 25, 28, 29 , illiteracy 25, 28, 29 , and having chronic diseases 19, 24, 25 to be associated with geriatric depression.Status of geriatric mental health in the Arab countries of the MENA regionThis comes on top of a general lack of services directed towards geriatric mental health in the Arab region.", [["chronic diseases", "DISEASE", 132, 148], ["geriatric depression", "DISEASE", 182, 202], ["chronic diseases", "PROBLEM", 132, 148], ["geriatric depression", "PROBLEM", 182, 202], ["chronic", "OBSERVATION_MODIFIER", 132, 139], ["diseases", "OBSERVATION", 140, 148], ["depression", "OBSERVATION", 192, 202]]], ["For instance, Sudan has no geriatricians or geriatric mental health clinics; most of the limited psychiatric services are restricted to the capital and major cities.", [["psychiatric", "DISEASE", 97, 108]]], ["Similarly, in Syria, geriatric medicine remains a foreign discipline taught along with the endocrinology and nutritional disorders module of medical schools.", [["nutritional disorders", "DISEASE", 109, 130], ["geriatric medicine", "TREATMENT", 21, 39]]], ["Other nations have some resources for geriatric medicine, but minimally available expertise.", [["geriatric medicine", "TREATMENT", 38, 56]]], ["The Oman Al Zahimer Association for dementia has also been providing support for patients with dementia and their caregivers throughout the country.", [["dementia", "DISEASE", 36, 44], ["dementia", "DISEASE", 95, 103], ["patients", "ORGANISM", 81, 89], ["patients", "SPECIES", 81, 89], ["dementia", "PROBLEM", 36, 44], ["dementia", "PROBLEM", 95, 103]]], ["In comparison, while there are no clinics dedicated to psychogeriatrics in Tunisia, except for some specialized units in dementia, a university diploma and a research unit exist at the faculty of medicine of Monastir in the center of the country.", [["psychogeriatrics", "DISEASE", 55, 71], ["dementia", "DISEASE", 121, 129], ["dementia", "PROBLEM", 121, 129], ["Monastir", "TREATMENT", 208, 216], ["dementia", "OBSERVATION", 121, 129]]], ["Geriatric psychiatry is currently one of the requirements in many of those training programs.", [["those training programs", "TREATMENT", 69, 92]]], ["The Egyptian Alzheimer Society has been leading the field and spreading awareness for years now.", [["Alzheimer", "DISEASE", 13, 22], ["Egyptian", "OBSERVATION_MODIFIER", 4, 12], ["Alzheimer", "OBSERVATION", 13, 22]]], ["Alternatively, geriatric psychiatric services in Qatar are provided through different models, including outpatient clinics, specialized memory clinics, consultations on the medical floors of general hospitals, and via residential and home visits for people who cannot reach out.", [["psychiatric", "DISEASE", 25, 36], ["people", "ORGANISM", 250, 256], ["people", "SPECIES", 250, 256]]], ["The service has been growing significantly in recent years, particularly following the launching of Qatar National Dementia Plan 2018-2022 and plans for 'Healthy Ageing' in the country 30, 31 .", [["Dementia", "DISEASE", 115, 123], ["growing", "OBSERVATION_MODIFIER", 21, 28], ["significantly", "OBSERVATION_MODIFIER", 29, 42]]], ["Table 1 summarizes the characteristics of the geriatric population and geriatric mental health training in each of the represented thirteen countries 32-38 .MENA regionSince the start of the COVID-19 outbreak, the Arab countries of the MENA region have implemented several measures to improve mental health outcomes during this pandemic (Table 2a 39DiscussionIn this part of the world, geriatrics and geriatric psychiatry remain a novel and, at times, an exotic field with minimal exposure or resources.", [["the geriatric population", "PROBLEM", 42, 66], ["geriatric mental health training", "TREATMENT", 71, 103], ["the COVID", "TREATMENT", 187, 196]]], ["It lacks the glamour of other specialties, and its limited training opportunities make it unappealing.DiscussionThe needs of this vulnerable population should be taken into consideration, particularly during the COVID-19 situation.", [["this vulnerable population", "TREATMENT", 125, 151]]], ["In this part of the world, changing family dynamics secondary to labor opportunities have caused a shift in family structures, with grandparents more commonly taking care of grandchildren, while parents work abroad.", [["labor opportunities", "PROBLEM", 65, 84]]], ["Should grandparents become infected or succumb to the illness, the implications on their extended families will be profound 11 .", [["infected", "PROBLEM", 27, 35], ["infected", "OBSERVATION", 27, 35]]], ["Second, self-isolation during the COVID-19 outbreak can severely affect older adults, whose only social contact is out-of-the home, such as at community centers and places of worship.", [["self-isolation", "TREATMENT", 8, 22]]], ["Also, increasing numbers of the elderly in the low-and middle-income countries are being cared for in nursing homes, which often are unregulated and have limited services 62 .", [["increasing", "OBSERVATION_MODIFIER", 6, 16], ["numbers", "OBSERVATION_MODIFIER", 17, 24], ["middle", "ANATOMY_MODIFIER", 55, 61]]], ["Since many healthcare systems of the MENA region face severe limitations and are unlikely able to provide the needed care for all COVID-19 patients, a disproportionate number of those are expected to be older.", [["patients", "ORGANISM", 139, 147], ["patients", "SPECIES", 139, 147], ["severe", "OBSERVATION", 54, 60]]], ["Subsequently, self-isolation among the elderly would become associated with considerable morbidity and mortality secondary to cardiovascular and neurocognitive complications 65 and mental health problems 65, 66 .DiscussionDuring the COVID-19 outbreak, five organizations in China, including the Chinese Society of Geriatric Psychiatry, promptly released expert recommendations on how to provide mental health support for the geriatric population 64 .", [["cardiovascular", "ANATOMY", 126, 140], ["cardiovascular and neurocognitive complications", "DISEASE", 126, 173], ["self-isolation", "TREATMENT", 14, 28], ["considerable morbidity", "PROBLEM", 76, 98], ["cardiovascular and neurocognitive complications", "PROBLEM", 126, 173], ["mental health problems", "PROBLEM", 181, 203], ["mental health support", "TREATMENT", 395, 416]]], ["Similarly, the international dementia experts and Alzheimer's Disease International called for urgent support for people living with dementia and their supporters 67 .", [["dementia", "DISEASE", 29, 37], ["Alzheimer's Disease", "DISEASE", 50, 69], ["dementia", "DISEASE", 133, 141], ["people", "ORGANISM", 114, 120], ["people", "SPECIES", 114, 120], ["the international dementia", "PROBLEM", 11, 37], ["Alzheimer's Disease", "PROBLEM", 50, 69], ["urgent support", "TREATMENT", 95, 109], ["dementia", "PROBLEM", 133, 141]]], ["An age perspective should be included in the development of any national or regional planning for COVID-19, with recommendations targeting the needs of older adults.", [["adults", "ORGANISM", 158, 164], ["COVID", "TEST", 98, 103]]], ["As an attempt to invite healthcare workers, policymakers, and stakeholders to look further into the needs of this population, we provide a comprehensive list of recommendations ( Table 3) that aim to enhance the general status of geriatric mental health in the Arab region, and particularly during the COVID-19 outbreak.", [["the COVID", "TEST", 298, 307]]], ["In the short-term, the focus should be on raising awareness about the importance of mental health in the geriatric population and providing appropriate resources for the elderly (whether by giving focused training to primary and mental health physicians or via employing innovative tools such as telepsychiatry and hotlines).DiscussionTreatment measures should follow a multidisciplinary approach within a collaborative care model.", [["Treatment measures", "TREATMENT", 335, 353], ["a multidisciplinary approach", "TREATMENT", 368, 396], ["short-term", "OBSERVATION_MODIFIER", 7, 17]]], ["Long-term recommendations should target improving geriatric medical training and allocating funds for the specific needs of older adults.ConclusionIn earlier epidemics, such as SARS, the impact on the mental health of the geriatric population was found to be detrimental.", [["SARS", "DISEASE", 177, 181], ["geriatric medical training", "TREATMENT", 50, 76], ["earlier epidemics", "PROBLEM", 150, 167], ["SARS", "PROBLEM", 177, 181]]], ["During the COVID-19 outbreak, vulnerable populations, particularly older adults, remain at high risk for the development and exacerbation of mental health problems.", [["the COVID", "TEST", 7, 16], ["exacerbation of mental health problems", "PROBLEM", 125, 163]]], ["This is of high concern in the Arab countries of the MENA region, where insufficient attention has been so far paid to the geriatric population.", [["high", "OBSERVATION_MODIFIER", 11, 15], ["MENA", "ANATOMY", 53, 57], ["region", "ANATOMY_MODIFIER", 58, 64]]], ["Mental health professionals, medical practitioners, stakeholders, health policymakers, and governmental and nongovernmental organizations should collaborate to develop an effective task force that strengthens the geriatric mental health response to the COVID-19 pandemic at both national and regional levels.Disclosure/conflict of interestThe authors report no conflicts with any product mentioned or concept discussed in this article.Short-term recommendationsRaising awareness -About the importance of mental health in the geriatric population, counteracting the erroneous perception that mental illness is an expected outcome of aging.Short-term recommendations-About the available mental health services provided to the geriatric population.Short-term recommendations-Against stigmatizing media coverage that marginalizes the geriatric population as the \"sacrifice age group\" during the COVID-19 outbreak.Short-term recommendations-About the importance of social distancing between family members and older adults, yet maintaining contact via other tools (phone calls, internet, etc.).Providing and improving mental health services-Via training mental health teams and primary care clinicians in providing essential mental health care for older adults.Providing and improving mental health services-Via teaching targeted psychological first aid to nonspecialized clinicians.Providing and improving mental health services-Via offering individual and group counseling to older adults in need.Providing and improving mental health services-Via catering for specific days dedicated to older adult visits and follow-ups at geriatric clinics in the health care centers and hospitals.Providing and improving mental health services-Via using telepsychiatry to assess and treat geriatric mental health problems during isolation.", [["illness", "DISEASE", 598, 605], ["the COVID", "TEST", 249, 258], ["mental illness", "PROBLEM", 591, 605], ["stigmatizing media coverage", "TREATMENT", 780, 807], ["the COVID", "TEST", 887, 896], ["geriatric mental health problems", "PROBLEM", 1773, 1805]]], ["At homes or nursing sites where telepsychiatry is not affordable, service teams could provide support and behavioral management through telephone hotlines.Providing and improving mental health services-Via creating mobile crisis teams and liaison services to reach out to those in rural areas.Implementing measures-Adequate documentation and appropriate use of mental health assessment tools to allow better assessment of symptoms, treatment interventions, and their efficacy.Implementing measures-Collaborative care between health care providers (geriatricians, geriatric psychiatrists, neurologists, primary health care physicians, psychologists, nutritionists, and social workers), patients, families, caregivers, and nursing home administrators to provide the best outcomes for the geriatric population.Implementing measures-Close follow-up on the status of governmental and non-governmental nursing homes to maintain an adequate quality of care and hygienic measures.Long-term recommendations-Creating or expanding geriatric medicine training positions.Long-term recommendations-Establishing appropriate and adequate exposure to the geriatric population as part of a mandatory rotation in all psychiatry training programs.Long-term recommendations-Providing training for clinicians in primary care in the mental health of older adults.Long-term recommendations-Recruiting more specialists in the field, including geriatricians and geriatric psychiatrists.Long-term recommendations-Establishing daycare facilities and nursing homes for older adults with mental health problems.Long-term recommendations-Allocating part of the governmental and non-governmental funds towards the needs of the geriatric population.Long-term recommendations-Decentralizing resources away from large cities and capitals to ensure service availability for all people.Long-term recommendations-Developing a national policy that protects the geriatric population's general health and mental health.", [["patients", "ORGANISM", 685, 693], ["people", "ORGANISM", 1842, 1848], ["patients", "SPECIES", 685, 693], ["people", "SPECIES", 1842, 1848], ["behavioral management", "TREATMENT", 106, 127], ["liaison services", "TREATMENT", 239, 255], ["mental health assessment", "TEST", 361, 385], ["symptoms", "PROBLEM", 422, 430], ["treatment interventions", "TREATMENT", 432, 455], ["the geriatric population", "TREATMENT", 782, 806], ["hygienic measures", "TREATMENT", 954, 971], ["expanding geriatric medicine training", "TREATMENT", 1010, 1047], ["the geriatric population", "TREATMENT", 1134, 1158], ["a mandatory rotation", "TREATMENT", 1170, 1190], ["all psychiatry training programs", "TREATMENT", 1194, 1226], ["mental health problems", "PROBLEM", 1558, 1580], ["the geriatric population", "TREATMENT", 1691, 1715]]]], "22cf6aaf9f7f07851592c1b9a1015275b21d5980": [["In a word, we report a useful information as to the etiology and evolution of canine 40 coronavirus in China based on the available sequences, which is urgent for the devise 41 of future effective disease prevention and control strategies.45Coronaviruses, as single-stranded RNA viruses, have been widely detected in a 46 variety of mammals and several birds [1, 2] .", [["canine 40 coronavirus", "DISEASE", 78, 99], ["canine", "ORGANISM", 78, 84], ["40 coronavirus", "ORGANISM", 85, 99], ["Coronaviruses", "GENE_OR_GENE_PRODUCT", 241, 254], ["canine 40 coronavirus", "SPECIES", 78, 99], ["canine 40 coronavirus", "PROBLEM", 78, 99], ["future effective disease prevention", "TREATMENT", 180, 215], ["control strategies", "TREATMENT", 220, 238], ["Coronaviruses", "PROBLEM", 241, 254], ["single-stranded RNA viruses", "PROBLEM", 259, 286], ["RNA viruses", "OBSERVATION", 275, 286], ["widely", "OBSERVATION_MODIFIER", 298, 304]]], ["Its genome has ranged from 26 to 32 kb in 47 Kit (CW Biotech, Jiangsu, China) protein among CCoV-IIa strains sequenced here and the classical CCoV-IIa strains.", [["CCoV-IIa", "GENE_OR_GENE_PRODUCT", 92, 100], ["CCoV-IIa", "GENE_OR_GENE_PRODUCT", 142, 150], ["Its genome", "TEST", 0, 10], ["protein", "TEST", 78, 85], ["CCoV", "TEST", 92, 96], ["IIa strains", "PROBLEM", 97, 108], ["IIa strains", "PROBLEM", 147, 158], ["IIa", "ANATOMY", 147, 150]]], ["165 We found amino acid changes in around 45 residues, most of these are located in S1 CCoV-II groups ( Figure 3B ).", [["amino acid", "CHEMICAL", 13, 23], ["amino acid", "CHEMICAL", 13, 23], ["amino acid", "AMINO_ACID", 13, 23], ["CCoV", "PROTEIN", 87, 91], ["amino acid changes", "PROBLEM", 13, 31], ["amino acid", "OBSERVATION", 13, 23], ["S1", "ANATOMY", 84, 86]]], ["In contrast, the sequence of S2 domain of 189 B906_ZJ_2019 clustered closely with these strains identified in this study which 190 belong to CCoV-IIa ( Figure 3C ).", [["CCoV-IIa", "GENE_OR_GENE_PRODUCT", 141, 149], ["S2 domain", "PROTEIN", 29, 38], ["CCoV", "PROTEIN", 141, 145], ["the sequence of S2 domain", "TEST", 13, 38], ["these strains", "PROBLEM", 82, 95], ["this study", "TEST", 110, 120], ["CCoV", "TEST", 141, 145]]], ["K-H L Ja pa n D Q 0 1 0 9 2 1 F C o V 7 9 -1 1 4 6 K P 1 4 3 5 0 7 F C o V 2 7 C 2 0 1 3 D 1 3 0 9 6 C C o V IN S A V C -1 K C 1 7 5 3 3 9 1 7 1 G e rm a n y 1 9 7 1 ree scale: 0.1", [["K", "CHEMICAL", 0, 1], ["K", "TEST", 0, 1], ["L Ja pa n D Q 0", "TEST", 4, 19], ["C o V", "TEST", 32, 37], ["K P", "TEST", 51, 54], ["C", "TEST", 69, 70], ["V", "TEST", 73, 74], ["C", "TEST", 79, 80], ["D", "TEST", 89, 90], ["C C", "TEST", 101, 104], ["o V", "TEST", 105, 108], ["A V C", "TEST", 114, 119], ["K C", "TEST", 123, 126], ["G e rm", "TEST", 145, 151], ["a n y", "TEST", 152, 157], ["ree scale", "TEST", 166, 175]]]], "PMC7300952": [["Patients and MethodsLung US examinations of pregnant women infected with COVID\u201019 were performed in an antenatal unit of a tertiary hospital, and the findings were retrospectively reviewed.", [["Patients", "ORGANISM", 0, 8], ["women", "ORGANISM", 53, 58], ["Patients", "SPECIES", 0, 8], ["women", "SPECIES", 53, 58], ["MethodsLung US examinations", "TEST", 13, 40]]], ["Pregnant women who underwent LUS examinations after obstetric US examinations were included.", [["women", "ORGANISM", 9, 14], ["women", "SPECIES", 9, 14], ["LUS examinations", "TEST", 29, 45], ["obstetric US examinations", "TEST", 52, 77]]], ["All diagnoses were confirmed by nasal/throat real\u2010time reverse transcription polymerase chain reaction (rRT\u2010PCR) testing.", [["nasal", "ANATOMY", 32, 37], ["nasal/throat real\u2010time", "TREATMENT", 32, 54], ["rRT\u2010PCR) testing", "TEST", 104, 120], ["nasal", "ANATOMY", 32, 37], ["throat", "ANATOMY", 38, 44]]], ["All LUS examination were performed by the first author, with 20 years of experience before the study.", [["All LUS examination", "TEST", 0, 19], ["the study", "TEST", 91, 100]]], ["The recently standardized 14\u2010area scanning protocol for the use of LUS on patients with COVID\u201019 was applied.12This protocol has also been proposed to be used in pregnant women.10, 12 Fourteen areas (3 posterior, 2 lateral, and 2 anterior) were scanned per patient for 10 seconds along the indicated lines.", [["patients", "ORGANISM", 74, 82], ["women", "ORGANISM", 171, 176], ["anterior", "ORGAN", 230, 238], ["patient", "ORGANISM", 257, 264], ["lines", "CELL", 300, 305], ["patients", "SPECIES", 74, 82], ["women", "SPECIES", 171, 176], ["patient", "SPECIES", 257, 264], ["LUS", "TEST", 67, 70], ["COVID\u2010", "TREATMENT", 88, 94], ["This protocol", "TREATMENT", 111, 124], ["lines", "OBSERVATION", 300, 305]]], ["Where applicable, scanning from the intercostal space was preferred.", [["intercostal space", "ANATOMY", 36, 53], ["intercostal space", "MULTI-TISSUE_STRUCTURE", 36, 53], ["scanning from the intercostal space", "TEST", 18, 53], ["intercostal", "ANATOMY", 36, 47]]], ["Each area was given a score between 0 and 3 according to the specific pattern.12The pattern with a continuous and regular pleural line and horizontal artifacts, referred to as A\u2010lines, was classified as score 0.", [["pleural line", "ANATOMY", 122, 134], ["pleural line", "CELL", 122, 134], ["a continuous and regular pleural line", "PROBLEM", 97, 134], ["horizontal artifacts", "PROBLEM", 139, 159], ["continuous", "OBSERVATION_MODIFIER", 99, 109], ["pleural", "ANATOMY", 122, 129], ["line", "OBSERVATION", 130, 134], ["horizontal artifacts", "OBSERVATION", 139, 159]]], ["The pattern with an indented pleural line and sporadic vertical white areas below the point of discontinuity in the pleural line, referred to as sporadic B\u2010lines, was classified as score 1.", [["pleural line", "ANATOMY", 29, 41], ["pleural line", "ANATOMY", 116, 128], ["B\u2010lines", "DISEASE", 154, 161], ["pleural line", "CELL", 29, 41], ["pleural line", "CELL", 116, 128], ["an indented pleural line", "PROBLEM", 17, 41], ["sporadic vertical white areas", "PROBLEM", 46, 75], ["discontinuity in the pleural line", "PROBLEM", 95, 128], ["indented", "OBSERVATION_MODIFIER", 20, 28], ["pleural", "ANATOMY", 29, 36], ["line", "OBSERVATION", 37, 41], ["sporadic", "OBSERVATION_MODIFIER", 46, 54], ["vertical", "OBSERVATION_MODIFIER", 55, 63], ["white", "OBSERVATION_MODIFIER", 64, 69], ["areas", "OBSERVATION_MODIFIER", 70, 75], ["discontinuity", "OBSERVATION", 95, 108], ["pleural", "ANATOMY", 116, 123], ["line", "OBSERVATION", 124, 128]]], ["The pattern with a broken pleura, small consolidated areas below the discontinuity, and multiple vertical white areas that reached the bottom of the field of view, referred to as multiple B\u2010lines, was classified as score 2.", [["pleura", "ANATOMY", 26, 32], ["pleura", "ORGAN", 26, 32], ["a broken pleura", "PROBLEM", 17, 32], ["small consolidated areas", "PROBLEM", 34, 58], ["the discontinuity", "PROBLEM", 65, 82], ["multiple vertical white areas", "PROBLEM", 88, 117], ["broken", "OBSERVATION_MODIFIER", 19, 25], ["pleura", "ANATOMY", 26, 32], ["small", "OBSERVATION_MODIFIER", 34, 39], ["consolidated", "OBSERVATION_MODIFIER", 40, 52], ["areas", "OBSERVATION_MODIFIER", 53, 58], ["discontinuity", "OBSERVATION_MODIFIER", 69, 82], ["multiple", "OBSERVATION_MODIFIER", 88, 96], ["vertical", "OBSERVATION_MODIFIER", 97, 105], ["white", "OBSERVATION_MODIFIER", 106, 111], ["areas", "OBSERVATION", 112, 117], ["bottom", "ANATOMY_MODIFIER", 135, 141]]], ["The pattern with a severely broken pleura and a dense and largely extended white lung pattern with or without larger consolidations was classified as score 3.", [["pleura", "ANATOMY", 35, 41], ["white lung", "ANATOMY", 75, 85], ["pleura", "CANCER", 35, 41], ["lung", "ORGAN", 81, 85], ["a severely broken pleura", "PROBLEM", 17, 41], ["a dense and largely extended white lung pattern", "PROBLEM", 46, 93], ["larger consolidations", "PROBLEM", 110, 131], ["severely", "OBSERVATION_MODIFIER", 19, 27], ["broken", "OBSERVATION", 28, 34], ["pleura", "ANATOMY", 35, 41], ["dense", "OBSERVATION_MODIFIER", 48, 53], ["largely", "OBSERVATION_MODIFIER", 58, 65], ["extended", "OBSERVATION_MODIFIER", 66, 74], ["white", "OBSERVATION_MODIFIER", 75, 80], ["lung", "ANATOMY", 81, 85], ["without", "UNCERTAINTY", 102, 109], ["larger", "OBSERVATION_MODIFIER", 110, 116], ["consolidations", "OBSERVATION", 117, 131]]], ["At the end of the procedure, the highest score obtained for each area was noted (eg, landmark 1, score 0; landmark 2, score 1; and so on).Patients and MethodsFollowing recommended high\u2010level protection rules,13lung images were obtained with convex transducers on a regular obstetric preset (EA720; Esaote SpA, Genoa, Italy).", [["Patients", "ORGANISM", 138, 146], ["Patients", "SPECIES", 138, 146], ["the procedure", "TREATMENT", 14, 27], ["the highest score", "TEST", 29, 46], ["landmark", "TEST", 85, 93], ["landmark", "TEST", 106, 114], ["high\u2010level protection rules", "TREATMENT", 180, 207], ["13lung images", "TEST", 208, 221], ["convex transducers", "TEST", 241, 259]]], ["Bilateral involvement, anterior/posterior and inferior/superior involvements, the thickness and irregularity of the pleura, sporadic/multiple B\u2010lines, small and large consolidations, air bronchograms, and pleural effusion were the focused US elements.Patients and MethodsThe clinical severity of the patients was interpreted by the COVID\u201019 Severity Scoring Tool.14All patients' COVID\u201019 medical treatments were supervised by an infectious disease specialist, as per the national COVID\u201019 treatment guideline.15As this was a case series, ethics approval was not needed.", [["anterior", "ANATOMY", 23, 31], ["inferior", "ANATOMY", 46, 54], ["pleura", "ANATOMY", 116, 122], ["pleural effusion", "ANATOMY", 205, 221], ["air bronchograms", "DISEASE", 183, 199], ["pleural effusion", "DISEASE", 205, 221], ["infectious disease", "DISEASE", 429, 447], ["pleura", "ORGAN", 116, 122], ["pleural effusion", "CANCER", 205, 221], ["Patients", "ORGANISM", 251, 259], ["patients", "ORGANISM", 300, 308], ["patients", "ORGANISM", 369, 377], ["US elements", "DNA", 239, 250], ["Patients", "SPECIES", 251, 259], ["patients", "SPECIES", 300, 308], ["patients", "SPECIES", 369, 377], ["Bilateral involvement", "PROBLEM", 0, 21], ["anterior/posterior and inferior/superior involvements", "PROBLEM", 23, 76], ["the thickness and irregularity of the pleura", "PROBLEM", 78, 122], ["sporadic/multiple B\u2010lines", "PROBLEM", 124, 149], ["small and large consolidations", "PROBLEM", 151, 181], ["air bronchograms", "PROBLEM", 183, 199], ["pleural effusion", "PROBLEM", 205, 221], ["medical treatments", "TREATMENT", 388, 406], ["ethics approval", "TREATMENT", 538, 553], ["involvement", "OBSERVATION", 10, 21], ["anterior", "ANATOMY_MODIFIER", 23, 31], ["posterior", "ANATOMY_MODIFIER", 32, 41], ["inferior", "ANATOMY_MODIFIER", 46, 54], ["superior", "ANATOMY_MODIFIER", 55, 63], ["thickness", "OBSERVATION_MODIFIER", 82, 91], ["irregularity", "OBSERVATION_MODIFIER", 96, 108], ["pleura", "ANATOMY", 116, 122], ["sporadic", "OBSERVATION_MODIFIER", 124, 132], ["multiple", "OBSERVATION_MODIFIER", 133, 141], ["B\u2010lines", "OBSERVATION", 142, 149], ["small", "OBSERVATION_MODIFIER", 151, 156], ["large", "OBSERVATION_MODIFIER", 161, 166], ["consolidations", "OBSERVATION", 167, 181], ["air bronchograms", "OBSERVATION", 183, 199], ["pleural", "ANATOMY", 205, 212], ["effusion", "OBSERVATION", 213, 221]]], ["Informed consent was obtained from patients for the anonymous use of LUS, CT, and chest radiographic results.", [["chest", "ANATOMY", 82, 87], ["patients", "ORGANISM", 35, 43], ["patients", "SPECIES", 35, 43], ["LUS, CT, and chest radiographic results", "TEST", 69, 108], ["chest", "ANATOMY", 82, 87]]]], "PMC7520666": [["INTRODUCTIONCells have to cope with challenging changes in their environment such as alterations in osmolarity, ion homeostasis, redox state, oxygen or nutrient supply, or exposure to ionizing radiation or potentially toxic substances.", [["oxygen", "CHEMICAL", 142, 148], ["oxygen", "CHEMICAL", 142, 148], ["ion", "SIMPLE_CHEMICAL", 112, 115], ["oxygen", "SIMPLE_CHEMICAL", 142, 148], ["INTRODUCTIONCells", "TREATMENT", 0, 17], ["challenging changes", "PROBLEM", 36, 55], ["oxygen", "TREATMENT", 142, 148], ["nutrient supply", "TREATMENT", 152, 167], ["ionizing radiation", "TREATMENT", 184, 202], ["toxic substances", "PROBLEM", 218, 234]]], ["Deviations from homeostatic conditions are often unfavorable to cellular life and elicit stress responses that have evolved to foster adaptation to the altered conditions and, thereby, promote cellular survival in adverse environments.", [["cellular", "ANATOMY", 64, 72], ["cellular", "ANATOMY", 193, 201], ["cellular", "CELL", 64, 72], ["cellular", "CELL", 193, 201], ["Deviations from homeostatic conditions", "PROBLEM", 0, 38], ["stress responses", "PROBLEM", 89, 105], ["the altered conditions", "PROBLEM", 148, 170]]], ["A prominent example is the heat shock response that is triggered by exposure to elevated temperatures [1].", [["shock", "DISEASE", 32, 37], ["the heat shock response", "PROBLEM", 23, 46], ["elevated temperatures", "PROBLEM", 80, 101], ["prominent", "OBSERVATION_MODIFIER", 2, 11], ["shock response", "OBSERVATION", 32, 46]]], ["In this case the impaired protein folding induced by heat stress is, at least partially, counteracted by an increased expression of chaperone proteins.", [["chaperone proteins", "PROTEIN", 132, 150], ["the impaired protein folding", "PROBLEM", 13, 41], ["heat stress", "PROBLEM", 53, 64], ["chaperone proteins", "TREATMENT", 132, 150], ["impaired", "OBSERVATION_MODIFIER", 17, 25], ["protein folding", "OBSERVATION", 26, 41], ["increased", "OBSERVATION_MODIFIER", 108, 117]]], ["These assist with protein folding and, thereby, help to keep the cellular protein machinery functional in spite of adverse thermal conditions.", [["cellular", "ANATOMY", 65, 73], ["cellular", "CELL", 65, 73], ["protein folding", "TREATMENT", 18, 33], ["adverse thermal conditions", "PROBLEM", 115, 141]]], ["While certain aspects of stress-elicited adaptive programs such as the heat shock response or the oxidative stress response are very well studied, the contribution of other cellular pathways including endocytosis to cellular adaptation is still elusive.INTRODUCTIONThe plasma membrane can be envisioned as a central compartment in the cellular adaptation to diverse stress conditions as it shapes the interactions between cells and their environment by harboring an elaborate complement of transmembrane proteins, e.g. transporters, channels, receptors, or adhesion proteins.", [["cellular", "ANATOMY", 173, 181], ["cellular", "ANATOMY", 216, 224], ["plasma membrane", "ANATOMY", 269, 284], ["cellular", "ANATOMY", 335, 343], ["cells", "ANATOMY", 422, 427], ["transmembrane", "ANATOMY", 490, 503], ["shock", "DISEASE", 76, 81], ["cellular", "CELL", 173, 181], ["cellular", "CELL", 216, 224], ["plasma membrane", "CELLULAR_COMPONENT", 269, 284], ["cellular", "CELL", 335, 343], ["cells", "CELL", 422, 427], ["transmembrane", "CELLULAR_COMPONENT", 490, 503], ["transmembrane proteins", "PROTEIN", 490, 512], ["channels", "PROTEIN", 533, 541], ["receptors", "PROTEIN", 543, 552], ["adhesion proteins", "PROTEIN", 557, 574], ["stress", "PROBLEM", 25, 31], ["adaptive programs", "TREATMENT", 41, 58], ["the heat shock response", "PROBLEM", 67, 90], ["the oxidative stress response", "PROBLEM", 94, 123], ["other cellular pathways", "PROBLEM", 167, 190], ["The plasma membrane", "TREATMENT", 265, 284], ["diverse stress conditions", "PROBLEM", 358, 383], ["transmembrane proteins", "PROBLEM", 490, 512], ["adhesion proteins", "TREATMENT", 557, 574], ["plasma membrane", "OBSERVATION", 269, 284], ["cellular adaptation", "OBSERVATION", 335, 354]]], ["These cell surface proteins impinge on the vast majority of all cellular functions by mediating nutrient uptake, preserving ion homeostasis and initiating complex signaling cascades in response to extracellular cues.", [["cell surface", "ANATOMY", 6, 18], ["cellular", "ANATOMY", 64, 72], ["extracellular", "ANATOMY", 197, 210], ["cell", "CELL", 6, 10], ["cellular", "CELL", 64, 72], ["ion", "SIMPLE_CHEMICAL", 124, 127], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 197, 210], ["cell surface proteins", "PROTEIN", 6, 27], ["These cell surface proteins impinge", "PROBLEM", 0, 35], ["mediating nutrient uptake", "PROBLEM", 86, 111], ["preserving ion homeostasis", "PROBLEM", 113, 139], ["complex signaling cascades", "PROBLEM", 155, 181], ["extracellular cues", "TEST", 197, 215], ["surface", "OBSERVATION_MODIFIER", 11, 18], ["cellular functions", "OBSERVATION", 64, 82], ["nutrient uptake", "OBSERVATION", 96, 111], ["ion homeostasis", "OBSERVATION", 124, 139], ["complex", "OBSERVATION_MODIFIER", 155, 162], ["signaling cascades", "OBSERVATION", 163, 181]]], ["Consequently, the dynamic remodeling of the cell surface proteome is likely a crucial process in the cellular adaptation to many stress conditions.INTRODUCTIONA powerful pathway for rapidly altering the protein composition of the plasma membrane is Clathrin-mediated endocytosis (CME).", [["cell surface", "ANATOMY", 44, 56], ["cellular", "ANATOMY", 101, 109], ["plasma membrane", "ANATOMY", 230, 245], ["cell surface", "CELLULAR_COMPONENT", 44, 56], ["cellular", "CELL", 101, 109], ["plasma membrane", "CELLULAR_COMPONENT", 230, 245], ["Clathrin", "GENE_OR_GENE_PRODUCT", 249, 257], ["Clathrin", "PROTEIN", 249, 257], ["the cell surface proteome", "TEST", 40, 65], ["a crucial process", "PROBLEM", 76, 93], ["many stress conditions", "PROBLEM", 124, 146], ["cell surface", "OBSERVATION", 44, 56], ["likely", "UNCERTAINTY", 69, 75], ["crucial", "OBSERVATION_MODIFIER", 78, 85], ["process", "OBSERVATION", 86, 93], ["cellular adaptation", "OBSERVATION", 101, 120], ["stress conditions", "OBSERVATION", 129, 146]]], ["In CME, Clathrin together with additional endocytic factors causes the invagination of a plasma membrane patch into a 100 nm-sized vesicle that delivers its cargo to the endosomal system [2].", [["plasma membrane", "ANATOMY", 89, 104], ["vesicle", "ANATOMY", 131, 138], ["endosomal system", "ANATOMY", 170, 186], ["Clathrin", "GENE_OR_GENE_PRODUCT", 8, 16], ["plasma", "CELLULAR_COMPONENT", 89, 95], ["membrane patch", "CELLULAR_COMPONENT", 96, 110], ["vesicle", "CELLULAR_COMPONENT", 131, 138], ["endosomal", "CELLULAR_COMPONENT", 170, 179], ["Clathrin", "PROTEIN", 8, 16], ["endocytic factors", "PROTEIN", 42, 59], ["Clathrin", "TREATMENT", 8, 16], ["additional endocytic factors", "TREATMENT", 31, 59], ["a plasma membrane patch", "TREATMENT", 87, 110]]], ["This pathway was proposed to account for ~95% of total protein endocytic flux [3] and, thus, is the prime candidate for modulating the surface proteome upon stress.", [["surface", "ANATOMY", 135, 142], ["total protein endocytic flux", "TEST", 49, 77]]], ["CME is especially well suited to this task by allowing the selective uptake of specific transmembrane proteins via the recognition of distinct sorting motifs by endocytic adaptor proteins.", [["transmembrane", "ANATOMY", 88, 101], ["transmembrane", "CELLULAR_COMPONENT", 88, 101], ["transmembrane proteins", "PROTEIN", 88, 110], ["sorting motifs", "PROTEIN", 143, 157], ["endocytic adaptor proteins", "PROTEIN", 161, 187], ["specific transmembrane proteins", "PROBLEM", 79, 110]]], ["In fact, different reports have highlighted that there is close crosstalk between endocytosis, early endosomal trafficking and cellular stress.INTRODUCTIONIn this review we summarize reported stress-induced adaptive changes in the surface proteome that may be brought about by alterations in CME or downstream endocytic trafficking and discuss how these might contribute to cellular survival.MECHANISM OF CMECME is initiated by the recruitment of early-acting endocytic proteins, termed adaptors, such as FCHo, Eps15, Eps15R, and the Clathrin assembly protein complex 2 (AP-2) as well as curvature-inducing proteins such as Epsins and CALM to the plasma membrane [2].", [["endosomal", "ANATOMY", 101, 110], ["cellular", "ANATOMY", 127, 135], ["surface", "ANATOMY", 231, 238], ["cellular", "ANATOMY", 374, 382], ["plasma membrane", "ANATOMY", 647, 662], ["endosomal", "CELLULAR_COMPONENT", 101, 110], ["cellular", "CELL", 127, 135], ["surface", "CELLULAR_COMPONENT", 231, 238], ["cellular", "CELL", 374, 382], ["FCHo", "GENE_OR_GENE_PRODUCT", 505, 509], ["Eps15", "GENE_OR_GENE_PRODUCT", 511, 516], ["Eps15R", "GENE_OR_GENE_PRODUCT", 518, 524], ["Clathrin assembly protein complex 2", "GENE_OR_GENE_PRODUCT", 534, 569], ["AP-2", "GENE_OR_GENE_PRODUCT", 571, 575], ["Epsins", "GENE_OR_GENE_PRODUCT", 624, 630], ["CALM", "GENE_OR_GENE_PRODUCT", 635, 639], ["plasma membrane", "CELLULAR_COMPONENT", 647, 662], ["early-acting endocytic proteins", "PROTEIN", 447, 478], ["adaptors", "PROTEIN", 487, 495], ["FCHo", "PROTEIN", 505, 509], ["Eps15", "PROTEIN", 511, 516], ["Eps15R", "PROTEIN", 518, 524], ["Clathrin assembly protein complex 2", "PROTEIN", 534, 569], ["AP", "PROTEIN", 571, 573], ["curvature-inducing proteins", "PROTEIN", 588, 615], ["Epsins", "PROTEIN", 624, 630], ["CALM", "PROTEIN", 635, 639], ["cellular stress", "PROBLEM", 127, 142], ["Eps", "TEST", 518, 521], ["the Clathrin assembly protein complex", "TEST", 530, 567], ["Epsins", "TREATMENT", 624, 630], ["endosomal trafficking", "OBSERVATION", 101, 122], ["cellular stress", "OBSERVATION", 127, 142]]], ["These adaptors link Clathrin to the underlying membrane via their association with charged plasma membrane lipids and couple the assembly of the Clathrin coat with the selection of transmembrane cargo proteins, e.g. receptors and their ligands.MECHANISM OF CMEEndocytic adaptors are crucial for the endocytic process as they conduct the selection of membrane proteins destined for endocytosis (i.e. cargo) [4].", [["membrane", "ANATOMY", 47, 55], ["plasma membrane", "ANATOMY", 91, 106], ["transmembrane", "ANATOMY", 181, 194], ["membrane", "ANATOMY", 350, 358], ["Clathrin", "GENE_OR_GENE_PRODUCT", 20, 28], ["membrane", "CELLULAR_COMPONENT", 47, 55], ["plasma", "CELLULAR_COMPONENT", 91, 97], ["membrane lipids", "CELLULAR_COMPONENT", 98, 113], ["Clathrin", "GENE_OR_GENE_PRODUCT", 145, 153], ["transmembrane", "CELLULAR_COMPONENT", 181, 194], ["membrane", "CELLULAR_COMPONENT", 350, 358], ["Clathrin", "PROTEIN", 20, 28], ["Clathrin coat", "PROTEIN", 145, 158], ["transmembrane cargo proteins", "PROTEIN", 181, 209], ["OF CMEEndocytic adaptors", "PROTEIN", 254, 278], ["membrane proteins", "PROTEIN", 350, 367], ["charged plasma membrane lipids", "TREATMENT", 83, 113], ["the Clathrin coat", "TREATMENT", 141, 158], ["CMEEndocytic adaptors", "TREATMENT", 257, 278], ["the endocytic process", "PROBLEM", 295, 316], ["membrane proteins", "PROBLEM", 350, 367], ["endocytosis", "PROBLEM", 381, 392], ["CMEEndocytic adaptors", "OBSERVATION", 257, 278]]], ["For example, specific adaptors such as ARH enable liver cells to internalize low-density lipoprotein receptors (LDLRs) to clear cholesterol from the circulation.", [["liver cells", "ANATOMY", 50, 61], ["cholesterol", "CHEMICAL", 128, 139], ["cholesterol", "CHEMICAL", 128, 139], ["ARH", "GENE_OR_GENE_PRODUCT", 39, 42], ["liver cells", "CELL", 50, 61], ["low-density lipoprotein receptors", "GENE_OR_GENE_PRODUCT", 77, 110], ["LDLRs", "GENE_OR_GENE_PRODUCT", 112, 117], ["cholesterol", "SIMPLE_CHEMICAL", 128, 139], ["ARH", "PROTEIN", 39, 42], ["liver cells", "CELL_TYPE", 50, 61], ["low-density lipoprotein receptors", "PROTEIN", 77, 110], ["LDLRs", "PROTEIN", 112, 117], ["specific adaptors", "TREATMENT", 13, 30], ["low-density lipoprotein receptors", "TREATMENT", 77, 110], ["liver", "ANATOMY", 50, 55], ["circulation", "ANATOMY", 149, 160]]], ["Loss of these adaptors causes hypercholesterolemia and atherosclerosis in humans [5].", [["hypercholesterolemia", "DISEASE", 30, 50], ["atherosclerosis", "DISEASE", 55, 70], ["humans", "ORGANISM", 74, 80], ["humans", "SPECIES", 74, 80], ["humans", "SPECIES", 74, 80], ["hypercholesterolemia", "PROBLEM", 30, 50], ["atherosclerosis in humans", "PROBLEM", 55, 80], ["hypercholesterolemia", "OBSERVATION", 30, 50], ["atherosclerosis", "OBSERVATION", 55, 70]]], ["Other examples include \u03b2-arrestins that sort active G-protein coupled receptors (GPCRs), Epsins, Eps15 and Eps15R that recognize ubiquitinated receptors [6], and CALM and AP180 which mediate the endocytosis of so-called SNARE proteins that are crucial for membrane fusion [7, 8].", [["membrane", "ANATOMY", 256, 264], ["\u03b2-arrestins", "GENE_OR_GENE_PRODUCT", 23, 34], ["G-protein coupled receptors", "GENE_OR_GENE_PRODUCT", 52, 79], ["Epsins", "GENE_OR_GENE_PRODUCT", 89, 95], ["Eps15", "GENE_OR_GENE_PRODUCT", 97, 102], ["Eps15R", "GENE_OR_GENE_PRODUCT", 107, 113], ["CALM", "GENE_OR_GENE_PRODUCT", 162, 166], ["AP180", "GENE_OR_GENE_PRODUCT", 171, 176], ["SNARE", "GENE_OR_GENE_PRODUCT", 220, 225], ["membrane", "CELLULAR_COMPONENT", 256, 264], ["\u03b2-arrestins", "PROTEIN", 23, 34], ["G-protein coupled receptors", "PROTEIN", 52, 79], ["GPCRs", "PROTEIN", 81, 86], ["Epsins", "PROTEIN", 89, 95], ["Eps15", "PROTEIN", 97, 102], ["Eps15R", "PROTEIN", 107, 113], ["ubiquitinated receptors", "PROTEIN", 129, 152], ["CALM", "PROTEIN", 162, 166], ["AP180", "PROTEIN", 171, 176], ["SNARE proteins", "PROTEIN", 220, 234], ["\u03b2-arrestins", "PROBLEM", 23, 34], ["Epsins", "TEST", 89, 95], ["Eps15", "TEST", 97, 102], ["membrane fusion", "TREATMENT", 256, 271]]], ["In addition, many internalized transmembrane proteins are recognized by the AP-2 complex, a heterotetramer of two large (\u03b1, \u03b22) and two small subunits (\u03bc2, \u03c32), that acts as a more general cargo adaptor.", [["transmembrane", "ANATOMY", 31, 44], ["transmembrane", "CELLULAR_COMPONENT", 31, 44], ["AP-2", "GENE_OR_GENE_PRODUCT", 76, 80], ["\u03b1, \u03b22", "GENE_OR_GENE_PRODUCT", 121, 126], ["\u03bc2", "GENE_OR_GENE_PRODUCT", 152, 154], ["\u03c32", "GENE_OR_GENE_PRODUCT", 156, 158], ["transmembrane proteins", "PROTEIN", 31, 53], ["AP-2 complex", "PROTEIN", 76, 88], ["heterotetramer", "PROTEIN", 92, 106], ["\u03b1", "PROTEIN", 121, 122], ["\u03b22", "PROTEIN", 124, 126], ["\u03bc2", "PROTEIN", 152, 154], ["\u03c32", "PROTEIN", 156, 158], ["cargo adaptor", "PROTEIN", 189, 202], ["many internalized transmembrane proteins", "PROBLEM", 13, 53], ["internalized", "OBSERVATION_MODIFIER", 18, 30], ["transmembrane proteins", "OBSERVATION", 31, 53], ["large", "OBSERVATION_MODIFIER", 114, 119], ["small", "OBSERVATION_MODIFIER", 136, 141], ["subunits", "OBSERVATION_MODIFIER", 142, 150]]], ["AP-2 harbors specific sites for its association with dileucine- (i.e.", [["dileucine", "CHEMICAL", 53, 62], ["dileucine", "CHEMICAL", 53, 62], ["AP-2", "GENE_OR_GENE_PRODUCT", 0, 4], ["dileucine", "SIMPLE_CHEMICAL", 53, 62], ["AP-2", "DNA", 0, 4], ["dileucine", "TREATMENT", 53, 62]]], ["[DE]XXXXL[LI], X = any amino acid) and tyrosine-based (i.e. Yxx\u00d8, X = any amino acid, \u00d8 = large hydrophobic residue) endocytic sorting motifs [9\u201311] as well as for basic C2 domains [12].", [["amino acid", "CHEMICAL", 23, 33], ["tyrosine", "CHEMICAL", 39, 47], ["[DE]XXXXL", "CHEMICAL", 0, 9], ["amino acid", "CHEMICAL", 23, 33], ["tyrosine", "CHEMICAL", 39, 47], ["amino acid", "CHEMICAL", 74, 84], ["amino acid", "AMINO_ACID", 23, 33], ["tyrosine", "AMINO_ACID", 39, 47], ["amino acid", "AMINO_ACID", 74, 84], ["endocytic sorting motifs", "PROTEIN", 117, 141], ["basic C2 domains", "PROTEIN", 164, 180], ["any amino acid", "TEST", 19, 33], ["tyrosine", "TEST", 39, 47], ["any amino acid", "TEST", 70, 84], ["large hydrophobic residue", "PROBLEM", 90, 115]]], ["The latter are also recognized by the AP-2\u00b5 related adaptor proteins Stonin2 [13] and SGIP1 [14].MECHANISM OF CMECargo selection is closely coordinated with the assembly of the Clathrin lattice to generate productive endocytic structures.", [["endocytic structures", "ANATOMY", 217, 237], ["AP-2", "GENE_OR_GENE_PRODUCT", 38, 42], ["Stonin2 [13]", "GENE_OR_GENE_PRODUCT", 69, 81], ["SGIP1", "GENE_OR_GENE_PRODUCT", 86, 91], ["Clathrin", "GENE_OR_GENE_PRODUCT", 177, 185], ["AP-2\u00b5 related adaptor proteins", "PROTEIN", 38, 68], ["Stonin2", "PROTEIN", 69, 76], ["SGIP1", "PROTEIN", 86, 91], ["Clathrin lattice", "PROTEIN", 177, 193], ["the AP", "TEST", 34, 40], ["Stonin2", "TEST", 69, 76], ["SGIP1", "TEST", 86, 91], ["CMECargo selection", "TREATMENT", 110, 128], ["the Clathrin lattice", "TREATMENT", 173, 193], ["productive endocytic", "OBSERVATION", 206, 226]]], ["AP-2 in this mechanism acts as a co-incidence detector by initially adopting a closed conformation in which all but one membrane binding site as well as its cargo and Clathrin binding sites are occluded [15, 16].", [["membrane", "ANATOMY", 120, 128], ["AP-2", "GENE_OR_GENE_PRODUCT", 0, 4], ["membrane", "CELLULAR_COMPONENT", 120, 128], ["cargo", "CELLULAR_COMPONENT", 157, 162], ["Clathrin", "GENE_OR_GENE_PRODUCT", 167, 175], ["membrane binding site", "DNA", 120, 141], ["Clathrin binding sites", "PROTEIN", 167, 189], ["AP", "TEST", 0, 2], ["a co-incidence detector", "TREATMENT", 31, 54], ["a closed conformation", "TREATMENT", 77, 98], ["one membrane binding site", "PROBLEM", 116, 141], ["occluded", "OBSERVATION", 194, 202]]], ["This inactive conformation prevents the association of AP-2 with cargo proteins at sites other than the plasma membrane.", [["sites", "ANATOMY", 83, 88], ["plasma membrane", "ANATOMY", 104, 119], ["AP-2", "GENE_OR_GENE_PRODUCT", 55, 59], ["plasma membrane", "CELLULAR_COMPONENT", 104, 119], ["AP", "PROTEIN", 55, 57], ["cargo proteins", "PROTEIN", 65, 79], ["cargo proteins at sites", "PROBLEM", 65, 88], ["plasma membrane", "ANATOMY", 104, 119]]], ["The switch to the active open conformation is promoted by the coincident binding of AP-2 to the plasma membrane lipid phosphatidylinositol(4,5)bisphosphate (PIP2) and the AP-2 activating domain of FCHo proteins [17].", [["plasma membrane", "ANATOMY", 96, 111], ["phosphatidylinositol(4,5)bisphosphate", "CHEMICAL", 118, 155], ["phosphatidylinositol(4,5)bisphosphate", "CHEMICAL", 118, 155], ["PIP2", "CHEMICAL", 157, 161], ["AP-2", "GENE_OR_GENE_PRODUCT", 84, 88], ["plasma membrane", "CELLULAR_COMPONENT", 96, 111], ["lipid phosphatidylinositol(4,5)bisphosphate", "GENE_OR_GENE_PRODUCT", 112, 155], ["PIP2", "SIMPLE_CHEMICAL", 157, 161], ["AP-2", "GENE_OR_GENE_PRODUCT", 171, 175], ["FCHo", "GENE_OR_GENE_PRODUCT", 197, 201], ["AP", "PROTEIN", 84, 86], ["plasma membrane lipid phosphatidylinositol(4,5)bisphosphate", "PROTEIN", 96, 155], ["PIP2", "PROTEIN", 157, 161], ["AP-2 activating domain", "PROTEIN", 171, 193], ["FCHo proteins", "PROTEIN", 197, 210], ["the active open conformation", "TREATMENT", 14, 42], ["the plasma membrane lipid phosphatidylinositol", "TEST", 92, 138], ["bisphosphate (PIP2", "TEST", 143, 161], ["the AP", "TEST", 167, 173], ["FCHo proteins", "TEST", 197, 210], ["active", "OBSERVATION_MODIFIER", 18, 24]]], ["In the open conformation further PIP2 binding sites are exposed, and the interaction surfaces for cargo and Clathrin become accessible.", [["Clathrin", "CHEMICAL", 108, 116], ["PIP2", "SIMPLE_CHEMICAL", 33, 37], ["cargo", "CELLULAR_COMPONENT", 98, 103], ["Clathrin", "SIMPLE_CHEMICAL", 108, 116], ["PIP2 binding sites", "PROTEIN", 33, 51], ["Clathrin", "PROTEIN", 108, 116], ["PIP2 binding sites", "PROBLEM", 33, 51], ["cargo and Clathrin", "TREATMENT", 98, 116]]], ["Cargo, PIP2, and Clathrin binding stabilize the open conformation.", [["Cargo", "GENE_OR_GENE_PRODUCT", 0, 5], ["PIP2", "GENE_OR_GENE_PRODUCT", 7, 11], ["Clathrin", "GENE_OR_GENE_PRODUCT", 17, 25], ["PIP2", "PROTEIN", 7, 11], ["Clathrin", "PROTEIN", 17, 25], ["PIP2", "TREATMENT", 7, 11], ["Clathrin binding", "TREATMENT", 17, 33]]], ["Phosphorylation of the \u00b52 subunit by the adaptor associated kinase 1 (AAK1) or GAK [18, 19] promotes the open conformation, whereas NECAPs convert the phosphorylated open conformation of AP-2 into its inactive closed form [20, 21].", [["\u00b52 subunit by the adaptor associated kinase 1", "GENE_OR_GENE_PRODUCT", 23, 68], ["AAK1", "GENE_OR_GENE_PRODUCT", 70, 74], ["GAK", "GENE_OR_GENE_PRODUCT", 79, 82], ["NECAPs", "SIMPLE_CHEMICAL", 132, 138], ["AP-2", "GENE_OR_GENE_PRODUCT", 187, 191], ["\u00b52 subunit", "PROTEIN", 23, 33], ["adaptor associated kinase 1", "PROTEIN", 41, 68], ["AAK1", "PROTEIN", 70, 74], ["GAK", "PROTEIN", 79, 82], ["NECAPs", "PROTEIN", 132, 138], ["AP-2", "PROTEIN", 187, 191], ["Phosphorylation of the \u00b52 subunit", "TREATMENT", 0, 33]]], ["Hence, AP-2 is a central target for regulation in CME.", [["AP-2", "GENE_OR_GENE_PRODUCT", 7, 11], ["AP", "PROTEIN", 7, 9]]], ["One of the physiological triggers for AP-2\u00b5 phosphorylation is for example dopamine.", [["dopamine", "CHEMICAL", 75, 83], ["dopamine", "CHEMICAL", 75, 83], ["AP-2", "GENE_OR_GENE_PRODUCT", 38, 42], ["dopamine", "SIMPLE_CHEMICAL", 75, 83], ["AP", "PROTEIN", 38, 40], ["AP", "TEST", 38, 40], ["example dopamine", "TREATMENT", 67, 83]]], ["Dopamine binding to its cognate GPCR leads via the activation of AAK1 and PKC-\u03b6 to AP-2\u00b5 phosphorylation, thereby promoting endocytosis, e.g. of the Na+/K+-ATPase [22].MECHANISM OF CMEAs cargo selection and concomitant Clathrin assembly progress, the assembled coat and the underlying membrane bend inward, into the direction of the cytoplasm, until eventually a vesicle-like structure is formed, the endocytic pit, which remains connected to the membrane only via a narrow stalk [2].", [["membrane", "ANATOMY", 285, 293], ["cytoplasm", "ANATOMY", 333, 342], ["vesicle", "ANATOMY", 363, 370], ["endocytic pit", "ANATOMY", 401, 414], ["membrane", "ANATOMY", 447, 455], ["Dopamine", "CHEMICAL", 0, 8], ["K", "CHEMICAL", 153, 154], ["Dopamine", "CHEMICAL", 0, 8], ["Na+", "CHEMICAL", 149, 152], ["K", "CHEMICAL", 153, 154], ["Dopamine", "SIMPLE_CHEMICAL", 0, 8], ["GPCR", "GENE_OR_GENE_PRODUCT", 32, 36], ["AAK1", "GENE_OR_GENE_PRODUCT", 65, 69], ["PKC-\u03b6", "GENE_OR_GENE_PRODUCT", 74, 79], ["AP-2", "GENE_OR_GENE_PRODUCT", 83, 87], ["Na+/K+-ATPase", "GENE_OR_GENE_PRODUCT", 149, 162], ["membrane", "CELLULAR_COMPONENT", 285, 293], ["cytoplasm", "ORGANISM_SUBSTANCE", 333, 342], ["vesicle", "CELLULAR_COMPONENT", 363, 370], ["membrane", "CELLULAR_COMPONENT", 447, 455], ["GPCR", "PROTEIN", 32, 36], ["AAK1", "PROTEIN", 65, 69], ["PKC", "PROTEIN", 74, 77], ["\u03b6", "PROTEIN", 78, 79], ["AP", "PROTEIN", 83, 85], ["Na+/K+-ATPase", "PROTEIN", 149, 162], ["Clathrin", "PROTEIN", 219, 227], ["vesicle-like structure", "PROTEIN", 363, 385], ["endocytic pit", "PROTEIN", 401, 414], ["Dopamine binding", "TREATMENT", 0, 16], ["AAK1", "TEST", 65, 69], ["PKC", "TEST", 74, 77], ["AP", "TEST", 83, 85], ["the Na+", "TEST", 145, 152], ["ATPase", "TEST", 156, 162], ["CMEAs cargo selection", "TREATMENT", 181, 202], ["a vesicle-like structure", "PROBLEM", 361, 385], ["the endocytic pit", "PROBLEM", 397, 414], ["cargo selection", "OBSERVATION", 187, 202], ["cytoplasm", "OBSERVATION", 333, 342], ["endocytic pit", "OBSERVATION", 401, 414]]], ["Active membrane remodeling during this transition from a flat Clathrin lattice to a deeply invaginated endocytic pit is facilitated by curvature-sensing and -inducing Bin-Amphiphysin-Rvs (BAR) domain-containing proteins such as FCHo, Sorting Nexin 9 (SNX9), Amphiphysin, and Endophilin.", [["membrane", "ANATOMY", 7, 15], ["endocytic pit", "ANATOMY", 103, 116], ["membrane", "CELLULAR_COMPONENT", 7, 15], ["Bin-Amphiphysin-Rvs", "GENE_OR_GENE_PRODUCT", 167, 186], ["FCHo", "GENE_OR_GENE_PRODUCT", 228, 232], ["Sorting Nexin 9", "GENE_OR_GENE_PRODUCT", 234, 249], ["SNX9", "GENE_OR_GENE_PRODUCT", 251, 255], ["Amphiphysin", "GENE_OR_GENE_PRODUCT", 258, 269], ["Endophilin", "GENE_OR_GENE_PRODUCT", 275, 285], ["-inducing Bin-Amphiphysin-Rvs (BAR) domain-containing proteins", "PROTEIN", 157, 219], ["FCHo", "PROTEIN", 228, 232], ["Sorting Nexin 9", "PROTEIN", 234, 249], ["SNX9", "PROTEIN", 251, 255], ["Amphiphysin", "PROTEIN", 258, 269], ["Endophilin", "PROTEIN", 275, 285], ["Active membrane remodeling", "PROBLEM", 0, 26], ["a flat Clathrin lattice", "TREATMENT", 55, 78], ["a deeply invaginated endocytic pit", "PROBLEM", 82, 116], ["FCHo", "TREATMENT", 228, 232], ["Sorting Nexin", "TREATMENT", 234, 247], ["Amphiphysin", "TREATMENT", 258, 269], ["Endophilin", "TREATMENT", 275, 285], ["membrane", "OBSERVATION_MODIFIER", 7, 15], ["remodeling", "OBSERVATION", 16, 26], ["endocytic pit", "OBSERVATION", 103, 116]]], ["Finally, the membrane stalk is fissioned by the GTP hydrolyzing mechano-chemical enzyme Dynamin [23], and the Clathrin coat is shed with the help of the chaperone Hsc70 and auxilin or GAK [24] resulting in the release of a cargo-filled vesicle into the cytoplasm.", [["membrane stalk", "ANATOMY", 13, 27], ["vesicle", "ANATOMY", 236, 243], ["cytoplasm", "ANATOMY", 253, 262], ["GTP", "CHEMICAL", 48, 51], ["Dynamin [23]", "CHEMICAL", 88, 100], ["GTP", "CHEMICAL", 48, 51], ["membrane", "CELLULAR_COMPONENT", 13, 21], ["GTP", "SIMPLE_CHEMICAL", 48, 51], ["Dynamin [23]", "SIMPLE_CHEMICAL", 88, 100], ["Clathrin", "GENE_OR_GENE_PRODUCT", 110, 118], ["Hsc70", "GENE_OR_GENE_PRODUCT", 163, 168], ["auxilin", "GENE_OR_GENE_PRODUCT", 173, 180], ["vesicle", "CELLULAR_COMPONENT", 236, 243], ["cytoplasm", "ORGANISM_SUBSTANCE", 253, 262], ["Clathrin coat", "PROTEIN", 110, 123], ["Hsc70", "PROTEIN", 163, 168], ["auxilin", "PROTEIN", 173, 180], ["GAK [24]", "PROTEIN", 184, 192], ["the membrane stalk", "PROBLEM", 9, 27], ["chemical enzyme Dynamin", "TEST", 72, 95], ["the Clathrin coat", "TEST", 106, 123], ["cytoplasm", "ANATOMY", 253, 262]]], ["The neuronal isoform 1 of Dynamin and FCHSD2, a protein that promotes actin polymerization at the base of Clathrin-coated pits [25], were both shown to be phosphorylated as downstream targets of oncogenic signaling cascades that stimulate endocytosis [26, 27] making it likely that they also constitute regulatory points during stress.MECHANISM OF CMEDuring the late stages of endocytosis the forming endocytic vesicle is primed for its fusion with early endosomes via the activation of the small GTPase Rab5 at the onset of vesicle uncoating [28].", [["neuronal", "ANATOMY", 4, 12], ["endocytic vesicle", "ANATOMY", 401, 418], ["early endosomes", "ANATOMY", 449, 464], ["vesicle", "ANATOMY", 525, 532], ["neuronal isoform 1", "GENE_OR_GENE_PRODUCT", 4, 22], ["Dynamin", "GENE_OR_GENE_PRODUCT", 26, 33], ["FCHSD2", "GENE_OR_GENE_PRODUCT", 38, 44], ["actin", "GENE_OR_GENE_PRODUCT", 70, 75], ["endocytic vesicle", "CELLULAR_COMPONENT", 401, 418], ["early endosomes", "CELLULAR_COMPONENT", 449, 464], ["Rab5", "GENE_OR_GENE_PRODUCT", 504, 508], ["vesicle", "CELLULAR_COMPONENT", 525, 532], ["neuronal isoform 1", "PROTEIN", 4, 22], ["Dynamin", "PROTEIN", 26, 33], ["FCHSD2", "PROTEIN", 38, 44], ["actin", "PROTEIN", 70, 75], ["Clathrin", "PROTEIN", 106, 114], ["small GTPase", "PROTEIN", 491, 503], ["Rab5", "PROTEIN", 504, 508], ["Dynamin and FCHSD2", "TREATMENT", 26, 44], ["a protein", "TREATMENT", 46, 55], ["actin polymerization", "TREATMENT", 70, 90], ["Clathrin-coated pits", "TREATMENT", 106, 126], ["oncogenic signaling cascades", "PROBLEM", 195, 223], ["endocytosis the forming endocytic vesicle", "PROBLEM", 377, 418], ["its fusion", "TREATMENT", 433, 443], ["early endosomes", "PROBLEM", 449, 464], ["the small GTPase Rab5", "PROBLEM", 487, 508], ["vesicle uncoating", "PROBLEM", 525, 542], ["actin polymerization", "OBSERVATION", 70, 90], ["late stages", "OBSERVATION_MODIFIER", 362, 373], ["endocytosis", "OBSERVATION", 377, 388], ["endocytic vesicle", "OBSERVATION", 401, 418], ["small", "OBSERVATION_MODIFIER", 491, 496], ["GTPase Rab5", "OBSERVATION", 497, 508], ["vesicle uncoating", "OBSERVATION", 525, 542]]], ["Rab5-containing endosomes act as sorting platforms for cargo delivery either to a recycling pathway or for lysosomal degradation.", [["endosomes", "ANATOMY", 16, 25], ["lysosomal", "ANATOMY", 107, 116], ["Rab5", "GENE_OR_GENE_PRODUCT", 0, 4], ["endosomes", "CELLULAR_COMPONENT", 16, 25], ["lysosomal", "CELLULAR_COMPONENT", 107, 116], ["Rab5", "PROTEIN", 0, 4], ["Rab5", "TEST", 0, 4], ["cargo delivery", "TREATMENT", 55, 69], ["a recycling pathway", "TREATMENT", 80, 99], ["lysosomal degradation", "PROBLEM", 107, 128]]], ["Consistently, loss of function of Rab5 has been shown to impair endocytosis [28, 29] and to inhibit early endosome fusion [30].", [["early endosome", "ANATOMY", 100, 114], ["Rab5", "GENE_OR_GENE_PRODUCT", 34, 38], ["endosome", "CELLULAR_COMPONENT", 106, 114], ["Rab5", "PROTEIN", 34, 38], ["loss of function of Rab5", "PROBLEM", 14, 38], ["endosome fusion", "OBSERVATION", 106, 121]]], ["The balance between the delivery of newly synthesized membrane proteins, their endocytosis, recycling and degradation will determine the pool of membrane proteins present at the plasma membrane.", [["membrane", "ANATOMY", 54, 62], ["membrane", "ANATOMY", 145, 153], ["plasma membrane", "ANATOMY", 178, 193], ["membrane", "CELLULAR_COMPONENT", 54, 62], ["membrane", "CELLULAR_COMPONENT", 145, 153], ["plasma membrane", "CELLULAR_COMPONENT", 178, 193], ["membrane proteins", "PROTEIN", 54, 71], ["membrane proteins", "PROTEIN", 145, 162], ["newly synthesized membrane proteins", "TREATMENT", 36, 71], ["membrane proteins", "PROBLEM", 145, 162], ["balance", "OBSERVATION", 4, 11]]], ["Therefore, alterations in endocytosis constitute a rapid means of altering the surface levels of select proteins and identify CME as an attractive mechanism for the acute cellular adaptation to stressful environmental changes.MECHANISMS OF REGULATION OF CME UPON STRESS CONDITIONSAdaptive programs elicited by environmental stresses such as starvation, hypoxia, or alterations in ion strength or composition, among many other challenges, could either regulate bulk endocytic flux or alter the uptake of select proteins.", [["surface", "ANATOMY", 79, 86], ["cellular", "ANATOMY", 171, 179], ["hypoxia", "DISEASE", 353, 360], ["cellular", "CELL", 171, 179], ["alterations in endocytosis", "PROBLEM", 11, 37], ["the acute cellular adaptation", "PROBLEM", 161, 190], ["STRESS CONDITIONSAdaptive programs", "TREATMENT", 263, 297], ["hypoxia", "PROBLEM", 353, 360], ["alterations in ion strength", "PROBLEM", 365, 392], ["the uptake of select proteins", "PROBLEM", 489, 518]]], ["Altering bulk endocytic flux would result in a non-selective increase or decrease in the endocytic uptake of various cargos.", [["Altering bulk endocytic flux", "PROBLEM", 0, 28], ["a non-selective increase", "PROBLEM", 45, 69], ["the endocytic uptake of various cargos", "PROBLEM", 85, 123], ["bulk", "OBSERVATION_MODIFIER", 9, 13], ["endocytic flux", "OBSERVATION", 14, 28], ["increase", "OBSERVATION_MODIFIER", 61, 69], ["decrease", "OBSERVATION_MODIFIER", 73, 81], ["endocytic uptake", "OBSERVATION", 89, 105]]], ["This might have general benefits, for example, energy preservation when overall endocytosis is downregulated or the restoration of membrane tension when endocytosis is upregulated.", [["membrane", "ANATOMY", 131, 139], ["membrane", "CELLULAR_COMPONENT", 131, 139], ["overall endocytosis", "PROBLEM", 72, 91], ["membrane tension", "PROBLEM", 131, 147], ["membrane tension", "OBSERVATION", 131, 147]]], ["An increase in endocytosis during stress might also be beneficial to elevate nutrient intake and thereby strengthen cellular resilience (Figure 1).", [["cellular", "ANATOMY", 116, 124], ["cellular", "CELL", 116, 124], ["An increase in endocytosis", "PROBLEM", 0, 26], ["increase", "OBSERVATION_MODIFIER", 3, 11], ["endocytosis", "OBSERVATION", 15, 26]]], ["For example, iron, which is taken up via CME of transferrin, is an important cofactor for a range of cellular enzymes including those required for mitochondrial oxidative phosphorylation [31].", [["cellular", "ANATOMY", 101, 109], ["mitochondrial", "ANATOMY", 147, 160], ["iron", "CHEMICAL", 13, 17], ["iron", "CHEMICAL", 13, 17], ["iron", "SIMPLE_CHEMICAL", 13, 17], ["transferrin", "GENE_OR_GENE_PRODUCT", 48, 59], ["cellular", "CELL", 101, 109], ["mitochondrial", "CELLULAR_COMPONENT", 147, 160], ["transferrin", "PROTEIN", 48, 59], ["cellular enzymes", "PROTEIN", 101, 117], ["iron", "TREATMENT", 13, 17], ["cellular enzymes", "TEST", 101, 117], ["mitochondrial oxidative phosphorylation", "TREATMENT", 147, 186]]], ["To induce an overall change in endocytosis, key players in CME such as Clathrin, AP-2, or Dynamin may be altered in their activities or levels.MECHANISMS OF REGULATION OF CME UPON STRESS CONDITIONSStress-induced changes in the endocytosis of select membrane proteins on the other hand could be used to switch on or to amplify specific cellular pathways counteracting deleterious stress effects.", [["membrane", "ANATOMY", 249, 257], ["cellular", "ANATOMY", 335, 343], ["Dynamin", "CHEMICAL", 90, 97], ["Clathrin", "GENE_OR_GENE_PRODUCT", 71, 79], ["AP-2", "GENE_OR_GENE_PRODUCT", 81, 85], ["Dynamin", "GENE_OR_GENE_PRODUCT", 90, 97], ["membrane", "CELLULAR_COMPONENT", 249, 257], ["cellular", "CELL", 335, 343], ["Clathrin", "PROTEIN", 71, 79], ["AP", "PROTEIN", 81, 83], ["Dynamin", "PROTEIN", 90, 97], ["membrane proteins", "PROTEIN", 249, 266], ["an overall change in endocytosis", "PROBLEM", 10, 42], ["STRESS CONDITIONSStress", "PROBLEM", 180, 203], ["induced changes", "PROBLEM", 204, 219], ["the endocytosis", "PROBLEM", 223, 238], ["deleterious stress effects", "PROBLEM", 367, 393], ["overall", "OBSERVATION_MODIFIER", 13, 20], ["change", "OBSERVATION", 21, 27], ["endocytosis", "OBSERVATION", 31, 42]]], ["To achieve a selective change in the endocytosis of a specific membrane protein, the first option would be to modify the protein itself to alter its affinity for the endocytic machinery.", [["membrane", "ANATOMY", 63, 71], ["membrane", "CELLULAR_COMPONENT", 63, 71], ["membrane protein", "PROTEIN", 63, 79], ["a selective change", "PROBLEM", 11, 29], ["a specific membrane protein", "TREATMENT", 52, 79], ["selective", "OBSERVATION_MODIFIER", 13, 22], ["change", "OBSERVATION", 23, 29]]], ["For example, proteins can be marked for endocytosis via phosphorylation.", [["endocytosis via phosphorylation", "PROBLEM", 40, 71]]], ["This is the case for GPCRs that following phosphorylation by G-protein coupled receptor kinases (GRKs) bind to their specific endocytic adaptor, \u03b2-arrestin.", [["G-protein coupled receptor kinases", "GENE_OR_GENE_PRODUCT", 61, 95], ["GRKs", "GENE_OR_GENE_PRODUCT", 97, 101], ["\u03b2-arrestin", "GENE_OR_GENE_PRODUCT", 145, 155], ["G-protein coupled receptor kinases", "PROTEIN", 61, 95], ["GRKs", "PROTEIN", 97, 101], ["endocytic adaptor", "PROTEIN", 126, 143], ["\u03b2-arrestin", "PROTEIN", 145, 155], ["GPCRs", "PROBLEM", 21, 26], ["phosphorylation", "TREATMENT", 42, 57], ["endocytic adaptor", "OBSERVATION", 126, 143]]], ["Alternatively, cargo proteins can become ubiquitinated like the epidermal growth factor receptor (EGFR) or vascular endothelial growth factor receptor 2 (VEGFR2) for sorting by endocytic adaptors such as Eps15, Eps15R and Epsins that carry ubiquitin interaction motifs.", [["epidermal growth factor receptor", "GENE_OR_GENE_PRODUCT", 64, 96], ["EGFR", "GENE_OR_GENE_PRODUCT", 98, 102], ["vascular endothelial growth factor receptor 2", "GENE_OR_GENE_PRODUCT", 107, 152], ["VEGFR2", "GENE_OR_GENE_PRODUCT", 154, 160], ["Eps15", "GENE_OR_GENE_PRODUCT", 204, 209], ["Eps15R", "GENE_OR_GENE_PRODUCT", 211, 217], ["Epsins", "GENE_OR_GENE_PRODUCT", 222, 228], ["cargo proteins", "PROTEIN", 15, 29], ["epidermal growth factor receptor", "PROTEIN", 64, 96], ["EGFR", "PROTEIN", 98, 102], ["vascular endothelial growth factor receptor 2", "PROTEIN", 107, 152], ["VEGFR2", "PROTEIN", 154, 160], ["endocytic adaptors", "PROTEIN", 177, 195], ["Eps15", "PROTEIN", 204, 209], ["Eps", "PROTEIN", 211, 214], ["15R", "PROTEIN", 214, 217], ["Epsins", "PROTEIN", 222, 228], ["ubiquitin interaction motifs", "PROTEIN", 240, 268], ["cargo proteins", "PROBLEM", 15, 29], ["the epidermal growth factor receptor (EGFR)", "PROBLEM", 60, 103], ["vascular endothelial growth factor receptor", "PROBLEM", 107, 150], ["Epsins", "TREATMENT", 222, 228], ["vascular endothelial", "ANATOMY", 107, 127]]], ["Alternatively, modifications of specific adaptor proteins might be employed to trigger changes in the endocytosis of select cargos.", [["cargos", "CELLULAR_COMPONENT", 124, 130], ["adaptor proteins", "PROTEIN", 41, 57], ["specific adaptor proteins", "TREATMENT", 32, 57]]], ["For example, ARH, the endocytic adaptor that facilitates the internalization of ligand-bound LDLRs, needs to be S-nitrosylated to interact with AP-2 [32].", [["ARH", "GENE_OR_GENE_PRODUCT", 13, 16], ["LDLRs", "GENE_OR_GENE_PRODUCT", 93, 98], ["AP-2", "GENE_OR_GENE_PRODUCT", 144, 148], ["ARH", "PROTEIN", 13, 16], ["endocytic adaptor", "PROTEIN", 22, 39], ["LDLRs", "PROTEIN", 93, 98], ["AP", "PROTEIN", 144, 146], ["ARH", "PROBLEM", 13, 16], ["the endocytic adaptor", "TREATMENT", 18, 39], ["AP", "TEST", 144, 146]]], ["This type of modification could conceivably be modulated by cellular redox state and, thus, be responsive to certain types of stress.", [["cellular", "ANATOMY", 60, 68], ["cellular", "CELL", 60, 68], ["stress", "PROBLEM", 126, 132], ["cellular redox", "OBSERVATION", 60, 74]]], ["Since a number of kinases such as protein kinase N (PKN) and the mitogen-activated protein kinase (MAPK) p38 are known to be sensitive to cellular stress conditions, such as changes in osmolarity, it is also conceivable how stress-induced signal cascades could lead to alterations in the uptake of specific proteins by introducing the phosphorylation of cargo or adaptor proteins.MECHANISMS OF REGULATION OF CME UPON STRESS CONDITIONSIn fact, the p38 pathway is one of the few stress-responsive signaling cascades that have been linked to alterations in endocytosis.", [["cellular", "ANATOMY", 138, 146], ["protein kinase N", "GENE_OR_GENE_PRODUCT", 34, 50], ["PKN", "GENE_OR_GENE_PRODUCT", 52, 55], ["mitogen-activated protein kinase", "GENE_OR_GENE_PRODUCT", 65, 97], ["MAPK", "GENE_OR_GENE_PRODUCT", 99, 103], ["p38", "GENE_OR_GENE_PRODUCT", 105, 108], ["cellular", "CELL", 138, 146], ["p38", "GENE_OR_GENE_PRODUCT", 447, 450], ["kinases", "PROTEIN", 18, 25], ["protein kinase N", "PROTEIN", 34, 50], ["PKN", "PROTEIN", 52, 55], ["mitogen-activated protein kinase", "PROTEIN", 65, 97], ["MAPK", "PROTEIN", 99, 103], ["p38", "PROTEIN", 105, 108], ["cargo", "PROTEIN", 354, 359], ["adaptor proteins", "PROTEIN", 363, 379], ["p38", "PROTEIN", 447, 450], ["kinases", "TEST", 18, 25], ["protein kinase N", "TEST", 34, 50], ["PKN", "TEST", 52, 55], ["the mitogen-activated protein kinase (MAPK) p38", "TEST", 61, 108], ["cellular stress conditions", "PROBLEM", 138, 164], ["changes in osmolarity", "PROBLEM", 174, 195], ["signal cascades", "PROBLEM", 239, 254], ["the uptake of specific proteins", "PROBLEM", 284, 315], ["the phosphorylation of cargo or adaptor proteins", "TREATMENT", 331, 379], ["the p38 pathway", "TEST", 443, 458], ["responsive signaling cascades", "PROBLEM", 484, 513], ["few", "OBSERVATION_MODIFIER", 473, 476], ["responsive signaling cascades", "OBSERVATION", 484, 513], ["endocytosis", "OBSERVATION_MODIFIER", 554, 565]]], ["Among other targets, the activation of this pathway was shown to alter the activity state of Rab5 [33], which is not only crucial for early endosomal membrane traffic, but is also known to affect endocytosis [29].", [["endosomal membrane", "ANATOMY", 140, 158], ["Rab5 [33]", "GENE_OR_GENE_PRODUCT", 93, 102], ["endosomal membrane", "CELLULAR_COMPONENT", 140, 158], ["Rab5", "PROTEIN", 93, 97], ["Rab5", "TEST", 93, 97], ["endosomal membrane traffic", "OBSERVATION", 140, 166]]], ["Rab5 in its cytosolic GDP-bound state is complexed to guanyl-nucleotide dissociation inhibitor (GDI), which promotes its extraction from membranes.", [["cytosolic", "ANATOMY", 12, 21], ["membranes", "ANATOMY", 137, 146], ["GDP", "CHEMICAL", 22, 25], ["guanyl-nucleotide", "CHEMICAL", 54, 71], ["GDP", "CHEMICAL", 22, 25], ["guanyl-nucleotide", "CHEMICAL", 54, 71], ["Rab5", "GENE_OR_GENE_PRODUCT", 0, 4], ["cytosolic", "CELLULAR_COMPONENT", 12, 21], ["GDP", "SIMPLE_CHEMICAL", 22, 25], ["guanyl-nucleotide", "SIMPLE_CHEMICAL", 54, 71], ["GDI", "SIMPLE_CHEMICAL", 96, 99], ["membranes", "CELLULAR_COMPONENT", 137, 146], ["Rab5", "PROTEIN", 0, 4], ["cytosolic GDP-bound state", "PROTEIN", 12, 37], ["Rab5", "TEST", 0, 4], ["guanyl-nucleotide dissociation inhibitor", "TREATMENT", 54, 94], ["cytosolic", "OBSERVATION_MODIFIER", 12, 21], ["GDP", "OBSERVATION_MODIFIER", 22, 25], ["bound state", "OBSERVATION_MODIFIER", 26, 37]]], ["GDI activity is stimulated by active p38, and the increase in Rab5:GDI complexes appears to promote endocytosis in line with earlier reports [28].", [["GDI", "GENE_OR_GENE_PRODUCT", 0, 3], ["p38", "GENE_OR_GENE_PRODUCT", 37, 40], ["Rab5", "GENE_OR_GENE_PRODUCT", 62, 66], ["GDI", "GENE_OR_GENE_PRODUCT", 67, 70], ["GDI", "PROTEIN", 0, 3], ["p38", "PROTEIN", 37, 40], ["Rab5:GDI complexes", "PROTEIN", 62, 80], ["GDI complexes", "PROBLEM", 67, 80]]], ["Even though this study only analyzed the uptake of HRP and dextrans [33], i.e. signature cargos of fluid phase endocytosis, it is likely that the findings can be extended to CME since Rab5:GDI has been proposed to act at Clathrin-coated pits [28].MECHANISMS OF REGULATION OF CME UPON STRESS CONDITIONSGiven the multitude of different environmental stresses and their potential impact on distinct cell and organ systems, it is not surprising that no systematic studies on the regulation of CME by various stress conditions have been performed and no consensus picture or mechanism has emerged yet.", [["cell", "ANATOMY", 396, 400], ["organ systems", "ANATOMY", 405, 418], ["dextrans", "CHEMICAL", 59, 67], ["HRP", "SIMPLE_CHEMICAL", 51, 54], ["dextrans [33]", "SIMPLE_CHEMICAL", 59, 72], ["Rab5", "GENE_OR_GENE_PRODUCT", 184, 188], ["GDI", "GENE_OR_GENE_PRODUCT", 189, 192], ["Clathrin", "SIMPLE_CHEMICAL", 221, 229], ["cell", "CELL", 396, 400], ["organ", "ORGAN", 405, 410], ["HRP", "PROTEIN", 51, 54], ["Rab5", "PROTEIN", 184, 188], ["GDI", "PROTEIN", 189, 192], ["Clathrin", "PROTEIN", 221, 229], ["this study", "TEST", 12, 22], ["the uptake of HRP and dextrans", "TEST", 37, 67], ["fluid phase endocytosis", "PROBLEM", 99, 122], ["different environmental stresses", "PROBLEM", 324, 356], ["organ systems", "TEST", 405, 418], ["systematic studies", "TEST", 449, 467], ["various stress conditions", "TEST", 496, 521], ["fluid phase", "OBSERVATION", 99, 110], ["distinct cell", "OBSERVATION", 387, 400]]], ["Moreover, in many studies, specific effects of environmental stresses on the endocytosis or plasma membrane level of a defined membrane protein have not always been discerned from effects on CME in general.", [["plasma membrane", "ANATOMY", 92, 107], ["membrane", "ANATOMY", 127, 135], ["plasma membrane", "CELLULAR_COMPONENT", 92, 107], ["membrane", "CELLULAR_COMPONENT", 127, 135], ["membrane protein", "PROTEIN", 127, 143], ["many studies", "TEST", 13, 25], ["environmental stresses", "PROBLEM", 47, 69], ["the endocytosis", "TEST", 73, 88], ["plasma membrane level", "TEST", 92, 113], ["a defined membrane protein", "PROBLEM", 117, 143]]], ["Hence, it often remains unclear whether a given stress elicits a cargo-selective endocytic change or a more global effect on CME and/or associated pathways, e.g. endosomal sorting downstream of CME.", [["endosomal", "ANATOMY", 162, 171], ["endosomal", "CELLULAR_COMPONENT", 162, 171], ["a cargo-selective endocytic change", "PROBLEM", 63, 97]]], ["We have therefore refrained from a clear distinction between these mechanisms.", [["clear", "OBSERVATION", 35, 40]]], ["Instead, we provide an overview of the various reports describing a regulatory role of different stress conditions on the endocytosis of distinct membrane proteins (Table 1).Oncogenic signaling ::: STRESS CONDITIONS THAT AFFECT ENDOCYTOSISThe most systematically addressed regulatory influence on CME so far is oncogenic signaling by which tumor cells \u201cadapt\u201d CME for their purposes [27].", [["membrane", "ANATOMY", 146, 154], ["tumor cells", "ANATOMY", 340, 351], ["tumor", "DISEASE", 340, 345], ["membrane", "CELLULAR_COMPONENT", 146, 154], ["tumor cells", "CELL", 340, 351], ["membrane proteins", "PROTEIN", 146, 163], ["Table 1", "PROTEIN", 165, 172], ["tumor cells", "CELL_TYPE", 340, 351], ["different stress conditions", "PROBLEM", 87, 114], ["oncogenic signaling", "PROBLEM", 311, 330]]], ["By screening a panel of oncogenic signaling kinase inhibitors, the Schmid lab uncovered that ten of the 21 studied pathways affected CME [27], even though for most of them it is still unclear how they influence CME mechanistically.", [["oncogenic signaling kinase inhibitors", "TREATMENT", 24, 61], ["the Schmid lab", "TEST", 63, 77]]], ["Concentrating on ERK1/2 signaling, Xiao et al. showed that ERK-dependent phosphorylation of FCHSD2, which acts in the maturation of Clathrin-coated pits [25], promotes FCHSD2 recruitment to the plasma membrane and, thereby, CME [27].", [["plasma membrane", "ANATOMY", 194, 209], ["ERK1/2", "GENE_OR_GENE_PRODUCT", 17, 23], ["ERK", "GENE_OR_GENE_PRODUCT", 59, 62], ["FCHSD2", "GENE_OR_GENE_PRODUCT", 92, 98], ["Clathrin", "GENE_OR_GENE_PRODUCT", 132, 140], ["FCHSD2", "GENE_OR_GENE_PRODUCT", 168, 174], ["plasma membrane", "CELLULAR_COMPONENT", 194, 209], ["ERK1", "PROTEIN", 17, 21], ["ERK", "PROTEIN", 59, 62], ["FCHSD2", "PROTEIN", 92, 98], ["Clathrin", "PROTEIN", 132, 140], ["FCHSD2", "PROTEIN", 168, 174], ["ERK", "TEST", 59, 62], ["dependent phosphorylation of FCHSD2", "PROBLEM", 63, 98]]], ["Thus, aberrant ERK signaling appears to be a crucial factor for the rapid CME observed in cancer cells.", [["cancer cells", "ANATOMY", 90, 102], ["cancer", "DISEASE", 90, 96], ["ERK", "GENE_OR_GENE_PRODUCT", 15, 18], ["cancer cells", "CELL", 90, 102], ["ERK", "PROTEIN", 15, 18], ["cancer cells", "CELL_TYPE", 90, 102], ["aberrant ERK signaling", "PROBLEM", 6, 28], ["a crucial factor", "PROBLEM", 43, 59], ["the rapid CME", "PROBLEM", 64, 77], ["cancer cells", "PROBLEM", 90, 102], ["ERK signaling", "OBSERVATION", 15, 28], ["appears to be", "UNCERTAINTY", 29, 42], ["cancer cells", "OBSERVATION", 90, 102]]], ["While the initial screening was based on transferrin uptake, subsequent experiments demonstrated that increased CME also leads to elevated EGFR uptake.", [["transferrin", "GENE_OR_GENE_PRODUCT", 41, 52], ["CME", "SIMPLE_CHEMICAL", 112, 115], ["EGFR", "GENE_OR_GENE_PRODUCT", 139, 143], ["transferrin", "PROTEIN", 41, 52], ["EGFR", "PROTEIN", 139, 143], ["the initial screening", "TEST", 6, 27], ["transferrin uptake", "TEST", 41, 59], ["increased CME", "PROBLEM", 102, 115], ["elevated EGFR uptake", "PROBLEM", 130, 150], ["increased", "OBSERVATION_MODIFIER", 102, 111], ["elevated", "OBSERVATION_MODIFIER", 130, 138], ["EGFR uptake", "OBSERVATION", 139, 150]]], ["This appears at first glance counterintuitive, given that increased receptor tyrosine kinase signaling is generally considered beneficial for oncogenesis.", [["tyrosine", "CHEMICAL", 77, 85], ["tyrosine", "CHEMICAL", 77, 85], ["receptor tyrosine kinase", "GENE_OR_GENE_PRODUCT", 68, 92], ["receptor tyrosine kinase", "PROTEIN", 68, 92], ["increased receptor tyrosine kinase signaling", "PROBLEM", 58, 102]]], ["However, as EGFR signaling is complex and takes place at both, the plasma membrane and early endosomes, the net signaling outcome in a given type of cancer cell is hard to predict.", [["plasma membrane", "ANATOMY", 67, 82], ["early endosomes", "ANATOMY", 87, 102], ["cancer cell", "ANATOMY", 149, 160], ["cancer", "DISEASE", 149, 155], ["EGFR", "GENE_OR_GENE_PRODUCT", 12, 16], ["plasma membrane", "CELLULAR_COMPONENT", 67, 82], ["early endosomes", "CELLULAR_COMPONENT", 87, 102], ["cancer cell", "CELL", 149, 160], ["EGFR", "PROTEIN", 12, 16], ["cancer cell", "CELL_TYPE", 149, 160], ["cancer cell", "PROBLEM", 149, 160], ["complex", "OBSERVATION_MODIFIER", 30, 37], ["cancer", "OBSERVATION", 149, 155]]], ["In fact, while a number of cancer cells show ERK- and FCHSD2-dependent upregulation of endocytosis, in non-small-cell lung cancer (NSCLC) loss of function of FCHSD2 has been suggested to promote cell proliferation and migration [27].", [["cancer cells", "ANATOMY", 27, 39], ["non-small-cell lung cancer", "ANATOMY", 103, 129], ["NSCLC", "ANATOMY", 131, 136], ["cell", "ANATOMY", 195, 199], ["cancer", "DISEASE", 27, 33], ["non-small-cell lung cancer", "DISEASE", 103, 129], ["NSCLC", "DISEASE", 131, 136], ["cancer cells", "CELL", 27, 39], ["ERK", "GENE_OR_GENE_PRODUCT", 45, 48], ["FCHSD2", "GENE_OR_GENE_PRODUCT", 54, 60], ["non-small-cell lung cancer", "CANCER", 103, 129], ["NSCLC", "CANCER", 131, 136], ["FCHSD2", "GENE_OR_GENE_PRODUCT", 158, 164], ["cell", "CELL", 195, 199], ["cancer cells", "CELL_TYPE", 27, 39], ["ERK", "PROTEIN", 45, 48], ["FCHSD2", "PROTEIN", 54, 60], ["FCHSD2", "PROTEIN", 158, 164], ["cancer cells", "PROBLEM", 27, 39], ["ERK", "TEST", 45, 48], ["FCHSD2", "TEST", 54, 60], ["dependent upregulation of endocytosis", "PROBLEM", 61, 98], ["non-small-cell lung cancer", "PROBLEM", 103, 129], ["NSCLC) loss of function of FCHSD2", "PROBLEM", 131, 164], ["dependent upregulation", "OBSERVATION_MODIFIER", 61, 83], ["endocytosis", "OBSERVATION_MODIFIER", 87, 98], ["non-small-cell", "OBSERVATION", 103, 117], ["lung", "ANATOMY", 118, 122], ["cancer", "OBSERVATION", 123, 129], ["NSCLC", "OBSERVATION", 131, 136], ["loss", "OBSERVATION_MODIFIER", 138, 142], ["suggested to", "UNCERTAINTY", 174, 186], ["promote cell proliferation", "OBSERVATION", 187, 213], ["migration", "OBSERVATION_MODIFIER", 218, 227]]], ["The complex effects of altered CME capacity on oncogenesis may depend on the tumor cell type as reflected by the fact that high FCHSD2 levels are correlated with increased survival in NSCLC [27], whereas elevated FCHSD2 may hamper survival in acute myeloid leukemia [34].", [["tumor cell", "ANATOMY", 77, 87], ["NSCLC", "ANATOMY", 184, 189], ["acute myeloid leukemia", "ANATOMY", 243, 265], ["tumor", "DISEASE", 77, 82], ["NSCLC", "DISEASE", 184, 189], ["acute myeloid leukemia", "DISEASE", 243, 265], ["tumor cell type", "CELL", 77, 92], ["FCHSD2", "GENE_OR_GENE_PRODUCT", 128, 134], ["NSCLC", "CANCER", 184, 189], ["FCHSD2", "GENE_OR_GENE_PRODUCT", 213, 219], ["acute myeloid leukemia", "CANCER", 243, 265], ["FCHSD2", "PROTEIN", 128, 134], ["FCHSD2", "PROTEIN", 213, 219], ["altered CME capacity", "PROBLEM", 23, 43], ["the tumor cell type", "PROBLEM", 73, 92], ["high FCHSD2 levels", "PROBLEM", 123, 141], ["increased survival in NSCLC", "PROBLEM", 162, 189], ["elevated FCHSD2", "PROBLEM", 204, 219], ["acute myeloid leukemia", "PROBLEM", 243, 265], ["complex", "OBSERVATION_MODIFIER", 4, 11], ["altered", "OBSERVATION_MODIFIER", 23, 30], ["CME capacity", "OBSERVATION", 31, 43], ["tumor cell", "OBSERVATION", 77, 87], ["increased", "OBSERVATION_MODIFIER", 162, 171], ["survival", "OBSERVATION_MODIFIER", 172, 180], ["acute", "OBSERVATION_MODIFIER", 243, 248], ["myeloid leukemia", "OBSERVATION", 249, 265]]], ["Thus, depending on concomitant signaling changes in cancer cells, further oncogenesis may be driven either by a down- or upregulation of endocytosis.", [["cancer cells", "ANATOMY", 52, 64], ["cancer", "DISEASE", 52, 58], ["cancer cells", "CELL", 52, 64], ["cancer cells", "CELL_TYPE", 52, 64], ["concomitant signaling changes in cancer cells", "PROBLEM", 19, 64], ["endocytosis", "PROBLEM", 137, 148], ["cancer cells", "OBSERVATION", 52, 64], ["endocytosis", "OBSERVATION", 137, 148]]], ["The differential regulation of CME in cancer cells might also reflect the fact that pro- and anti-oncogenic signaling pathways converge onto CME factors and may differentially adapt CME to cellular needs.", [["cancer cells", "ANATOMY", 38, 50], ["cellular", "ANATOMY", 189, 197], ["cancer", "DISEASE", 38, 44], ["CME", "GENE_OR_GENE_PRODUCT", 31, 34], ["cancer cells", "CELL", 38, 50], ["CME factors", "GENE_OR_GENE_PRODUCT", 141, 152], ["cellular", "CELL", 189, 197], ["cancer cells", "CELL_TYPE", 38, 50], ["CME factors", "PROTEIN", 141, 152], ["CME in cancer cells", "PROBLEM", 31, 50], ["anti-oncogenic signaling pathways", "PROBLEM", 93, 126], ["CME", "OBSERVATION_MODIFIER", 31, 34], ["cancer cells", "OBSERVATION", 38, 50]]], ["Analogous pathways likely exist for the adaptation of CME to other types of stress conditions.Endocytosis and nutrient signaling ::: Nutrient and energy deprivation ::: STRESS CONDITIONS THAT AFFECT ENDOCYTOSISEndocytosis provides cells with nutrients.", [["cells", "ANATOMY", 231, 236], ["cells", "CELL", 231, 236], ["Analogous pathways", "PROBLEM", 0, 18], ["stress conditions", "PROBLEM", 76, 93], ["nutrient signaling", "OBSERVATION", 110, 128], ["energy deprivation", "OBSERVATION", 146, 164]]], ["However, the role of endocytosis in nutrient supply and, conversely, the regulation of endocytosis by nutrients appears to be complex.", [["endocytosis", "OBSERVATION", 21, 32], ["endocytosis", "OBSERVATION", 87, 98], ["appears to be", "UNCERTAINTY", 112, 125]]], ["Work in yeast has revealed an elegant adaptive response by which nutrient deprivation not only activates autophagy for amino acid recycling, but also inhibits the endocytosis of specific amino acid transporters, e.g. the arginine transporter Can1, to promote amino acid uptake [35].", [["amino acid", "CHEMICAL", 119, 129], ["amino acid", "CHEMICAL", 187, 197], ["arginine", "CHEMICAL", 221, 229], ["amino acid", "CHEMICAL", 259, 269], ["amino acid", "CHEMICAL", 119, 129], ["amino acid", "CHEMICAL", 187, 197], ["arginine", "CHEMICAL", 221, 229], ["amino acid", "CHEMICAL", 259, 269], ["amino acid", "AMINO_ACID", 119, 129], ["amino acid", "AMINO_ACID", 187, 197], ["arginine", "AMINO_ACID", 221, 229], ["Can1", "GENE_OR_GENE_PRODUCT", 242, 246], ["amino acid", "AMINO_ACID", 259, 269], ["amino acid transporters", "PROTEIN", 187, 210], ["arginine transporter", "PROTEIN", 221, 241], ["Can1", "PROTEIN", 242, 246], ["yeast", "SPECIES", 8, 13], ["yeast", "SPECIES", 8, 13], ["amino acid recycling", "TREATMENT", 119, 139], ["specific amino acid transporters", "TREATMENT", 178, 210], ["the arginine transporter Can1", "TREATMENT", 217, 246], ["amino acid uptake", "TEST", 259, 276]]], ["This mechanism is regulated by nutrient signaling via mTORC1, the arrestin-like adaptor Art1, the ubiquitin ligase Rsp5, and the kinase Nrp1 (Figure 2).", [["mTORC1", "GENE_OR_GENE_PRODUCT", 54, 60], ["arrestin", "GENE_OR_GENE_PRODUCT", 66, 74], ["Art1", "GENE_OR_GENE_PRODUCT", 88, 92], ["Rsp5", "GENE_OR_GENE_PRODUCT", 115, 119], ["Nrp1", "GENE_OR_GENE_PRODUCT", 136, 140], ["Figure 2", "GENE_OR_GENE_PRODUCT", 142, 150], ["mTORC1", "PROTEIN", 54, 60], ["arrestin-like adaptor", "PROTEIN", 66, 87], ["Art1", "PROTEIN", 88, 92], ["ubiquitin ligase", "PROTEIN", 98, 114], ["Rsp5", "PROTEIN", 115, 119], ["kinase Nrp1", "PROTEIN", 129, 140], ["Figure 2", "PROTEIN", 142, 150], ["the ubiquitin ligase Rsp5", "TEST", 94, 119], ["ligase Rsp5", "OBSERVATION", 108, 119]]], ["At steady state, Can1 is ubiquitinated by the ubiquitin ligase Rsp5, which promotes Can1 endocytosis.", [["Can1", "GENE_OR_GENE_PRODUCT", 17, 21], ["Rsp5", "GENE_OR_GENE_PRODUCT", 63, 67], ["Can1", "GENE_OR_GENE_PRODUCT", 84, 88], ["Can1", "PROTEIN", 17, 21], ["ubiquitin ligase", "PROTEIN", 46, 62], ["Rsp5", "PROTEIN", 63, 67], ["Can1", "PROTEIN", 84, 88], ["ligase Rsp5", "OBSERVATION", 56, 67]]], ["The ubiquitin ligase adaptor Art1 is necessary to target Rsp5 to Can1.", [["Art1", "GENE_OR_GENE_PRODUCT", 29, 33], ["Rsp5", "GENE_OR_GENE_PRODUCT", 57, 61], ["Can1", "GENE_OR_GENE_PRODUCT", 65, 69], ["ubiquitin ligase", "PROTEIN", 4, 20], ["Art1", "PROTEIN", 29, 33], ["Rsp5", "PROTEIN", 57, 61], ["Can1", "PROTEIN", 65, 69], ["The ubiquitin ligase adaptor Art1", "TREATMENT", 0, 33], ["ubiquitin ligase", "OBSERVATION", 4, 20]]], ["Art1 is a substrate for the kinase Npr1, which phosphorylates Art1 and, thereby, causes its inactivation by limiting its plasma membrane association.", [["plasma membrane", "ANATOMY", 121, 136], ["Art1", "GENE_OR_GENE_PRODUCT", 0, 4], ["Npr1", "GENE_OR_GENE_PRODUCT", 35, 39], ["Art1", "GENE_OR_GENE_PRODUCT", 62, 66], ["plasma membrane", "CELLULAR_COMPONENT", 121, 136], ["Art1", "PROTEIN", 0, 4], ["kinase Npr1", "PROTEIN", 28, 39], ["Art1", "PROTEIN", 62, 66], ["the kinase Npr1", "TEST", 24, 39], ["its inactivation", "PROBLEM", 88, 104]]], ["Under conditions of energy sufficiency Npr1 is repressed by active mTORC1, thereby enabling Art1 to trigger the ubiquitina-tion-dependent endocytosis of Can1.", [["Npr1", "GENE_OR_GENE_PRODUCT", 39, 43], ["mTORC1", "GENE_OR_GENE_PRODUCT", 67, 73], ["Art1", "GENE_OR_GENE_PRODUCT", 92, 96], ["ubiquitina", "GENE_OR_GENE_PRODUCT", 112, 122], ["Can1", "GENE_OR_GENE_PRODUCT", 153, 157], ["Npr1", "PROTEIN", 39, 43], ["mTORC1", "PROTEIN", 67, 73], ["Art1", "PROTEIN", 92, 96], ["Can1", "PROTEIN", 153, 157], ["energy sufficiency Npr1", "TREATMENT", 20, 43], ["the ubiquitina", "TEST", 108, 122], ["dependent endocytosis of Can1", "PROBLEM", 128, 157], ["energy sufficiency", "OBSERVATION", 20, 38], ["dependent", "OBSERVATION_MODIFIER", 128, 137], ["endocytosis", "OBSERVATION", 138, 149]]], ["During starvation when mTORC1 activity is repressed, Npr1 becomes active, resulting in Art1 inhibition and a blockade of Can1 ubiquitination and endocytosis to promote the uptake of amino acids.", [["amino acids", "CHEMICAL", 182, 193], ["amino acids", "CHEMICAL", 182, 193], ["mTORC1", "GENE_OR_GENE_PRODUCT", 23, 29], ["Npr1", "GENE_OR_GENE_PRODUCT", 53, 57], ["Art1", "GENE_OR_GENE_PRODUCT", 87, 91], ["Can1", "GENE_OR_GENE_PRODUCT", 121, 125], ["amino acids", "AMINO_ACID", 182, 193], ["mTORC1", "PROTEIN", 23, 29], ["Npr1", "PROTEIN", 53, 57], ["Art1", "PROTEIN", 87, 91], ["Can1", "PROTEIN", 121, 125], ["Art1 inhibition", "PROBLEM", 87, 102], ["Can1 ubiquitination", "PROBLEM", 121, 140], ["endocytosis", "PROBLEM", 145, 156], ["amino acids", "TREATMENT", 182, 193], ["active", "OBSERVATION_MODIFIER", 66, 72]]], ["This work thus suggests a mechanism whereby mTORC1 promotes the internalization of amino acid transporters upon high nutrient availability, whereas under starvation decreased mTORC1 activity shuts down their endocytosis [35].Endocytosis and nutrient signaling ::: Nutrient and energy deprivation ::: STRESS CONDITIONS THAT AFFECT ENDOCYTOSISArt1 belongs to a family of arrestin-related proteins [36].", [["amino acid", "CHEMICAL", 83, 93], ["amino acid", "CHEMICAL", 83, 93], ["mTORC1", "GENE_OR_GENE_PRODUCT", 44, 50], ["amino acid", "AMINO_ACID", 83, 93], ["mTORC1", "GENE_OR_GENE_PRODUCT", 175, 181], ["arrestin-related proteins", "GENE_OR_GENE_PRODUCT", 369, 394], ["mTORC1", "PROTEIN", 44, 50], ["amino acid transporters", "PROTEIN", 83, 106], ["mTORC1", "PROTEIN", 175, 181], ["arrestin-related proteins", "PROTEIN", 369, 394], ["amino acid transporters", "TREATMENT", 83, 106], ["arrestin", "PROBLEM", 369, 377], ["nutrient signaling", "OBSERVATION", 241, 259], ["energy deprivation", "OBSERVATION", 277, 295]]], ["Therefore, it is conceivable that the outlined mechanism might encompass even more cargo proteins via the stress-dependent regulation of additional Art proteins.", [["Art", "GENE_OR_GENE_PRODUCT", 148, 151], ["cargo proteins", "PROTEIN", 83, 97], ["Art proteins", "PROTEIN", 148, 160], ["additional Art proteins", "TREATMENT", 137, 160]]], ["It is not clear yet whether this pathway also operates in mammalian cells.", [["cells", "ANATOMY", 68, 73], ["mammalian cells", "CELL", 58, 73], ["mammalian cells", "CELL_TYPE", 58, 73], ["not", "UNCERTAINTY", 6, 9], ["clear", "OBSERVATION", 10, 15], ["mammalian cells", "OBSERVATION", 58, 73]]], ["However, mammalian cells express a family of arrestin-domain-containing proteins that are known to link cargo proteins to ubiquitination.", [["mammalian cells", "ANATOMY", 9, 24], ["mammalian cells", "CELL", 9, 24], ["arrestin", "GENE_OR_GENE_PRODUCT", 45, 53], ["mammalian cells", "CELL_TYPE", 9, 24], ["arrestin-domain-containing proteins", "PROTEIN", 45, 80], ["cargo proteins", "PROTEIN", 104, 118], ["arrestin-domain-containing proteins", "TREATMENT", 45, 80], ["mammalian cells", "OBSERVATION", 9, 24]]], ["Although there is no obvious homolog of Npr1 in mammalian cells, it is interesting to note that it belongs to the same kinase family as the mammalian AMP-activated kinase (AMPK).", [["cells", "ANATOMY", 58, 63], ["AMP", "CHEMICAL", 150, 153], ["AMP", "CHEMICAL", 150, 153], ["Npr1", "GENE_OR_GENE_PRODUCT", 40, 44], ["mammalian cells", "CELL", 48, 63], ["AMP-activated kinase", "GENE_OR_GENE_PRODUCT", 150, 170], ["AMPK", "GENE_OR_GENE_PRODUCT", 172, 176], ["Npr1", "PROTEIN", 40, 44], ["mammalian cells", "CELL_TYPE", 48, 63], ["kinase family", "PROTEIN", 119, 132], ["mammalian AMP-activated kinase", "PROTEIN", 140, 170], ["AMPK", "PROTEIN", 172, 176], ["obvious homolog of Npr1 in mammalian cells", "PROBLEM", 21, 63], ["the mammalian AMP", "TEST", 136, 153], ["no obvious", "UNCERTAINTY", 18, 28], ["Npr1", "OBSERVATION", 40, 44], ["mammalian cells", "OBSERVATION", 48, 63]]], ["AMPK has recently been shown to be inhibited by mTORC1 [37] and might therefore be a possible candidate for the reported mTORC1-dependent downregulation of endocytosis [35].Endocytosis and nutrient signaling ::: Nutrient and energy deprivation ::: STRESS CONDITIONS THAT AFFECT ENDOCYTOSISIt is likely that the repression of Can1 internalization in nitrogen-starved yeast cells is a cargo-specific response rather than reflecting a general repression of endocytosis upon nutrient deprivation, since other studies propose that starvation rather favors endocytosis, conceivably to enhance protein degradation and, thereby, increase nutrient availability to maintain cell function.", [["yeast cells", "ANATOMY", 366, 377], ["cell", "ANATOMY", 664, 668], ["Can1", "CHEMICAL", 325, 329], ["nitrogen", "CHEMICAL", 349, 357], ["nitrogen", "CHEMICAL", 349, 357], ["AMPK", "GENE_OR_GENE_PRODUCT", 0, 4], ["mTORC1 [37]", "GENE_OR_GENE_PRODUCT", 48, 59], ["mTORC1", "GENE_OR_GENE_PRODUCT", 121, 127], ["Can1", "GENE_OR_GENE_PRODUCT", 325, 329], ["nitrogen", "SIMPLE_CHEMICAL", 349, 357], ["yeast cells", "CELL", 366, 377], ["cell", "CELL", 664, 668], ["AMPK", "PROTEIN", 0, 4], ["mTORC1", "PROTEIN", 48, 54], ["mTORC1", "PROTEIN", 121, 127], ["Can1", "PROTEIN", 325, 329], ["nitrogen-starved yeast cells", "CELL_LINE", 349, 377], ["yeast", "SPECIES", 366, 371], ["yeast", "SPECIES", 366, 371], ["AMPK", "TEST", 0, 4], ["Can1 internalization in nitrogen-starved yeast cells", "PROBLEM", 325, 377], ["a general repression of endocytosis", "PROBLEM", 430, 465], ["nutrient deprivation", "TREATMENT", 471, 491], ["other studies", "TEST", 499, 512], ["protein degradation", "PROBLEM", 587, 606], ["nutrient signaling", "OBSERVATION", 189, 207], ["energy deprivation", "OBSERVATION", 225, 243], ["yeast cells", "OBSERVATION", 366, 377], ["endocytosis", "OBSERVATION", 454, 465], ["cell function", "OBSERVATION", 664, 677]]], ["A recent study in mammalian cells combining SILAC with mass spectrometry reported that around 3% of the proteome is degraded following starvation [38].", [["cells", "ANATOMY", 28, 33], ["mammalian cells", "CELL", 18, 33], ["mammalian cells", "CELL_TYPE", 18, 33], ["A recent study", "TEST", 0, 14], ["mass spectrometry", "PROBLEM", 55, 72]]], ["Many of the substrates found were plasma membrane receptors that are degraded via endocytosis and subsequent lysosomal proteolysis to protect from starvation-induced cell death.Glucose and energy deprivation ::: Nutrient and energy deprivation ::: STRESS CONDITIONS THAT AFFECT ENDOCYTOSISAcute cellular energy deprivation requires adaptive changes such as increased uptake of glucose.", [["plasma membrane", "ANATOMY", 34, 49], ["lysosomal", "ANATOMY", 109, 118], ["cell", "ANATOMY", 166, 170], ["cellular", "ANATOMY", 295, 303], ["death", "DISEASE", 171, 176], ["Glucose", "CHEMICAL", 177, 184], ["glucose", "CHEMICAL", 377, 384], ["Glucose", "CHEMICAL", 177, 184], ["glucose", "CHEMICAL", 377, 384], ["plasma", "ORGANISM_SUBSTANCE", 34, 40], ["membrane", "CELLULAR_COMPONENT", 41, 49], ["lysosomal", "CELLULAR_COMPONENT", 109, 118], ["cell", "CELL", 166, 170], ["Glucose", "SIMPLE_CHEMICAL", 177, 184], ["cellular", "CELL", 295, 303], ["glucose", "SIMPLE_CHEMICAL", 377, 384], ["plasma membrane receptors", "PROTEIN", 34, 59], ["plasma membrane receptors", "TEST", 34, 59], ["subsequent lysosomal proteolysis", "PROBLEM", 98, 130], ["induced cell death", "PROBLEM", 158, 176], ["Glucose", "TEST", 177, 184], ["STRESS CONDITIONS", "PROBLEM", 248, 265], ["ENDOCYTOSISAcute cellular energy deprivation", "PROBLEM", 278, 322], ["adaptive changes", "PROBLEM", 332, 348], ["increased uptake of glucose", "PROBLEM", 357, 384], ["lysosomal proteolysis", "OBSERVATION", 109, 130], ["cell death", "OBSERVATION", 166, 176], ["energy deprivation", "OBSERVATION", 189, 207], ["energy deprivation", "OBSERVATION", 225, 243], ["energy deprivation", "OBSERVATION", 304, 322]]], ["Most cells take up glucose via the glucose transporter GLUT1, a membrane protein regulated by CME.", [["cells", "ANATOMY", 5, 10], ["membrane", "ANATOMY", 64, 72], ["glucose", "CHEMICAL", 19, 26], ["glucose", "CHEMICAL", 35, 42], ["glucose", "CHEMICAL", 19, 26], ["glucose", "CHEMICAL", 35, 42], ["cells", "CELL", 5, 10], ["glucose", "SIMPLE_CHEMICAL", 19, 26], ["glucose", "SIMPLE_CHEMICAL", 35, 42], ["GLUT1", "GENE_OR_GENE_PRODUCT", 55, 60], ["membrane", "CELLULAR_COMPONENT", 64, 72], ["glucose transporter", "PROTEIN", 35, 54], ["GLUT1", "PROTEIN", 55, 60], ["membrane protein", "PROTEIN", 64, 80], ["Most cells", "PROBLEM", 0, 10], ["glucose", "TEST", 19, 26], ["the glucose transporter GLUT1", "TEST", 31, 60], ["a membrane protein", "TEST", 62, 80]]], ["At steady state the surface levels of GLUT1 are kept in check by the arrestin-domain containing protein TXNIP, which promotes the internalization of GLUT1.", [["surface", "ANATOMY", 20, 27], ["surface", "CELLULAR_COMPONENT", 20, 27], ["GLUT1", "GENE_OR_GENE_PRODUCT", 38, 43], ["arrestin-domain", "GENE_OR_GENE_PRODUCT", 69, 84], ["TXNIP", "GENE_OR_GENE_PRODUCT", 104, 109], ["GLUT1", "GENE_OR_GENE_PRODUCT", 149, 154], ["GLUT1", "PROTEIN", 38, 43], ["arrestin-domain containing protein", "PROTEIN", 69, 103], ["TXNIP", "PROTEIN", 104, 109], ["GLUT1", "PROTEIN", 149, 154], ["the surface levels", "TEST", 16, 34], ["protein TXNIP", "TREATMENT", 96, 109], ["protein TXNIP", "OBSERVATION", 96, 109]]], ["When ATP is running low and the AMP/ATP ratio increases, AMPK gets activated and phosphorylates TXNIP, thereby inducing its degradation.", [["ATP", "CHEMICAL", 5, 8], ["AMP", "CHEMICAL", 32, 35], ["ATP", "CHEMICAL", 36, 39], ["ATP", "CHEMICAL", 5, 8], ["AMP", "CHEMICAL", 32, 35], ["ATP", "CHEMICAL", 36, 39], ["ATP", "SIMPLE_CHEMICAL", 5, 8], ["AMP", "SIMPLE_CHEMICAL", 32, 35], ["ATP", "SIMPLE_CHEMICAL", 36, 39], ["AMPK", "GENE_OR_GENE_PRODUCT", 57, 61], ["TXNIP", "GENE_OR_GENE_PRODUCT", 96, 101], ["AMPK", "PROTEIN", 57, 61], ["TXNIP", "PROTEIN", 96, 101], ["ATP", "TEST", 5, 8], ["the AMP/ATP ratio", "TEST", 28, 45], ["phosphorylates TXNIP", "TREATMENT", 81, 101]]], ["As a consequence, the endocytosis of GLUT1 is repressed and glucose uptake is promoted to relieve energy stress [39] (Figure 3).Glucose and energy deprivation ::: Nutrient and energy deprivation ::: STRESS CONDITIONS THAT AFFECT ENDOCYTOSISEndocytosis of non-essential proteins indeed may assist survival under conditions of limited energy supply.", [["glucose", "CHEMICAL", 60, 67], ["Glucose", "CHEMICAL", 128, 135], ["glucose", "CHEMICAL", 60, 67], ["Glucose", "CHEMICAL", 128, 135], ["GLUT1", "GENE_OR_GENE_PRODUCT", 37, 42], ["glucose", "SIMPLE_CHEMICAL", 60, 67], ["Glucose", "SIMPLE_CHEMICAL", 128, 135], ["GLUT1", "PROTEIN", 37, 42], ["non-essential proteins", "PROTEIN", 255, 277], ["the endocytosis of GLUT1", "PROBLEM", 18, 42], ["glucose uptake", "TEST", 60, 74], ["energy stress", "PROBLEM", 98, 111], ["Glucose", "TEST", 128, 135], ["non-essential proteins", "PROBLEM", 255, 277], ["energy deprivation", "OBSERVATION", 140, 158], ["energy deprivation", "OBSERVATION", 176, 194]]], ["In yeast, low glucose levels promote the endocytosis of plasma membrane proteins, such as the uracil permease Fur4 and the hydrophobic amino acid permease Tat2, to the vacuole/lysosome, while recycling to the surface is inhibited, thereby promoting endocytic flux to the vacuole [40].", [["plasma membrane", "ANATOMY", 56, 71], ["vacuole", "ANATOMY", 168, 175], ["lysosome", "ANATOMY", 176, 184], ["surface", "ANATOMY", 209, 216], ["vacuole", "ANATOMY", 271, 278], ["glucose", "CHEMICAL", 14, 21], ["uracil", "CHEMICAL", 94, 100], ["amino acid", "CHEMICAL", 135, 145], ["glucose", "CHEMICAL", 14, 21], ["uracil", "CHEMICAL", 94, 100], ["amino acid", "CHEMICAL", 135, 145], ["glucose", "SIMPLE_CHEMICAL", 14, 21], ["plasma membrane", "CELLULAR_COMPONENT", 56, 71], ["uracil", "SIMPLE_CHEMICAL", 94, 100], ["Fur4", "GENE_OR_GENE_PRODUCT", 110, 114], ["amino acid", "AMINO_ACID", 135, 145], ["Tat2", "GENE_OR_GENE_PRODUCT", 155, 159], ["vacuole", "CELLULAR_COMPONENT", 168, 175], ["lysosome", "CELLULAR_COMPONENT", 176, 184], ["surface", "CELLULAR_COMPONENT", 209, 216], ["vacuole", "CELLULAR_COMPONENT", 271, 278], ["plasma membrane proteins", "PROTEIN", 56, 80], ["uracil permease", "PROTEIN", 94, 109], ["Fur4", "PROTEIN", 110, 114], ["hydrophobic amino acid permease", "PROTEIN", 123, 154], ["Tat2", "PROTEIN", 155, 159], ["yeast", "SPECIES", 3, 8], ["yeast", "SPECIES", 3, 8], ["low glucose levels", "PROBLEM", 10, 28], ["plasma membrane proteins", "TEST", 56, 80], ["the uracil permease", "TEST", 90, 109], ["the hydrophobic amino acid permease Tat2", "TREATMENT", 119, 159], ["the vacuole/lysosome", "TREATMENT", 164, 184], ["endocytic flux", "OBSERVATION", 249, 263]]], ["The mechanism that renders the recycling pathway sensitive to glucose starvation remains incompletely understood.Glucose and energy deprivation ::: Nutrient and energy deprivation ::: STRESS CONDITIONS THAT AFFECT ENDOCYTOSISIn the brain, impaired energy metabolism is linked to ischemia and to neurodegenerative diseases.", [["brain", "ANATOMY", 232, 237], ["glucose", "CHEMICAL", 62, 69], ["Glucose", "CHEMICAL", 113, 120], ["ischemia", "DISEASE", 279, 287], ["neurodegenerative diseases", "DISEASE", 295, 321], ["glucose", "CHEMICAL", 62, 69], ["Glucose", "CHEMICAL", 113, 120], ["glucose", "SIMPLE_CHEMICAL", 62, 69], ["Glucose", "SIMPLE_CHEMICAL", 113, 120], ["brain", "ORGAN", 232, 237], ["glucose starvation", "TREATMENT", 62, 80], ["Glucose", "TEST", 113, 120], ["ENDOCYTOSISIn the brain", "PROBLEM", 214, 237], ["impaired energy metabolism", "PROBLEM", 239, 265], ["ischemia", "PROBLEM", 279, 287], ["neurodegenerative diseases", "PROBLEM", 295, 321], ["energy deprivation", "OBSERVATION", 125, 143], ["energy deprivation", "OBSERVATION", 161, 179], ["brain", "ANATOMY", 232, 237], ["impaired", "OBSERVATION_MODIFIER", 239, 247], ["energy metabolism", "OBSERVATION", 248, 265], ["ischemia", "OBSERVATION", 279, 287], ["neurodegenerative", "OBSERVATION_MODIFIER", 295, 312], ["diseases", "OBSERVATION", 313, 321]]], ["Oxygen and glucose deprivation (OGD) invoke pathogenic processes such as increased glutamate excitotoxicity, Ca2+ overload, mitochondrial impairment, oxidative and endoplasmic reticulum stress, inflammation, and apoptosis explaining the ischemia-induced cerebral injury.", [["mitochondrial", "ANATOMY", 124, 137], ["endoplasmic reticulum", "ANATOMY", 164, 185], ["cerebral", "ANATOMY", 254, 262], ["Oxygen", "CHEMICAL", 0, 6], ["glucose", "CHEMICAL", 11, 18], ["glutamate", "CHEMICAL", 83, 92], ["excitotoxicity", "DISEASE", 93, 107], ["Ca2", "CHEMICAL", 109, 112], ["mitochondrial impairment", "DISEASE", 124, 148], ["inflammation", "DISEASE", 194, 206], ["cerebral injury", "DISEASE", 254, 269], ["Oxygen", "CHEMICAL", 0, 6], ["glucose", "CHEMICAL", 11, 18], ["glutamate", "CHEMICAL", 83, 92], ["Ca2+", "CHEMICAL", 109, 113], ["Oxygen", "SIMPLE_CHEMICAL", 0, 6], ["glucose", "SIMPLE_CHEMICAL", 11, 18], ["glutamate", "SIMPLE_CHEMICAL", 83, 92], ["Ca2+", "SIMPLE_CHEMICAL", 109, 113], ["mitochondrial", "CELLULAR_COMPONENT", 124, 137], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 164, 185], ["cerebral", "ORGAN", 254, 262], ["Oxygen", "TREATMENT", 0, 6], ["glucose deprivation", "TREATMENT", 11, 30], ["pathogenic processes", "PROBLEM", 44, 64], ["increased glutamate excitotoxicity", "PROBLEM", 73, 107], ["Ca2+ overload", "PROBLEM", 109, 122], ["mitochondrial impairment", "PROBLEM", 124, 148], ["oxidative and endoplasmic reticulum stress", "PROBLEM", 150, 192], ["inflammation", "PROBLEM", 194, 206], ["apoptosis", "PROBLEM", 212, 221], ["the ischemia-induced cerebral injury", "PROBLEM", 233, 269], ["glucose deprivation", "OBSERVATION", 11, 30], ["increased", "OBSERVATION_MODIFIER", 73, 82], ["glutamate excitotoxicity", "OBSERVATION", 83, 107], ["overload", "OBSERVATION", 114, 122], ["mitochondrial impairment", "OBSERVATION", 124, 148], ["endoplasmic reticulum stress", "OBSERVATION", 164, 192], ["inflammation", "OBSERVATION", 194, 206], ["ischemia-induced", "OBSERVATION_MODIFIER", 237, 253], ["cerebral", "ANATOMY", 254, 262], ["injury", "OBSERVATION", 263, 269]]], ["Hypoxia inducible factors (HIFs) and the AMPK signaling pathway are known to be involved in the response to OGD.", [["Hypoxia inducible factors", "GENE_OR_GENE_PRODUCT", 0, 25], ["HIFs", "GENE_OR_GENE_PRODUCT", 27, 31], ["AMPK", "GENE_OR_GENE_PRODUCT", 41, 45], ["Hypoxia inducible factors", "PROTEIN", 0, 25], ["HIFs", "PROTEIN", 27, 31], ["AMPK", "PROTEIN", 41, 45], ["Hypoxia inducible factors", "PROBLEM", 0, 25], ["the AMPK signaling pathway", "PROBLEM", 37, 63], ["OGD", "PROBLEM", 108, 111]]], ["Moreover, endocytosis of the ionotropic glutamate receptors GluA2 and GluA3 in rat hippocampal neurons has been proposed to contribute to excitotoxic neuronal cell death following OGD, as more Ca2+-permeable glutamate receptors such as GluA1 homomers remain on the neuronal surface under these conditions [41].", [["hippocampal neurons", "ANATOMY", 83, 102], ["neuronal cell", "ANATOMY", 150, 163], ["neuronal surface", "ANATOMY", 265, 281], ["glutamate", "CHEMICAL", 40, 49], ["death", "DISEASE", 164, 169], ["Ca2", "CHEMICAL", 193, 196], ["glutamate", "CHEMICAL", 208, 217], ["glutamate", "CHEMICAL", 40, 49], ["Ca2", "CHEMICAL", 193, 196], ["glutamate", "CHEMICAL", 208, 217], ["GluA2", "GENE_OR_GENE_PRODUCT", 60, 65], ["GluA3", "GENE_OR_GENE_PRODUCT", 70, 75], ["rat", "ORGANISM", 79, 82], ["hippocampal neurons", "CELL", 83, 102], ["neuronal cell", "CELL", 150, 163], ["Ca2+-permeable glutamate receptors", "GENE_OR_GENE_PRODUCT", 193, 227], ["GluA1", "GENE_OR_GENE_PRODUCT", 236, 241], ["neuronal surface", "CELLULAR_COMPONENT", 265, 281], ["ionotropic glutamate receptors", "PROTEIN", 29, 59], ["GluA2", "PROTEIN", 60, 65], ["GluA3", "PROTEIN", 70, 75], ["rat hippocampal neurons", "CELL_TYPE", 79, 102], ["Ca2", "PROTEIN", 193, 196], ["glutamate receptors", "PROTEIN", 208, 227], ["GluA1 homomers", "PROTEIN", 236, 250], ["rat", "SPECIES", 79, 82], ["the ionotropic glutamate receptors GluA2", "TEST", 25, 65], ["GluA3 in rat hippocampal neurons", "PROBLEM", 70, 102], ["excitotoxic neuronal cell death", "PROBLEM", 138, 169], ["OGD", "PROBLEM", 180, 183], ["Ca2+-permeable glutamate receptors", "TREATMENT", 193, 227], ["GluA1 homomers", "PROBLEM", 236, 250], ["excitotoxic neuronal cell", "OBSERVATION", 138, 163]]], ["How GluA1 endocytosis upon OGD is prevented and why endocytosis of GluA2/3 happens specifically in hippocampal, but not in cortical neurons is unclear.", [["hippocampal", "ANATOMY", 99, 110], ["cortical neurons", "ANATOMY", 123, 139], ["GluA1", "GENE_OR_GENE_PRODUCT", 4, 9], ["GluA2/3", "GENE_OR_GENE_PRODUCT", 67, 74], ["hippocampal", "MULTI-TISSUE_STRUCTURE", 99, 110], ["cortical neurons", "CELL", 123, 139], ["GluA1", "PROTEIN", 4, 9], ["GluA2/3", "PROTEIN", 67, 74], ["cortical neurons", "CELL_TYPE", 123, 139], ["GluA1 endocytosis", "PROBLEM", 4, 21], ["OGD", "PROBLEM", 27, 30], ["endocytosis of GluA2/3", "PROBLEM", 52, 74], ["cortical", "ANATOMY_MODIFIER", 123, 131], ["neurons", "ANATOMY", 132, 139]]], ["Likewise, AP-2 mediated-internalization of GABAA receptors from the surface of dendrites, via recognition of a specific AP-2 binding motif in the GABAA receptor \u03b23 subunit, is promoted during OGD.", [["surface", "ANATOMY", 68, 75], ["dendrites", "ANATOMY", 79, 88], ["GABAA", "CHEMICAL", 43, 48], ["AP-2", "GENE_OR_GENE_PRODUCT", 10, 14], ["GABAA receptors", "GENE_OR_GENE_PRODUCT", 43, 58], ["surface", "CELLULAR_COMPONENT", 68, 75], ["dendrites", "CELLULAR_COMPONENT", 79, 88], ["AP-2", "GENE_OR_GENE_PRODUCT", 120, 124], ["GABAA receptor \u03b23", "GENE_OR_GENE_PRODUCT", 146, 163], ["AP", "PROTEIN", 10, 12], ["GABAA receptors", "PROTEIN", 43, 58], ["AP-2 binding motif", "PROTEIN", 120, 138], ["GABAA receptor \u03b23 subunit", "PROTEIN", 146, 171], ["AP", "TEST", 10, 12], ["GABAA receptors", "TREATMENT", 43, 58]]], ["Blocking OGD-associated GABAA receptor endocytosis therapeutically to safeguard GABAA receptor surface levels and, thereby, inhibitory neurotransmission would likely be beneficial for limiting OGD-induced cell death [42].Osmotic stress ::: STRESS CONDITIONS THAT AFFECT ENDOCYTOSISThe control of osmotic homeostasis is crucial for a multitude of cellular functions.", [["surface", "ANATOMY", 95, 102], ["cell", "ANATOMY", 205, 209], ["cellular", "ANATOMY", 346, 354], ["death", "DISEASE", 210, 215], ["OGD", "SIMPLE_CHEMICAL", 9, 12], ["GABAA receptor", "GENE_OR_GENE_PRODUCT", 24, 38], ["GABAA receptor", "GENE_OR_GENE_PRODUCT", 80, 94], ["OGD", "SIMPLE_CHEMICAL", 193, 196], ["cell", "CELL", 205, 209], ["cellular", "CELL", 346, 354], ["GABAA receptor", "PROTEIN", 24, 38], ["GABAA receptor", "PROTEIN", 80, 94], ["Blocking OGD", "PROBLEM", 0, 12], ["GABAA receptor endocytosis", "TREATMENT", 24, 50], ["GABAA receptor surface levels", "TEST", 80, 109], ["cell death", "PROBLEM", 205, 215], ["Osmotic stress", "PROBLEM", 221, 235], ["osmotic homeostasis", "PROBLEM", 296, 315], ["osmotic homeostasis", "OBSERVATION", 296, 315], ["cellular functions", "OBSERVATION", 346, 364]]], ["Consequently, cells have established various mechanisms for counteracting disturbances in cell volume.", [["cells", "ANATOMY", 14, 19], ["cell", "ANATOMY", 90, 94], ["cells", "CELL", 14, 19], ["cell", "CELL", 90, 94], ["counteracting disturbances in cell volume", "PROBLEM", 60, 101], ["cell volume", "OBSERVATION", 90, 101]]], ["On the one hand, adaptive responses following osmotic swelling or shrinkage activate signaling pathways that initiate regulatory volume programs, which allow cells to recover their initial volume.", [["cells", "ANATOMY", 158, 163], ["swelling", "DISEASE", 54, 62], ["cells", "CELL", 158, 163], ["osmotic swelling", "PROBLEM", 46, 62], ["shrinkage activate signaling pathways", "PROBLEM", 66, 103], ["regulatory volume programs", "TREATMENT", 118, 144], ["swelling", "OBSERVATION", 54, 62]]], ["On the other hand, mechanisms are triggered that help cells to cope with the impairments associated with changes in ionic strength such as protein aggregation.", [["cells", "ANATOMY", 54, 59], ["cells", "CELL", 54, 59], ["the impairments", "PROBLEM", 73, 88], ["changes in ionic strength", "PROBLEM", 105, 130], ["protein aggregation", "PROBLEM", 139, 158], ["protein aggregation", "OBSERVATION", 139, 158]]], ["If swelling or shrinkage persist without adaptation, cell death is caused.", [["cell", "ANATOMY", 53, 57], ["swelling", "DISEASE", 3, 11], ["death", "DISEASE", 58, 63], ["cell", "CELL", 53, 57], ["swelling", "PROBLEM", 3, 11], ["shrinkage", "PROBLEM", 15, 24], ["cell death", "PROBLEM", 53, 63], ["swelling", "OBSERVATION", 3, 11], ["shrinkage", "OBSERVATION", 15, 24]]], ["Impaired volume regulation is associated with several pathologies such as ischemia/reperfusion, hypovolemia, hypernatremia and diabetic shock [43].Osmotic stress ::: STRESS CONDITIONS THAT AFFECT ENDOCYTOSISHypotonic extracellular medium will cause cell swelling and an increase in membrane tension, while hypertonic conditions induce cell shrinkage and a decrease in membrane tension.", [["extracellular", "ANATOMY", 217, 230], ["cell", "ANATOMY", 249, 253], ["membrane", "ANATOMY", 282, 290], ["cell", "ANATOMY", 335, 339], ["membrane", "ANATOMY", 368, 376], ["ischemia/reperfusion", "DISEASE", 74, 94], ["hypovolemia", "DISEASE", 96, 107], ["hypernatremia", "DISEASE", 109, 122], ["diabetic shock", "DISEASE", 127, 141], ["cell", "CELL", 249, 253], ["membrane", "CELLULAR_COMPONENT", 282, 290], ["cell", "CELL", 335, 339], ["membrane", "CELLULAR_COMPONENT", 368, 376], ["Impaired volume regulation", "PROBLEM", 0, 26], ["several pathologies", "PROBLEM", 46, 65], ["ischemia", "PROBLEM", 74, 82], ["reperfusion", "PROBLEM", 83, 94], ["hypovolemia", "PROBLEM", 96, 107], ["hypernatremia", "PROBLEM", 109, 122], ["diabetic shock", "PROBLEM", 127, 141], ["Osmotic stress", "PROBLEM", 147, 161], ["ENDOCYTOSISHypotonic extracellular medium", "PROBLEM", 196, 237], ["cell swelling", "PROBLEM", 249, 262], ["an increase in membrane tension", "PROBLEM", 267, 298], ["hypertonic conditions", "PROBLEM", 306, 327], ["cell shrinkage", "PROBLEM", 335, 349], ["a decrease in membrane tension", "PROBLEM", 354, 384], ["volume regulation", "OBSERVATION", 9, 26], ["ischemia", "OBSERVATION", 74, 82], ["reperfusion", "OBSERVATION", 83, 94], ["hypovolemia", "OBSERVATION", 96, 107], ["hypernatremia", "OBSERVATION", 109, 122], ["diabetic shock", "OBSERVATION", 127, 141], ["cell swelling", "OBSERVATION", 249, 262], ["increase", "OBSERVATION_MODIFIER", 270, 278], ["membrane tension", "OBSERVATION", 282, 298], ["cell shrinkage", "OBSERVATION", 335, 349], ["decrease", "OBSERVATION_MODIFIER", 356, 364], ["membrane tension", "OBSERVATION", 368, 384]]], ["Given that endocytosis in essence is a plasma membrane remodeling mechanism, conditions that alter plasma membrane tension are expected to affect the efficiency of internalization.", [["plasma membrane", "ANATOMY", 39, 54], ["plasma membrane", "ANATOMY", 99, 114], ["plasma membrane", "CELLULAR_COMPONENT", 39, 54], ["plasma membrane", "CELLULAR_COMPONENT", 99, 114], ["a plasma membrane remodeling mechanism", "TREATMENT", 37, 75], ["alter plasma membrane tension", "PROBLEM", 93, 122], ["membrane tension", "OBSERVATION", 106, 122]]], ["Elevated membrane tension makes it harder to deform the membrane and, hence, hypotonic conditions oppose endocytosis.", [["membrane", "ANATOMY", 9, 17], ["membrane", "ANATOMY", 56, 64], ["membrane", "CELLULAR_COMPONENT", 9, 17], ["membrane", "CELLULAR_COMPONENT", 56, 64], ["Elevated membrane tension", "PROBLEM", 0, 25], ["hypotonic conditions oppose endocytosis", "PROBLEM", 77, 116], ["membrane tension", "OBSERVATION", 9, 25], ["membrane", "ANATOMY", 56, 64]]], ["Consistently, impaired endocytosis of transferrin, \u03b2-VLDL, or dextrans under hypotonic conditions has been reported in various mammalian cell types [44\u201346].", [["cell", "ANATOMY", 137, 141], ["dextrans", "CHEMICAL", 62, 70], ["transferrin", "GENE_OR_GENE_PRODUCT", 38, 49], ["\u03b2-VLDL", "SIMPLE_CHEMICAL", 51, 57], ["dextrans", "SIMPLE_CHEMICAL", 62, 70], ["mammalian cell", "CELL", 127, 141], ["transferrin", "PROTEIN", 38, 49], ["\u03b2-VLDL", "PROTEIN", 51, 57], ["impaired endocytosis of transferrin", "PROBLEM", 14, 49], ["dextrans under hypotonic conditions", "PROBLEM", 62, 97], ["impaired", "OBSERVATION_MODIFIER", 14, 22], ["endocytosis", "OBSERVATION", 23, 34], ["mammalian cell", "OBSERVATION", 127, 141]]], ["Hypotonic stress can be counteracted to some degree by the actin cytoskeleton such that endocytosis persists even under conditions of increased membrane tension [47].", [["cytoskeleton", "ANATOMY", 65, 77], ["membrane", "ANATOMY", 144, 152], ["actin", "GENE_OR_GENE_PRODUCT", 59, 64], ["cytoskeleton", "CELLULAR_COMPONENT", 65, 77], ["membrane", "CELLULAR_COMPONENT", 144, 152], ["actin", "PROTEIN", 59, 64], ["Hypotonic stress", "PROBLEM", 0, 16], ["increased membrane tension", "PROBLEM", 134, 160], ["stress", "OBSERVATION", 10, 16], ["some degree", "OBSERVATION_MODIFIER", 40, 51], ["actin cytoskeleton", "OBSERVATION", 59, 77], ["increased", "OBSERVATION_MODIFIER", 134, 143], ["membrane tension", "OBSERVATION", 144, 160]]], ["Based on these considerations, hypertonic conditions would be expected to facilitate endocytosis.", [["hypertonic conditions", "PROBLEM", 31, 52]]], ["Elegant electron microscopic studies revealed that hypertonicity leads to the formation of abnormal membrane-free Clathrin microcages, thereby preventing the assembly of normal Clathrin-coated vesicles.", [["membrane", "ANATOMY", 100, 108], ["vesicles", "ANATOMY", 193, 201], ["membrane", "CELLULAR_COMPONENT", 100, 108], ["Clathrin", "GENE_OR_GENE_PRODUCT", 114, 122], ["Clathrin", "GENE_OR_GENE_PRODUCT", 177, 185], ["vesicles", "CELLULAR_COMPONENT", 193, 201], ["Clathrin", "PROTEIN", 177, 185], ["Elegant electron microscopic studies", "TEST", 0, 36], ["hypertonicity", "PROBLEM", 51, 64], ["abnormal membrane-free Clathrin microcages", "PROBLEM", 91, 133], ["hypertonicity", "OBSERVATION", 51, 64], ["abnormal", "OBSERVATION_MODIFIER", 91, 99], ["membrane", "OBSERVATION_MODIFIER", 100, 108], ["free Clathrin microcages", "OBSERVATION", 109, 133], ["normal Clathrin", "OBSERVATION", 170, 185], ["coated vesicles", "OBSERVATION", 186, 201]]], ["This might be due to the fact that cell shrinkage is accompanied by cytosolic acidification, a condition known to trigger Clathrin assembly [49].", [["cell", "ANATOMY", 35, 39], ["cytosolic", "ANATOMY", 68, 77], ["cell", "CELL", 35, 39], ["cytosolic", "ORGANISM_SUBSTANCE", 68, 77], ["Clathrin", "GENE_OR_GENE_PRODUCT", 122, 130], ["Clathrin", "PROTEIN", 122, 130], ["cell shrinkage", "PROBLEM", 35, 49], ["cytosolic acidification", "PROBLEM", 68, 91], ["a condition", "PROBLEM", 93, 104], ["cell shrinkage", "OBSERVATION", 35, 49], ["cytosolic acidification", "OBSERVATION", 68, 91]]], ["Additional factors, such as the increased concentration of proteins and divalent cations in the shrunken cells, might also contribute.", [["shrunken cells", "ANATOMY", 96, 110], ["cations", "SIMPLE_CHEMICAL", 81, 88], ["cells", "CELL", 105, 110], ["shrunken cells", "CELL_TYPE", 96, 110], ["Additional factors", "PROBLEM", 0, 18], ["the increased concentration of proteins and divalent cations", "TREATMENT", 28, 88], ["the shrunken cells", "PROBLEM", 92, 110], ["divalent cations", "OBSERVATION", 72, 88], ["shrunken cells", "OBSERVATION", 96, 110], ["might also contribute", "UNCERTAINTY", 112, 133]]], ["Decreased receptor endocytosis upon hypertonicity has been confirmed in a variety of cell types such as polymorphonuclear leukocytes [48], Dictyostelium [50] and type I alveolar epithelial cells [51].", [["cell", "ANATOMY", 85, 89], ["polymorphonuclear leukocytes", "ANATOMY", 104, 132], ["alveolar epithelial cells", "ANATOMY", 169, 194], ["cell", "CELL", 85, 89], ["polymorphonuclear leukocytes", "CELL", 104, 132], ["type I", "CELL", 162, 168], ["alveolar epithelial cells", "CELL", 169, 194], ["polymorphonuclear leukocytes", "CELL_TYPE", 104, 132], ["type I alveolar epithelial cells", "CELL_TYPE", 162, 194], ["Decreased receptor endocytosis", "PROBLEM", 0, 30], ["hypertonicity", "PROBLEM", 36, 49], ["polymorphonuclear leukocytes", "TEST", 104, 132], ["Dictyostelium", "TEST", 139, 152], ["type I alveolar epithelial cells", "PROBLEM", 162, 194], ["receptor endocytosis", "OBSERVATION", 10, 30], ["hypertonicity", "OBSERVATION", 36, 49], ["cell types", "OBSERVATION", 85, 95], ["polymorphonuclear leukocytes", "OBSERVATION", 104, 132], ["alveolar", "ANATOMY", 169, 177], ["epithelial cells", "OBSERVATION", 178, 194]]], ["In addition, some studies also found fluid-phase endocytosis to be affected under osmotic shock [50, 51].", [["shock", "DISEASE", 90, 95], ["some studies", "TEST", 13, 25], ["fluid-phase endocytosis", "PROBLEM", 37, 60], ["osmotic shock", "PROBLEM", 82, 95], ["osmotic shock", "OBSERVATION", 82, 95]]], ["Hence, hypo- and hypertonic stress both impair CME.Osmotic stress ::: STRESS CONDITIONS THAT AFFECT ENDOCYTOSISAn important trigger for plasma hyperosmolarity is elevated blood glucose (hyperglycemia).", [["plasma", "ANATOMY", 136, 142], ["blood", "ANATOMY", 171, 176], ["glucose", "CHEMICAL", 177, 184], ["hyperglycemia", "DISEASE", 186, 199], ["glucose", "CHEMICAL", 177, 184], ["plasma", "ORGANISM_SUBSTANCE", 136, 142], ["blood", "ORGANISM_SUBSTANCE", 171, 176], ["glucose", "SIMPLE_CHEMICAL", 177, 184], ["hypo", "PROBLEM", 7, 11], ["hypertonic stress", "PROBLEM", 17, 34], ["plasma hyperosmolarity", "PROBLEM", 136, 158], ["elevated blood glucose", "PROBLEM", 162, 184], ["hyperglycemia", "PROBLEM", 186, 199], ["hypo", "OBSERVATION", 7, 11], ["hypertonic stress", "OBSERVATION", 17, 34]]], ["Like insulin, hyperosmolarity causes a reduction in the AP-2-dependent [52] endocytosis of GLUT4, thereby elevating its surface pool.", [["surface", "ANATOMY", 120, 127], ["insulin", "GENE_OR_GENE_PRODUCT", 5, 12], ["AP-2", "GENE_OR_GENE_PRODUCT", 56, 60], ["[52]", "SIMPLE_CHEMICAL", 71, 75], ["GLUT4", "GENE_OR_GENE_PRODUCT", 91, 96], ["AP", "PROTEIN", 56, 58], ["GLUT4", "PROTEIN", 91, 96], ["insulin", "TREATMENT", 5, 12], ["hyperosmolarity", "PROBLEM", 14, 29], ["a reduction", "TREATMENT", 37, 48], ["the AP", "TEST", 52, 58], ["endocytosis of GLUT4", "PROBLEM", 76, 96], ["reduction", "OBSERVATION_MODIFIER", 39, 48], ["GLUT4", "ANATOMY", 91, 96]]], ["This osmoadaptive mechanism contributes to the clearance of glucose from the blood [53].", [["blood", "ANATOMY", 77, 82], ["glucose", "CHEMICAL", 60, 67], ["glucose", "CHEMICAL", 60, 67], ["glucose", "SIMPLE_CHEMICAL", 60, 67], ["blood", "ORGANISM_SUBSTANCE", 77, 82], ["This osmoadaptive mechanism", "PROBLEM", 0, 27]]], ["Similarly, in epithelial renal cells aquoporin2 (AQP2) displays elevated cell surface levels upon hyperosmotic shock [54], mainly due to lower rates of AQP2 endocytosis.", [["epithelial renal cells", "ANATOMY", 14, 36], ["cell surface", "ANATOMY", 73, 85], ["shock", "DISEASE", 111, 116], ["epithelial renal cells aquoporin2", "CELL", 14, 47], ["AQP2", "GENE_OR_GENE_PRODUCT", 49, 53], ["cell surface", "CELLULAR_COMPONENT", 73, 85], ["AQP2", "GENE_OR_GENE_PRODUCT", 152, 156], ["epithelial renal cells", "CELL_TYPE", 14, 36], ["aquoporin2", "PROTEIN", 37, 47], ["AQP2", "PROTEIN", 49, 53], ["AQP2", "PROTEIN", 152, 156], ["elevated cell surface levels", "PROBLEM", 64, 92], ["hyperosmotic shock", "PROBLEM", 98, 116], ["AQP2 endocytosis", "PROBLEM", 152, 168], ["epithelial", "ANATOMY_MODIFIER", 14, 24], ["renal cells", "ANATOMY", 25, 36], ["elevated", "OBSERVATION_MODIFIER", 64, 72], ["cell", "OBSERVATION", 73, 77], ["surface", "OBSERVATION_MODIFIER", 78, 85], ["hyperosmotic shock", "OBSERVATION", 98, 116], ["AQP2 endocytosis", "OBSERVATION", 152, 168]]], ["This adaptation will promote transcellular water flux that might be beneficial for surviving under severe hypertonic stress.Osmotic stress ::: STRESS CONDITIONS THAT AFFECT ENDOCYTOSISMost recently, our laboratory discovered that the differential endocytic sorting of the intracellular Na+/H+ exchanger NHE7 is important for coping with hypertonic stress [55].", [["intracellular", "ANATOMY", 272, 285], ["Na+", "CHEMICAL", 286, 289], ["H", "CHEMICAL", 290, 291], ["Na+", "CHEMICAL", 286, 289], ["H+", "CHEMICAL", 290, 292], ["transcellular", "IMMATERIAL_ANATOMICAL_ENTITY", 29, 42], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 272, 285], ["H+ exchanger NHE7", "GENE_OR_GENE_PRODUCT", 290, 307], ["intracellular Na+/H+ exchanger", "PROTEIN", 272, 302], ["NHE7", "PROTEIN", 303, 307], ["transcellular water flux", "TREATMENT", 29, 53], ["severe hypertonic stress", "PROBLEM", 99, 123], ["Osmotic stress", "PROBLEM", 124, 138], ["exchanger NHE7", "TREATMENT", 293, 307], ["hypertonic stress", "PROBLEM", 337, 354], ["severe", "OBSERVATION_MODIFIER", 99, 105], ["hypertonic stress", "OBSERVATION", 106, 123]]], ["Whereas NHE7 under isotonic steady-state conditions primarily resides on endosomes and the trans-Golgi-network, it is redistributed to the cell surface during the early events associated with hyperosmotic shock.", [["endosomes", "ANATOMY", 73, 82], ["cell surface", "ANATOMY", 139, 151], ["shock", "DISEASE", 205, 210], ["NHE7", "GENE_OR_GENE_PRODUCT", 8, 12], ["endosomes", "CELLULAR_COMPONENT", 73, 82], ["Golgi-network", "CELLULAR_COMPONENT", 97, 110], ["cell surface", "CELLULAR_COMPONENT", 139, 151], ["NHE7", "PROTEIN", 8, 12], ["hyperosmotic shock", "PROBLEM", 192, 210], ["cell surface", "OBSERVATION", 139, 151], ["hyperosmotic shock", "OBSERVATION", 192, 210]]], ["A similar redistribution of NHE7 is observed when CME is impaired, suggesting that NHE7 is constitutively endocytosed.", [["NHE7", "GENE_OR_GENE_PRODUCT", 28, 32], ["NHE7", "GENE_OR_GENE_PRODUCT", 83, 87], ["NHE7", "PROTEIN", 28, 32], ["NHE7", "PROTEIN", 83, 87], ["A similar redistribution of NHE7", "PROBLEM", 0, 32], ["constitutively endocytosed", "PROBLEM", 91, 117], ["similar", "OBSERVATION_MODIFIER", 2, 9], ["redistribution", "OBSERVATION", 10, 24], ["constitutively endocytosed", "OBSERVATION", 91, 117]]], ["The surface enrichment of NHE7 upon hyperosmotic stress is beneficial for cell survival: Plasma membrane NHE7 via downstream changes in cellular ion homeostasis and the resulting activation of the transcription factors TFEB/TFE3 promotes autophagosome and lysosome biogenesis to potentiate the degradative capacity of osmotically stressed cells.", [["surface", "ANATOMY", 4, 11], ["cell", "ANATOMY", 74, 78], ["Plasma membrane", "ANATOMY", 89, 104], ["cellular", "ANATOMY", 136, 144], ["autophagosome", "ANATOMY", 238, 251], ["lysosome", "ANATOMY", 256, 264], ["cells", "ANATOMY", 339, 344], ["NHE7", "CHEMICAL", 26, 30], ["surface", "CELLULAR_COMPONENT", 4, 11], ["NHE7", "GENE_OR_GENE_PRODUCT", 26, 30], ["cell", "CELL", 74, 78], ["Plasma membrane", "CELLULAR_COMPONENT", 89, 104], ["NHE7", "GENE_OR_GENE_PRODUCT", 105, 109], ["cellular", "CELL", 136, 144], ["TFEB", "GENE_OR_GENE_PRODUCT", 219, 223], ["TFE3", "GENE_OR_GENE_PRODUCT", 224, 228], ["autophagosome", "CELLULAR_COMPONENT", 238, 251], ["lysosome", "CELLULAR_COMPONENT", 256, 264], ["cells", "CELL", 339, 344], ["NHE7", "PROTEIN", 26, 30], ["NHE7", "PROTEIN", 105, 109], ["transcription factors", "PROTEIN", 197, 218], ["TFEB", "PROTEIN", 219, 223], ["TFE3", "PROTEIN", 224, 228], ["osmotically stressed cells", "CELL_TYPE", 318, 344], ["hyperosmotic stress", "PROBLEM", 36, 55], ["cell survival", "TREATMENT", 74, 87], ["Plasma membrane NHE7", "TREATMENT", 89, 109], ["downstream changes", "PROBLEM", 114, 132], ["cellular ion homeostasis", "TREATMENT", 136, 160], ["lysosome biogenesis", "TREATMENT", 256, 275], ["osmotically stressed cells", "PROBLEM", 318, 344], ["surface", "OBSERVATION_MODIFIER", 4, 11], ["cellular ion homeostasis", "OBSERVATION", 136, 160], ["osmotically stressed cells", "OBSERVATION", 318, 344]]], ["The osmotic stress-induced activation of the NHE7-TFEB pathway enables cells to cope with the increased load of aggregated proteins that accumulate during the osmotic insult and, thereby, promotes cellular survival (Figure 4).", [["cells", "ANATOMY", 71, 76], ["cellular", "ANATOMY", 197, 205], ["NHE7", "GENE_OR_GENE_PRODUCT", 45, 49], ["TFEB", "GENE_OR_GENE_PRODUCT", 50, 54], ["cells", "CELL", 71, 76], ["cellular", "CELL", 197, 205], ["NHE7", "PROTEIN", 45, 49], ["TFEB", "PROTEIN", 50, 54], ["aggregated proteins", "PROTEIN", 112, 131], ["The osmotic stress", "TEST", 0, 18], ["the increased load of aggregated proteins", "PROBLEM", 90, 131], ["the osmotic insult", "PROBLEM", 155, 173], ["osmotic stress", "OBSERVATION", 4, 18], ["osmotic insult", "OBSERVATION", 159, 173]]], ["How CME of NHE7 is repressed upon hypertonic stress at the mechanistic level requires further investigations.Osmotic stress ::: STRESS CONDITIONS THAT AFFECT ENDOCYTOSISThe NHE7-TFEB/TFE3 mechanism likely contributes to the observed induction of autophagy triggered by hypertonic stress [56, 57] and may synergize with the increased synthesis of phosphatidylinositol-3,5-bisphosphate, a lipid crucially required for lysosomal proteolysis, in yeast [58, 59] and mammalian cells challenged with hyperosmotic conditions [60].", [["lysosomal", "ANATOMY", 416, 425], ["cells", "ANATOMY", 471, 476], ["phosphatidylinositol-3,5-bisphosphate", "CHEMICAL", 346, 383], ["phosphatidylinositol-3,5-bisphosphate", "CHEMICAL", 346, 383], ["NHE7", "GENE_OR_GENE_PRODUCT", 11, 15], ["NHE7-TFEB", "GENE_OR_GENE_PRODUCT", 173, 182], ["TFE3", "GENE_OR_GENE_PRODUCT", 183, 187], ["phosphatidylinositol-3,5-bisphosphate", "SIMPLE_CHEMICAL", 346, 383], ["lipid", "SIMPLE_CHEMICAL", 387, 392], ["lysosomal", "CELLULAR_COMPONENT", 416, 425], ["mammalian cells", "CELL", 461, 476], ["NHE7", "PROTEIN", 11, 15], ["NHE7", "PROTEIN", 173, 177], ["TFEB", "PROTEIN", 178, 182], ["TFE3", "PROTEIN", 183, 187], ["mammalian cells", "CELL_TYPE", 461, 476], ["yeast", "SPECIES", 442, 447], ["yeast", "SPECIES", 442, 447], ["hypertonic stress", "PROBLEM", 34, 51], ["further investigations", "TEST", 86, 108], ["Osmotic stress", "PROBLEM", 109, 123], ["autophagy", "PROBLEM", 246, 255], ["hypertonic stress", "PROBLEM", 269, 286], ["the increased synthesis of phosphatidylinositol", "TREATMENT", 319, 366], ["bisphosphate", "TREATMENT", 371, 383], ["lysosomal proteolysis", "PROBLEM", 416, 437], ["mammalian cells", "PROBLEM", 461, 476], ["hyperosmotic conditions", "PROBLEM", 493, 516], ["mammalian cells", "OBSERVATION", 461, 476], ["hyperosmotic conditions", "OBSERVATION", 493, 516]]], ["These examples illustrate how alterations in endocytosis and adaptations within the autophagy/endolysosomal system downstream of endocytosis may play a key role in the intracellular anti-stress response.Osmotic stress ::: STRESS CONDITIONS THAT AFFECT ENDOCYTOSISStudies in yeast have added some insight into the possible mechanism underlying osmotically induced changes in endocytosis.", [["endolysosomal system", "ANATOMY", 94, 114], ["intracellular", "ANATOMY", 168, 181], ["endolysosomal", "CELLULAR_COMPONENT", 94, 107], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 168, 181], ["yeast", "SPECIES", 274, 279], ["yeast", "SPECIES", 274, 279], ["alterations in endocytosis", "PROBLEM", 30, 56], ["Osmotic stress", "PROBLEM", 203, 217], ["STRESS CONDITIONS", "PROBLEM", 222, 239], ["AFFECT ENDOCYTOSISStudies in yeast", "PROBLEM", 245, 279], ["osmotically induced changes in endocytosis", "PROBLEM", 343, 385], ["endolysosomal system", "OBSERVATION", 94, 114], ["osmotically induced", "OBSERVATION", 343, 362], ["endocytosis", "OBSERVATION", 374, 385]]], ["Hypertonicity was reported to trigger alterations in intracellular Ca2+, thereby activating the Ca2+/Calmodulin\u2013dependent phosphatase Calcineurin.", [["intracellular", "ANATOMY", 53, 66], ["Hypertonicity", "DISEASE", 0, 13], ["Ca2", "CHEMICAL", 67, 70], ["Ca2+", "CHEMICAL", 67, 71], ["Ca2+", "CHEMICAL", 96, 100], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 53, 66], ["Ca2+", "SIMPLE_CHEMICAL", 67, 71], ["Ca2+", "SIMPLE_CHEMICAL", 96, 100], ["Calcineurin", "GENE_OR_GENE_PRODUCT", 134, 145], ["Ca2", "PROTEIN", 67, 70], ["Ca2", "PROTEIN", 96, 99], ["Calmodulin\u2013dependent phosphatase", "PROTEIN", 101, 133], ["Calcineurin", "PROTEIN", 134, 145], ["Hypertonicity", "PROBLEM", 0, 13], ["intracellular Ca2", "TEST", 53, 70], ["the Ca2", "TEST", 92, 99], ["Calmodulin\u2013dependent phosphatase Calcineurin", "TREATMENT", 101, 145]]], ["Calcineurin dephosphorylates and activates the endocytic lipid phosphatase Synaptojanin/Inp53, thereby promoting endocytosis to compensate the excess of membrane caused by hypertonicity [61].", [["membrane", "ANATOMY", 153, 161], ["Calcineurin", "GENE_OR_GENE_PRODUCT", 0, 11], ["Synaptojanin", "GENE_OR_GENE_PRODUCT", 75, 87], ["Inp53", "GENE_OR_GENE_PRODUCT", 88, 93], ["membrane", "CELLULAR_COMPONENT", 153, 161], ["Calcineurin", "PROTEIN", 0, 11], ["endocytic lipid phosphatase", "PROTEIN", 47, 74], ["Synaptojanin", "PROTEIN", 75, 87], ["Inp53", "PROTEIN", 88, 93], ["Calcineurin dephosphorylates", "TREATMENT", 0, 28], ["the endocytic lipid phosphatase Synaptojanin", "TREATMENT", 43, 87], ["hypertonicity", "PROBLEM", 172, 185], ["hypertonicity", "OBSERVATION", 172, 185]]], ["A similar Calcineurin-dependent bulk endocytic response can be triggered at synapses of mammalian neurons by sustained high-frequency firing activity [62].Osmotic stress ::: STRESS CONDITIONS THAT AFFECT ENDOCYTOSISInterestingly, changes in tonicity have been suggested to induce endocytosis in cells of the immune system to regulate inflammatory responses.", [["synapses", "ANATOMY", 76, 84], ["neurons", "ANATOMY", 98, 105], ["cells", "ANATOMY", 295, 300], ["immune system", "ANATOMY", 308, 321], ["Calcineurin", "GENE_OR_GENE_PRODUCT", 10, 21], ["neurons", "CELL", 98, 105], ["cells", "CELL", 295, 300], ["immune system", "ANATOMICAL_SYSTEM", 308, 321], ["Calcineurin", "PROTEIN", 10, 21], ["mammalian neurons", "CELL_TYPE", 88, 105], ["A similar Calcineurin-dependent bulk endocytic response", "PROBLEM", 0, 55], ["mammalian neurons", "PROBLEM", 88, 105], ["Osmotic stress", "PROBLEM", 155, 169], ["changes in tonicity", "PROBLEM", 230, 249], ["endocytosis in cells", "PROBLEM", 280, 300], ["similar", "OBSERVATION_MODIFIER", 2, 9], ["Calcineurin", "OBSERVATION", 10, 21], ["dependent", "OBSERVATION_MODIFIER", 22, 31], ["bulk", "OBSERVATION_MODIFIER", 32, 36], ["endocytic response", "OBSERVATION", 37, 55], ["inflammatory", "OBSERVATION_MODIFIER", 334, 346]]], ["For example, hypotonic stress was reported to promote the immune function of macrophages by boosting their endocytic ability [63].", [["macrophages", "ANATOMY", 77, 88], ["macrophages", "CELL", 77, 88], ["macrophages", "CELL_TYPE", 77, 88], ["hypotonic stress", "PROBLEM", 13, 29], ["hypotonic stress", "OBSERVATION", 13, 29]]], ["The chloride channel ClC-3 was implicated in this pathway, however, the underlying mechanism is presently unclear.", [["chloride", "CHEMICAL", 4, 12], ["chloride", "CHEMICAL", 4, 12], ["chloride", "SIMPLE_CHEMICAL", 4, 12], ["ClC-3", "GENE_OR_GENE_PRODUCT", 21, 26], ["chloride channel ClC-3", "PROTEIN", 4, 26], ["The chloride channel ClC", "TEST", 0, 24]]], ["In contrast, the endocytosis of claudin-1 and -2 in epithelial tubular cells in the kidney upon osmotic stress caused by alterations in the osmolarity of the tubule fluid [64] rather represents a detrimental response, since breakdown of tight junctions and the ensuing paracellular transport accelerate renal cell injury.Mechanical Stress ::: STRESS CONDITIONS THAT AFFECT ENDOCYTOSISOther types of mechanical stress aside from changes in membrane tension induced by altered osmolarity have also been shown to affect endocytosis.", [["epithelial tubular cells", "ANATOMY", 52, 76], ["kidney", "ANATOMY", 84, 90], ["tubule fluid", "ANATOMY", 158, 170], ["tight junctions", "ANATOMY", 237, 252], ["paracellular", "ANATOMY", 269, 281], ["renal cell", "ANATOMY", 303, 313], ["membrane", "ANATOMY", 439, 447], ["renal cell injury", "DISEASE", 303, 320], ["claudin-1", "GENE_OR_GENE_PRODUCT", 32, 41], ["-2", "GENE_OR_GENE_PRODUCT", 46, 48], ["epithelial tubular cells", "CELL", 52, 76], ["kidney", "ORGAN", 84, 90], ["tubule", "TISSUE", 158, 164], ["tight junctions", "CELLULAR_COMPONENT", 237, 252], ["paracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 269, 281], ["renal cell", "CELL", 303, 313], ["membrane", "CELLULAR_COMPONENT", 439, 447], ["claudin-1 and -2", "PROTEIN", 32, 48], ["epithelial tubular cells", "CELL_TYPE", 52, 76], ["claudin", "TEST", 32, 39], ["osmotic stress", "PROBLEM", 96, 110], ["the osmolarity of the tubule fluid", "PROBLEM", 136, 170], ["breakdown of tight junctions", "PROBLEM", 224, 252], ["renal cell injury", "PROBLEM", 303, 320], ["mechanical stress", "PROBLEM", 399, 416], ["changes in membrane tension", "PROBLEM", 428, 455], ["altered osmolarity", "PROBLEM", 467, 485], ["epithelial", "ANATOMY_MODIFIER", 52, 62], ["tubular cells", "OBSERVATION", 63, 76], ["kidney", "ANATOMY", 84, 90], ["osmotic stress", "OBSERVATION", 96, 110], ["tubule fluid", "OBSERVATION", 158, 170], ["detrimental response", "OBSERVATION", 196, 216], ["tight junctions", "OBSERVATION", 237, 252], ["paracellular", "ANATOMY_MODIFIER", 269, 281], ["renal", "ANATOMY", 303, 308], ["cell injury", "OBSERVATION", 309, 320], ["mechanical stress", "OBSERVATION", 399, 416], ["membrane tension", "OBSERVATION", 439, 455]]], ["The best example is shear stress that is experienced by cells lining vessel walls such as endothelial cells.", [["cells", "ANATOMY", 56, 61], ["vessel walls", "ANATOMY", 69, 81], ["endothelial cells", "ANATOMY", 90, 107], ["cells", "CELL", 56, 61], ["vessel walls", "MULTI-TISSUE_STRUCTURE", 69, 81], ["endothelial cells", "CELL", 90, 107], ["endothelial cells", "CELL_TYPE", 90, 107], ["shear stress", "PROBLEM", 20, 32], ["endothelial cells", "PROBLEM", 90, 107], ["shear stress", "OBSERVATION", 20, 32], ["lining", "ANATOMY_MODIFIER", 62, 68], ["vessel", "ANATOMY", 69, 75], ["walls", "ANATOMY_MODIFIER", 76, 81], ["endothelial cells", "OBSERVATION", 90, 107]]], ["The uptake of LDL into endothelial cells is increased under conditions of shear stress [65\u201368].", [["endothelial cells", "ANATOMY", 23, 40], ["LDL", "SIMPLE_CHEMICAL", 14, 17], ["endothelial cells", "CELL", 23, 40], ["LDL", "PROTEIN", 14, 17], ["endothelial cells", "CELL_TYPE", 23, 40], ["The uptake of LDL into endothelial cells", "PROBLEM", 0, 40], ["shear stress", "TEST", 74, 86], ["uptake of LDL", "OBSERVATION", 4, 17], ["endothelial cells", "OBSERVATION", 23, 40], ["increased", "OBSERVATION_MODIFIER", 44, 53]]], ["Interestingly, LDLR family members such as LRP1 also contribute to the shear stress-induced uptake of a complex between the coagulation factor VIII (FVIII) and its carrier protein von Willebrand factor (VWF) into macrophages [69].Mechanical Stress ::: STRESS CONDITIONS THAT AFFECT ENDOCYTOSISIn the kidney, cells sheathing the proximal tubule are highly specialized in retrieving proteins and other small molecules from the glomerular filtrate, and impaired endocytosis is known to contribute to the pathogenesis of several renal diseases.", [["macrophages", "ANATOMY", 213, 224], ["kidney", "ANATOMY", 300, 306], ["cells", "ANATOMY", 308, 313], ["proximal tubule", "ANATOMY", 328, 343], ["glomerular filtrate", "ANATOMY", 425, 444], ["renal", "ANATOMY", 525, 530], ["renal diseases", "DISEASE", 525, 539], ["LDLR", "GENE_OR_GENE_PRODUCT", 15, 19], ["LRP1", "GENE_OR_GENE_PRODUCT", 43, 47], ["coagulation factor VIII", "GENE_OR_GENE_PRODUCT", 124, 147], ["FVIII", "GENE_OR_GENE_PRODUCT", 149, 154], ["von Willebrand factor", "GENE_OR_GENE_PRODUCT", 180, 201], ["VWF", "GENE_OR_GENE_PRODUCT", 203, 206], ["kidney", "ORGAN", 300, 306], ["cells", "CELL", 308, 313], ["proximal tubule", "TISSUE", 328, 343], ["glomerular filtrate", "CELLULAR_COMPONENT", 425, 444], ["renal", "ORGAN", 525, 530], ["LDLR family members", "PROTEIN", 15, 34], ["LRP1", "PROTEIN", 43, 47], ["coagulation factor VIII", "PROTEIN", 124, 147], ["FVIII", "PROTEIN", 149, 154], ["carrier protein", "PROTEIN", 164, 179], ["von Willebrand factor", "PROTEIN", 180, 201], ["VWF", "PROTEIN", 203, 206], ["macrophages", "CELL_TYPE", 213, 224], ["the shear stress", "PROBLEM", 67, 83], ["other small molecules", "PROBLEM", 394, 415], ["the glomerular filtrate", "TEST", 421, 444], ["impaired endocytosis", "PROBLEM", 450, 470], ["several renal diseases", "PROBLEM", 517, 539], ["Stress", "OBSERVATION", 241, 247], ["kidney", "ANATOMY", 300, 306], ["proximal", "ANATOMY_MODIFIER", 328, 336], ["tubule", "ANATOMY_MODIFIER", 337, 343], ["small", "OBSERVATION_MODIFIER", 400, 405], ["molecules", "OBSERVATION", 406, 415], ["glomerular", "ANATOMY", 425, 435], ["filtrate", "OBSERVATION", 436, 444], ["impaired", "OBSERVATION_MODIFIER", 450, 458], ["endocytosis", "OBSERVATION", 459, 470], ["several", "OBSERVATION_MODIFIER", 517, 524], ["renal", "ANATOMY", 525, 530], ["diseases", "OBSERVATION", 531, 539]]], ["To adapt their uptake capacity to changes in glomerular filtration rate, proximal tubule cells are responsive to shear stress.", [["glomerular", "ANATOMY", 45, 55], ["tubule cells", "ANATOMY", 82, 94], ["glomerular", "TISSUE", 45, 55], ["tubule cells", "CELL", 82, 94], ["proximal tubule cells", "CELL_TYPE", 73, 94], ["their uptake capacity", "PROBLEM", 9, 30], ["glomerular filtration rate", "TEST", 45, 71], ["proximal tubule cells", "PROBLEM", 73, 94], ["shear stress", "PROBLEM", 113, 125], ["uptake capacity", "OBSERVATION", 15, 30], ["glomerular", "ANATOMY", 45, 55], ["proximal", "ANATOMY_MODIFIER", 73, 81], ["tubule cells", "OBSERVATION", 82, 94]]], ["In fact, the shear stress induced by the flow of the glomerular filtrate determines the extent of endocytosis on the lumenal side of proximal tubule cells [70, 71].", [["glomerular filtrate", "ANATOMY", 53, 72], ["lumenal", "ANATOMY", 117, 124], ["proximal tubule cells", "ANATOMY", 133, 154], ["glomerular", "TISSUE", 53, 63], ["tubule cells", "CELL", 142, 154], ["proximal tubule cells", "CELL_TYPE", 133, 154], ["the shear stress", "PROBLEM", 9, 25], ["the glomerular filtrate", "TEST", 49, 72], ["glomerular", "ANATOMY", 53, 63], ["filtrate", "OBSERVATION", 64, 72], ["extent", "OBSERVATION_MODIFIER", 88, 94], ["endocytosis", "OBSERVATION", 98, 109], ["lumenal", "ANATOMY_MODIFIER", 117, 124], ["proximal", "ANATOMY_MODIFIER", 133, 141], ["tubule cells", "OBSERVATION", 142, 154]]], ["The important role of CME in proximal tubule-derived epithelial cells exposed to shear stress was confirmed by demonstrating that increased shear stress leads to a ~2-fold increase in the Clathrin-dependent uptake of albumin and dextran via the multiligand receptors Megalin and Cubilin.", [["proximal tubule", "ANATOMY", 29, 44], ["epithelial cells", "ANATOMY", 53, 69], ["dextran", "CHEMICAL", 229, 236], ["Cubilin", "CHEMICAL", 279, 286], ["proximal tubule-derived epithelial cells", "CELL", 29, 69], ["Clathrin", "SIMPLE_CHEMICAL", 188, 196], ["albumin", "GENE_OR_GENE_PRODUCT", 217, 224], ["dextran", "SIMPLE_CHEMICAL", 229, 236], ["Megalin", "GENE_OR_GENE_PRODUCT", 267, 274], ["Cubilin", "GENE_OR_GENE_PRODUCT", 279, 286], ["proximal tubule-derived epithelial cells", "CELL_TYPE", 29, 69], ["Clathrin", "PROTEIN", 188, 196], ["albumin", "PROTEIN", 217, 224], ["multiligand receptors", "PROTEIN", 245, 266], ["Megalin", "PROTEIN", 267, 274], ["Cubilin", "PROTEIN", 279, 286], ["shear stress", "TEST", 81, 93], ["increased shear stress", "PROBLEM", 130, 152], ["the Clathrin", "TEST", 184, 196], ["albumin", "TREATMENT", 217, 224], ["dextran", "TREATMENT", 229, 236], ["the multiligand receptors Megalin", "TREATMENT", 241, 274], ["Cubilin", "TREATMENT", 279, 286], ["epithelial cells", "OBSERVATION", 53, 69], ["increased", "OBSERVATION_MODIFIER", 130, 139], ["shear stress", "OBSERVATION", 140, 152]]], ["This pathway involves the shear-stress induced bending of cilia that may trigger Ca2+ influx via mechanosensitive channels and Ca2+ release from the endoplasmatic reticulum downstream of ATP-activated purinergic P2YR receptors.", [["cilia", "ANATOMY", 58, 63], ["endoplasmatic reticulum", "ANATOMY", 149, 172], ["Ca2", "CHEMICAL", 81, 84], ["Ca2", "CHEMICAL", 127, 130], ["ATP", "CHEMICAL", 187, 190], ["Ca2+", "CHEMICAL", 81, 85], ["Ca2+", "CHEMICAL", 127, 131], ["ATP", "CHEMICAL", 187, 190], ["cilia", "CELLULAR_COMPONENT", 58, 63], ["Ca2+", "SIMPLE_CHEMICAL", 81, 85], ["Ca2+", "SIMPLE_CHEMICAL", 127, 131], ["endoplasmatic reticulum", "CELLULAR_COMPONENT", 149, 172], ["ATP", "SIMPLE_CHEMICAL", 187, 190], ["purinergic P2YR receptors", "GENE_OR_GENE_PRODUCT", 201, 226], ["Ca2", "PROTEIN", 81, 84], ["Ca2", "PROTEIN", 127, 130], ["ATP-activated purinergic P2YR receptors", "PROTEIN", 187, 226], ["stress induced bending of cilia", "PROBLEM", 32, 63], ["Ca2", "TEST", 81, 84], ["mechanosensitive channels", "TEST", 97, 122], ["Ca2", "TEST", 127, 130], ["ATP", "TEST", 187, 190], ["endoplasmatic reticulum", "ANATOMY", 149, 172]]], ["Elevated cytosolic Ca2+ via Calmodulin induces the activation of Cdc42 [72], which by promoting actin polymerization may facilitate endocytosis (Figure 5).", [["cytosolic", "ANATOMY", 9, 18], ["Ca2", "CHEMICAL", 19, 22], ["Ca2+", "CHEMICAL", 19, 23], ["Ca2+", "SIMPLE_CHEMICAL", 19, 23], ["Calmodulin", "GENE_OR_GENE_PRODUCT", 28, 38], ["Cdc42 [72]", "GENE_OR_GENE_PRODUCT", 65, 75], ["actin", "GENE_OR_GENE_PRODUCT", 96, 101], ["Ca2", "PROTEIN", 19, 22], ["Calmodulin", "PROTEIN", 28, 38], ["Cdc42", "PROTEIN", 65, 70], ["actin", "PROTEIN", 96, 101], ["Elevated cytosolic Ca2", "PROBLEM", 0, 22], ["Cdc42", "TEST", 65, 70], ["cytosolic Ca2", "OBSERVATION", 9, 22]]], ["In fact, actin is known to be important for endocytosis at the apical side of polarized cells to overcome membrane tension [47].", [["cells", "ANATOMY", 88, 93], ["membrane", "ANATOMY", 106, 114], ["actin", "GENE_OR_GENE_PRODUCT", 9, 14], ["cells", "CELL", 88, 93], ["membrane", "CELLULAR_COMPONENT", 106, 114], ["actin", "PROTEIN", 9, 14], ["polarized cells", "CELL_TYPE", 78, 93], ["endocytosis", "PROBLEM", 44, 55], ["membrane tension", "PROBLEM", 106, 122], ["apical", "ANATOMY_MODIFIER", 63, 69], ["polarized cells", "OBSERVATION", 78, 93]]], ["This appears to be a very cell-type specific pathway that only operates in cells of proximal tubule origin [71].Hypoxia \u2013 O2 stress ::: Stress due to imbalances in O2/CO2 supply and oxidative species ::: STRESS CONDITIONS THAT AFFECT ENDOCYTOSISHypoxia, inadequate oxygen supply, is a common stressor that cells face during fetal development, upon environmental variations such as high altitudes, and during pathological conditions like myocardial or cerebral ischemia, and in cancer (see \u201dOncogenic signaling\u201d) where hypoxia is very common in solid tumors [73].", [["cell", "ANATOMY", 26, 30], ["cells", "ANATOMY", 75, 80], ["proximal tubule", "ANATOMY", 84, 99], ["cells", "ANATOMY", 306, 311], ["fetal", "ANATOMY", 324, 329], ["myocardial", "ANATOMY", 437, 447], ["cerebral", "ANATOMY", 451, 459], ["cancer", "ANATOMY", 477, 483], ["solid tumors", "ANATOMY", 544, 556], ["O2", "CHEMICAL", 122, 124], ["Stress", "DISEASE", 136, 142], ["O2", "CHEMICAL", 164, 166], ["CO2", "CHEMICAL", 167, 170], ["oxygen", "CHEMICAL", 265, 271], ["myocardial or cerebral ischemia", "DISEASE", 437, 468], ["cancer", "DISEASE", 477, 483], ["hypoxia", "DISEASE", 518, 525], ["tumors", "DISEASE", 550, 556], ["O2", "CHEMICAL", 122, 124], ["O2", "CHEMICAL", 164, 166], ["CO2", "CHEMICAL", 167, 170], ["oxygen", "CHEMICAL", 265, 271], ["cell", "CELL", 26, 30], ["cells", "CELL", 75, 80], ["proximal tubule", "TISSUE", 84, 99], ["O2", "SIMPLE_CHEMICAL", 122, 124], ["O2", "SIMPLE_CHEMICAL", 164, 166], ["CO2", "SIMPLE_CHEMICAL", 167, 170], ["oxygen", "SIMPLE_CHEMICAL", 265, 271], ["cells", "CELL", 306, 311], ["fetal", "DEVELOPING_ANATOMICAL_STRUCTURE", 324, 329], ["myocardial", "MULTI-TISSUE_STRUCTURE", 437, 447], ["cerebral", "ORGAN", 451, 459], ["cancer", "CANCER", 477, 483], ["solid tumors", "CANCER", 544, 556], ["Hypoxia", "PROBLEM", 112, 119], ["O2/CO2 supply", "TREATMENT", 164, 177], ["AFFECT ENDOCYTOSISHypoxia", "PROBLEM", 227, 252], ["inadequate oxygen supply", "TREATMENT", 254, 278], ["a common stressor that cells face", "PROBLEM", 283, 316], ["high altitudes", "PROBLEM", 381, 395], ["myocardial or cerebral ischemia", "PROBLEM", 437, 468], ["hypoxia", "PROBLEM", 518, 525], ["solid tumors", "PROBLEM", 544, 556], ["appears to be", "UNCERTAINTY", 5, 18], ["very", "OBSERVATION_MODIFIER", 21, 25], ["cell", "OBSERVATION", 26, 30], ["proximal", "ANATOMY_MODIFIER", 84, 92], ["tubule", "ANATOMY_MODIFIER", 93, 99], ["origin", "ANATOMY_MODIFIER", 100, 106], ["oxygen supply", "OBSERVATION", 265, 278], ["myocardial", "ANATOMY", 437, 447], ["cerebral", "ANATOMY", 451, 459], ["ischemia", "OBSERVATION", 460, 468], ["cancer", "OBSERVATION", 477, 483]]], ["Hypoxic conditions lead to the stabilization of the transcription factor HIF, which drives a transcriptional stress response for the adaptation to oxygen deprivation.", [["oxygen", "CHEMICAL", 147, 153], ["oxygen", "CHEMICAL", 147, 153], ["HIF", "GENE_OR_GENE_PRODUCT", 73, 76], ["oxygen", "SIMPLE_CHEMICAL", 147, 153], ["transcription factor", "PROTEIN", 52, 72], ["HIF", "PROTEIN", 73, 76], ["Hypoxic conditions", "PROBLEM", 0, 18], ["a transcriptional stress response", "PROBLEM", 91, 124], ["oxygen deprivation", "TREATMENT", 147, 165], ["oxygen deprivation", "OBSERVATION", 147, 165]]], ["Interestingly, the HIF system is also activated by oncogenes and tumor suppressor mutations [74].", [["tumor", "ANATOMY", 65, 70], ["tumor", "DISEASE", 65, 70], ["HIF", "GENE_OR_GENE_PRODUCT", 19, 22], ["tumor", "CANCER", 65, 70], ["HIF", "PROTEIN", 19, 22], ["oncogenes", "DNA", 51, 60], ["tumor suppressor mutations", "PROBLEM", 65, 91]]], ["In addition to triggering the HIF-mediated signaling pathway, it has been suggested that hypoxia facilitates endocytosis, thereby altering the composition of the surface proteome.", [["surface proteome", "ANATOMY", 162, 178], ["hypoxia", "DISEASE", 89, 96], ["HIF", "GENE_OR_GENE_PRODUCT", 30, 33], ["surface", "CELLULAR_COMPONENT", 162, 169], ["HIF", "PROTEIN", 30, 33], ["hypoxia facilitates endocytosis", "PROBLEM", 89, 120], ["hypoxia", "OBSERVATION", 89, 96]]], ["For example, hypoxia promotes the internalization of the Na+/K+-ATPase in lung alveolar epithelium, possibly in an attempt to reduce ATP consumption [75].", [["lung alveolar epithelium", "ANATOMY", 74, 98], ["hypoxia", "DISEASE", 13, 20], ["K", "CHEMICAL", 61, 62], ["ATP", "CHEMICAL", 133, 136], ["Na+", "CHEMICAL", 57, 60], ["K", "CHEMICAL", 61, 62], ["ATP", "CHEMICAL", 133, 136], ["Na+/K+-ATPase", "GENE_OR_GENE_PRODUCT", 57, 70], ["lung alveolar epithelium", "TISSUE", 74, 98], ["ATP", "SIMPLE_CHEMICAL", 133, 136], ["Na+/K+-ATPase", "PROTEIN", 57, 70], ["hypoxia", "PROBLEM", 13, 20], ["the Na+", "TEST", 53, 60], ["ATPase in lung alveolar epithelium", "PROBLEM", 64, 98], ["ATP consumption", "TEST", 133, 148], ["hypoxia", "OBSERVATION", 13, 20], ["lung", "ANATOMY", 74, 78], ["alveolar epithelium", "ANATOMY", 79, 98]]], ["CME of the Na+/K+-ATPase was shown to require recognition of a Yxx\u00d8 motif in its \u03b1 subunit by AP-2\u00b5 [76] and the reactive oxygen species (ROS)-induced activation of PKC-\u03b6, which phosphorylates both, the Na+/K+-ATPase and AP-2\u00b5 to induce Na+/K+-ATPase internalization [75] (Figure 6).", [["Na+", "CHEMICAL", 11, 14], ["K", "CHEMICAL", 15, 16], ["oxygen", "CHEMICAL", 122, 128], ["ROS", "CHEMICAL", 138, 141], ["K", "CHEMICAL", 207, 208], ["K", "CHEMICAL", 241, 242], ["K", "CHEMICAL", 15, 16], ["oxygen", "CHEMICAL", 122, 128], ["Na+", "CHEMICAL", 203, 206], ["K", "CHEMICAL", 207, 208], ["Na+", "CHEMICAL", 237, 240], ["K", "CHEMICAL", 241, 242], ["Na+/K+-ATPase", "GENE_OR_GENE_PRODUCT", 11, 24], ["Yxx\u00d8", "GENE_OR_GENE_PRODUCT", 63, 67], ["AP-2", "GENE_OR_GENE_PRODUCT", 94, 98], ["reactive oxygen species", "SIMPLE_CHEMICAL", 113, 136], ["ROS", "SIMPLE_CHEMICAL", 138, 141], ["PKC-\u03b6", "GENE_OR_GENE_PRODUCT", 165, 170], ["Na+/K+-ATPase", "GENE_OR_GENE_PRODUCT", 203, 216], ["AP-2", "GENE_OR_GENE_PRODUCT", 221, 225], ["Na+/K+-ATPase", "GENE_OR_GENE_PRODUCT", 237, 250], ["Na+/K+-ATPase", "PROTEIN", 11, 24], ["Yxx\u00d8 motif", "PROTEIN", 63, 73], ["\u03b1 subunit", "PROTEIN", 81, 90], ["AP", "PROTEIN", 94, 96], ["PKC", "PROTEIN", 165, 168], ["\u03b6", "PROTEIN", 169, 170], ["Na+/K+-ATPase", "PROTEIN", 203, 216], ["AP-2\u00b5", "PROTEIN", 221, 226], ["K", "PROTEIN", 241, 242], ["ATPase", "PROTEIN", 244, 250], ["the Na+", "TEST", 7, 14], ["a Yxx\u00d8 motif", "TREATMENT", 61, 73], ["AP", "TEST", 94, 96], ["the reactive oxygen species", "PROBLEM", 109, 136], ["PKC", "TEST", 165, 168], ["the Na+", "TEST", 199, 206], ["K", "TEST", 207, 208], ["ATPase", "TEST", 210, 216], ["AP", "TEST", 221, 223], ["Na+", "TEST", 237, 240], ["K", "TEST", 241, 242], ["ATPase internalization", "TEST", 244, 266], ["reactive", "OBSERVATION_MODIFIER", 113, 121], ["oxygen species", "OBSERVATION", 122, 136]]], ["Interestingly, hypoxia-induced Na+/K+-ATPase internalization was shown to be HIF-independent.", [["hypoxia", "DISEASE", 15, 22], ["K", "CHEMICAL", 35, 36], ["Na+", "CHEMICAL", 31, 34], ["K", "CHEMICAL", 35, 36], ["Na+/K+-ATPase", "GENE_OR_GENE_PRODUCT", 31, 44], ["HIF", "GENE_OR_GENE_PRODUCT", 77, 80], ["ATPase", "PROTEIN", 38, 44], ["HIF", "PROTEIN", 77, 80], ["hypoxia", "PROBLEM", 15, 22], ["Na+", "TEST", 31, 34], ["ATPase internalization", "TEST", 38, 60], ["hypoxia", "OBSERVATION", 15, 22]]], ["Hypoxia also appears to facilitate the endocytosis and degradation of the alveolar epithelial sodium channel (ENaC) [77], although the underlying mechanism is less clear in this case.Hypoxia \u2013 O2 stress ::: Stress due to imbalances in O2/CO2 supply and oxidative species ::: STRESS CONDITIONS THAT AFFECT ENDOCYTOSISThe hypoxia-induced endocytosis of the Na+/K+-ATPase and ENaC are likely a cellular adaptation for preserving energy.", [["alveolar epithelial", "ANATOMY", 74, 93], ["cellular", "ANATOMY", 391, 399], ["Hypoxia", "DISEASE", 0, 7], ["sodium", "CHEMICAL", 94, 100], ["O2", "CHEMICAL", 193, 195], ["Stress", "DISEASE", 207, 213], ["O2", "CHEMICAL", 235, 237], ["CO2", "CHEMICAL", 238, 241], ["hypoxia", "DISEASE", 320, 327], ["K", "CHEMICAL", 359, 360], ["sodium", "CHEMICAL", 94, 100], ["O2", "CHEMICAL", 193, 195], ["O2", "CHEMICAL", 235, 237], ["CO2", "CHEMICAL", 238, 241], ["Na+", "CHEMICAL", 355, 358], ["K", "CHEMICAL", 359, 360], ["alveolar epithelial sodium channel", "GENE_OR_GENE_PRODUCT", 74, 108], ["ENaC", "GENE_OR_GENE_PRODUCT", 110, 114], ["O2", "SIMPLE_CHEMICAL", 193, 195], ["O2", "SIMPLE_CHEMICAL", 235, 237], ["CO2", "SIMPLE_CHEMICAL", 238, 241], ["Na+/K+-ATPase", "GENE_OR_GENE_PRODUCT", 355, 368], ["ENaC", "GENE_OR_GENE_PRODUCT", 373, 377], ["cellular", "CELL", 391, 399], ["alveolar epithelial sodium channel", "PROTEIN", 74, 108], ["ENaC", "PROTEIN", 110, 114], ["Na+/K+-ATPase", "PROTEIN", 355, 368], ["ENaC", "PROTEIN", 373, 377], ["Hypoxia", "PROBLEM", 0, 7], ["the endocytosis", "PROBLEM", 35, 50], ["the alveolar epithelial sodium channel", "TEST", 70, 108], ["Hypoxia", "PROBLEM", 183, 190], ["O2/CO2 supply", "TREATMENT", 235, 248], ["The hypoxia-induced endocytosis", "PROBLEM", 316, 347], ["the Na+", "TEST", 351, 358], ["K", "TEST", 359, 360], ["ENaC", "TREATMENT", 373, 377], ["endocytosis", "OBSERVATION", 39, 50], ["alveolar", "ANATOMY_MODIFIER", 74, 82], ["epithelial", "ANATOMY_MODIFIER", 83, 93], ["sodium channel", "OBSERVATION", 94, 108], ["less", "OBSERVATION_MODIFIER", 159, 163], ["clear", "OBSERVATION", 164, 169], ["hypoxia", "OBSERVATION", 320, 327], ["endocytosis", "OBSERVATION_MODIFIER", 336, 347], ["cellular adaptation", "OBSERVATION", 391, 410]]], ["However, a harmful consequence is the concomitant impairment of alveolar fluid clearance, which requires Na+ absorption via ENaC at the apical side and Na+ extrusion by the Na+/K+ ATPase at the basolateral membrane [78].", [["alveolar fluid", "ANATOMY", 64, 78], ["apical", "ANATOMY", 136, 142], ["basolateral membrane", "ANATOMY", 194, 214], ["Na", "CHEMICAL", 105, 107], ["Na", "CHEMICAL", 152, 154], ["Na+", "CHEMICAL", 173, 176], ["K", "CHEMICAL", 177, 178], ["Na+", "CHEMICAL", 105, 108], ["Na+", "CHEMICAL", 152, 155], ["Na+", "CHEMICAL", 173, 176], ["K+", "CHEMICAL", 177, 179], ["alveolar fluid", "MULTI-TISSUE_STRUCTURE", 64, 78], ["Na+", "SIMPLE_CHEMICAL", 105, 108], ["ENaC", "GENE_OR_GENE_PRODUCT", 124, 128], ["apical side", "CELLULAR_COMPONENT", 136, 147], ["Na+", "SIMPLE_CHEMICAL", 152, 155], ["Na+/K+ ATPase", "GENE_OR_GENE_PRODUCT", 173, 186], ["basolateral membrane", "CELLULAR_COMPONENT", 194, 214], ["ENaC", "PROTEIN", 124, 128], ["Na+/K+ ATPase", "PROTEIN", 173, 186], ["alveolar fluid clearance", "PROBLEM", 64, 88], ["Na", "TEST", 152, 154], ["the Na+", "TEST", 169, 176], ["alveolar", "ANATOMY_MODIFIER", 64, 72], ["fluid clearance", "OBSERVATION", 73, 88], ["apical", "ANATOMY_MODIFIER", 136, 142], ["basolateral membrane", "ANATOMY", 194, 214]]], ["To limit the extent of the resulting alveolar edema, cells activate a pro-survival response that prevents excessive Na+/K+-ATPase endocytosis under severe hypoxia.", [["alveolar edema", "ANATOMY", 37, 51], ["cells", "ANATOMY", 53, 58], ["alveolar edema", "DISEASE", 37, 51], ["K", "CHEMICAL", 120, 121], ["hypoxia", "DISEASE", 155, 162], ["Na+", "CHEMICAL", 116, 119], ["K", "CHEMICAL", 120, 121], ["alveolar edema", "PATHOLOGICAL_FORMATION", 37, 51], ["cells", "CELL", 53, 58], ["Na+/K+-ATPase", "GENE_OR_GENE_PRODUCT", 116, 129], ["Na+/K+-ATPase", "PROTEIN", 116, 129], ["the resulting alveolar edema", "PROBLEM", 23, 51], ["excessive Na+/K", "PROBLEM", 106, 121], ["ATPase endocytosis", "PROBLEM", 123, 141], ["severe hypoxia", "PROBLEM", 148, 162], ["alveolar", "ANATOMY_MODIFIER", 37, 45], ["edema", "OBSERVATION", 46, 51], ["severe", "OBSERVATION_MODIFIER", 148, 154], ["hypoxia", "OBSERVATION", 155, 162]]], ["Hypoxia-induced HIF signaling increases the levels of the E3 ubiquitin ligase HOIL-1L, which promotes the ubiquitination of PKC-\u03b6 leading to its degradation.", [["Hypoxia", "DISEASE", 0, 7], ["HIF", "GENE_OR_GENE_PRODUCT", 16, 19], ["E3", "GENE_OR_GENE_PRODUCT", 58, 60], ["HOIL-1L", "GENE_OR_GENE_PRODUCT", 78, 85], ["PKC-\u03b6", "GENE_OR_GENE_PRODUCT", 124, 129], ["HIF", "PROTEIN", 16, 19], ["E3 ubiquitin ligase", "PROTEIN", 58, 77], ["HOIL", "PROTEIN", 78, 82], ["1L", "PROTEIN", 83, 85], ["PKC", "PROTEIN", 124, 127], ["\u03b6", "PROTEIN", 128, 129], ["Hypoxia", "PROBLEM", 0, 7], ["HIF signaling", "PROBLEM", 16, 29], ["the E3 ubiquitin ligase HOIL", "TREATMENT", 54, 82], ["PKC", "PROBLEM", 124, 127], ["its degradation", "PROBLEM", 141, 156], ["HIF", "OBSERVATION_MODIFIER", 16, 19], ["signaling", "OBSERVATION_MODIFIER", 20, 29], ["increases", "OBSERVATION_MODIFIER", 30, 39]]], ["Consequently, PKC-\u03b6 is prevented from further stimulating Na+/K+-ATPase internalization [79].", [["K", "CHEMICAL", 62, 63], ["Na+", "CHEMICAL", 58, 61], ["K", "CHEMICAL", 62, 63], ["PKC-\u03b6", "GENE_OR_GENE_PRODUCT", 14, 19], ["Na+/K+-ATPase", "GENE_OR_GENE_PRODUCT", 58, 71], ["PKC", "PROTEIN", 14, 17], ["\u03b6", "PROTEIN", 18, 19], ["K", "PROTEIN", 62, 63], ["ATPase", "PROTEIN", 65, 71], ["PKC", "TEST", 14, 17], ["K", "TEST", 62, 63], ["ATPase internalization", "TEST", 65, 87]]], ["This mechanism allows cells to achieve a balance between preserving ATP and safeguarding a certain amount of alveolar fluid clearance to support survival of individual cells and the organism.Hypoxia \u2013 O2 stress ::: Stress due to imbalances in O2/CO2 supply and oxidative species ::: STRESS CONDITIONS THAT AFFECT ENDOCYTOSISStudies in Caenorhabditis elegans suggest that neurons may modulate endocytosis in response to hypoxia.", [["cells", "ANATOMY", 22, 27], ["alveolar fluid", "ANATOMY", 109, 123], ["cells", "ANATOMY", 168, 173], ["neurons", "ANATOMY", 371, 378], ["ATP", "CHEMICAL", 68, 71], ["O2", "CHEMICAL", 201, 203], ["Stress", "DISEASE", 215, 221], ["O2", "CHEMICAL", 243, 245], ["CO2", "CHEMICAL", 246, 249], ["hypoxia", "DISEASE", 419, 426], ["ATP", "CHEMICAL", 68, 71], ["O2", "CHEMICAL", 201, 203], ["O2", "CHEMICAL", 243, 245], ["CO2", "CHEMICAL", 246, 249], ["cells", "CELL", 22, 27], ["ATP", "SIMPLE_CHEMICAL", 68, 71], ["alveolar fluid", "TISSUE", 109, 123], ["cells", "CELL", 168, 173], ["O2", "SIMPLE_CHEMICAL", 201, 203], ["O2", "SIMPLE_CHEMICAL", 243, 245], ["CO2", "SIMPLE_CHEMICAL", 246, 249], ["Caenorhabditis elegans", "ORGANISM", 335, 357], ["neurons", "CELL", 371, 378], ["Caenorhabditis elegans", "SPECIES", 335, 357], ["Caenorhabditis elegans", "SPECIES", 335, 357], ["preserving ATP", "TREATMENT", 57, 71], ["alveolar fluid clearance", "TREATMENT", 109, 133], ["individual cells", "PROBLEM", 157, 173], ["the organism", "PROBLEM", 178, 190], ["Hypoxia", "PROBLEM", 191, 198], ["O2/CO2 supply", "TREATMENT", 243, 256], ["Caenorhabditis elegans", "PROBLEM", 335, 357], ["modulate endocytosis", "PROBLEM", 383, 403], ["hypoxia", "PROBLEM", 419, 426], ["alveolar", "ANATOMY", 109, 117], ["hypoxia", "OBSERVATION", 419, 426]]], ["Hypoxic conditions or loss of activity of the cellular oxygen sensor EGL-9 facilitate endocytosis but impair the recycling of the glutamate receptor GLR-1 [80], leading to reduced GLR-1-associated currents and behavior changes.", [["cellular", "ANATOMY", 46, 54], ["oxygen", "CHEMICAL", 55, 61], ["EGL-9", "CHEMICAL", 69, 74], ["glutamate", "CHEMICAL", 130, 139], ["oxygen", "CHEMICAL", 55, 61], ["glutamate", "CHEMICAL", 130, 139], ["cellular", "CELL", 46, 54], ["oxygen", "SIMPLE_CHEMICAL", 55, 61], ["EGL-9", "GENE_OR_GENE_PRODUCT", 69, 74], ["GLR-1", "GENE_OR_GENE_PRODUCT", 149, 154], ["GLR-1", "GENE_OR_GENE_PRODUCT", 180, 185], ["glutamate receptor", "PROTEIN", 130, 148], ["GLR", "PROTEIN", 149, 152], ["GLR", "PROTEIN", 180, 183], ["Hypoxic conditions", "PROBLEM", 0, 18], ["loss of activity", "PROBLEM", 22, 38], ["the cellular oxygen sensor EGL", "TEST", 42, 72], ["endocytosis", "PROBLEM", 86, 97], ["the glutamate receptor GLR", "TEST", 126, 152], ["reduced GLR", "PROBLEM", 172, 183], ["behavior changes", "PROBLEM", 210, 226], ["loss", "OBSERVATION_MODIFIER", 22, 26]]], ["The downregulation of surface glutamate receptors triggered by hypoxia may be considered as a neuroprotective response in order to preserve neurons from glutamate receptor-mediated excitotoxicity.", [["surface", "ANATOMY", 22, 29], ["neurons", "ANATOMY", 140, 147], ["glutamate", "CHEMICAL", 30, 39], ["hypoxia", "DISEASE", 63, 70], ["glutamate", "CHEMICAL", 153, 162], ["excitotoxicity", "DISEASE", 181, 195], ["glutamate", "CHEMICAL", 30, 39], ["glutamate", "CHEMICAL", 153, 162], ["surface glutamate receptors", "GENE_OR_GENE_PRODUCT", 22, 49], ["neurons", "CELL", 140, 147], ["glutamate receptor", "GENE_OR_GENE_PRODUCT", 153, 171], ["surface glutamate receptors", "PROTEIN", 22, 49], ["glutamate receptor", "PROTEIN", 153, 171], ["surface glutamate receptors", "PROBLEM", 22, 49], ["hypoxia", "PROBLEM", 63, 70], ["glutamate receptor-mediated excitotoxicity", "PROBLEM", 153, 195], ["surface", "OBSERVATION_MODIFIER", 22, 29], ["hypoxia", "OBSERVATION", 63, 70], ["may be considered", "UNCERTAINTY", 71, 88]]], ["Whether similar pathways operate in mammalian neurons remains to be studied.", [["mammalian neurons", "ANATOMY", 36, 53], ["neurons", "CELL", 46, 53], ["mammalian neurons", "CELL_TYPE", 36, 53]]], ["These results are consistent with the downregulation of the ionotropic glutamate receptors GluA2 and GluA3 in mammalian neurons under OGD (see \u201dGlucose and energy deprivation\u201d).Hypoxia \u2013 O2 stress ::: Stress due to imbalances in O2/CO2 supply and oxidative species ::: STRESS CONDITIONS THAT AFFECT ENDOCYTOSISEGFR signaling is also over-activated under hypoxia.", [["neurons", "ANATOMY", 120, 127], ["glutamate", "CHEMICAL", 71, 80], ["O2", "CHEMICAL", 187, 189], ["Stress", "DISEASE", 201, 207], ["O2", "CHEMICAL", 229, 231], ["CO2", "CHEMICAL", 232, 235], ["hypoxia", "DISEASE", 354, 361], ["glutamate", "CHEMICAL", 71, 80], ["Glucose", "CHEMICAL", 144, 151], ["O2", "CHEMICAL", 187, 189], ["O2", "CHEMICAL", 229, 231], ["CO2", "CHEMICAL", 232, 235], ["GluA2", "GENE_OR_GENE_PRODUCT", 91, 96], ["GluA3", "GENE_OR_GENE_PRODUCT", 101, 106], ["neurons", "CELL", 120, 127], ["Glucose", "SIMPLE_CHEMICAL", 144, 151], ["O2", "SIMPLE_CHEMICAL", 187, 189], ["O2", "SIMPLE_CHEMICAL", 229, 231], ["CO2", "SIMPLE_CHEMICAL", 232, 235], ["ionotropic glutamate receptors", "PROTEIN", 60, 90], ["GluA2", "PROTEIN", 91, 96], ["GluA3", "PROTEIN", 101, 106], ["mammalian neurons", "CELL_TYPE", 110, 127], ["Hypoxia", "PROBLEM", 177, 184], ["O2/CO2 supply", "TREATMENT", 229, 242], ["hypoxia", "PROBLEM", 354, 361], ["consistent with", "UNCERTAINTY", 18, 33], ["hypoxia", "OBSERVATION", 354, 361]]], ["Low oxygen conditions prolong the EGFR half-life in a HIF-dependent manner by diminishing the rate of endosome fusion caused by reduced expression of Rab5 and its effector Rabaptin5.", [["endosome", "ANATOMY", 102, 110], ["oxygen", "CHEMICAL", 4, 10], ["oxygen", "CHEMICAL", 4, 10], ["oxygen", "SIMPLE_CHEMICAL", 4, 10], ["EGFR", "GENE_OR_GENE_PRODUCT", 34, 38], ["HIF", "GENE_OR_GENE_PRODUCT", 54, 57], ["endosome", "CELLULAR_COMPONENT", 102, 110], ["Rab5", "GENE_OR_GENE_PRODUCT", 150, 154], ["Rabaptin5", "GENE_OR_GENE_PRODUCT", 172, 181], ["EGFR", "PROTEIN", 34, 38], ["HIF", "PROTEIN", 54, 57], ["Rab5", "PROTEIN", 150, 154], ["Rabaptin5", "PROTEIN", 172, 181], ["Low oxygen conditions", "PROBLEM", 0, 21], ["endosome fusion", "TREATMENT", 102, 117], ["reduced expression of Rab5", "PROBLEM", 128, 154], ["oxygen conditions", "OBSERVATION", 4, 21], ["endosome fusion", "OBSERVATION", 102, 117]]], ["Rabaptin5 is normally recruited by Rab5 and stimulates the Rab5 guanine nucleotide exchange factor (GEF) Rabex5, thereby increasing Rab5 activity and early endosome fusion.", [["endosome", "ANATOMY", 156, 164], ["Rabaptin5", "CHEMICAL", 0, 9], ["guanine nucleotide", "CHEMICAL", 64, 82], ["guanine nucleotide", "CHEMICAL", 64, 82], ["Rabaptin5", "GENE_OR_GENE_PRODUCT", 0, 9], ["Rab5", "GENE_OR_GENE_PRODUCT", 35, 39], ["Rab5 guanine nucleotide exchange factor", "GENE_OR_GENE_PRODUCT", 59, 98], ["GEF", "GENE_OR_GENE_PRODUCT", 100, 103], ["Rabex5", "GENE_OR_GENE_PRODUCT", 105, 111], ["Rab5", "GENE_OR_GENE_PRODUCT", 132, 136], ["endosome", "CELLULAR_COMPONENT", 156, 164], ["Rabaptin5", "PROTEIN", 0, 9], ["Rab5", "PROTEIN", 35, 39], ["Rab5 guanine nucleotide exchange factor", "PROTEIN", 59, 98], ["GEF", "PROTEIN", 100, 103], ["Rabex5", "PROTEIN", 105, 111], ["Rab5", "PROTEIN", 132, 136], ["Rabaptin5", "TREATMENT", 0, 9], ["the Rab5 guanine nucleotide exchange factor", "TREATMENT", 55, 98], ["increasing Rab5 activity", "TREATMENT", 121, 145], ["early endosome fusion", "TREATMENT", 150, 171], ["increasing", "OBSERVATION_MODIFIER", 121, 131], ["Rab5 activity", "OBSERVATION", 132, 145], ["endosome fusion", "OBSERVATION", 156, 171]]], ["Downregulation of Rabaptin5, hence, leads to a decrease of early endosome fusion and to a delay in the downstream trafficking to lysosomes and in cargo degradation [81].", [["endosome", "ANATOMY", 65, 73], ["lysosomes", "ANATOMY", 129, 138], ["Rabaptin5", "GENE_OR_GENE_PRODUCT", 18, 27], ["endosome", "CELLULAR_COMPONENT", 65, 73], ["lysosomes", "CELLULAR_COMPONENT", 129, 138], ["Rabaptin5", "PROTEIN", 18, 27], ["Downregulation of Rabaptin5", "TREATMENT", 0, 27], ["early endosome fusion", "TREATMENT", 59, 80], ["a delay", "PROBLEM", 88, 95], ["decrease", "OBSERVATION_MODIFIER", 47, 55], ["early", "OBSERVATION_MODIFIER", 59, 64], ["endosome fusion", "OBSERVATION", 65, 80]]], ["Consequently, the affected receptor tyrosine kinases, which are able to signal from endosomes, display prolonged signaling responses.", [["endosomes", "ANATOMY", 84, 93], ["tyrosine", "CHEMICAL", 36, 44], ["tyrosine", "CHEMICAL", 36, 44], ["receptor tyrosine kinases", "GENE_OR_GENE_PRODUCT", 27, 52], ["endosomes", "CELLULAR_COMPONENT", 84, 93], ["receptor tyrosine kinases", "PROTEIN", 27, 52], ["the affected receptor tyrosine kinases", "PROBLEM", 14, 52], ["prolonged signaling responses", "PROBLEM", 103, 132], ["tyrosine kinases", "OBSERVATION", 36, 52]]], ["Prolonged receptor tyrosine kinase signaling represents an important adaptive response of the cancer cells for further oncogenesis in the hypoxic tumor environment.Hypercapnia - CO2 stress ::: Stress due to imbalances in O2/CO2 supply and oxidative species ::: STRESS CONDITIONS THAT AFFECT ENDOCYTOSISHypercapnia is a condition in which CO2 levels in the blood are elevated, for example, due to insufficient ventilation of the alveolar epithelium, the site of gas exchange.", [["cancer cells", "ANATOMY", 94, 106], ["tumor", "ANATOMY", 146, 151], ["blood", "ANATOMY", 356, 361], ["alveolar epithelium", "ANATOMY", 428, 447], ["tyrosine", "CHEMICAL", 19, 27], ["cancer", "DISEASE", 94, 100], ["tumor", "DISEASE", 146, 151], ["Hypercapnia", "DISEASE", 164, 175], ["CO2", "CHEMICAL", 178, 181], ["Stress", "DISEASE", 193, 199], ["O2", "CHEMICAL", 221, 223], ["CO2", "CHEMICAL", 224, 227], ["CO2", "CHEMICAL", 338, 341], ["tyrosine", "CHEMICAL", 19, 27], ["CO2", "CHEMICAL", 178, 181], ["O2", "CHEMICAL", 221, 223], ["CO2", "CHEMICAL", 224, 227], ["CO2", "CHEMICAL", 338, 341], ["receptor tyrosine kinase", "GENE_OR_GENE_PRODUCT", 10, 34], ["cancer cells", "CELL", 94, 106], ["tumor", "CANCER", 146, 151], ["Hypercapnia", "SIMPLE_CHEMICAL", 164, 175], ["CO2", "SIMPLE_CHEMICAL", 178, 181], ["O2", "SIMPLE_CHEMICAL", 221, 223], ["CO2", "SIMPLE_CHEMICAL", 224, 227], ["CO2", "SIMPLE_CHEMICAL", 338, 341], ["blood", "ORGANISM_SUBSTANCE", 356, 361], ["alveolar epithelium", "TISSUE", 428, 447], ["receptor tyrosine kinase", "PROTEIN", 10, 34], ["cancer cells", "CELL_TYPE", 94, 106], ["Prolonged receptor tyrosine kinase signaling", "TREATMENT", 0, 44], ["the cancer cells", "PROBLEM", 90, 106], ["further oncogenesis", "PROBLEM", 111, 130], ["the hypoxic tumor environment", "PROBLEM", 134, 163], ["Hypercapnia", "PROBLEM", 164, 175], ["CO2 stress", "TEST", 178, 188], ["imbalances", "PROBLEM", 207, 217], ["O2/CO2 supply", "TREATMENT", 221, 234], ["oxidative species", "PROBLEM", 239, 256], ["AFFECT ENDOCYTOSISHypercapnia", "PROBLEM", 284, 313], ["a condition", "PROBLEM", 317, 328], ["CO2 levels", "TEST", 338, 348], ["elevated", "PROBLEM", 366, 374], ["insufficient ventilation of the alveolar epithelium", "PROBLEM", 396, 447], ["tyrosine kinase", "OBSERVATION", 19, 34], ["cancer", "OBSERVATION", 94, 100], ["hypoxic", "OBSERVATION_MODIFIER", 138, 145], ["tumor", "OBSERVATION", 146, 151], ["oxidative species", "OBSERVATION", 239, 256], ["blood", "ANATOMY", 356, 361], ["elevated", "OBSERVATION", 366, 374], ["insufficient", "OBSERVATION_MODIFIER", 396, 408], ["ventilation", "OBSERVATION", 409, 420], ["alveolar epithelium", "ANATOMY", 428, 447], ["gas exchange", "OBSERVATION", 461, 473]]], ["This can occur, for example, during lung diseases such as COVID-19.", [["lung", "ANATOMY", 36, 40], ["lung diseases", "DISEASE", 36, 49], ["COVID-19", "CHEMICAL", 58, 66], ["lung", "ORGAN", 36, 40], ["lung diseases", "PROBLEM", 36, 49], ["COVID", "TEST", 58, 63], ["lung", "ANATOMY", 36, 40], ["diseases", "OBSERVATION", 41, 49]]], ["Moreover, acute hypercapnic respiratory failure (AHRF) can be triggered by chronic obstructive pulmonary disease (COPD) and some forms of neuromuscular disease (e.g. myasthenia gravis and obesity hypoventilation syndrome) or any type of respiratory failure where the muscles that are needed for breathing are exhausted (e.g. severe pneumonia, acute severe asthma).", [["respiratory", "ANATOMY", 28, 39], ["pulmonary", "ANATOMY", 95, 104], ["neuromuscular", "ANATOMY", 138, 151], ["respiratory", "ANATOMY", 237, 248], ["muscles", "ANATOMY", 267, 274], ["hypercapnic respiratory failure", "DISEASE", 16, 47], ["AHRF", "DISEASE", 49, 53], ["chronic obstructive pulmonary disease", "DISEASE", 75, 112], ["COPD", "DISEASE", 114, 118], ["neuromuscular disease", "DISEASE", 138, 159], ["myasthenia gravis", "DISEASE", 166, 183], ["obesity hypoventilation syndrome", "DISEASE", 188, 220], ["respiratory failure", "DISEASE", 237, 256], ["pneumonia", "DISEASE", 332, 341], ["asthma", "DISEASE", 356, 362], ["pulmonary", "ORGAN", 95, 104], ["muscles", "ORGAN", 267, 274], ["acute hypercapnic respiratory failure", "PROBLEM", 10, 47], ["AHRF", "PROBLEM", 49, 53], ["chronic obstructive pulmonary disease", "PROBLEM", 75, 112], ["COPD)", "PROBLEM", 114, 119], ["neuromuscular disease", "PROBLEM", 138, 159], ["myasthenia gravis", "PROBLEM", 166, 183], ["obesity hypoventilation syndrome", "PROBLEM", 188, 220], ["respiratory failure", "PROBLEM", 237, 256], ["breathing", "PROBLEM", 295, 304], ["severe pneumonia", "PROBLEM", 325, 341], ["acute severe asthma)", "PROBLEM", 343, 363], ["acute", "OBSERVATION_MODIFIER", 10, 15], ["hypercapnic", "OBSERVATION_MODIFIER", 16, 27], ["respiratory failure", "OBSERVATION", 28, 47], ["chronic", "OBSERVATION_MODIFIER", 75, 82], ["obstructive", "OBSERVATION_MODIFIER", 83, 94], ["pulmonary", "ANATOMY", 95, 104], ["disease", "OBSERVATION", 105, 112], ["COPD", "OBSERVATION", 114, 118], ["neuromuscular", "ANATOMY", 138, 151], ["disease", "OBSERVATION", 152, 159], ["respiratory failure", "OBSERVATION", 237, 256], ["muscles", "ANATOMY", 267, 274], ["severe", "OBSERVATION_MODIFIER", 325, 331], ["pneumonia", "OBSERVATION", 332, 341], ["acute", "OBSERVATION_MODIFIER", 343, 348], ["severe", "OBSERVATION_MODIFIER", 349, 355], ["asthma", "OBSERVATION", 356, 362]]], ["To keep gas exchange optimal, alveolar epithelial cells with the help of the Na+/K+-ATPase and the Na+ channel ENaC normally reabsorb fluid that leaks into the airspaces [78].", [["alveolar epithelial cells", "ANATOMY", 30, 55], ["airspaces", "ANATOMY", 160, 169], ["K", "CHEMICAL", 81, 82], ["Na", "CHEMICAL", 99, 101], ["Na+", "CHEMICAL", 77, 80], ["K", "CHEMICAL", 81, 82], ["Na+", "CHEMICAL", 99, 102], ["alveolar epithelial cells", "CELL", 30, 55], ["Na+/K+-ATPase", "GENE_OR_GENE_PRODUCT", 77, 90], ["Na+ channel ENaC", "GENE_OR_GENE_PRODUCT", 99, 115], ["alveolar epithelial cells", "CELL_TYPE", 30, 55], ["Na+/K+-ATPase", "PROTEIN", 77, 90], ["Na+ channel", "PROTEIN", 99, 110], ["ENaC", "PROTEIN", 111, 115], ["gas exchange", "TEST", 8, 20], ["alveolar epithelial cells", "PROBLEM", 30, 55], ["the Na+", "TEST", 73, 80], ["K", "TEST", 81, 82], ["ATPase", "TEST", 84, 90], ["the Na", "TEST", 95, 101], ["+ channel ENaC", "TREATMENT", 101, 115], ["leaks into the airspaces", "PROBLEM", 145, 169], ["alveolar epithelial cells", "OBSERVATION", 30, 55], ["reabsorb", "OBSERVATION_MODIFIER", 125, 133], ["fluid", "OBSERVATION", 134, 139], ["leaks", "OBSERVATION", 145, 150], ["airspaces", "ANATOMY_MODIFIER", 160, 169]]], ["However, elevated CO2 levels cause a Ca2+ influx triggering a kinase cascade involving the successive activation of CaMKK-\u03b2 (Ca2+/Calmodulin-dependent kinase kinase-\u03b2), AMPK and PKC-\u03b6 [78].", [["CO2", "CHEMICAL", 18, 21], ["Ca2", "CHEMICAL", 37, 40], ["CO2", "CHEMICAL", 18, 21], ["Ca2+", "CHEMICAL", 37, 41], ["Ca2+", "CHEMICAL", 125, 129], ["CO2", "SIMPLE_CHEMICAL", 18, 21], ["Ca2+", "SIMPLE_CHEMICAL", 37, 41], ["CaMKK-\u03b2", "GENE_OR_GENE_PRODUCT", 116, 123], ["Ca2+/Calmodulin-dependent kinase kinase-\u03b2", "GENE_OR_GENE_PRODUCT", 125, 166], ["AMPK", "GENE_OR_GENE_PRODUCT", 169, 173], ["PKC-\u03b6 [78]", "GENE_OR_GENE_PRODUCT", 178, 188], ["Ca2", "PROTEIN", 37, 40], ["CaMKK", "PROTEIN", 116, 121], ["\u03b2", "PROTEIN", 122, 123], ["Ca2+/Calmodulin-dependent kinase kinase", "PROTEIN", 125, 164], ["\u03b2", "PROTEIN", 165, 166], ["AMPK", "PROTEIN", 169, 173], ["PKC", "PROTEIN", 178, 181], ["elevated CO2 levels", "PROBLEM", 9, 28], ["a Ca2+ influx", "PROBLEM", 35, 48], ["a kinase cascade", "TREATMENT", 60, 76], ["CaMKK", "TEST", 116, 121], ["Ca2", "TEST", 125, 128], ["Calmodulin", "TEST", 130, 140], ["dependent kinase kinase", "TEST", 141, 164], ["PKC", "TEST", 178, 181], ["elevated", "OBSERVATION_MODIFIER", 9, 17], ["CO2 levels", "OBSERVATION", 18, 28]]], ["Thus, the signaling cascade converges here on the same kinase that is also induced in hypoxic alveolar epithelium and leads, among other changes, via AP-2 phosphorylation to increased uptake of Na+/K+-ATPase as described in section \u201dHypoxia \u2013 O2 stress\u201d.", [["alveolar epithelium", "ANATOMY", 94, 113], ["Na+", "CHEMICAL", 194, 197], ["K", "CHEMICAL", 198, 199], ["Na+", "CHEMICAL", 194, 197], ["K", "CHEMICAL", 198, 199], ["O2", "CHEMICAL", 243, 245], ["hypoxic alveolar epithelium", "TISSUE", 86, 113], ["AP-2", "GENE_OR_GENE_PRODUCT", 150, 154], ["Na+/K+-ATPase", "GENE_OR_GENE_PRODUCT", 194, 207], ["Hypoxia \u2013 O2", "SIMPLE_CHEMICAL", 233, 245], ["kinase", "PROTEIN", 55, 61], ["AP", "PROTEIN", 150, 152], ["Na+/K+-ATPase", "PROTEIN", 194, 207], ["the signaling cascade converges", "PROBLEM", 6, 37], ["hypoxic alveolar epithelium", "PROBLEM", 86, 113], ["AP", "TEST", 150, 152], ["increased uptake of Na+", "PROBLEM", 174, 197], ["Hypoxia", "PROBLEM", 233, 240], ["O2 stress\u201d", "PROBLEM", 243, 253], ["hypoxic", "OBSERVATION_MODIFIER", 86, 93], ["alveolar epithelium", "OBSERVATION", 94, 113]]], ["In addition, AMPK also triggers activation of JNK, which in turn phosphorylates the scaffolding protein Lim domain-only 7b (LMO7b).", [["AMPK", "GENE_OR_GENE_PRODUCT", 13, 17], ["JNK", "GENE_OR_GENE_PRODUCT", 46, 49], ["Lim domain-only 7b", "GENE_OR_GENE_PRODUCT", 104, 122], ["LMO7b", "GENE_OR_GENE_PRODUCT", 124, 129], ["AMPK", "PROTEIN", 13, 17], ["JNK", "PROTEIN", 46, 49], ["scaffolding protein Lim domain-only 7b", "PROTEIN", 84, 122], ["LMO7b", "PROTEIN", 124, 129], ["JNK", "TEST", 46, 49], ["the scaffolding protein Lim domain", "TEST", 80, 114]]], ["Phosphorylated LMO7b on the one hand shows enhanced colocalization with the Na+/K+-ATPase, and on the other hand may interact with AP-2\u00b5, thereby possibly promoting the endocytosis of the Na+/K+-ATPase [82].Hypercapnia - CO2 stress ::: Stress due to imbalances in O2/CO2 supply and oxidative species ::: STRESS CONDITIONS THAT AFFECT ENDOCYTOSISAnother critical alveolar protein whose endocytosis is upregulated upon hypercapnia is ENaC.", [["alveolar", "ANATOMY", 362, 370], ["K", "CHEMICAL", 80, 81], ["K", "CHEMICAL", 192, 193], ["Hypercapnia", "DISEASE", 207, 218], ["CO2", "CHEMICAL", 221, 224], ["Stress", "DISEASE", 236, 242], ["O2", "CHEMICAL", 264, 266], ["CO2", "CHEMICAL", 267, 270], ["K", "CHEMICAL", 80, 81], ["Na+", "CHEMICAL", 188, 191], ["K", "CHEMICAL", 192, 193], ["CO2", "CHEMICAL", 221, 224], ["O2", "CHEMICAL", 264, 266], ["CO2", "CHEMICAL", 267, 270], ["LMO7b", "GENE_OR_GENE_PRODUCT", 15, 20], ["Na+/K+-ATPase", "GENE_OR_GENE_PRODUCT", 76, 89], ["AP-2\u00b5", "GENE_OR_GENE_PRODUCT", 131, 136], ["Na+/K+-ATPase", "GENE_OR_GENE_PRODUCT", 188, 201], ["Hypercapnia", "SIMPLE_CHEMICAL", 207, 218], ["CO2", "SIMPLE_CHEMICAL", 221, 224], ["O2", "SIMPLE_CHEMICAL", 264, 266], ["CO2", "SIMPLE_CHEMICAL", 267, 270], ["alveolar", "MULTI-TISSUE_STRUCTURE", 362, 370], ["ENaC", "GENE_OR_GENE_PRODUCT", 432, 436], ["LMO7b", "PROTEIN", 15, 20], ["Na+/K+-ATPase", "PROTEIN", 76, 89], ["AP", "PROTEIN", 131, 133], ["2\u00b5", "PROTEIN", 134, 136], ["Na+/K+-ATPase", "PROTEIN", 188, 201], ["alveolar protein", "PROTEIN", 362, 378], ["ENaC", "PROTEIN", 432, 436], ["Phosphorylated LMO7b", "TEST", 0, 20], ["the Na+", "TEST", 72, 79], ["ATPase", "TEST", 83, 89], ["AP", "TEST", 131, 133], ["the Na+", "TEST", 184, 191], ["ATPase", "TEST", 195, 201], ["Hypercapnia", "PROBLEM", 207, 218], ["CO2 stress", "TEST", 221, 231], ["O2/CO2 supply", "TREATMENT", 264, 277], ["hypercapnia", "PROBLEM", 417, 428], ["enhanced", "OBSERVATION_MODIFIER", 43, 51], ["colocalization", "OBSERVATION", 52, 66], ["alveolar protein", "OBSERVATION", 362, 378], ["hypercapnia", "OBSERVATION", 417, 428]]], ["CO2 was shown to induce the ERK1/2-mediated phosphorylation of the \u03b2-subunit of ENaC.", [["CO2", "CHEMICAL", 0, 3], ["CO2", "CHEMICAL", 0, 3], ["CO2", "SIMPLE_CHEMICAL", 0, 3], ["ERK1/2", "GENE_OR_GENE_PRODUCT", 28, 34], ["ENaC", "GENE_OR_GENE_PRODUCT", 80, 84], ["ERK1", "PROTEIN", 28, 32], ["\u03b2-subunit", "PROTEIN", 67, 76], ["ENaC", "PROTEIN", 80, 84], ["CO2", "TEST", 0, 3], ["the ERK1", "TEST", 24, 32]]], ["In addition, ERK1/2 causes the activation of AMPK and JNK1/2, which, in turn, phosphorylate and activate Nedd4-2.", [["ERK1/2", "GENE_OR_GENE_PRODUCT", 13, 19], ["AMPK", "GENE_OR_GENE_PRODUCT", 45, 49], ["JNK1/2", "GENE_OR_GENE_PRODUCT", 54, 60], ["Nedd4-2", "GENE_OR_GENE_PRODUCT", 105, 112], ["ERK1/2", "PROTEIN", 13, 19], ["AMPK", "PROTEIN", 45, 49], ["JNK1/2", "PROTEIN", 54, 60], ["Nedd4-2", "PROTEIN", 105, 112], ["ERK1", "TEST", 13, 17], ["AMPK", "TEST", 45, 49], ["JNK1", "TEST", 54, 58], ["phosphorylate", "TREATMENT", 78, 91], ["Nedd4", "TEST", 105, 110]]], ["These phosphorylations lead to the Nedd4-2-dependent polyubiquitination of the \u03b2-subunit of ENaC, thereby triggering CME of the ENaC complex [83].Hypercapnia - CO2 stress ::: Stress due to imbalances in O2/CO2 supply and oxidative species ::: STRESS CONDITIONS THAT AFFECT ENDOCYTOSISAkin to hypoxia, the drawback of the lack of Na+/K+-ATPase and ENaC activities under hypercapnia is the impaired alveolar fluid reabsorption that further aggravates lung injury.", [["alveolar fluid", "ANATOMY", 397, 411], ["lung", "ANATOMY", 449, 453], ["Hypercapnia", "DISEASE", 146, 157], ["CO2", "CHEMICAL", 160, 163], ["Stress", "DISEASE", 175, 181], ["O2", "CHEMICAL", 203, 205], ["CO2", "CHEMICAL", 206, 209], ["hypoxia", "DISEASE", 292, 299], ["K", "CHEMICAL", 333, 334], ["hypercapnia", "DISEASE", 369, 380], ["lung injury", "DISEASE", 449, 460], ["CO2", "CHEMICAL", 160, 163], ["O2", "CHEMICAL", 203, 205], ["CO2", "CHEMICAL", 206, 209], ["Na+", "CHEMICAL", 329, 332], ["K", "CHEMICAL", 333, 334], ["Nedd4-2", "GENE_OR_GENE_PRODUCT", 35, 42], ["ENaC", "GENE_OR_GENE_PRODUCT", 92, 96], ["ENaC", "GENE_OR_GENE_PRODUCT", 128, 132], ["Hypercapnia", "SIMPLE_CHEMICAL", 146, 157], ["CO2", "SIMPLE_CHEMICAL", 160, 163], ["O2", "SIMPLE_CHEMICAL", 203, 205], ["CO2", "SIMPLE_CHEMICAL", 206, 209], ["Na+/K+-ATPase", "GENE_OR_GENE_PRODUCT", 329, 342], ["ENaC", "GENE_OR_GENE_PRODUCT", 347, 351], ["alveolar fluid", "MULTI-TISSUE_STRUCTURE", 397, 411], ["lung", "ORGAN", 449, 453], ["Nedd4", "PROTEIN", 35, 40], ["\u03b2-subunit", "PROTEIN", 79, 88], ["ENaC", "PROTEIN", 92, 96], ["ENaC complex", "PROTEIN", 128, 140], ["Na+/K+-ATPase", "PROTEIN", 329, 342], ["ENaC", "PROTEIN", 347, 351], ["These phosphorylations", "PROBLEM", 0, 22], ["the Nedd4", "TEST", 31, 40], ["Hypercapnia", "PROBLEM", 146, 157], ["CO2 stress", "TEST", 160, 170], ["imbalances", "PROBLEM", 189, 199], ["O2/CO2 supply", "TREATMENT", 203, 216], ["oxidative species", "PROBLEM", 221, 238], ["hypoxia", "PROBLEM", 292, 299], ["Na+", "TEST", 329, 332], ["K", "TEST", 333, 334], ["ATPase", "TEST", 336, 342], ["ENaC activities under hypercapnia", "PROBLEM", 347, 380], ["the impaired alveolar fluid reabsorption", "PROBLEM", 384, 424], ["further aggravates lung injury", "PROBLEM", 430, 460], ["dependent", "OBSERVATION_MODIFIER", 43, 52], ["polyubiquitination", "OBSERVATION", 53, 71], ["oxidative species", "OBSERVATION", 221, 238], ["hypoxia", "OBSERVATION", 292, 299], ["hypercapnia", "OBSERVATION", 369, 380], ["impaired", "OBSERVATION_MODIFIER", 388, 396], ["alveolar", "ANATOMY_MODIFIER", 397, 405], ["fluid reabsorption", "OBSERVATION", 406, 424], ["lung", "ANATOMY", 449, 453], ["injury", "OBSERVATION", 454, 460]]], ["Therefore, preventing the CO2-induced downregulation of Na+/K+-ATPase and ENaC might be beneficial in conditions of lung edema.", [["lung", "ANATOMY", 116, 120], ["CO2", "CHEMICAL", 26, 29], ["Na+", "CHEMICAL", 56, 59], ["K", "CHEMICAL", 60, 61], ["lung edema", "DISEASE", 116, 126], ["CO2", "CHEMICAL", 26, 29], ["Na+", "CHEMICAL", 56, 59], ["K", "CHEMICAL", 60, 61], ["CO2", "SIMPLE_CHEMICAL", 26, 29], ["Na+/K+-ATPase", "GENE_OR_GENE_PRODUCT", 56, 69], ["ENaC", "GENE_OR_GENE_PRODUCT", 74, 78], ["lung", "ORGAN", 116, 120], ["edema", "PATHOLOGICAL_FORMATION", 121, 126], ["Na+/K+-ATPase", "PROTEIN", 56, 69], ["ENaC", "PROTEIN", 74, 78], ["the CO2", "TEST", 22, 29], ["Na+", "TEST", 56, 59], ["ENaC", "TREATMENT", 74, 78], ["lung edema", "PROBLEM", 116, 126], ["might be", "UNCERTAINTY", 79, 87], ["lung", "ANATOMY", 116, 120], ["edema", "OBSERVATION", 121, 126]]], ["Strikingly, hypocapnia, i.e. reduced blood CO2 levels, was found to worsen alveolar fluid reabsorption similar to hypercapnia during lung injury by promoting endocytosis of Na+/K+ATPase [84].", [["blood", "ANATOMY", 37, 42], ["alveolar fluid", "ANATOMY", 75, 89], ["lung", "ANATOMY", 133, 137], ["hypocapnia", "DISEASE", 12, 22], ["CO2", "CHEMICAL", 43, 46], ["hypercapnia", "DISEASE", 114, 125], ["lung injury", "DISEASE", 133, 144], ["Na+", "CHEMICAL", 173, 176], ["K", "CHEMICAL", 177, 178], ["CO2", "CHEMICAL", 43, 46], ["Na+", "CHEMICAL", 173, 176], ["K+", "CHEMICAL", 177, 179], ["blood", "ORGANISM_SUBSTANCE", 37, 42], ["CO2", "SIMPLE_CHEMICAL", 43, 46], ["alveolar fluid", "TISSUE", 75, 89], ["lung", "ORGAN", 133, 137], ["Na+/K+ATPase", "GENE_OR_GENE_PRODUCT", 173, 185], ["Na+/K+ATPase", "PROTEIN", 173, 185], ["hypocapnia", "PROBLEM", 12, 22], ["reduced blood CO2 levels", "PROBLEM", 29, 53], ["alveolar fluid reabsorption", "PROBLEM", 75, 102], ["hypercapnia", "PROBLEM", 114, 125], ["lung injury", "PROBLEM", 133, 144], ["Na+", "TEST", 173, 176], ["K", "TEST", 177, 178], ["hypocapnia", "OBSERVATION", 12, 22], ["alveolar", "ANATOMY_MODIFIER", 75, 83], ["fluid reabsorption", "OBSERVATION", 84, 102], ["hypercapnia", "OBSERVATION", 114, 125], ["lung", "ANATOMY", 133, 137], ["injury", "OBSERVATION", 138, 144]]], ["Thus, opposite levels of the same stress stimulus converge on similar effects.Oxidative stress ::: Stress due to imbalances in O2/CO2 supply and oxidative species ::: STRESS CONDITIONS THAT AFFECT ENDOCYTOSISCells experience oxidative stress when the generation of ROS such as peroxides, superoxides and free radicals is higher than their elimination.", [["Stress", "DISEASE", 99, 105], ["O2", "CHEMICAL", 127, 129], ["CO2", "CHEMICAL", 130, 133], ["ROS", "CHEMICAL", 265, 268], ["superoxides", "CHEMICAL", 288, 299], ["O2", "CHEMICAL", 127, 129], ["CO2", "CHEMICAL", 130, 133], ["peroxides", "CHEMICAL", 277, 286], ["superoxides", "CHEMICAL", 288, 299], ["O2", "SIMPLE_CHEMICAL", 127, 129], ["CO2", "SIMPLE_CHEMICAL", 130, 133], ["ROS", "SIMPLE_CHEMICAL", 265, 268], ["peroxides", "SIMPLE_CHEMICAL", 277, 286], ["superoxides", "SIMPLE_CHEMICAL", 288, 299], ["free radicals", "SIMPLE_CHEMICAL", 304, 317], ["O2/CO2 supply", "TREATMENT", 127, 140], ["oxidative stress", "PROBLEM", 225, 241], ["peroxides, superoxides and free radicals", "PROBLEM", 277, 317]]], ["Oxidative imbalance arises either by an excess of ROS accumulation or a reduction in the amount of antioxidative enzymes.", [["ROS", "CHEMICAL", 50, 53], ["ROS", "SIMPLE_CHEMICAL", 50, 53], ["antioxidative enzymes", "PROTEIN", 99, 120], ["Oxidative imbalance", "PROBLEM", 0, 19], ["ROS accumulation", "PROBLEM", 50, 66], ["a reduction", "PROBLEM", 70, 81], ["antioxidative enzymes", "TEST", 99, 120], ["imbalance", "OBSERVATION", 10, 19], ["reduction", "OBSERVATION_MODIFIER", 72, 81]]], ["If cells encounter an excess of ROS, they need to activate programs to cope with the ROS-induced harmful changes.", [["cells", "ANATOMY", 3, 8], ["ROS", "CHEMICAL", 32, 35], ["ROS", "CHEMICAL", 85, 88], ["cells", "CELL", 3, 8], ["ROS", "SIMPLE_CHEMICAL", 32, 35], ["ROS", "SIMPLE_CHEMICAL", 85, 88], ["the ROS", "TEST", 81, 88], ["harmful changes", "PROBLEM", 97, 112]]], ["The stress response is turned on mainly via transcriptional activation of target genes that will either enhance survival or promote cell death.Oxidative stress ::: Stress due to imbalances in O2/CO2 supply and oxidative species ::: STRESS CONDITIONS THAT AFFECT ENDOCYTOSISSeveral studies suggest that increased oxidative stress directly or indirectly causes defects in the CME of LDL [85\u201389].", [["cell", "ANATOMY", 132, 136], ["death", "DISEASE", 137, 142], ["Stress", "DISEASE", 164, 170], ["O2", "CHEMICAL", 192, 194], ["CO2", "CHEMICAL", 195, 198], ["O2", "CHEMICAL", 192, 194], ["CO2", "CHEMICAL", 195, 198], ["cell", "CELL", 132, 136], ["O2", "SIMPLE_CHEMICAL", 192, 194], ["CO2", "SIMPLE_CHEMICAL", 195, 198], ["LDL", "SIMPLE_CHEMICAL", 381, 384], ["target genes", "DNA", 74, 86], ["LDL", "PROTEIN", 381, 384], ["promote cell death", "PROBLEM", 124, 142], ["O2/CO2 supply", "TREATMENT", 192, 205], ["ENDOCYTOSISSeveral studies", "TEST", 262, 288], ["increased oxidative stress", "PROBLEM", 302, 328], ["defects", "PROBLEM", 359, 366], ["stress response", "OBSERVATION", 4, 19], ["cell death", "OBSERVATION", 132, 142], ["increased", "OBSERVATION_MODIFIER", 302, 311], ["oxidative stress", "OBSERVATION", 312, 328]]], ["Altered endocytosis of other cargoes was also reported.", [["Altered endocytosis of other cargoes", "PROBLEM", 0, 36], ["endocytosis", "OBSERVATION", 8, 19]]], ["For example, elevated ROS were shown to inhibit EGFR and lectin receptor endocytosis in fibroblasts, likely by preventing their ubiquitination [90].", [["fibroblasts", "ANATOMY", 88, 99], ["ROS", "CHEMICAL", 22, 25], ["ROS", "SIMPLE_CHEMICAL", 22, 25], ["EGFR", "GENE_OR_GENE_PRODUCT", 48, 52], ["lectin receptor", "GENE_OR_GENE_PRODUCT", 57, 72], ["fibroblasts", "CELL", 88, 99], ["EGFR", "PROTEIN", 48, 52], ["lectin receptor", "PROTEIN", 57, 72], ["fibroblasts", "CELL_TYPE", 88, 99], ["elevated ROS", "PROBLEM", 13, 25], ["EGFR", "TEST", 48, 52], ["lectin receptor endocytosis in fibroblasts", "PROBLEM", 57, 99]]], ["Similarly, ROS were observed to impair the internalization of GLUT4 in cardiomyocytes [91], aquaporin 4 (AQP4), transferrin and LDL in astrocytes [92, 93], and of synaptic vesicle membranes in neurons [94].Oxidative stress ::: Stress due to imbalances in O2/CO2 supply and oxidative species ::: STRESS CONDITIONS THAT AFFECT ENDOCYTOSISRegarding the potential underlying mechanism, oxidative conditions in astrocytes were reported to lead to the downregulation of the transcription factor Sp1, which promotes the transcription of Hsc70 [93], a constitutively expressed heat shock protein and an essential cofactor for the uncoating of Clathrin-coated vesicles in CME [24].", [["cardiomyocytes", "ANATOMY", 71, 85], ["astrocytes", "ANATOMY", 135, 145], ["synaptic vesicle membranes", "ANATOMY", 163, 189], ["neurons", "ANATOMY", 193, 200], ["astrocytes", "ANATOMY", 406, 416], ["vesicles", "ANATOMY", 651, 659], ["ROS", "CHEMICAL", 11, 14], ["Stress", "DISEASE", 227, 233], ["O2", "CHEMICAL", 255, 257], ["CO2", "CHEMICAL", 258, 261], ["O2", "CHEMICAL", 255, 257], ["CO2", "CHEMICAL", 258, 261], ["ROS", "SIMPLE_CHEMICAL", 11, 14], ["GLUT4", "GENE_OR_GENE_PRODUCT", 62, 67], ["cardiomyocytes [91]", "GENE_OR_GENE_PRODUCT", 71, 90], ["aquaporin 4", "GENE_OR_GENE_PRODUCT", 92, 103], ["AQP4", "GENE_OR_GENE_PRODUCT", 105, 109], ["transferrin", "GENE_OR_GENE_PRODUCT", 112, 123], ["LDL", "GENE_OR_GENE_PRODUCT", 128, 131], ["astrocytes", "CELL", 135, 145], ["synaptic", "CELLULAR_COMPONENT", 163, 171], ["vesicle membranes", "CELLULAR_COMPONENT", 172, 189], ["neurons", "CELL", 193, 200], ["O2", "SIMPLE_CHEMICAL", 255, 257], ["CO2", "SIMPLE_CHEMICAL", 258, 261], ["astrocytes", "CELL", 406, 416], ["Sp1", "GENE_OR_GENE_PRODUCT", 489, 492], ["Hsc70 [93]", "GENE_OR_GENE_PRODUCT", 530, 540], ["heat shock protein", "GENE_OR_GENE_PRODUCT", 569, 587], ["Clathrin", "GENE_OR_GENE_PRODUCT", 635, 643], ["vesicles", "CELLULAR_COMPONENT", 651, 659], ["GLUT4", "PROTEIN", 62, 67], ["cardiomyocytes", "CELL_TYPE", 71, 85], ["aquaporin 4", "PROTEIN", 92, 103], ["AQP4", "PROTEIN", 105, 109], ["transferrin", "PROTEIN", 112, 123], ["LDL", "PROTEIN", 128, 131], ["astrocytes", "CELL_TYPE", 135, 145], ["astrocytes", "CELL_TYPE", 406, 416], ["transcription factor", "PROTEIN", 468, 488], ["Sp1", "PROTEIN", 489, 492], ["Hsc70", "PROTEIN", 530, 535], ["heat shock protein", "PROTEIN", 569, 587], ["Clathrin", "PROTEIN", 635, 643], ["GLUT4 in cardiomyocytes", "TEST", 62, 85], ["aquaporin", "TEST", 92, 101], ["AQP4", "TEST", 105, 109], ["transferrin", "TEST", 112, 123], ["LDL in astrocytes", "TEST", 128, 145], ["O2/CO2 supply", "TREATMENT", 255, 268], ["oxidative conditions in astrocytes", "PROBLEM", 382, 416], ["a constitutively expressed heat shock protein", "PROBLEM", 542, 587], ["an essential cofactor", "TREATMENT", 592, 613], ["cardiomyocytes", "ANATOMY", 71, 85], ["LDL", "ANATOMY", 128, 131], ["vesicle membranes", "ANATOMY", 172, 189]]], ["Decreased levels of Hsc70 are expected to reduce the availability of free Clathrin for new rounds of endocytosis, since it would be sequestered in uncoating-deficient Clathrin-coated vesicles or Clathrin cages [93].", [["vesicles", "ANATOMY", 183, 191], ["Clathrin", "CHEMICAL", 74, 82], ["Clathrin", "CHEMICAL", 74, 82], ["Hsc70", "GENE_OR_GENE_PRODUCT", 20, 25], ["Clathrin", "SIMPLE_CHEMICAL", 74, 82], ["Hsc70", "PROTEIN", 20, 25], ["Clathrin", "PROTEIN", 167, 175], ["Decreased levels of Hsc70", "PROBLEM", 0, 25], ["free Clathrin", "TREATMENT", 69, 82], ["endocytosis", "PROBLEM", 101, 112], ["uncoating-deficient Clathrin", "TREATMENT", 147, 175], ["Clathrin cages", "TREATMENT", 195, 209]]], ["However, it is unclear whether this mechanism extends to other cell types and conditions.Oxidative stress ::: Stress due to imbalances in O2/CO2 supply and oxidative species ::: STRESS CONDITIONS THAT AFFECT ENDOCYTOSISOn the other hand, oxidative conditions have been suggested to enhance the endocytosis of apically-located transporters in liver cells.", [["cell", "ANATOMY", 63, 67], ["liver cells", "ANATOMY", 342, 353], ["Stress", "DISEASE", 110, 116], ["O2", "CHEMICAL", 138, 140], ["CO2", "CHEMICAL", 141, 144], ["O2", "CHEMICAL", 138, 140], ["CO2", "CHEMICAL", 141, 144], ["cell", "CELL", 63, 67], ["O2", "SIMPLE_CHEMICAL", 138, 140], ["CO2", "SIMPLE_CHEMICAL", 141, 144], ["liver cells", "CELL", 342, 353], ["liver cells", "CELL_TYPE", 342, 353], ["this mechanism", "PROBLEM", 31, 45], ["O2/CO2 supply", "TREATMENT", 138, 151], ["oxidative conditions", "PROBLEM", 238, 258], ["cell types", "OBSERVATION", 63, 73], ["liver", "ANATOMY", 342, 347]]], ["These include the multidrug resistance-associated protein 2 (Mrp2) and the bile salt export pump (Bsep) [95\u201397], a protein important for canalicular bile secretion.", [["canalicular bile", "ANATOMY", 137, 153], ["bile salt", "CHEMICAL", 75, 84], ["multidrug resistance-associated protein 2", "GENE_OR_GENE_PRODUCT", 18, 59], ["Mrp2", "GENE_OR_GENE_PRODUCT", 61, 65], ["bile salt", "SIMPLE_CHEMICAL", 75, 84], ["Bsep", "GENE_OR_GENE_PRODUCT", 98, 102], ["canalicular bile", "MULTI-TISSUE_STRUCTURE", 137, 153], ["multidrug resistance-associated protein 2", "PROTEIN", 18, 59], ["Mrp2", "PROTEIN", 61, 65], ["bile salt export pump", "PROTEIN", 75, 96], ["Bsep", "PROTEIN", 98, 102], ["the multidrug resistance", "TEST", 14, 38], ["a protein", "TEST", 113, 122], ["canalicular bile secretion", "PROBLEM", 137, 163], ["multidrug resistance", "OBSERVATION", 18, 38], ["bile", "ANATOMY", 75, 79], ["export pump", "OBSERVATION", 85, 96]]], ["A disorganization of the actin cytoskeleton appears to be the reason for the elevated endocytosis of Mrp2 and Bsep, most likely as a consequence of ROS-induced altered Ca2+ homeostasis and PKC activation.", [["actin cytoskeleton", "ANATOMY", 25, 43], ["ROS", "CHEMICAL", 148, 151], ["Ca2", "CHEMICAL", 168, 171], ["Ca2+", "CHEMICAL", 168, 172], ["actin", "GENE_OR_GENE_PRODUCT", 25, 30], ["cytoskeleton", "CELLULAR_COMPONENT", 31, 43], ["Mrp2", "GENE_OR_GENE_PRODUCT", 101, 105], ["Bsep", "GENE_OR_GENE_PRODUCT", 110, 114], ["ROS", "SIMPLE_CHEMICAL", 148, 151], ["Ca2+", "SIMPLE_CHEMICAL", 168, 172], ["PKC", "GENE_OR_GENE_PRODUCT", 189, 192], ["actin", "PROTEIN", 25, 30], ["Mrp2", "PROTEIN", 101, 105], ["Bsep", "PROTEIN", 110, 114], ["Ca2", "PROTEIN", 168, 171], ["PKC", "PROTEIN", 189, 192], ["A disorganization of the actin cytoskeleton", "PROBLEM", 0, 43], ["the elevated endocytosis of Mrp2 and Bsep", "PROBLEM", 73, 114], ["ROS", "PROBLEM", 148, 151], ["altered Ca2+ homeostasis", "PROBLEM", 160, 184], ["PKC activation", "PROBLEM", 189, 203], ["disorganization", "OBSERVATION", 2, 17], ["actin cytoskeleton", "OBSERVATION", 25, 43], ["appears to be", "UNCERTAINTY", 44, 57], ["elevated", "OBSERVATION", 77, 85], ["most likely", "UNCERTAINTY", 116, 127], ["Ca2+ homeostasis", "OBSERVATION", 168, 184]]], ["Importantly, exogenous application of bilirubin, known for its antioxidant properties, rescues the ROS-induced changes in actin disruption and Mrp2 and Bsep downregulation [97], thereby counteracting the hepatocanalicular dysfunction associated with oxidative stress.", [["hepatocanalicular", "ANATOMY", 204, 221], ["bilirubin", "CHEMICAL", 38, 47], ["ROS", "CHEMICAL", 99, 102], ["hepatocanalicular dysfunction", "DISEASE", 204, 233], ["bilirubin", "CHEMICAL", 38, 47], ["bilirubin", "GENE_OR_GENE_PRODUCT", 38, 47], ["ROS", "SIMPLE_CHEMICAL", 99, 102], ["actin", "GENE_OR_GENE_PRODUCT", 122, 127], ["Mrp2", "GENE_OR_GENE_PRODUCT", 143, 147], ["Bsep", "GENE_OR_GENE_PRODUCT", 152, 156], ["hepatocanalicular", "CANCER", 204, 221], ["actin", "PROTEIN", 122, 127], ["Mrp2", "PROTEIN", 143, 147], ["Bsep", "PROTEIN", 152, 156], ["bilirubin", "TEST", 38, 47], ["its antioxidant properties", "TREATMENT", 59, 85], ["the ROS", "PROBLEM", 95, 102], ["changes in actin disruption", "PROBLEM", 111, 138], ["Mrp2", "TEST", 143, 147], ["Bsep downregulation", "TEST", 152, 171], ["the hepatocanalicular dysfunction", "PROBLEM", 200, 233], ["oxidative stress", "PROBLEM", 250, 266], ["actin disruption", "OBSERVATION", 122, 138], ["hepatocanalicular dysfunction", "OBSERVATION", 204, 233], ["oxidative stress", "OBSERVATION", 250, 266]]], ["A recent study also shows similar results for Rifampicin, an antibiotic commonly used to treat tuberculosis, but with detrimental side effects like hepatotoxicity.", [["Rifampicin", "CHEMICAL", 46, 56], ["tuberculosis", "DISEASE", 95, 107], ["hepatotoxicity", "DISEASE", 148, 162], ["Rifampicin", "CHEMICAL", 46, 56], ["Rifampicin", "SIMPLE_CHEMICAL", 46, 56], ["A recent study", "TEST", 0, 14], ["Rifampicin", "TREATMENT", 46, 56], ["an antibiotic", "TREATMENT", 58, 71], ["tuberculosis", "PROBLEM", 95, 107], ["detrimental side effects", "PROBLEM", 118, 142], ["hepatotoxicity", "PROBLEM", 148, 162], ["tuberculosis", "OBSERVATION", 95, 107], ["hepatotoxicity", "OBSERVATION", 148, 162]]], ["Rifampicin leads to increased Mrp2 endocytosis by causing oxidative stress and by activating PKC-ERK/JNK/p38 and PI3K signaling pathways.", [["Rifampicin", "CHEMICAL", 0, 10], ["Rifampicin", "CHEMICAL", 0, 10], ["Rifampicin", "SIMPLE_CHEMICAL", 0, 10], ["Mrp2", "GENE_OR_GENE_PRODUCT", 30, 34], ["PKC", "GENE_OR_GENE_PRODUCT", 93, 96], ["ERK", "GENE_OR_GENE_PRODUCT", 97, 100], ["JNK", "GENE_OR_GENE_PRODUCT", 101, 104], ["p38", "GENE_OR_GENE_PRODUCT", 105, 108], ["PI3K", "GENE_OR_GENE_PRODUCT", 113, 117], ["Mrp2", "PROTEIN", 30, 34], ["PKC", "PROTEIN", 93, 96], ["ERK", "PROTEIN", 97, 100], ["JNK", "PROTEIN", 101, 104], ["p38", "PROTEIN", 105, 108], ["PI3K", "PROTEIN", 113, 117], ["Rifampicin", "TREATMENT", 0, 10], ["increased Mrp2 endocytosis", "PROBLEM", 20, 46], ["oxidative stress", "PROBLEM", 58, 74], ["activating PKC", "TEST", 82, 96], ["ERK", "TEST", 97, 100], ["JNK", "TEST", 101, 104], ["p38", "TEST", 105, 108], ["PI3K signaling pathways", "TEST", 113, 136], ["increased", "OBSERVATION_MODIFIER", 20, 29], ["Mrp2 endocytosis", "OBSERVATION", 30, 46], ["oxidative stress", "OBSERVATION", 58, 74]]], ["Interestingly, the Rifampicin-induced elevation in Mrp2 endocytosis might also be due to transcriptional/protein upregulation of Clathrin and AP-2, changes that are suppressed by antioxidants [98].Oxidative stress ::: Stress due to imbalances in O2/CO2 supply and oxidative species ::: STRESS CONDITIONS THAT AFFECT ENDOCYTOSISClearly, further studies are needed to examine the effects of ROS on endocytosis and the underlying molecular mechanisms.Iron ::: Stress caused by exposure to metals: Iron, platinum, and heavy metals ::: STRESS CONDITIONS THAT AFFECT ENDOCYTOSISEndocytosis is the main route for cellular iron uptake, which is a crucial cofactor of cellular enzymes including those required for mitochondrial oxidative phosphorylation [99].", [["cellular", "ANATOMY", 606, 614], ["cellular", "ANATOMY", 659, 667], ["mitochondrial", "ANATOMY", 705, 718], ["Rifampicin", "CHEMICAL", 19, 29], ["Stress", "DISEASE", 218, 224], ["O2", "CHEMICAL", 246, 248], ["CO2", "CHEMICAL", 249, 252], ["ROS", "CHEMICAL", 389, 392], ["Iron", "CHEMICAL", 448, 452], ["Stress", "DISEASE", 457, 463], ["metals", "CHEMICAL", 486, 492], ["Iron", "CHEMICAL", 494, 498], ["platinum", "CHEMICAL", 500, 508], ["iron", "CHEMICAL", 615, 619], ["Rifampicin", "CHEMICAL", 19, 29], ["O2", "CHEMICAL", 246, 248], ["CO2", "CHEMICAL", 249, 252], ["Iron", "CHEMICAL", 448, 452], ["Iron", "CHEMICAL", 494, 498], ["platinum", "CHEMICAL", 500, 508], ["iron", "CHEMICAL", 615, 619], ["Rifampicin", "SIMPLE_CHEMICAL", 19, 29], ["Mrp2", "GENE_OR_GENE_PRODUCT", 51, 55], ["Clathrin", "GENE_OR_GENE_PRODUCT", 129, 137], ["AP-2", "GENE_OR_GENE_PRODUCT", 142, 146], ["O2", "SIMPLE_CHEMICAL", 246, 248], ["CO2", "SIMPLE_CHEMICAL", 249, 252], ["ROS", "SIMPLE_CHEMICAL", 389, 392], ["Iron", "SIMPLE_CHEMICAL", 494, 498], ["platinum", "SIMPLE_CHEMICAL", 500, 508], ["heavy metals", "SIMPLE_CHEMICAL", 514, 526], ["cellular", "CELL", 606, 614], ["iron", "SIMPLE_CHEMICAL", 615, 619], ["cellular", "CELL", 659, 667], ["mitochondrial", "CELLULAR_COMPONENT", 705, 718], ["Mrp2", "PROTEIN", 51, 55], ["Clathrin", "PROTEIN", 129, 137], ["AP", "PROTEIN", 142, 144], ["cellular enzymes", "PROTEIN", 659, 675], ["the Rifampicin", "TREATMENT", 15, 29], ["induced elevation in Mrp2 endocytosis", "PROBLEM", 30, 67], ["transcriptional/protein upregulation of Clathrin", "TREATMENT", 89, 137], ["AP", "TEST", 142, 144], ["imbalances", "PROBLEM", 232, 242], ["O2/CO2 supply", "TREATMENT", 246, 259], ["oxidative species", "PROBLEM", 264, 281], ["further studies", "TEST", 336, 351], ["ROS on endocytosis", "PROBLEM", 389, 407], ["Iron", "TREATMENT", 448, 452], ["Iron, platinum", "TREATMENT", 494, 508], ["cellular iron uptake", "PROBLEM", 606, 626], ["cellular enzymes", "TEST", 659, 675], ["mitochondrial oxidative phosphorylation", "TREATMENT", 705, 744], ["elevation", "OBSERVATION_MODIFIER", 38, 47], ["Mrp2 endocytosis", "OBSERVATION", 51, 67], ["might also be due to", "UNCERTAINTY", 68, 88], ["oxidative species", "OBSERVATION", 264, 281], ["iron uptake", "OBSERVATION", 615, 626]]], ["Its uptake is also associated with an increased generation of ROS, explaining why iron trafficking and metabolism must be exquisitely regulated.", [["ROS", "CHEMICAL", 62, 65], ["iron", "CHEMICAL", 82, 86], ["iron", "CHEMICAL", 82, 86], ["ROS", "SIMPLE_CHEMICAL", 62, 65], ["iron", "SIMPLE_CHEMICAL", 82, 86], ["an increased generation of ROS", "PROBLEM", 35, 65], ["iron trafficking", "PROBLEM", 82, 98], ["uptake", "OBSERVATION", 4, 10], ["increased", "OBSERVATION_MODIFIER", 38, 47]]], ["Iron homeostasis is under control of iron regulatory proteins (IRPs) that transcriptionally regulate the expression of target genes to maintain cellular iron metabolism such as genes encoding proteins involved in iron uptake [100].Iron ::: Stress caused by exposure to metals: Iron, platinum, and heavy metals ::: STRESS CONDITIONS THAT AFFECT ENDOCYTOSISOne of the causes of iron overload is an elevated intake via intestinal absorption.", [["cellular", "ANATOMY", 144, 152], ["intestinal", "ANATOMY", 416, 426], ["Iron", "CHEMICAL", 0, 4], ["iron", "CHEMICAL", 37, 41], ["iron", "CHEMICAL", 153, 157], ["iron", "CHEMICAL", 213, 217], ["Iron", "CHEMICAL", 231, 235], ["Stress", "DISEASE", 240, 246], ["metals", "CHEMICAL", 269, 275], ["Iron", "CHEMICAL", 277, 281], ["platinum", "CHEMICAL", 283, 291], ["iron", "CHEMICAL", 376, 380], ["Iron", "CHEMICAL", 0, 4], ["iron", "CHEMICAL", 37, 41], ["iron", "CHEMICAL", 153, 157], ["iron", "CHEMICAL", 213, 217], ["Iron", "CHEMICAL", 231, 235], ["Iron", "CHEMICAL", 277, 281], ["platinum", "CHEMICAL", 283, 291], ["iron", "CHEMICAL", 376, 380], ["Iron", "SIMPLE_CHEMICAL", 0, 4], ["iron regulatory proteins", "GENE_OR_GENE_PRODUCT", 37, 61], ["IRPs", "GENE_OR_GENE_PRODUCT", 63, 67], ["cellular", "CELL", 144, 152], ["iron", "SIMPLE_CHEMICAL", 153, 157], ["iron", "SIMPLE_CHEMICAL", 213, 217], ["Iron", "SIMPLE_CHEMICAL", 231, 235], ["Iron", "SIMPLE_CHEMICAL", 277, 281], ["platinum", "SIMPLE_CHEMICAL", 283, 291], ["heavy metals", "SIMPLE_CHEMICAL", 297, 309], ["iron", "SIMPLE_CHEMICAL", 376, 380], ["intestinal", "ORGAN", 416, 426], ["iron regulatory proteins", "PROTEIN", 37, 61], ["IRPs", "PROTEIN", 63, 67], ["target genes", "DNA", 119, 131], ["Iron homeostasis", "TREATMENT", 0, 16], ["iron regulatory proteins", "TREATMENT", 37, 61], ["cellular iron metabolism", "PROBLEM", 144, 168], ["genes encoding proteins", "PROBLEM", 177, 200], ["iron uptake", "TEST", 213, 224], ["Iron, platinum", "TREATMENT", 277, 291], ["iron overload", "PROBLEM", 376, 389], ["an elevated intake", "PROBLEM", 393, 411], ["intestinal absorption", "PROBLEM", 416, 437], ["iron overload", "OBSERVATION", 376, 389], ["elevated", "OBSERVATION", 396, 404], ["intestinal", "ANATOMY", 416, 426]]], ["In enterocytes, iron is mainly taken up by the iron/H+ cotransporter DMT1.", [["enterocytes", "ANATOMY", 3, 14], ["iron", "CHEMICAL", 16, 20], ["iron", "CHEMICAL", 47, 51], ["H", "CHEMICAL", 52, 53], ["iron", "CHEMICAL", 16, 20], ["iron", "CHEMICAL", 47, 51], ["H+", "CHEMICAL", 52, 54], ["enterocytes", "CELL", 3, 14], ["iron", "SIMPLE_CHEMICAL", 16, 20], ["iron", "SIMPLE_CHEMICAL", 47, 51], ["H+ cotransporter DMT1", "GENE_OR_GENE_PRODUCT", 52, 73], ["enterocytes", "CELL_TYPE", 3, 14], ["iron/H+ cotransporter", "PROTEIN", 47, 68], ["DMT1", "PROTEIN", 69, 73], ["cotransporter DMT1", "PROBLEM", 55, 73], ["enterocytes", "ANATOMY", 3, 14], ["cotransporter DMT1", "OBSERVATION", 55, 73]]], ["In Caco-2 human intestinal epithelial cells, a consequence of ROS production due to overdoses of iron is a reduced plasma membrane level of DMT1, possibly as a consequence of its iron-induced endocytosis, thereby decreasing iron uptake rates [101].Iron ::: Stress caused by exposure to metals: Iron, platinum, and heavy metals ::: STRESS CONDITIONS THAT AFFECT ENDOCYTOSISIn contrast, iron deficiency leads to adaptive responses that involve an increase in the activity of iron-transporters in the small intestine as well as morphological adaptations in the intestinal mucosa such as an increase in its thickness and the length of the villi to enhance the absorption of iron by enterocytes [102].", [["Caco-2 human intestinal epithelial cells", "ANATOMY", 3, 43], ["plasma membrane", "ANATOMY", 115, 130], ["small intestine", "ANATOMY", 498, 513], ["intestinal mucosa", "ANATOMY", 558, 575], ["villi", "ANATOMY", 635, 640], ["enterocytes", "ANATOMY", 678, 689], ["ROS", "CHEMICAL", 62, 65], ["iron", "CHEMICAL", 97, 101], ["iron", "CHEMICAL", 224, 228], ["Iron", "CHEMICAL", 248, 252], ["Stress", "DISEASE", 257, 263], ["metals", "CHEMICAL", 286, 292], ["Iron", "CHEMICAL", 294, 298], ["platinum", "CHEMICAL", 300, 308], ["iron", "CHEMICAL", 385, 389], ["iron", "CHEMICAL", 670, 674], ["iron", "CHEMICAL", 97, 101], ["iron", "CHEMICAL", 224, 228], ["Iron", "CHEMICAL", 248, 252], ["Iron", "CHEMICAL", 294, 298], ["platinum", "CHEMICAL", 300, 308], ["iron", "CHEMICAL", 385, 389], ["iron", "CHEMICAL", 670, 674], ["Caco-2 human intestinal epithelial cells", "CELL", 3, 43], ["ROS", "SIMPLE_CHEMICAL", 62, 65], ["iron", "SIMPLE_CHEMICAL", 97, 101], ["plasma membrane", "CELLULAR_COMPONENT", 115, 130], ["DMT1", "GENE_OR_GENE_PRODUCT", 140, 144], ["iron", "SIMPLE_CHEMICAL", 224, 228], ["Iron", "SIMPLE_CHEMICAL", 248, 252], ["Iron", "SIMPLE_CHEMICAL", 294, 298], ["platinum", "SIMPLE_CHEMICAL", 300, 308], ["heavy metals", "SIMPLE_CHEMICAL", 314, 326], ["iron", "SIMPLE_CHEMICAL", 385, 389], ["iron-transporters", "GENE_OR_GENE_PRODUCT", 473, 490], ["small intestine", "ORGAN", 498, 513], ["intestinal mucosa", "MULTI-TISSUE_STRUCTURE", 558, 575], ["villi", "MULTI-TISSUE_STRUCTURE", 635, 640], ["iron", "SIMPLE_CHEMICAL", 670, 674], ["Caco-2 human intestinal epithelial cells", "CELL_LINE", 3, 43], ["DMT1", "PROTEIN", 140, 144], ["iron-transporters", "PROTEIN", 473, 490], ["human", "SPECIES", 10, 15], ["human", "SPECIES", 10, 15], ["ROS production", "PROBLEM", 62, 76], ["iron", "TREATMENT", 97, 101], ["a reduced plasma membrane level of DMT1", "PROBLEM", 105, 144], ["its iron-induced endocytosis", "PROBLEM", 175, 203], ["decreasing iron uptake rates", "PROBLEM", 213, 241], ["Iron, platinum", "TREATMENT", 294, 308], ["iron deficiency", "PROBLEM", 385, 400], ["morphological adaptations in the intestinal mucosa", "PROBLEM", 525, 575], ["an increase in its thickness", "PROBLEM", 584, 612], ["2 human", "ANATOMY_MODIFIER", 8, 15], ["intestinal", "ANATOMY", 16, 26], ["epithelial cells", "OBSERVATION", 27, 43], ["ROS production", "OBSERVATION", 62, 76], ["iron-induced endocytosis", "OBSERVATION", 179, 203], ["increase", "OBSERVATION_MODIFIER", 445, 453], ["small intestine", "ANATOMY", 498, 513], ["intestinal mucosa", "ANATOMY", 558, 575], ["increase", "OBSERVATION_MODIFIER", 587, 595], ["villi", "ANATOMY", 635, 640]]], ["The surface expression of transferrin receptor is also maximized in many other cell types [100].Platinum ::: Stress caused by exposure to metals: Iron, platinum, and heavy metals ::: STRESS CONDITIONS THAT AFFECT ENDOCYTOSISPlatinum drugs such as Cisplatin are common standard treatments for many types of tumors.", [["surface", "ANATOMY", 4, 11], ["cell", "ANATOMY", 79, 83], ["tumors", "ANATOMY", 306, 312], ["Platinum", "CHEMICAL", 96, 104], ["Stress", "DISEASE", 109, 115], ["metals", "CHEMICAL", 138, 144], ["Iron", "CHEMICAL", 146, 150], ["platinum", "CHEMICAL", 152, 160], ["Cisplatin", "CHEMICAL", 247, 256], ["tumors", "DISEASE", 306, 312], ["Iron", "CHEMICAL", 146, 150], ["platinum", "CHEMICAL", 152, 160], ["Cisplatin", "CHEMICAL", 247, 256], ["surface", "CELLULAR_COMPONENT", 4, 11], ["transferrin receptor", "GENE_OR_GENE_PRODUCT", 26, 46], ["cell", "CELL", 79, 83], ["Iron", "SIMPLE_CHEMICAL", 146, 150], ["platinum", "SIMPLE_CHEMICAL", 152, 160], ["heavy metals", "SIMPLE_CHEMICAL", 166, 178], ["Cisplatin", "SIMPLE_CHEMICAL", 247, 256], ["tumors", "CANCER", 306, 312], ["transferrin receptor", "PROTEIN", 26, 46], ["transferrin receptor", "TREATMENT", 26, 46], ["Iron, platinum", "TREATMENT", 146, 160], ["ENDOCYTOSISPlatinum drugs", "TREATMENT", 213, 238], ["Cisplatin", "TREATMENT", 247, 256], ["common standard treatments", "TREATMENT", 261, 287], ["tumors", "PROBLEM", 306, 312], ["surface", "OBSERVATION_MODIFIER", 4, 11], ["tumors", "OBSERVATION", 306, 312]]], ["One of their side effects is nephrotoxicity.", [["nephrotoxicity", "DISEASE", 29, 43], ["nephrotoxicity", "PROBLEM", 29, 43], ["side effects", "OBSERVATION_MODIFIER", 13, 25], ["nephrotoxicity", "OBSERVATION", 29, 43]]], ["A possible mechanism underlying Cisplatin-induced proteinuria is the decreased CME of proteins in the proximal tubule and the inhibition of the vATPase [103].", [["proximal tubule", "ANATOMY", 102, 117], ["Cisplatin", "CHEMICAL", 32, 41], ["proteinuria", "DISEASE", 50, 61], ["Cisplatin", "CHEMICAL", 32, 41], ["Cisplatin", "SIMPLE_CHEMICAL", 32, 41], ["tubule", "MULTI-TISSUE_STRUCTURE", 111, 117], ["Cisplatin", "TREATMENT", 32, 41], ["induced proteinuria", "PROBLEM", 42, 61], ["the vATPase", "TEST", 140, 151], ["possible", "UNCERTAINTY", 2, 10], ["Cisplatin", "OBSERVATION", 32, 41], ["proteinuria", "OBSERVATION", 50, 61], ["decreased", "OBSERVATION_MODIFIER", 69, 78], ["proximal", "ANATOMY_MODIFIER", 102, 110], ["tubule", "ANATOMY_MODIFIER", 111, 117]]], ["Cisplatin has also been proposed to stimulate EGFR endocytosis.", [["Cisplatin", "CHEMICAL", 0, 9], ["Cisplatin", "CHEMICAL", 0, 9], ["Cisplatin", "SIMPLE_CHEMICAL", 0, 9], ["EGFR", "GENE_OR_GENE_PRODUCT", 46, 50], ["EGFR", "PROTEIN", 46, 50], ["Cisplatin", "TREATMENT", 0, 9], ["EGFR endocytosis", "PROBLEM", 46, 62]]], ["However, in this case EGFR does not appear to be degraded in lysosomes or recycled to the plasma membrane, but accumulates in a subpopulation of non-degradative perinuclear multivesicular bodies.", [["lysosomes", "ANATOMY", 61, 70], ["plasma membrane", "ANATOMY", 90, 105], ["perinuclear multivesicular bodies", "ANATOMY", 161, 194], ["EGFR", "GENE_OR_GENE_PRODUCT", 22, 26], ["lysosomes", "CELLULAR_COMPONENT", 61, 70], ["plasma membrane", "CELLULAR_COMPONENT", 90, 105], ["perinuclear", "CELLULAR_COMPONENT", 161, 172], ["multivesicular bodies", "CELLULAR_COMPONENT", 173, 194], ["EGFR", "PROTEIN", 22, 26], ["this case EGFR", "TEST", 12, 26], ["the plasma membrane", "TEST", 86, 105], ["non-degradative perinuclear multivesicular bodies", "PROBLEM", 145, 194], ["subpopulation", "OBSERVATION_MODIFIER", 128, 141], ["perinuclear", "OBSERVATION_MODIFIER", 161, 172], ["multivesicular bodies", "OBSERVATION", 173, 194]]], ["In contrast to normal EGFR internalization, the Cisplatin-dependent EGFR endocytosis does not require ubiquitination, but is Dynamin- and AP-2 dependent.", [["Cisplatin", "CHEMICAL", 48, 57], ["Cisplatin", "CHEMICAL", 48, 57], ["EGFR", "GENE_OR_GENE_PRODUCT", 22, 26], ["Cisplatin", "SIMPLE_CHEMICAL", 48, 57], ["EGFR", "GENE_OR_GENE_PRODUCT", 68, 72], ["Dynamin", "GENE_OR_GENE_PRODUCT", 125, 132], ["AP-2", "GENE_OR_GENE_PRODUCT", 138, 142], ["EGFR", "PROTEIN", 22, 26], ["EGFR", "PROTEIN", 68, 72], ["Dynamin", "PROTEIN", 125, 132], ["AP", "PROTEIN", 138, 140], ["the Cisplatin-dependent EGFR endocytosis", "TREATMENT", 44, 84], ["Dynamin", "TEST", 125, 132], ["AP", "TEST", 138, 140], ["EGFR internalization", "OBSERVATION", 22, 42], ["dependent", "OBSERVATION_MODIFIER", 58, 67], ["EGFR endocytosis", "OBSERVATION", 68, 84], ["does not require", "UNCERTAINTY", 85, 101], ["ubiquitination", "OBSERVATION", 102, 116]]], ["This pathway appears to be crucial for survival as AP-2 loss induces apoptosis of Cisplatin-treated cells [104].Heavy metals ::: Stress caused by exposure to metals: Iron, platinum, and heavy metals ::: STRESS CONDITIONS THAT AFFECT ENDOCYTOSISProlonged exposure to heavy metals such as cadmium, arsenic, mercury and lead is known to induce deleterious health effects, since they can bind to proteins and replace the original metals causing protein malfunctioning.", [["cells", "ANATOMY", 100, 105], ["Cisplatin", "CHEMICAL", 82, 91], ["Stress", "DISEASE", 129, 135], ["metals", "CHEMICAL", 158, 164], ["Iron", "CHEMICAL", 166, 170], ["platinum", "CHEMICAL", 172, 180], ["cadmium", "CHEMICAL", 287, 294], ["arsenic", "CHEMICAL", 296, 303], ["mercury", "CHEMICAL", 305, 312], ["Cisplatin", "CHEMICAL", 82, 91], ["Iron", "CHEMICAL", 166, 170], ["platinum", "CHEMICAL", 172, 180], ["cadmium", "CHEMICAL", 287, 294], ["arsenic", "CHEMICAL", 296, 303], ["mercury", "CHEMICAL", 305, 312], ["AP-2", "GENE_OR_GENE_PRODUCT", 51, 55], ["Cisplatin", "SIMPLE_CHEMICAL", 82, 91], ["cells", "CELL", 100, 105], ["Iron", "SIMPLE_CHEMICAL", 166, 170], ["platinum", "SIMPLE_CHEMICAL", 172, 180], ["heavy metals", "SIMPLE_CHEMICAL", 186, 198], ["cadmium", "SIMPLE_CHEMICAL", 287, 294], ["arsenic", "SIMPLE_CHEMICAL", 296, 303], ["mercury", "SIMPLE_CHEMICAL", 305, 312], ["AP", "PROTEIN", 51, 53], ["Cisplatin-treated cells", "CELL_LINE", 82, 105], ["AP", "TEST", 51, 53], ["Cisplatin-treated cells", "TREATMENT", 82, 105], ["Iron, platinum", "TREATMENT", 166, 180], ["the original metals", "TREATMENT", 413, 432], ["protein malfunctioning", "PROBLEM", 441, 463], ["appears to be", "UNCERTAINTY", 13, 26], ["protein malfunctioning", "OBSERVATION", 441, 463]]], ["At the cellular level, several studies have indicated oxidative stress leading to apoptosis as a common mechanism underlying their toxicity [105].", [["cellular", "ANATOMY", 7, 15], ["toxicity", "DISEASE", 131, 139], ["cellular", "CELL", 7, 15], ["several studies", "TEST", 23, 38], ["oxidative stress", "PROBLEM", 54, 70], ["apoptosis", "PROBLEM", 82, 91], ["their toxicity", "PROBLEM", 125, 139], ["oxidative stress", "OBSERVATION", 54, 70]]], ["As metal ions can enter into the cell via endocytosis complexed to chelating proteins such as metallothioneins, it is easy to conceive that decreasing endocytic rates can be considered as a protective mechanism to avoid metal-induced toxicity.", [["cell", "ANATOMY", 33, 37], ["metal", "CHEMICAL", 220, 225], ["toxicity", "DISEASE", 234, 242], ["metal ions", "SIMPLE_CHEMICAL", 3, 13], ["cell", "CELL", 33, 37], ["metallothioneins", "GENE_OR_GENE_PRODUCT", 94, 110], ["chelating proteins", "PROTEIN", 67, 85], ["metallothioneins", "PROTEIN", 94, 110], ["metal ions", "TREATMENT", 3, 13], ["chelating proteins", "TREATMENT", 67, 85], ["decreasing endocytic rates", "PROBLEM", 140, 166], ["a protective mechanism", "TREATMENT", 188, 210], ["metal-induced toxicity", "PROBLEM", 220, 242]]], ["In agreement, several studies have reported a downregulation of endocytosis in proximal tubule cells exposed to cadmium [106] and a reduced endocytosis/phagocytosis capacity in dendritic cells and macrophages subjected to arsenic stress [107\u2013109].", [["proximal tubule cells", "ANATOMY", 79, 100], ["dendritic cells", "ANATOMY", 177, 192], ["macrophages", "ANATOMY", 197, 208], ["cadmium", "CHEMICAL", 112, 119], ["arsenic", "CHEMICAL", 222, 229], ["cadmium", "CHEMICAL", 112, 119], ["arsenic", "CHEMICAL", 222, 229], ["proximal tubule cells", "CELL", 79, 100], ["cadmium [106]", "SIMPLE_CHEMICAL", 112, 125], ["dendritic cells", "CELL", 177, 192], ["macrophages", "CELL", 197, 208], ["arsenic", "SIMPLE_CHEMICAL", 222, 229], ["proximal tubule cells", "CELL_TYPE", 79, 100], ["dendritic cells", "CELL_TYPE", 177, 192], ["macrophages", "CELL_TYPE", 197, 208], ["several studies", "TEST", 14, 29], ["a downregulation of endocytosis", "PROBLEM", 44, 75], ["proximal tubule cells", "PROBLEM", 79, 100], ["cadmium", "TEST", 112, 119], ["a reduced endocytosis/phagocytosis capacity", "PROBLEM", 130, 173], ["dendritic cells", "PROBLEM", 177, 192], ["macrophages", "PROBLEM", 197, 208], ["arsenic stress", "PROBLEM", 222, 236], ["proximal", "ANATOMY_MODIFIER", 79, 87], ["tubule cells", "OBSERVATION", 88, 100], ["reduced", "OBSERVATION_MODIFIER", 132, 139], ["endocytosis", "OBSERVATION", 140, 151], ["phagocytosis capacity", "OBSERVATION", 152, 173], ["dendritic cells", "OBSERVATION", 177, 192]]], ["However, downregulation of endocytosis to bypass metallotoxicity has harmful side effects such as cadmium-induced proteinuria or arsenic-induced immunosuppression.Radiation stress ::: STRESS CONDITIONS THAT AFFECT ENDOCYTOSISRadiotherapy is a common cancer treatment due to its contribution to cell death.", [["cancer", "ANATOMY", 250, 256], ["cell", "ANATOMY", 294, 298], ["cadmium", "CHEMICAL", 98, 105], ["proteinuria", "DISEASE", 114, 125], ["arsenic", "CHEMICAL", 129, 136], ["cancer", "DISEASE", 250, 256], ["death", "DISEASE", 299, 304], ["cadmium", "CHEMICAL", 98, 105], ["arsenic", "CHEMICAL", 129, 136], ["cadmium", "SIMPLE_CHEMICAL", 98, 105], ["arsenic", "SIMPLE_CHEMICAL", 129, 136], ["cancer", "CANCER", 250, 256], ["cell", "CELL", 294, 298], ["downregulation of endocytosis", "PROBLEM", 9, 38], ["bypass metallotoxicity", "TREATMENT", 42, 64], ["harmful side effects", "PROBLEM", 69, 89], ["proteinuria", "PROBLEM", 114, 125], ["arsenic-induced immunosuppression", "TREATMENT", 129, 162], ["a common cancer treatment", "TREATMENT", 241, 266], ["cell death", "PROBLEM", 294, 304], ["endocytosis", "OBSERVATION", 27, 38], ["bypass", "OBSERVATION", 42, 48], ["proteinuria", "OBSERVATION", 114, 125], ["common", "OBSERVATION_MODIFIER", 243, 249], ["cancer", "OBSERVATION", 250, 256], ["cell death", "OBSERVATION", 294, 304]]], ["It is known that penetrating radiation leads to cellular stress [110], mainly via ROS generation, protein misfolding, DNA breaks and organelle damage.", [["cellular", "ANATOMY", 48, 56], ["organelle", "ANATOMY", 133, 142], ["ROS", "CHEMICAL", 82, 85], ["cellular", "CELL", 48, 56], ["ROS", "SIMPLE_CHEMICAL", 82, 85], ["DNA", "CELLULAR_COMPONENT", 118, 121], ["organelle", "CELLULAR_COMPONENT", 133, 142], ["penetrating radiation", "TREATMENT", 17, 38], ["cellular stress", "PROBLEM", 48, 63], ["protein misfolding", "PROBLEM", 98, 116], ["DNA breaks", "PROBLEM", 118, 128], ["organelle damage", "PROBLEM", 133, 149], ["penetrating", "OBSERVATION_MODIFIER", 17, 28], ["radiation", "OBSERVATION", 29, 38], ["organelle damage", "OBSERVATION", 133, 149]]], ["However, radiotherapy has limitations due to cytotoxic effects on healthy cells and the associated radioresistance.", [["cells", "ANATOMY", 74, 79], ["cells", "CELL", 74, 79], ["healthy cells", "CELL_TYPE", 66, 79], ["radiotherapy", "TREATMENT", 9, 21], ["cytotoxic effects on healthy cells", "PROBLEM", 45, 79], ["the associated radioresistance", "PROBLEM", 84, 114], ["healthy cells", "OBSERVATION_MODIFIER", 66, 79], ["radioresistance", "OBSERVATION", 99, 114]]], ["Several papers have shown a differential impact of radiation on endocytosis.", [["radiation on endocytosis", "PROBLEM", 51, 75], ["radiation", "OBSERVATION", 51, 60]]], ["For example, defects in the migratory capacity of Langerhans cell-like dendritic cells subjected to ultraviolet B radiation was related to reduced receptor-mediated and fluid-phase endocytosis [111].", [["Langerhans cell", "ANATOMY", 50, 65], ["dendritic cells", "ANATOMY", 71, 86], ["ultraviolet B", "CHEMICAL", 100, 113], ["Langerhans cell-like dendritic cells", "CELL", 50, 86], ["Langerhans cell", "CELL_TYPE", 50, 65], ["dendritic cells", "CELL_TYPE", 71, 86], ["defects in the migratory capacity", "PROBLEM", 13, 46], ["Langerhans cell", "PROBLEM", 50, 65], ["dendritic cells", "PROBLEM", 71, 86], ["ultraviolet B radiation", "TREATMENT", 100, 123], ["fluid-phase endocytosis", "TEST", 169, 192], ["defects", "OBSERVATION", 13, 20], ["migratory", "OBSERVATION_MODIFIER", 28, 37], ["capacity", "OBSERVATION_MODIFIER", 38, 46], ["Langerhans cell", "OBSERVATION", 50, 65], ["dendritic cells", "OBSERVATION", 71, 86]]], ["In contrast, work by [112] suggests that albumin uptake and fluid-phase endocytosis remain normal in irradiated inmature and mature dendritic cells.", [["inmature", "ANATOMY", 112, 120], ["dendritic cells", "ANATOMY", 132, 147], ["albumin", "GENE_OR_GENE_PRODUCT", 41, 48], ["inmature", "CELL", 112, 120], ["dendritic cells", "CELL", 132, 147], ["irradiated inmature and mature dendritic cells", "CELL_TYPE", 101, 147], ["albumin uptake", "TEST", 41, 55], ["fluid-phase endocytosis", "TEST", 60, 83], ["normal", "OBSERVATION", 91, 97], ["irradiated inmature", "OBSERVATION_MODIFIER", 101, 120], ["mature", "OBSERVATION_MODIFIER", 125, 131], ["dendritic cells", "OBSERVATION", 132, 147]]], ["Carbon ion irradiation is also used as cancer therapy, being considered more effective than photon irradiation.", [["cancer", "ANATOMY", 39, 45], ["Carbon ion", "CHEMICAL", 0, 10], ["cancer", "DISEASE", 39, 45], ["Carbon", "CHEMICAL", 0, 6], ["Carbon ion", "SIMPLE_CHEMICAL", 0, 10], ["cancer", "CANCER", 39, 45], ["Carbon ion irradiation", "TREATMENT", 0, 22], ["cancer therapy", "TREATMENT", 39, 53], ["photon irradiation", "TREATMENT", 92, 110]]], ["This type of radiation was shown to promote apoptosis in both immature and mature dendritic cells, in part due to impaired endocytosis [113].", [["dendritic cells", "ANATOMY", 82, 97], ["dendritic cells", "CELL", 82, 97], ["immature and mature dendritic cells", "CELL_TYPE", 62, 97], ["radiation", "TREATMENT", 13, 22], ["apoptosis", "PROBLEM", 44, 53], ["impaired endocytosis", "PROBLEM", 114, 134], ["apoptosis", "OBSERVATION", 44, 53], ["both immature", "OBSERVATION_MODIFIER", 57, 70], ["mature", "OBSERVATION_MODIFIER", 75, 81], ["dendritic cells", "OBSERVATION", 82, 97], ["impaired", "OBSERVATION_MODIFIER", 114, 122], ["endocytosis", "OBSERVATION", 123, 134]]], ["Like other types of stress, e.g. cisplatin, irradiation also promotes ligand-independent endocytosis of EGFR [114, 115] via an unknown mechanism.OUTLOOKBeyond the examples provided here, there is little systematic knowledge about (i) which specific alterations in endocytosis are triggered by different stress conditions, (ii) how stress triggers changes in the overall endocytic capacity, (iii) which changes in the endocytic sorting of individual proteins are induced by stress, and (iv) how those changes contribute to a successful cellular adaptation to stress.", [["cellular", "ANATOMY", 535, 543], ["cisplatin", "CHEMICAL", 33, 42], ["cisplatin", "CHEMICAL", 33, 42], ["cisplatin", "SIMPLE_CHEMICAL", 33, 42], ["EGFR", "GENE_OR_GENE_PRODUCT", 104, 108], ["cellular", "CELL", 535, 543], ["EGFR", "PROTEIN", 104, 108], ["stress", "PROBLEM", 20, 26], ["cisplatin", "TREATMENT", 33, 42], ["irradiation", "TREATMENT", 44, 55], ["EGFR", "TEST", 104, 108], ["different stress conditions", "PROBLEM", 293, 320], ["stress triggers changes", "PROBLEM", 331, 354], ["endocytic capacity", "OBSERVATION", 370, 388]]], ["Clearly, more systematic and unbiased approaches are needed to compare the effects of different stressors on endocytic flux in general and on specific endocytic cargo proteins.OUTLOOKIn addition, it is increasingly being recognized that stress responses are not confined to individual cells.", [["cells", "ANATOMY", 285, 290], ["cells", "CELL", 285, 290], ["endocytic cargo proteins", "PROTEIN", 151, 175], ["different stressors", "PROBLEM", 86, 105], ["endocytic flux", "TEST", 109, 123], ["stress responses", "PROBLEM", 237, 253], ["endocytic flux", "OBSERVATION", 109, 123]]], ["To coordinate adaptive responses within the organism, stressed cells communicate their status to their environment, either by displaying specific proteins on their surface or by releasing signal factors [116], e.g. with the help of surface-localized transport proteins.", [["cells", "ANATOMY", 63, 68], ["surface", "ANATOMY", 164, 171], ["surface", "ANATOMY", 232, 239], ["cells", "CELL", 63, 68], ["surface", "CELLULAR_COMPONENT", 164, 171], ["stressed cells", "CELL_TYPE", 54, 68], ["signal factors", "PROTEIN", 188, 202], ["surface-localized transport proteins", "PROTEIN", 232, 268], ["stressed cells", "PROBLEM", 54, 68]]], ["These aspects of the stress response could be supported by alterations in endocytosis.", [["the stress response", "PROBLEM", 17, 36], ["alterations in endocytosis", "PROBLEM", 59, 85], ["stress response", "OBSERVATION", 21, 36], ["endocytosis", "OBSERVATION", 74, 85]]], ["However, so far this possibility has not been investigated.OUTLOOKOur lack of understanding of the adaptation of endocytosis under stress conditions goes hand in hand with our limited knowledge about endocytic regulation in other physiological conditions.", [["hand", "ANATOMY", 154, 158], ["hand", "ANATOMY", 162, 166], ["hand", "ORGANISM_SUBDIVISION", 154, 158], ["hand", "ORGANISM_SUBDIVISION", 162, 166], ["endocytosis under stress conditions", "PROBLEM", 113, 148]]], ["Even though numerous kinase pathways have been implicated in the regulation of endocytosis [27, 117] including some recent additions like the NIMA family kinases in C. elegans [118], how different signal transduction cascades modulate specific endocytic factors and cargo sorting in most cases has remained enigmatic.", [["NIMA family kinases", "GENE_OR_GENE_PRODUCT", 142, 161], ["C. elegans", "ORGANISM", 165, 175], ["cargo", "CELLULAR_COMPONENT", 266, 271], ["NIMA family kinases", "PROTEIN", 142, 161], ["endocytic factors", "PROTEIN", 244, 261], ["C. elegans", "SPECIES", 165, 175], ["C. elegans", "SPECIES", 165, 175], ["numerous kinase pathways", "PROBLEM", 12, 36], ["different signal transduction cascades modulate specific endocytic factors", "PROBLEM", 187, 261], ["cargo sorting", "TEST", 266, 279], ["enigmatic", "OBSERVATION_MODIFIER", 307, 316]]], ["In addition to phosphorylation, ubiquitination events play a critical role in regulating the uptake of specific cargo proteins.", [["cargo proteins", "PROTEIN", 112, 126], ["phosphorylation", "TREATMENT", 15, 30], ["ubiquitination events", "PROBLEM", 32, 53]]], ["Moreover, recent data suggest that both endocytosed cargo proteins and endocytic factors such as AP180 and AAK1 (reviewed in [119]) can also be subject to modification by carbohydrates such as O-GlcNAc that may regulate endocytosis by so far unknown mechanisms.", [["carbohydrates", "CHEMICAL", 171, 184], ["O-GlcNAc", "CHEMICAL", 193, 201], ["AP180", "GENE_OR_GENE_PRODUCT", 97, 102], ["AAK1", "GENE_OR_GENE_PRODUCT", 107, 111], ["carbohydrates", "SIMPLE_CHEMICAL", 171, 184], ["O-GlcNAc", "GENE_OR_GENE_PRODUCT", 193, 201], ["endocytosed cargo proteins", "PROTEIN", 40, 66], ["endocytic factors", "PROTEIN", 71, 88], ["AP180", "PROTEIN", 97, 102], ["AAK1", "PROTEIN", 107, 111], ["GlcNAc", "TREATMENT", 195, 201]]], ["Aside from these post-translational mechanisms, the regulation of endocytosis at the transcriptional level including the possible role of alternative splicing is only now starting to be appreciated.", [["endocytosis at the transcriptional level", "PROBLEM", 66, 106], ["alternative splicing", "TREATMENT", 138, 158], ["post-translational mechanisms", "OBSERVATION", 17, 46], ["endocytosis", "OBSERVATION", 66, 77], ["alternative splicing", "OBSERVATION", 138, 158]]], ["With advanced mass spectrometry and RNAseq-based approaches that allow to study different posttranslational modifications as well as mRNA abundance and splicing, it should become feasible to map the transcriptional and posttranslational regulation of cargo proteins and their associated endocytic factors upon different stress conditions and to delineate the underlying signaling pathways.", [["cargo proteins", "PROTEIN", 251, 265], ["endocytic factors", "PROTEIN", 287, 304], ["advanced mass spectrometry", "PROBLEM", 5, 31], ["RNAseq-based approaches", "TREATMENT", 36, 59], ["different posttranslational modifications", "TREATMENT", 80, 121], ["cargo proteins", "PROBLEM", 251, 265], ["their associated endocytic factors", "PROBLEM", 270, 304], ["different stress conditions", "PROBLEM", 310, 337], ["mass", "OBSERVATION", 14, 18], ["cargo proteins", "OBSERVATION", 251, 265]]], ["This will pave the way for a more detailed understanding of how endocytosis is employed by mammalian cells to promote survival under stress.", [["cells", "ANATOMY", 101, 106], ["mammalian cells", "CELL", 91, 106], ["mammalian cells", "CELL_TYPE", 91, 106]]]], "PMC7267328": [], "2602be22482e091908ce4d8100e34f4c82bfc5a7": [["Introduction and Statement of ProblemA blood transfusion generally is a life-saving measure, but absolute safety can never be guaranteed.", [["blood", "ANATOMY", 39, 44], ["blood", "ORGANISM_SUBSTANCE", 39, 44], ["ProblemA blood transfusion", "TREATMENT", 30, 56]]], ["In addition to immune-mediated reactions caused by infusion of allogeneic cells or proteins, bloodborne infectious organisms can be transmitted by transfusion, potentially causing disease in the transfused recipient.", [["cells", "ANATOMY", 74, 79], ["bloodborne infectious organisms", "DISEASE", 93, 124], ["cells", "CELL", 74, 79], ["allogeneic cells", "CELL_TYPE", 63, 79], ["immune-mediated reactions", "PROBLEM", 15, 40], ["infusion of allogeneic cells", "TREATMENT", 51, 79], ["proteins", "TREATMENT", 83, 91], ["bloodborne infectious organisms", "PROBLEM", 93, 124], ["transfusion", "TREATMENT", 147, 158], ["disease", "PROBLEM", 180, 187], ["the transfused recipient", "TREATMENT", 191, 215], ["allogeneic cells", "OBSERVATION", 63, 79], ["transfused recipient", "OBSERVATION", 195, 215]]], ["In an effort to reduce the potential for and actual incidence of disease transmission, all blood donors should be appropriately screened for infectious disease.Introduction and Statement of ProblemWhat screening is appropriate?", [["blood", "ANATOMY", 91, 96], ["infectious disease", "DISEASE", 141, 159], ["blood", "ORGANISM_SUBSTANCE", 91, 96], ["donors", "ORGANISM", 97, 103], ["disease transmission", "PROBLEM", 65, 85], ["all blood donors", "TREATMENT", 87, 103], ["infectious disease", "PROBLEM", 141, 159], ["ProblemWhat screening", "TEST", 190, 211]]], ["An exhaustive treatise on each infectious disease and its causative agent is not the objective of this article.", [["infectious disease", "DISEASE", 31, 49], ["each infectious disease", "PROBLEM", 26, 49], ["infectious", "OBSERVATION", 31, 41]]], ["Rather, our intent is to provide a summary of canine and feline diseases that pose potential risk to transfusion recipients.Introduction and Statement of ProblemThe following recommendations are based on the information available at the time of this writing.", [["feline diseases", "DISEASE", 57, 72], ["canine", "ORGANISM", 46, 52], ["feline", "ORGANISM", 57, 63], ["recipients", "ORGANISM", 113, 123], ["canine", "SPECIES", 46, 52], ["transfusion recipients", "TREATMENT", 101, 123]]], ["The area of infectious disease is extremely dynamic, with new organisms being recognized and previously recognized organisms being renamed.", [["infectious disease", "DISEASE", 12, 30], ["infectious disease", "PROBLEM", 12, 30], ["new organisms", "PROBLEM", 58, 71], ["area", "OBSERVATION_MODIFIER", 4, 8], ["infectious", "OBSERVATION", 12, 22], ["dynamic", "OBSERVATION_MODIFIER", 44, 51], ["new", "OBSERVATION_MODIFIER", 58, 61], ["organisms", "OBSERVATION", 62, 71]]], ["For the sake of clarity, the consensus panel subdivided diseases into the following categories for the dog and cat:Introduction and Statement of Problem1.", [["dog", "ORGANISM", 103, 106], ["the consensus panel", "TEST", 25, 44]]], ["Vectorborne diseases-testing recommended 2.", [["Vectorborne diseases", "DISEASE", 0, 20], ["Vectorborne diseases", "PROBLEM", 0, 20]]], ["Nonvectorborne diseases-testing recommended 3.", [["Nonvectorborne diseases", "PROBLEM", 0, 23]]], ["Vectorborne diseases-conditional testing (ie, to be considered) 4.", [["Vectorborne diseases", "PROBLEM", 0, 20], ["conditional testing", "TEST", 21, 40]]], ["Other diseases-testing not recommended Diseases for which testing is recommended met at least 3 of the following criteria: (1) the disease agent is documented to cause clinical infection in recipients via blood transmission, (2) the disease agent is capable of causing subclinical infection such that asymptomatic carriers could erroneously be used as blood donors, (3) the disease agent can be cultured from the blood of an infected animal, and (4) the resultant disease in the recipient is severe or difficult to clear.", [["blood", "ANATOMY", 205, 210], ["blood", "ANATOMY", 352, 357], ["blood", "ANATOMY", 413, 418], ["infection", "DISEASE", 177, 186], ["infection", "DISEASE", 281, 290], ["recipients", "ORGANISM", 190, 200], ["blood", "ORGANISM_SUBSTANCE", 205, 210], ["blood", "ORGANISM_SUBSTANCE", 352, 357], ["blood", "ORGANISM_SUBSTANCE", 413, 418], ["Other diseases", "PROBLEM", 0, 14], ["Diseases", "PROBLEM", 39, 47], ["testing", "TEST", 58, 65], ["the disease agent", "PROBLEM", 127, 144], ["clinical infection", "PROBLEM", 168, 186], ["blood transmission", "TEST", 205, 223], ["the disease agent", "PROBLEM", 229, 246], ["subclinical infection", "PROBLEM", 269, 290], ["asymptomatic carriers", "PROBLEM", 301, 322], ["blood donors", "TEST", 352, 364], ["the disease agent", "PROBLEM", 370, 387], ["the blood", "TEST", 409, 418], ["the resultant disease", "PROBLEM", 450, 471], ["diseases", "OBSERVATION", 6, 14], ["infection", "OBSERVATION", 177, 186], ["subclinical", "OBSERVATION_MODIFIER", 269, 280], ["infection", "OBSERVATION", 281, 290], ["infected", "OBSERVATION", 425, 433], ["resultant", "OBSERVATION_MODIFIER", 454, 463], ["disease", "OBSERVATION", 464, 471], ["severe", "OBSERVATION_MODIFIER", 492, 498], ["clear", "OBSERVATION", 515, 520]]], ["Some of the included diseases also are endemic in restricted areas of North America or occur at higher prevalence in certain breeds, and screening for these diseases outside the endemic region or breed is not routinely recommended.Introduction and Statement of ProblemDiseases for which testing is conditionally recommended (ie, to be considered) met the following criteria: (1) experimental transmission is documented, but clinical transmission via transfusion is not described or (2) the disease does not represent a threat to most recipients or is easily cleared.", [["recipients", "ORGANISM", 534, 544], ["the included diseases", "PROBLEM", 8, 29], ["screening", "TEST", 137, 146], ["these diseases", "PROBLEM", 151, 165], ["testing", "TEST", 287, 294], ["transfusion", "TREATMENT", 450, 461], ["the disease", "PROBLEM", 486, 497], ["diseases", "OBSERVATION", 21, 29], ["endemic", "OBSERVATION_MODIFIER", 39, 46], ["restricted", "OBSERVATION_MODIFIER", 50, 60], ["areas", "OBSERVATION_MODIFIER", 61, 66], ["North", "OBSERVATION_MODIFIER", 70, 75], ["America", "OBSERVATION_MODIFIER", 76, 83], ["disease", "OBSERVATION", 490, 497]]], ["As our knowledge base grows, and as some diseases become more endemic, diseases which are only to be considered for screening at this time could become diseases for which testing is recommended in the future.", [["some diseases", "PROBLEM", 36, 49], ["diseases", "PROBLEM", 71, 79], ["screening", "TEST", 116, 125], ["diseases", "PROBLEM", 152, 160], ["testing", "TEST", 171, 178]]], ["Veterinarians using blood donors are advised to read the current literature and recognize potential infectious diseases in their area.Introduction and Statement of ProblemCanine and feline heartworm disease were not included, because they did not meet the criteria for infectious diseases that can be transmitted by transfusion (ie, transfusion of microfilaria from an infected donor does not produce heartworm disease in the recipient).", [["blood", "ANATOMY", 20, 25], ["infectious diseases", "DISEASE", 100, 119], ["feline heartworm disease", "DISEASE", 182, 206], ["infectious diseases", "DISEASE", 269, 288], ["heartworm disease", "DISEASE", 401, 418], ["blood", "ORGANISM_SUBSTANCE", 20, 25], ["feline", "ORGANISM", 182, 188], ["heartworm", "ORGANISM", 189, 198], ["heartworm", "ORGANISM_SUBDIVISION", 401, 410], ["feline", "SPECIES", 182, 188], ["blood donors", "TREATMENT", 20, 32], ["potential infectious diseases in their area", "PROBLEM", 90, 133], ["ProblemCanine", "TREATMENT", 164, 177], ["feline heartworm disease", "PROBLEM", 182, 206], ["infectious diseases", "PROBLEM", 269, 288], ["microfilaria", "PROBLEM", 348, 360], ["an infected donor", "TREATMENT", 366, 383], ["heartworm disease", "PROBLEM", 401, 418], ["infectious", "OBSERVATION", 100, 110], ["infected", "OBSERVATION", 369, 377]]], ["For the health of the blood donor, however, dogs and cats in heartworm endemic areas should be tested and placed on preventative therapy.Introduction and Statement of ProblemThe consensus panel did not explore frequency of testing, but it seems prudent to retest frequently in endemic areas and to retest donors with repeated exposure to risk factors (eg, tick exposure).", [["blood", "ANATOMY", 22, 27], ["blood", "ORGANISM_SUBSTANCE", 22, 27], ["dogs", "ORGANISM", 44, 48], ["cats", "ORGANISM", 53, 57], ["heartworm", "ORGANISM", 61, 70], ["donors", "ORGANISM", 305, 311], ["dogs", "SPECIES", 44, 48], ["cats", "SPECIES", 53, 57], ["the blood donor", "TREATMENT", 18, 33], ["dogs and cats in heartworm endemic areas", "PROBLEM", 44, 84], ["preventative therapy", "TREATMENT", 116, 136], ["The consensus panel", "TEST", 174, 193], ["testing", "TEST", 223, 230], ["risk factors", "PROBLEM", 338, 350]]], ["The consensus panel agreed that prevention of disease in blood donors and prevention of contamination of collected blood products by management techniques also should be considered, and appropriate recommendations are included in the consensus statement.General Comments on Infectious Disease TestingNo tests have 100% sensitivity and specificity.", [["blood", "ANATOMY", 57, 62], ["blood", "ANATOMY", 115, 120], ["blood", "ORGANISM_SUBSTANCE", 57, 62], ["blood", "ORGANISM_SUBSTANCE", 115, 120], ["The consensus panel", "TEST", 0, 19], ["disease in blood donors", "PROBLEM", 46, 69], ["collected blood products", "TREATMENT", 105, 129], ["management techniques", "TREATMENT", 133, 154], ["Infectious Disease TestingNo tests", "TEST", 274, 308], ["specificity", "TEST", 335, 346], ["disease", "OBSERVATION", 46, 53]]], ["Consequently, accurate diagnosis of infectious diseases often requires an integrated approach, including physical examination, hematologic and biochemical testing, and several test methodologies directed at the organism of interest.", [["infectious diseases", "DISEASE", 36, 55], ["infectious diseases", "PROBLEM", 36, 55], ["physical examination", "TEST", 105, 125], ["biochemical testing", "TEST", 143, 162], ["several test methodologies", "TEST", 168, 194], ["infectious", "OBSERVATION", 36, 46]]], ["The following is a brief discussion of the basic utility and limitations of these tests.Organism or Antigen TestsLight Microscopy.", [["these tests", "TEST", 76, 87], ["Organism", "PROBLEM", 88, 96], ["Antigen TestsLight Microscopy", "TEST", 100, 129]]], ["Documentation of an infectious agent by light microscopy usually is specific, but requires skilled personnel and is time consuming (an adequate blood film examination can take 20-30 minutes).", [["blood", "ANATOMY", 144, 149], ["blood", "ORGANISM_SUBSTANCE", 144, 149], ["light microscopy", "TEST", 40, 56], ["an adequate blood film examination", "TEST", 132, 166], ["infectious", "OBSERVATION", 20, 30]]], ["Because false-negative results can occur with blood film scans, potential donors with no microscopic evidence of infection might need to be assessed by other testing methodologies.Organism or Antigen TestsCulture.", [["blood", "ANATOMY", 46, 51], ["infection", "DISEASE", 113, 122], ["blood", "ORGANISM_SUBSTANCE", 46, 51], ["donors", "ORGANISM", 74, 80], ["blood film scans", "TEST", 46, 62], ["infection", "PROBLEM", 113, 122], ["Organism", "PROBLEM", 180, 188], ["Antigen TestsCulture", "TEST", 192, 212], ["infection", "OBSERVATION", 113, 122]]], ["Positive blood culture results indicate the presence of ongoing infection, and the positive predictive value of culture is high.", [["blood", "ANATOMY", 9, 14], ["infection", "DISEASE", 64, 73], ["blood", "ORGANISM_SUBSTANCE", 9, 14], ["blood culture", "TEST", 9, 22], ["ongoing infection", "PROBLEM", 56, 73], ["culture", "TEST", 112, 119], ["ongoing", "OBSERVATION_MODIFIER", 56, 63], ["infection", "OBSERVATION", 64, 73]]], ["Some infectious agents of interest to transfusion medicine, however, have never been successfully cultured, and culture techniques for some organisms are not commercially available, have poor sensitivity, are expensive, or are time consuming.Organism or Antigen TestsSerum Antigen Tests.", [["transfusion medicine", "TREATMENT", 38, 58], ["culture techniques", "TEST", 112, 130], ["some organisms", "PROBLEM", 135, 149], ["Organism", "TEST", 242, 250], ["Antigen TestsSerum Antigen Tests", "TEST", 254, 286], ["infectious", "OBSERVATION_MODIFIER", 5, 15]]], ["Assays for detection of antigens of a number of infectious agents are commercially available, and positive results document current infection.", [["infection", "DISEASE", 132, 141], ["antigens", "PROTEIN", 24, 32], ["Assays", "TEST", 0, 6], ["infectious agents", "TREATMENT", 48, 65], ["current infection", "PROBLEM", 124, 141], ["infectious", "OBSERVATION", 48, 58], ["infection", "OBSERVATION", 132, 141]]], ["Dirofilaria immitis (dogs and cats) and feline leukemia virus (FeLV) tests are the serum antigen tests used most frequently for donor screening and health assessment.", [["serum", "ANATOMY", 83, 88], ["Dirofilaria immitis", "DISEASE", 0, 19], ["feline leukemia", "DISEASE", 40, 55], ["Dirofilaria immitis", "ORGANISM", 0, 19], ["dogs", "ORGANISM", 21, 25], ["cats", "ORGANISM", 30, 34], ["feline leukemia virus", "ORGANISM", 40, 61], ["FeLV", "ORGANISM", 63, 67], ["serum", "ORGANISM_SUBSTANCE", 83, 88], ["Dirofilaria immitis", "SPECIES", 0, 19], ["dogs", "SPECIES", 21, 25], ["cats", "SPECIES", 30, 34], ["feline leukemia virus", "SPECIES", 40, 61], ["Dirofilaria immitis", "SPECIES", 0, 19], ["feline leukemia virus", "SPECIES", 40, 61], ["FeLV", "SPECIES", 63, 67], ["Dirofilaria immitis", "PROBLEM", 0, 19], ["feline leukemia virus", "PROBLEM", 40, 61], ["FeLV) tests", "TEST", 63, 74], ["the serum antigen tests", "TEST", 79, 102], ["donor screening", "TEST", 128, 143], ["health assessment", "TEST", 148, 165], ["leukemia virus", "OBSERVATION", 47, 61]]], ["Pointof-care tests are available for both organisms, and the potential for inaccurate results from operator error is small.Organism or Antigen TestsPolymerase Chain Reaction Testing.", [["Pointof-care tests", "TEST", 0, 18], ["Organism", "TEST", 123, 131], ["Antigen Tests", "TEST", 135, 148], ["Testing", "TEST", 174, 181], ["small", "OBSERVATION_MODIFIER", 117, 122]]], ["Polymerase chain reaction (PCR) assays amplify DNA sequences specific for each agent, thereby indicating current infection.", [["infection", "DISEASE", 113, 122], ["DNA", "CELLULAR_COMPONENT", 47, 50], ["DNA sequences", "DNA", 47, 60], ["Polymerase chain reaction", "PROBLEM", 0, 25], ["PCR) assays", "TEST", 27, 38], ["DNA sequences", "TEST", 47, 60], ["current infection", "PROBLEM", 105, 122], ["infection", "OBSERVATION", 113, 122]]], ["The major advantage of PCR assays is that the positive predictive value generally is 100% when the tests are performed correctly.", [["PCR assays", "TEST", 23, 33], ["the tests", "TEST", 95, 104]]], ["Disadvantages include lack of point-of-care tests; lack of standardization among laboratories, which could result in different sensitivities and specificities; lack of test availability for some infectious agents; and expense.", [["standardization among laboratories", "TEST", 59, 93], ["some infectious agents", "PROBLEM", 190, 212]]], ["Veterinarians should ask laboratories about the sensitivity, specificity, and detection limits of their PCR tests.", [["the sensitivity", "TEST", 44, 59], ["their PCR tests", "TEST", 98, 113]]], ["Falsenegative tests can occur with some PCR assays if the DNA is present only in small concentrations.", [["DNA", "CELLULAR_COMPONENT", 58, 61], ["Falsenegative tests", "TEST", 0, 19], ["some PCR assays", "TEST", 35, 50], ["the DNA", "PROBLEM", 54, 61], ["small concentrations", "OBSERVATION_MODIFIER", 81, 101]]], ["In addition, most PCR tests evaluate a very small sample of blood (microliters), and patients can receive over 10,000 times that amount during a transfusion.", [["blood", "ANATOMY", 60, 65], ["blood", "ORGANISM_SUBSTANCE", 60, 65], ["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93], ["most PCR tests", "TEST", 13, 27], ["a transfusion", "TREATMENT", 143, 156]]], ["In some cases, PCR-negative animals should be further evaluated by repeated PCR tests, serology, or blood culture before inclusion in the donor pool.Organism or Antigen TestsAnimals that have microscopic evidence of infection, are culture-positive, are antigen-positive, or are positive by PCR assay should be excluded from the donor pool.", [["blood", "ANATOMY", 100, 105], ["infection", "DISEASE", 216, 225], ["blood", "ORGANISM_SUBSTANCE", 100, 105], ["PCR", "TEST", 15, 18], ["repeated PCR tests", "TEST", 67, 85], ["serology", "TEST", 87, 95], ["blood culture", "TEST", 100, 113], ["Organism", "PROBLEM", 149, 157], ["Antigen Tests", "TEST", 161, 174], ["infection", "PROBLEM", 216, 225], ["culture", "TEST", 231, 238], ["antigen", "TEST", 253, 260], ["PCR assay", "TEST", 290, 299], ["evidence of", "UNCERTAINTY", 204, 215], ["infection", "OBSERVATION", 216, 225]]], ["For some agents, complete information is not available to prove that infection can be eliminated by treatment, and previously positive animals should not be used as blood donors.Serum Antibody TestsTrue positive serum antibody test results document exposure to the agent in question but do not prove current infection.", [["blood", "ANATOMY", 165, 170], ["Serum", "ANATOMY", 178, 183], ["serum", "ANATOMY", 212, 217], ["infection", "DISEASE", 69, 78], ["infection", "DISEASE", 308, 317], ["blood", "ORGANISM_SUBSTANCE", 165, 170], ["Serum", "ORGANISM_SUBSTANCE", 178, 183], ["serum", "ORGANISM_SUBSTANCE", 212, 217], ["infection", "PROBLEM", 69, 78], ["blood donors", "TEST", 165, 177], ["Serum Antibody Tests", "TEST", 178, 198], ["True positive serum antibody test", "TEST", 198, 231], ["current infection", "PROBLEM", 300, 317], ["infection", "OBSERVATION", 69, 78], ["infection", "OBSERVATION", 308, 317]]], ["In general, the specificities and negative predictive values of these tests often are very good, but PCR assays might be indicated to further evaluate infectious status of some seronegative animals in endemic areas (see specific agent discussions).Serum Antibody TestsMany techniques are used to detect specific antibodies, including immunofluorescent antibody tests (IFA), enzymelinked immunosorbent antibody assays (ELISA), western blot immunoassay, agar gel immunodiffusion, and a variety of agglutination and hemagglutination procedures.", [["Serum", "ANATOMY", 248, 253], ["Serum", "ORGANISM_SUBSTANCE", 248, 253], ["antibodies", "PROTEIN", 312, 322], ["the specificities", "TEST", 12, 29], ["these tests", "TEST", 64, 75], ["PCR assays", "TEST", 101, 111], ["some seronegative animals in endemic areas", "PROBLEM", 172, 214], ["Serum Antibody TestsMany techniques", "TEST", 248, 283], ["specific antibodies", "TEST", 303, 322], ["immunofluorescent antibody tests", "TEST", 334, 366], ["IFA", "TEST", 368, 371], ["enzymelinked immunosorbent antibody assays", "TEST", 374, 416], ["ELISA", "TEST", 418, 423], ["western blot immunoassay", "TEST", 426, 450], ["agar gel immunodiffusion", "TEST", 452, 476], ["agglutination", "PROBLEM", 495, 508], ["hemagglutination procedures", "TREATMENT", 513, 540]]], ["Gold standard techniques vary from 1 infectious agent to another.", [["Gold standard techniques", "TREATMENT", 0, 24]]], ["IFA and ELISA are used frequently, and results can be expressed as titers or as positive or negative (point-of-care ELISA).", [["IFA", "SIMPLE_CHEMICAL", 0, 3], ["IFA and ELISA", "TEST", 0, 13]]], ["Point-of-care ELISAs are available for some infectious agents and have the advantages of being rapid and inexpensive, and the potential for operator error is small.", [["some infectious agents", "TREATMENT", 39, 61], ["small", "OBSERVATION_MODIFIER", 158, 163]]], ["There is no standardization of serological tests for infectious agents offered by commercial laboratories.", [["serological tests", "TEST", 31, 48], ["infectious agents", "TREATMENT", 53, 70], ["no", "UNCERTAINTY", 9, 11]]], ["Differences in antigen, antigen preparation, reagents, and protocol and inherent subjectivity in interpretation of the IFA tests are some disadvantages.Serum Antibody TestsIn general, because seropositive animals still might be infected, we recommend exclusion of seropositive animals from the donor pool.", [["Serum", "ANATOMY", 152, 157], ["antigen", "GENE_OR_GENE_PRODUCT", 24, 31], ["Serum", "ORGANISM_SUBSTANCE", 152, 157], ["animals", "ORGANISM", 205, 212], ["protocol", "TEST", 59, 67], ["the IFA tests", "TEST", 115, 128], ["Serum Antibody TestsIn", "TEST", 152, 174], ["seropositive animals", "PROBLEM", 192, 212], ["seropositive animals", "PROBLEM", 264, 284]]], ["Similar to the situation that exists with antigen tests, it often is unknown whether or not treatment has cleared the infection, and previously positive animals should not be used as blood donors.", [["blood", "ANATOMY", 183, 188], ["infection", "DISEASE", 118, 127], ["blood", "ORGANISM_SUBSTANCE", 183, 188], ["antigen tests", "TEST", 42, 55], ["treatment", "TREATMENT", 92, 101], ["the infection", "PROBLEM", 114, 127], ["blood donors", "TEST", 183, 195], ["infection", "OBSERVATION", 118, 127]]], ["Only in diseases for which the organism is believed to be totally eliminated after treatment of infection, such as in Rocky Mountain Spotted Fever in dogs, can a seropositive, healthy animal be considered for use as a blood donor after recovery from disease.Canine DiseasesVectorborne Diseases-Testing Recommended.", [["blood", "ANATOMY", 218, 223], ["infection", "DISEASE", 96, 105], ["Fever", "DISEASE", 141, 146], ["DiseasesVectorborne Diseases", "DISEASE", 265, 293], ["dogs", "ORGANISM", 150, 154], ["blood", "ORGANISM_SUBSTANCE", 218, 223], ["dogs", "SPECIES", 150, 154], ["Canine", "SPECIES", 258, 264], ["diseases", "PROBLEM", 8, 16], ["infection", "PROBLEM", 96, 105], ["Spotted Fever in dogs", "PROBLEM", 133, 154], ["a blood donor", "TREATMENT", 216, 229], ["disease", "PROBLEM", 250, 257], ["Canine DiseasesVectorborne Diseases", "PROBLEM", 258, 293], ["diseases", "OBSERVATION", 8, 16], ["believed to be", "UNCERTAINTY", 43, 57], ["infection", "OBSERVATION", 96, 105]]], ["Babesiosis: Babesiosis is a disease caused by organisms of the genus Babesia.", [["Babesiosis", "DISEASE", 0, 10], ["Babesiosis", "DISEASE", 12, 22], ["Babesia", "ORGANISM", 69, 76], ["Babesiosis", "PROBLEM", 0, 10], ["Babesiosis", "PROBLEM", 12, 22], ["a disease", "PROBLEM", 26, 35], ["organisms of the genus Babesia", "PROBLEM", 46, 76], ["Babesiosis", "OBSERVATION", 12, 22], ["genus Babesia", "OBSERVATION", 63, 76]]], ["Babesia canis and Babesia gibsoni are the most common species that occur naturally in the dog.", [["Babesia canis", "DISEASE", 0, 13], ["Babesia gibsoni", "DISEASE", 18, 33], ["Babesia canis", "ORGANISM", 0, 13], ["Babesia gibsoni", "ORGANISM", 18, 33], ["dog", "ORGANISM", 90, 93], ["Babesia canis", "SPECIES", 0, 13], ["Babesia gibsoni", "SPECIES", 18, 33], ["dog", "SPECIES", 90, 93], ["Babesia canis", "SPECIES", 0, 13], ["Babesia gibsoni", "SPECIES", 18, 33], ["Babesia canis", "PROBLEM", 0, 13], ["Babesia gibsoni", "PROBLEM", 18, 33], ["Babesia gibsoni", "OBSERVATION", 18, 33], ["most common", "OBSERVATION_MODIFIER", 42, 53]]], ["The infections normally are transmitted by an infected ixodid tick vector, by perinatal transmission, or by direct transmission via mechanical vectors.", [["infections", "DISEASE", 4, 14], ["The infections", "PROBLEM", 0, 14], ["an infected ixodid tick vector", "TREATMENT", 43, 73], ["mechanical vectors", "TREATMENT", 132, 150], ["infections", "OBSERVATION", 4, 14], ["infected", "OBSERVATION_MODIFIER", 46, 54], ["ixodid tick vector", "OBSERVATION", 55, 73]]], ["Transmission of Babesia sp. by transfusion is well documented in both humans 1,2 and dogs.", [["Babesia sp", "ORGANISM", 16, 26], ["humans", "ORGANISM", 70, 76], ["dogs", "ORGANISM", 85, 89], ["humans", "SPECIES", 70, 76], ["dogs", "SPECIES", 85, 89], ["humans", "SPECIES", 70, 76], ["Babesia", "PROBLEM", 16, 23], ["Babesia", "OBSERVATION", 16, 23]]], ["3, 4 The disease in dogs can be peracute, acute, chronic, or subclinical.", [["dogs", "ORGANISM", 20, 24], ["dogs", "SPECIES", 20, 24], ["The disease in dogs", "PROBLEM", 5, 24], ["disease", "OBSERVATION", 9, 16], ["can be", "UNCERTAINTY", 25, 31], ["acute", "OBSERVATION_MODIFIER", 42, 47], ["chronic", "OBSERVATION_MODIFIER", 49, 56], ["subclinical", "OBSERVATION_MODIFIER", 61, 72]]], ["A high seroprevalence of B canis occurs in Greyhounds, 5 and an increased prevalence of B gibsoni occurs in American Pit Bull Terriers and American Staffordshire Terriers, as detected by PCR.", [["B canis", "DISEASE", 25, 32], ["B gibsoni", "CHEMICAL", 88, 97], ["B canis", "ORGANISM", 25, 32], ["B gibsoni", "ORGANISM", 88, 97], ["B canis", "SPECIES", 25, 32], ["B gibsoni", "SPECIES", 88, 97], ["B canis", "SPECIES", 25, 32], ["B gibsoni", "SPECIES", 88, 97], ["A high seroprevalence of B canis", "PROBLEM", 0, 32], ["B gibsoni", "PROBLEM", 88, 97]]], ["6, 7 The consensus of the panel is that potential blood donors, especially greyhounds, American Pit Bull Terriers, and Staffordshire Terriers, be screened for both B canis and B gibsoni.", [["blood", "ANATOMY", 50, 55], ["B canis", "DISEASE", 164, 171], ["blood", "ORGANISM_SUBSTANCE", 50, 55], ["B canis", "ORGANISM", 164, 171], ["B gibsoni", "ORGANISM", 176, 185], ["B canis", "SPECIES", 164, 171], ["B gibsoni", "SPECIES", 176, 185], ["B canis", "SPECIES", 164, 171], ["B gibsoni", "SPECIES", 176, 185], ["blood donors", "PROBLEM", 50, 62], ["canis", "OBSERVATION", 166, 171], ["gibsoni", "OBSERVATION", 178, 185]]], ["Serologic testing for antibodies can be performed initially, with seropositive dogs excluded.", [["dogs", "ORGANISM", 79, 83], ["antibodies", "PROTEIN", 22, 32], ["dogs", "SPECIES", 79, 83], ["Serologic testing", "TEST", 0, 17], ["antibodies", "TEST", 22, 32], ["seropositive dogs", "TEST", 66, 83]]], ["Seronegative dogs can be additionally screened with PCR for Babesia spp.Canine DiseasesLeishmaniasis: Leishmaniasis is a disease caused by protozoal organisms of the genus Leishmania and is transmitted in Mediterranean regions by the bite of an infected female sand fly.", [["Babesia spp", "DISEASE", 60, 71], ["DiseasesLeishmaniasis", "DISEASE", 79, 100], ["Leishmaniasis", "DISEASE", 102, 115], ["dogs", "ORGANISM", 13, 17], ["Babesia spp", "ORGANISM", 60, 71], ["Canine", "ORGANISM", 72, 78], ["Leishmania", "ORGANISM", 172, 182], ["dogs", "SPECIES", 13, 17], ["Canine", "SPECIES", 72, 78], ["Babesia spp", "SPECIES", 60, 71], ["Seronegative dogs", "PROBLEM", 0, 17], ["PCR", "TEST", 52, 55], ["Babesia spp", "PROBLEM", 60, 71], ["Canine DiseasesLeishmaniasis", "PROBLEM", 72, 100], ["Leishmaniasis", "PROBLEM", 102, 115], ["a disease", "PROBLEM", 119, 128], ["protozoal organisms", "PROBLEM", 139, 158], ["the genus Leishmania", "PROBLEM", 162, 182], ["Diseases", "OBSERVATION_MODIFIER", 79, 87], ["Leishmaniasis", "OBSERVATION", 87, 100], ["Leishmaniasis", "OBSERVATION", 102, 115], ["protozoal", "OBSERVATION_MODIFIER", 139, 148], ["genus Leishmania", "OBSERVATION", 166, 182], ["infected", "OBSERVATION", 245, 253]]], ["The vector in North America is not known.", [["not known", "UNCERTAINTY", 31, 40]]], ["In the United States, the disease is considered endemic in Texas, Ohio, and Oklahoma 8 but also has been reported in several other states.", [["the disease", "PROBLEM", 22, 33], ["disease", "OBSERVATION", 26, 33], ["endemic", "OBSERVATION_MODIFIER", 48, 55]]], ["Several forms of the disease, including cutaneous, mucocutaneous, and visceral forms, have been identified in dogs.", [["cutaneous", "ANATOMY", 40, 49], ["mucocutaneous", "ANATOMY", 51, 64], ["visceral", "ANATOMY", 70, 78], ["cutaneous, mucocutaneous, and visceral forms", "DISEASE", 40, 84], ["cutaneous", "ORGANISM_SUBDIVISION", 40, 49], ["dogs", "ORGANISM", 110, 114], ["dogs", "SPECIES", 110, 114], ["the disease, including cutaneous, mucocutaneous, and visceral forms", "PROBLEM", 17, 84], ["disease", "OBSERVATION", 21, 28], ["cutaneous", "ANATOMY", 40, 49], ["mucocutaneous", "OBSERVATION", 51, 64], ["visceral", "ANATOMY", 70, 78]]], ["Visceral leishmaniasis, caused by Leishmania donovani, has been transmitted clinically by blood transfusions in dogs, with clinically healthy foxhounds as blood donors.", [["blood", "ANATOMY", 90, 95], ["blood", "ANATOMY", 155, 160], ["Visceral leishmaniasis", "DISEASE", 0, 22], ["Leishmania donovani", "DISEASE", 34, 53], ["Leishmania donovani", "ORGANISM", 34, 53], ["blood", "ORGANISM_SUBSTANCE", 90, 95], ["dogs", "ORGANISM", 112, 116], ["blood", "ORGANISM_SUBSTANCE", 155, 160], ["Leishmania donovani", "SPECIES", 34, 53], ["dogs", "SPECIES", 112, 116], ["Leishmania donovani", "SPECIES", 34, 53], ["Visceral leishmaniasis", "PROBLEM", 0, 22], ["Leishmania donovani", "PROBLEM", 34, 53], ["blood transfusions in dogs", "TREATMENT", 90, 116], ["leishmaniasis", "OBSERVATION", 9, 22], ["Leishmania donovani", "OBSERVATION", 34, 53]]], ["9 In 1 study, 30% of English Foxhounds tested were seropositive for Leishmania spp.", [["Leishmania spp", "DISEASE", 68, 82], ["Leishmania spp", "ORGANISM", 68, 82], ["1 study", "TEST", 5, 12], ["English Foxhounds", "TEST", 21, 38], ["Leishmania spp", "PROBLEM", 68, 82]]], ["9 Another study examining the seroprevalence of antibodies against Leishmania in the United States found 2 non-foxhound dogs to be seropositive.", [["dogs", "ORGANISM", 120, 124], ["antibodies", "PROTEIN", 48, 58], ["dogs", "SPECIES", 120, 124], ["Another study", "TEST", 2, 15], ["Leishmania", "PROBLEM", 67, 77], ["2 non-foxhound dogs", "PROBLEM", 105, 124], ["seropositive", "PROBLEM", 131, 143]]], ["Both of these dogs had negative test results by PCR assays.", [["dogs", "ORGANISM", 14, 18], ["dogs", "SPECIES", 14, 18], ["PCR assays", "TEST", 48, 58]]], ["10 Because of the severity of the clinical disease and its known transmission via blood transfusion, it is recommended that all foxhounds and dogs with travel history to or from endemic areas be screened for Leishmania spp.", [["blood", "ANATOMY", 82, 87], ["Leishmania spp", "DISEASE", 208, 222], ["blood", "ORGANISM_SUBSTANCE", 82, 87], ["dogs", "ORGANISM", 142, 146], ["Leishmania spp", "ORGANISM", 208, 222], ["dogs", "SPECIES", 142, 146], ["the clinical disease", "PROBLEM", 30, 50], ["blood transfusion", "TREATMENT", 82, 99], ["Leishmania spp", "PROBLEM", 208, 222]]], ["As with Babesia, screening for Leishmania involves initial IFA testing, with seropositive dogs excluded.", [["Leishmania", "ORGANISM", 31, 41], ["dogs", "ORGANISM", 90, 94], ["dogs", "SPECIES", 90, 94], ["Babesia", "PROBLEM", 8, 15], ["screening", "TEST", 17, 26], ["Leishmania", "PROBLEM", 31, 41], ["initial IFA testing", "TEST", 51, 70], ["seropositive dogs", "PROBLEM", 77, 94]]], ["Seronegative dogs can be screened additionally with Leishmania PCR.", [["dogs", "ORGANISM", 13, 17], ["dogs", "SPECIES", 13, 17], ["Seronegative dogs", "PROBLEM", 0, 17], ["Leishmania PCR", "TEST", 52, 66]]], ["It should be noted that the IFA for Leishmania spp. can cross-react with Trypanosoma cruzi, and seropositive animals should also be evaluated for the presence of specific antibody against T cruzi.", [["Trypanosoma cruzi", "DISEASE", 73, 90], ["Leishmania spp.", "ORGANISM", 36, 51], ["Trypanosoma cruzi", "ORGANISM", 73, 90], ["T cruzi", "ORGANISM", 188, 195], ["specific antibody", "PROTEIN", 162, 179], ["Leishmania spp.", "SPECIES", 36, 51], ["Trypanosoma cruzi", "SPECIES", 73, 90], ["T cruzi", "SPECIES", 188, 195], ["Leishmania spp.", "SPECIES", 36, 51], ["Trypanosoma cruzi", "SPECIES", 73, 90], ["T cruzi", "SPECIES", 188, 195], ["the IFA", "TEST", 24, 31], ["Leishmania spp.", "PROBLEM", 36, 51], ["Trypanosoma cruzi", "PROBLEM", 73, 90], ["T cruzi", "PROBLEM", 188, 195]]], ["10 Ehrlichiosis, Anaplasmosis, Neorickettsiosis: Dogs are known to be infected by a variety of Ehrlichia spp., Anaplasma spp., and Neorickettsia spp. organisms in the family Rickettsiaceae.", [["Neorickettsiosis", "CHEMICAL", 31, 47], ["Ehrlichia spp.", "DISEASE", 95, 109], ["Anaplasma spp.", "DISEASE", 111, 125], ["Dogs", "ORGANISM", 49, 53], ["Ehrlichia spp.", "ORGANISM", 95, 109], ["Anaplasma spp.", "ORGANISM", 111, 125], ["Neorickettsia spp.", "ORGANISM", 131, 149], ["Ehrlichia spp.", "SPECIES", 95, 109], ["Anaplasma spp.", "SPECIES", 111, 125], ["Neorickettsia spp.", "SPECIES", 131, 149], ["Ehrlichia spp.", "SPECIES", 95, 109], ["Anaplasma spp.", "SPECIES", 111, 125], ["Neorickettsia spp.", "SPECIES", 131, 149], ["Ehrlichiosis", "PROBLEM", 3, 15], ["Anaplasmosis", "PROBLEM", 17, 29], ["Dogs", "PROBLEM", 49, 53], ["Ehrlichia spp.", "TREATMENT", 95, 109], ["Anaplasma spp.", "TREATMENT", 111, 125], ["Ehrlichiosis", "OBSERVATION", 3, 15], ["Anaplasmosis", "OBSERVATION", 17, 29], ["infected", "OBSERVATION", 70, 78]]], ["In general, these organisms are arthropodborne; several are known to be tickborne.", [["arthropodborne", "PROBLEM", 32, 46]]], ["Ehrlichia canis, Ehrlichia ewingii, Ehrlichia chaffeensis, Anaplasma phagocytophilum (previously Ehrlichia equi, the human granulocytic ehrlichial agent), and Anaplasma platys (previously Ehrlichia platys) are known to infect dogs naturally and can produce disease.", [["Ehrlichia canis", "DISEASE", 0, 15], ["Ehrlichia ewingii", "DISEASE", 17, 34], ["Ehrlichia chaffeensis", "DISEASE", 36, 57], ["Anaplasma phagocytophilum", "DISEASE", 59, 84], ["Anaplasma platys", "DISEASE", 159, 175], ["Ehrlichia canis", "ORGANISM", 0, 15], ["Ehrlichia ewingii", "ORGANISM", 17, 34], ["Ehrlichia chaffeensis", "ORGANISM", 36, 57], ["Anaplasma phagocytophilum", "ORGANISM", 59, 84], ["Ehrlichia equi", "ORGANISM", 97, 111], ["human", "ORGANISM", 117, 122], ["Anaplasma platys", "ORGANISM", 159, 175], ["Ehrlichia platys", "ORGANISM", 188, 204], ["dogs", "ORGANISM", 226, 230], ["Ehrlichia canis", "SPECIES", 0, 15], ["Ehrlichia ewingii", "SPECIES", 17, 34], ["Ehrlichia chaffeensis", "SPECIES", 36, 57], ["Anaplasma phagocytophilum", "SPECIES", 59, 84], ["Ehrlichia equi", "SPECIES", 97, 111], ["human", "SPECIES", 117, 122], ["Anaplasma platys", "SPECIES", 159, 175], ["Ehrlichia platys", "SPECIES", 188, 204], ["dogs", "SPECIES", 226, 230], ["Ehrlichia canis", "SPECIES", 0, 15], ["Ehrlichia ewingii", "SPECIES", 17, 34], ["Ehrlichia chaffeensis", "SPECIES", 36, 57], ["Anaplasma phagocytophilum", "SPECIES", 59, 84], ["Ehrlichia equi", "SPECIES", 97, 111], ["human", "SPECIES", 117, 122], ["Anaplasma platys", "SPECIES", 159, 175], ["Ehrlichia platys", "SPECIES", 188, 204], ["Ehrlichia canis", "PROBLEM", 0, 15], ["Ehrlichia ewingii", "PROBLEM", 17, 34], ["Ehrlichia chaffeensis", "PROBLEM", 36, 57], ["Anaplasma phagocytophilum", "PROBLEM", 59, 84], ["Ehrlichia equi", "TEST", 97, 111], ["the human granulocytic ehrlichial agent", "TREATMENT", 113, 152], ["Anaplasma platys", "PROBLEM", 159, 175], ["Ehrlichia platys", "PROBLEM", 188, 204], ["disease", "PROBLEM", 257, 264], ["Ehrlichia ewingii", "OBSERVATION", 17, 34], ["Ehrlichia chaffeensis", "OBSERVATION", 36, 57], ["Anaplasma platys", "OBSERVATION", 159, 175]]], ["Neorickettsia risticii (previously E risticii var. atypicalis) and Neorickettsia helmintheca are the most common organisms in this genera known to infect dogs.", [["Neorickettsia risticii", "ORGANISM", 0, 22], ["E risticii", "ORGANISM", 35, 45], ["Neorickettsia helmintheca", "ORGANISM", 67, 92], ["dogs", "ORGANISM", 154, 158], ["Neorickettsia risticii", "SPECIES", 0, 22], ["E risticii", "SPECIES", 35, 45], ["atypicalis", "SPECIES", 51, 61], ["Neorickettsia helmintheca", "SPECIES", 67, 92], ["dogs", "SPECIES", 154, 158], ["Neorickettsia risticii", "SPECIES", 0, 22], ["E risticii", "SPECIES", 35, 45], ["atypicalis", "SPECIES", 51, 61], ["Neorickettsia helmintheca", "SPECIES", 67, 92], ["Neorickettsia risticii", "PROBLEM", 0, 22], ["atypicalis", "PROBLEM", 51, 61], ["Neorickettsia helmintheca", "TREATMENT", 67, 92], ["most common", "OBSERVATION_MODIFIER", 101, 112]]], ["11 Of all of these agents, E canis is probably the most commonly described in the dog and causes acute, chronic, and subclinical syndromes.", [["E canis", "ORGANISM", 27, 34], ["dog", "ORGANISM", 82, 85], ["E canis", "SPECIES", 27, 34], ["dog", "SPECIES", 82, 85], ["E canis", "SPECIES", 27, 34], ["acute, chronic, and subclinical syndromes", "PROBLEM", 97, 138], ["most commonly", "OBSERVATION_MODIFIER", 51, 64], ["acute", "OBSERVATION_MODIFIER", 97, 102], ["chronic", "OBSERVATION_MODIFIER", 104, 111], ["subclinical syndromes", "OBSERVATION", 117, 138]]], ["Experimentally, subcutaneous inoculation of the organism, mimicking natural transmission by tick vectors, results in dose-dependent infection and positive blood cultures.", [["subcutaneous", "ANATOMY", 16, 28], ["blood cultures", "ANATOMY", 155, 169], ["infection", "DISEASE", 132, 141], ["blood", "ORGANISM_SUBSTANCE", 155, 160], ["positive blood cultures", "CELL_LINE", 146, 169], ["subcutaneous inoculation of the organism", "PROBLEM", 16, 56], ["tick vectors", "TREATMENT", 92, 104], ["dependent infection", "PROBLEM", 122, 141], ["positive blood cultures", "PROBLEM", 146, 169], ["subcutaneous", "ANATOMY", 16, 28], ["inoculation", "OBSERVATION", 29, 40], ["dependent", "OBSERVATION_MODIFIER", 122, 131], ["infection", "OBSERVATION", 132, 141]]], ["12 Screening of potential blood donor dogs for antibodies against E canis can be performed by IFA assay.", [["blood", "ANATOMY", 26, 31], ["blood", "ORGANISM_SUBSTANCE", 26, 31], ["dogs", "ORGANISM", 38, 42], ["E canis", "ORGANISM", 66, 73], ["antibodies", "PROTEIN", 47, 57], ["dogs", "SPECIES", 38, 42], ["E canis", "SPECIES", 66, 73], ["E canis", "SPECIES", 66, 73], ["potential blood", "TEST", 16, 31], ["antibodies", "PROBLEM", 47, 57], ["E canis", "PROBLEM", 66, 73]]], ["The consensus of the ACVIM Ehrlichial Disease Infectious Disease Study Group in 2002 was that IFA titers to E canis \u03fd1 : 80 should be interpreted with caution because they could be false positives but that titers \u03fe1 : 80 were likely to be true positives.", [["Infectious Disease", "DISEASE", 46, 64], ["E canis", "ORGANISM", 108, 115], ["E canis", "SPECIES", 108, 115], ["E canis", "SPECIES", 108, 115], ["the ACVIM Ehrlichial Disease", "PROBLEM", 17, 45], ["IFA titers", "TEST", 94, 104], ["false positives", "PROBLEM", 181, 196], ["titers", "TEST", 206, 212]]], ["13 For dogs with low titers, repeated serologic testing (within 2-3 weeks), PCR, or Western immunoblotting is recommended.", [["dogs", "ORGANISM", 7, 11], ["dogs", "SPECIES", 7, 11], ["low titers", "PROBLEM", 17, 27], ["repeated serologic testing", "TEST", 29, 55], ["PCR", "TEST", 76, 79], ["Western immunoblotting", "TEST", 84, 106]]], ["A commercial point-of-care E canis enzyme immunoassay (EIA) antibody screening test a also is available for screening for E canis antibodies.", [["E canis", "ORGANISM", 122, 129], ["E canis antibodies", "PROTEIN", 122, 140], ["E canis", "SPECIES", 27, 34], ["E canis", "SPECIES", 122, 129], ["E canis", "SPECIES", 27, 34], ["E canis", "SPECIES", 122, 129], ["care E canis enzyme immunoassay", "TEST", 22, 53], ["EIA) antibody screening test", "TEST", 55, 83], ["screening", "TEST", 108, 117], ["E canis antibodies", "PROBLEM", 122, 140]]], ["This assay requires a ''threshold'' antibody titer of at least 1 : 100 for positive results.", [["a ''threshold'' antibody titer", "TEST", 20, 50]]], ["Given the widespread geographical distribution of the disease and its subclinical form, the consensus is that potential blood donor dogs should be screened by IFA or screened with the point-ofcare test for E canis, and positive animals should be excluded as blood donors.", [["blood", "ANATOMY", 120, 125], ["blood", "ANATOMY", 258, 263], ["blood", "ORGANISM_SUBSTANCE", 120, 125], ["dogs", "ORGANISM", 132, 136], ["E canis", "ORGANISM", 206, 213], ["animals", "ORGANISM", 228, 235], ["blood", "ORGANISM_SUBSTANCE", 258, 263], ["dogs", "SPECIES", 132, 136], ["E canis", "SPECIES", 206, 213], ["E canis", "SPECIES", 206, 213], ["the disease", "PROBLEM", 50, 61], ["potential blood donor dogs", "PROBLEM", 110, 136], ["E canis", "PROBLEM", 206, 213], ["blood donors", "TEST", 258, 270], ["widespread", "OBSERVATION_MODIFIER", 10, 20], ["geographical", "OBSERVATION_MODIFIER", 21, 33], ["distribution", "OBSERVATION_MODIFIER", 34, 46], ["disease", "OBSERVATION", 54, 61]]], ["Because cross-reactivity among E canis, E ewingii, and E chaffeensis might not always occur, dogs that are seronegative for E canis antibodies should be additionally screened by genus-specific PCR, especially in those areas where E ewingii or E chaffeensis are endemic.", [["E canis", "ORGANISM", 31, 38], ["E ewingii", "ORGANISM", 40, 49], ["E chaffeensis", "ORGANISM", 55, 68], ["dogs", "ORGANISM", 93, 97], ["E canis", "ORGANISM", 124, 131], ["E ewingii", "ORGANISM", 230, 239], ["E chaffeensis", "ORGANISM", 243, 256], ["E canis antibodies", "PROTEIN", 124, 142], ["E canis", "SPECIES", 31, 38], ["E ewingii", "SPECIES", 40, 49], ["E chaffeensis", "SPECIES", 55, 68], ["dogs", "SPECIES", 93, 97], ["E canis", "SPECIES", 124, 131], ["E ewingii", "SPECIES", 230, 239], ["E chaffeensis", "SPECIES", 243, 256], ["E canis", "SPECIES", 31, 38], ["E ewingii", "SPECIES", 40, 49], ["E chaffeensis", "SPECIES", 55, 68], ["E canis", "SPECIES", 124, 131], ["E ewingii", "SPECIES", 230, 239], ["E chaffeensis", "SPECIES", 243, 256], ["E canis antibodies", "PROBLEM", 124, 142], ["specific PCR", "TEST", 184, 196]]], ["Individual blood banking programs also might want to pursue further testing with PCR or IFA for other Anaplasma or Neorickettsia species.Canine DiseasesNon-Vectorborne Diseases-Testing Recommended.", [["blood", "ANATOMY", 11, 16], ["DiseasesNon-Vectorborne Diseases", "DISEASE", 144, 176], ["blood", "ORGANISM_SUBSTANCE", 11, 16], ["Neorickettsia species", "ORGANISM", 115, 136], ["Canine", "SPECIES", 137, 143], ["Individual blood banking programs", "TREATMENT", 0, 33], ["further testing", "TEST", 60, 75], ["PCR", "TEST", 81, 84], ["IFA", "TEST", 88, 91], ["Anaplasma", "PROBLEM", 102, 111], ["Neorickettsia species", "PROBLEM", 115, 136], ["Canine DiseasesNon-Vectorborne Diseases", "PROBLEM", 137, 176]]], ["Brucellosis: Brucellosis is a disease caused by the gramnegative bacteria Brucella canis.", [["Brucellosis", "DISEASE", 0, 11], ["Brucellosis", "DISEASE", 13, 24], ["Brucella canis", "DISEASE", 74, 88], ["Brucella canis", "ORGANISM", 74, 88], ["Brucella canis", "SPECIES", 74, 88], ["Brucella canis", "SPECIES", 74, 88], ["Brucellosis", "PROBLEM", 0, 11], ["Brucellosis", "PROBLEM", 13, 24], ["a disease", "PROBLEM", 28, 37], ["the gramnegative bacteria Brucella canis", "PROBLEM", 48, 88], ["Brucellosis", "OBSERVATION", 13, 24], ["bacteria", "OBSERVATION_MODIFIER", 65, 73], ["Brucella canis", "OBSERVATION", 74, 88]]], ["The disease primarily affects the reproductive organs of male and female dogs.", [["reproductive organs", "ANATOMY", 34, 53], ["reproductive organs", "ORGAN", 34, 53], ["dogs", "ORGANISM", 73, 77], ["dogs", "SPECIES", 73, 77], ["The disease", "PROBLEM", 0, 11], ["disease", "OBSERVATION", 4, 11]]], ["Infected female dogs can transmit the organism during breeding or via oronasal contact with vaginal discharge or aborted material.", [["vaginal", "ANATOMY", 92, 99], ["dogs", "ORGANISM", 16, 20], ["oronasal", "ORGANISM_SUBDIVISION", 70, 78], ["vaginal", "ORGANISM_SUBDIVISION", 92, 99], ["dogs", "SPECIES", 16, 20], ["vaginal discharge", "PROBLEM", 92, 109], ["aborted material", "PROBLEM", 113, 129], ["vaginal", "ANATOMY", 92, 99]]], ["Male dogs can harbor the organism in the prostate and epididymides, and urine and seminal fluid can serve as the source of infection.", [["prostate", "ANATOMY", 41, 49], ["epididymides", "ANATOMY", 54, 66], ["urine", "ANATOMY", 72, 77], ["seminal fluid", "ANATOMY", 82, 95], ["infection", "DISEASE", 123, 132], ["dogs", "ORGANISM", 5, 9], ["prostate", "ORGAN", 41, 49], ["epididymides", "ORGANISM_SUBSTANCE", 54, 66], ["urine", "ORGANISM_SUBSTANCE", 72, 77], ["seminal fluid", "ORGANISM_SUBSTANCE", 82, 95], ["dogs", "SPECIES", 5, 9], ["urine and seminal fluid", "TEST", 72, 95], ["infection", "PROBLEM", 123, 132], ["prostate", "ANATOMY", 41, 49], ["epididymides", "ANATOMY", 54, 66], ["seminal", "ANATOMY", 82, 89], ["fluid", "OBSERVATION", 90, 95], ["infection", "OBSERVATION", 123, 132]]], ["Transmission via blood transfusion has been documented in humans 14 but not in dogs.", [["blood", "ANATOMY", 17, 22], ["blood", "ORGANISM_SUBSTANCE", 17, 22], ["humans", "ORGANISM", 58, 64], ["dogs", "ORGANISM", 79, 83], ["humans", "SPECIES", 58, 64], ["dogs", "SPECIES", 79, 83], ["humans", "SPECIES", 58, 64], ["blood transfusion", "TEST", 17, 34]]], ["However, bacteremia in dogs occurs and isolation of the organism from blood is a technique performed when serologic testing is ambiguous.", [["blood", "ANATOMY", 70, 75], ["bacteremia", "DISEASE", 9, 19], ["dogs", "ORGANISM", 23, 27], ["blood", "ORGANISM_SUBSTANCE", 70, 75], ["dogs", "SPECIES", 23, 27], ["bacteremia", "PROBLEM", 9, 19], ["dogs", "PROBLEM", 23, 27], ["the organism", "PROBLEM", 52, 64], ["a technique", "TEST", 79, 90], ["serologic testing", "TEST", 106, 123], ["bacteremia", "OBSERVATION", 9, 19]]], ["Experimentally infected dogs have remained blood culture-positive for several years.", [["blood", "ANATOMY", 43, 48], ["dogs", "ORGANISM", 24, 28], ["blood", "ORGANISM_SUBSTANCE", 43, 48], ["dogs", "SPECIES", 24, 28], ["Experimentally infected dogs", "PROBLEM", 0, 28], ["blood culture", "TEST", 43, 56], ["infected", "OBSERVATION", 15, 23]]], ["15 Serological screening of potential donors for antibodies by the rapid slide agglutination test (RSAT) should be performed initially, with blood culture, tube agglutination tests, agarose gel immunodiffusion tests, or ELISA tests used for confirmation of infection.", [["blood", "ANATOMY", 141, 146], ["infection", "DISEASE", 257, 266], ["donors", "ORGANISM", 38, 44], ["blood", "ORGANISM_SUBSTANCE", 141, 146], ["tube", "TISSUE", 156, 160], ["agarose", "SIMPLE_CHEMICAL", 182, 189], ["antibodies", "PROTEIN", 49, 59], ["Serological screening", "TEST", 3, 24], ["antibodies", "TEST", 49, 59], ["the rapid slide agglutination test", "TEST", 63, 97], ["blood culture", "TEST", 141, 154], ["tube agglutination tests", "TEST", 156, 180], ["agarose gel immunodiffusion tests", "TEST", 182, 215], ["ELISA tests", "TEST", 220, 231], ["infection", "PROBLEM", 257, 266], ["infection", "OBSERVATION", 257, 266]]], ["16 All positive dogs should be excluded as blood donors.", [["blood", "ANATOMY", 43, 48], ["dogs", "ORGANISM", 16, 20], ["blood", "ORGANISM_SUBSTANCE", 43, 48], ["dogs", "SPECIES", 16, 20], ["All positive dogs", "PROBLEM", 3, 20], ["blood donors", "TEST", 43, 55], ["positive dogs", "OBSERVATION", 7, 20], ["should be excluded", "UNCERTAINTY", 21, 39]]], ["A single negative RSAT is sufficient for neutered donors, but blood donor programs that include sexually active intact dogs should perform the RSAT.Canine DiseasesVectorborne Diseases-Conditional Testing.", [["blood", "ANATOMY", 62, 67], ["donors", "ORGANISM", 50, 56], ["blood", "ORGANISM_SUBSTANCE", 62, 67], ["dogs", "ORGANISM", 119, 123], ["Canine", "ORGANISM", 148, 154], ["dogs", "SPECIES", 119, 123], ["Canine", "SPECIES", 148, 154], ["neutered donors", "PROBLEM", 41, 56], ["blood donor programs", "TREATMENT", 62, 82], ["sexually active intact dogs", "PROBLEM", 96, 123], ["Canine DiseasesVectorborne Diseases", "PROBLEM", 148, 183]]], ["Trypanosomiasis: American trypanosomiasis, also known as ''Chagas disease,'' is caused by T cruzi, a hemoflagellate protozoan with an insect vector.", [["Trypanosomiasis", "DISEASE", 0, 15], ["American trypanosomiasis", "DISEASE", 17, 41], ["Chagas disease", "DISEASE", 59, 73], ["T cruzi", "ORGANISM", 90, 97], ["T cruzi", "SPECIES", 90, 97], ["T cruzi", "SPECIES", 90, 97], ["American trypanosomiasis", "PROBLEM", 17, 41], ["Chagas disease", "PROBLEM", 59, 73], ["T cruzi", "PROBLEM", 90, 97], ["a hemoflagellate protozoan", "TREATMENT", 99, 125], ["an insect vector", "TREATMENT", 131, 147]]], ["The disease in dogs generally results in either an acute or chronic myocarditis and cardiac failure, but in 1 study, 17 dogs that were experimentally inoculated with a canine isolate of T cruzi were parasitemic but developed only transient lymphadenopathy.", [["cardiac", "ANATOMY", 84, 91], ["myocarditis", "DISEASE", 68, 79], ["cardiac failure", "DISEASE", 84, 99], ["T cruzi", "DISEASE", 186, 193], ["lymphadenopathy", "DISEASE", 240, 255], ["dogs", "ORGANISM", 15, 19], ["cardiac", "ORGAN", 84, 91], ["dogs", "ORGANISM", 120, 124], ["canine", "ORGANISM", 168, 174], ["T cruzi", "ORGANISM", 186, 193], ["dogs", "SPECIES", 15, 19], ["dogs", "SPECIES", 120, 124], ["canine", "SPECIES", 168, 174], ["T cruzi", "SPECIES", 186, 193], ["canine", "SPECIES", 168, 174], ["T cruzi", "SPECIES", 186, 193], ["The disease in dogs", "PROBLEM", 0, 19], ["an acute or chronic myocarditis", "PROBLEM", 48, 79], ["cardiac failure", "PROBLEM", 84, 99], ["1 study", "TEST", 108, 115], ["T cruzi", "PROBLEM", 186, 193], ["transient lymphadenopathy", "PROBLEM", 230, 255], ["disease", "OBSERVATION", 4, 11], ["acute", "OBSERVATION_MODIFIER", 51, 56], ["chronic", "OBSERVATION_MODIFIER", 60, 67], ["myocarditis", "OBSERVATION", 68, 79], ["cardiac", "ANATOMY", 84, 91], ["failure", "OBSERVATION", 92, 99], ["transient", "OBSERVATION_MODIFIER", 230, 239], ["lymphadenopathy", "OBSERVATION", 240, 255]]], ["Survivors of the acute disease can be asymptomatic for several months until chronic myocarditis develops.", [["myocarditis", "DISEASE", 84, 95], ["the acute disease", "PROBLEM", 13, 30], ["chronic myocarditis", "PROBLEM", 76, 95], ["acute", "OBSERVATION_MODIFIER", 17, 22], ["disease", "OBSERVATION", 23, 30], ["chronic", "OBSERVATION_MODIFIER", 76, 83], ["myocarditis", "OBSERVATION", 84, 95]]], ["Infection is characterized by detectable concentrations of specific antibodies and low concentrations of circulating parasites.", [["Infection", "DISEASE", 0, 9], ["specific antibodies", "PROTEIN", 59, 78], ["Infection", "PROBLEM", 0, 9], ["detectable concentrations of specific antibodies", "PROBLEM", 30, 78], ["low concentrations of circulating parasites", "PROBLEM", 83, 126], ["detectable", "OBSERVATION_MODIFIER", 30, 40], ["concentrations", "OBSERVATION_MODIFIER", 41, 55], ["low concentrations", "OBSERVATION_MODIFIER", 83, 101], ["circulating parasites", "OBSERVATION", 105, 126]]], ["18 Most canine cases of trypanosomiasis in the United States occur in Texas or the southwestern region.", [["trypanosomiasis", "DISEASE", 24, 39], ["canine", "ORGANISM", 8, 14], ["trypanosomiasis", "PROBLEM", 24, 39], ["trypanosomiasis", "OBSERVATION", 24, 39]]], ["Transmission by blood transfusion has not been documented in the literature.", [["blood", "ANATOMY", 16, 21], ["blood", "ORGANISM_SUBSTANCE", 16, 21], ["blood transfusion", "TEST", 16, 33]]], ["Dogs with a history of travel to and from endemic areas should be considered for serological screening by IFA, and seropositive donors should be excluded from the donor pool.Canine DiseasesBartonellosis: Bartonella vinsonii subspecies berkhoffi is a vector-transmitted, intraerythrocytic bacteria that has been isolated from dogs with endocarditis, myocarditis, and granulomatous disease.", [["granulomatous", "ANATOMY", 366, 379], ["DiseasesBartonellosis", "DISEASE", 181, 202], ["Bartonella vinsonii subspecies berkhoffi", "DISEASE", 204, 244], ["endocarditis", "DISEASE", 335, 347], ["myocarditis", "DISEASE", 349, 360], ["granulomatous disease", "DISEASE", 366, 387], ["Dogs", "ORGANISM", 0, 4], ["donors", "ORGANISM", 128, 134], ["Canine", "ORGANISM", 174, 180], ["Bartonella vinsonii subspecies berkhoffi", "ORGANISM", 204, 244], ["dogs", "ORGANISM", 325, 329], ["Canine", "SPECIES", 174, 180], ["Bartonella vinsonii", "SPECIES", 204, 223], ["subspecies berkhoffi", "SPECIES", 224, 244], ["dogs", "SPECIES", 325, 329], ["Bartonella vinsonii subspecies berkhoffi", "SPECIES", 204, 244], ["serological screening", "TEST", 81, 102], ["IFA", "TEST", 106, 109], ["seropositive donors", "TREATMENT", 115, 134], ["Canine DiseasesBartonellosis", "PROBLEM", 174, 202], ["Bartonella vinsonii subspecies", "PROBLEM", 204, 234], ["intraerythrocytic bacteria", "PROBLEM", 270, 296], ["endocarditis", "PROBLEM", 335, 347], ["myocarditis", "PROBLEM", 349, 360], ["granulomatous disease", "PROBLEM", 366, 387], ["Diseases", "OBSERVATION", 181, 189], ["Bartonella vinsonii", "OBSERVATION", 204, 223], ["intraerythrocytic bacteria", "OBSERVATION", 270, 296], ["endocarditis", "OBSERVATION", 335, 347], ["myocarditis", "OBSERVATION", 349, 360], ["granulomatous disease", "OBSERVATION", 366, 387]]], ["Both affected and clinically healthy dogs can be seropositive.", [["dogs", "ORGANISM", 37, 41], ["dogs", "SPECIES", 37, 41], ["seropositive", "PROBLEM", 49, 61]]], ["19, 20 Transfusion transmission has not been reported, but chronic infection has resulted from experimental IV inoculation of the organism.", [["infection", "DISEASE", 67, 76], ["Transfusion transmission", "TEST", 7, 31], ["chronic infection", "PROBLEM", 59, 76], ["experimental IV inoculation of the organism", "PROBLEM", 95, 138], ["chronic", "OBSERVATION_MODIFIER", 59, 66], ["infection", "OBSERVATION", 67, 76], ["IV inoculation", "OBSERVATION_MODIFIER", 108, 122]]], ["21 Screening is performed by IFA, with a single titer \u05461 : 64 evidence of prior exposure or infection.", [["infection", "DISEASE", 92, 101], ["prior exposure", "PROBLEM", 74, 88], ["infection", "PROBLEM", 92, 101], ["infection", "OBSERVATION", 92, 101]]], ["19 B vinsonii is a newly emerging organism, and its potential for transmission from blood products is unclear.", [["blood", "ANATOMY", 84, 89], ["B vinsonii", "CHEMICAL", 3, 13], ["B vinsonii", "ORGANISM", 3, 13], ["blood", "ORGANISM_SUBSTANCE", 84, 89], ["B vinsonii", "SPECIES", 3, 13], ["B vinsonii", "SPECIES", 3, 13], ["a newly emerging organism", "PROBLEM", 17, 42], ["blood products", "TREATMENT", 84, 98]]], ["Therefore, screening of blood donors is only conditionally recommended.Canine DiseasesHemoplasmosis: Mycoplasma haemocanis (formerly Hemobartonella canis) is an epicellular parasite of erythrocytes that is transmitted by tick.", [["blood", "ANATOMY", 24, 29], ["erythrocytes", "ANATOMY", 185, 197], ["DiseasesHemoplasmosis", "DISEASE", 78, 99], ["Mycoplasma haemocanis", "DISEASE", 101, 122], ["Hemobartonella canis", "DISEASE", 133, 153], ["blood", "ORGANISM_SUBSTANCE", 24, 29], ["donors", "ORGANISM", 30, 36], ["Canine", "ORGANISM", 71, 77], ["Mycoplasma haemocanis", "ORGANISM", 101, 122], ["Hemobartonella canis", "ORGANISM", 133, 153], ["erythrocytes", "CELL", 185, 197], ["erythrocytes", "CELL_TYPE", 185, 197], ["Canine", "SPECIES", 71, 77], ["Mycoplasma haemocanis", "SPECIES", 101, 122], ["Hemobartonella canis", "SPECIES", 133, 153], ["Mycoplasma haemocanis", "SPECIES", 101, 122], ["Hemobartonella canis", "SPECIES", 133, 153], ["screening of blood donors", "TEST", 11, 36], ["Canine DiseasesHemoplasmosis", "PROBLEM", 71, 99], ["Mycoplasma haemocanis", "PROBLEM", 101, 122], ["Hemobartonella canis", "PROBLEM", 133, 153], ["an epicellular parasite of erythrocytes", "PROBLEM", 158, 197], ["Diseases", "OBSERVATION", 78, 86], ["Mycoplasma haemocanis", "OBSERVATION", 101, 122], ["epicellular", "OBSERVATION_MODIFIER", 161, 172], ["parasite", "OBSERVATION", 173, 181], ["erythrocytes", "OBSERVATION", 185, 197]]], ["Unlike cats with hemoplasmosis, the majority of normal dogs infected with M haemocanis do not develop clinical evidence of disease.", [["hemoplasmosis", "DISEASE", 17, 30], ["cats", "ORGANISM", 7, 11], ["dogs", "ORGANISM", 55, 59], ["M haemocanis", "ORGANISM", 74, 86], ["cats", "SPECIES", 7, 11], ["dogs", "SPECIES", 55, 59], ["M haemocanis", "SPECIES", 74, 86], ["M haemocanis", "SPECIES", 74, 86], ["hemoplasmosis", "PROBLEM", 17, 30], ["disease", "PROBLEM", 123, 130], ["normal", "OBSERVATION_MODIFIER", 48, 54], ["dogs", "OBSERVATION_MODIFIER", 55, 59], ["infected", "OBSERVATION", 60, 68], ["disease", "OBSERVATION", 123, 130]]], ["Diagnosis is based on visualization of the organism in erythrocytes (unlikely in carrier dogs) or by PCR assay.", [["erythrocytes", "ANATOMY", 55, 67], ["erythrocytes", "CELL", 55, 67], ["dogs", "ORGANISM", 89, 93], ["erythrocytes", "CELL_TYPE", 55, 67], ["the organism in erythrocytes", "PROBLEM", 39, 67], ["PCR assay", "TEST", 101, 110]]], ["22 Other Diseases-Testing Not Recommended.", [["Diseases", "OBSERVATION", 9, 17]]], ["Lyme Disease: Lyme borreliosis, or Lyme disease, is caused by the spirochete Borrelia burgdorferi.", [["Lyme Disease", "DISEASE", 0, 12], ["Lyme borreliosis", "DISEASE", 14, 30], ["Lyme disease", "DISEASE", 35, 47], ["Borrelia burgdorferi", "DISEASE", 77, 97], ["spirochete", "ORGANISM", 66, 76], ["Borrelia burgdorferi", "ORGANISM", 77, 97], ["Borrelia burgdorferi", "SPECIES", 77, 97], ["Borrelia burgdorferi", "SPECIES", 77, 97], ["Lyme Disease", "PROBLEM", 0, 12], ["Lyme borreliosis", "PROBLEM", 14, 30], ["Lyme disease", "PROBLEM", 35, 47], ["the spirochete Borrelia burgdorferi", "PROBLEM", 62, 97], ["Lyme", "OBSERVATION_MODIFIER", 14, 18], ["borreliosis", "OBSERVATION", 19, 30], ["Lyme disease", "OBSERVATION", 35, 47]]], ["Ticks of the Ixodes spp. are known vectors.", [["Ixodes spp", "ORGANISM", 13, 23], ["Ixodes spp", "SPECIES", 13, 23], ["the Ixodes spp", "PROBLEM", 9, 23], ["Ixodes spp", "OBSERVATION", 13, 23]]], ["23 Although most infections in dogs likely are inapparent, the most common clinical sign in dogs is lameness as a result of polyarthritis.", [["infections", "DISEASE", 17, 27], ["lameness", "DISEASE", 100, 108], ["polyarthritis", "DISEASE", 124, 137], ["dogs", "ORGANISM", 31, 35], ["dogs", "ORGANISM", 92, 96], ["dogs", "SPECIES", 31, 35], ["dogs", "SPECIES", 92, 96], ["most infections in dogs", "PROBLEM", 12, 35], ["lameness", "PROBLEM", 100, 108], ["polyarthritis", "PROBLEM", 124, 137], ["most", "OBSERVATION_MODIFIER", 12, 16], ["infections", "OBSERVATION", 17, 27], ["polyarthritis", "OBSERVATION", 124, 137]]], ["Fever, lymphadenopathy, and glomerulonephritis also are described.", [["Fever", "DISEASE", 0, 5], ["lymphadenopathy", "DISEASE", 7, 22], ["glomerulonephritis", "DISEASE", 28, 46], ["Fever", "PROBLEM", 0, 5], ["lymphadenopathy", "PROBLEM", 7, 22], ["glomerulonephritis", "PROBLEM", 28, 46], ["lymphadenopathy", "OBSERVATION", 7, 22], ["glomerulonephritis", "OBSERVATION", 28, 46]]], ["Widespread seropositivity exists in some areas of the United States, especially in the northeastern region.", [["Widespread seropositivity", "PROBLEM", 0, 25], ["seropositivity", "OBSERVATION", 11, 25], ["some", "OBSERVATION_MODIFIER", 36, 40], ["areas", "OBSERVATION_MODIFIER", 41, 46], ["northeastern", "ANATOMY_MODIFIER", 87, 99], ["region", "ANATOMY_MODIFIER", 100, 106]]], ["24 Currently, disease transmitted by transfusion has not been reported.", [["transfusion", "TREATMENT", 37, 48], ["disease", "OBSERVATION", 14, 21]]], ["Despite the ability to culture B burgdorferi from human blood, 25 a study in humans demonstrated that the risk of acquiring Lyme disease from a transfused unit of packed red blood cells or platelets was negligible.", [["blood", "ANATOMY", 56, 61], ["red blood cells", "ANATOMY", 170, 185], ["platelets", "ANATOMY", 189, 198], ["Lyme disease", "DISEASE", 124, 136], ["B burgdorferi", "ORGANISM", 31, 44], ["human", "ORGANISM", 50, 55], ["blood", "ORGANISM_SUBSTANCE", 56, 61], ["humans", "ORGANISM", 77, 83], ["red blood cells", "CELL", 170, 185], ["platelets", "CELL", 189, 198], ["packed red blood cells", "CELL_TYPE", 163, 185], ["platelets", "CELL_TYPE", 189, 198], ["B burgdorferi", "SPECIES", 31, 44], ["human", "SPECIES", 50, 55], ["humans", "SPECIES", 77, 83], ["B burgdorferi", "SPECIES", 31, 44], ["human", "SPECIES", 50, 55], ["humans", "SPECIES", 77, 83], ["human blood", "TEST", 50, 61], ["a study", "TEST", 66, 73], ["acquiring Lyme disease", "PROBLEM", 114, 136], ["packed red blood cells", "TREATMENT", 163, 185], ["platelets", "TREATMENT", 189, 198], ["Lyme disease", "OBSERVATION", 124, 136]]], ["26 In a study in dogs, only 1.6% of 576 blood samples from experimentally infected dogs was positive for B burgdorferi by PCR.", [["blood samples", "ANATOMY", 40, 53], ["dogs", "ORGANISM", 17, 21], ["blood samples", "ORGANISM_SUBSTANCE", 40, 53], ["dogs", "ORGANISM", 83, 87], ["B burgdorferi", "ORGANISM", 105, 118], ["dogs", "SPECIES", 17, 21], ["dogs", "SPECIES", 83, 87], ["B burgdorferi", "SPECIES", 105, 118], ["B burgdorferi", "SPECIES", 105, 118], ["a study", "TEST", 6, 13], ["blood samples", "TEST", 40, 53], ["experimentally infected dogs", "PROBLEM", 59, 87], ["B burgdorferi by PCR", "PROBLEM", 105, 125]]], ["27 The consensus of the panel is that healthy canine blood donors do not require screening for B burgdorferi.Canine DiseasesRocky Mountain Spotted Fever: Rocky Mountain Spotted Fever (RMSF) is a tickborne rickettsial disease affecting dogs and humans.", [["blood", "ANATOMY", 53, 58], ["B burgdorferi", "DISEASE", 95, 108], ["Fever", "DISEASE", 147, 152], ["Spotted Fever", "DISEASE", 169, 182], ["RMSF", "DISEASE", 184, 188], ["rickettsial disease", "DISEASE", 205, 224], ["canine", "ORGANISM", 46, 52], ["blood", "ORGANISM_SUBSTANCE", 53, 58], ["donors", "ORGANISM", 59, 65], ["B burgdorferi", "ORGANISM", 95, 108], ["Canine", "ORGANISM", 109, 115], ["Rocky Mountain Spotted Fever", "ORGANISM", 154, 182], ["dogs", "ORGANISM", 235, 239], ["humans", "ORGANISM", 244, 250], ["B burgdorferi", "SPECIES", 95, 108], ["Canine", "SPECIES", 109, 115], ["dogs", "SPECIES", 235, 239], ["humans", "SPECIES", 244, 250], ["canine", "SPECIES", 46, 52], ["B burgdorferi", "SPECIES", 95, 108], ["Canine DiseasesRocky Mountain Spotted Fever: Rocky Mountain Spotted Fever (RMSF)", "SPECIES", 109, 189], ["humans", "SPECIES", 244, 250], ["the panel", "TEST", 20, 29], ["screening", "TEST", 81, 90], ["B burgdorferi", "PROBLEM", 95, 108], ["Spotted Fever", "PROBLEM", 139, 152], ["Spotted Fever (RMSF)", "PROBLEM", 169, 189], ["a tickborne rickettsial disease affecting dogs", "PROBLEM", 193, 239]]], ["The causative organism is Rickettsia rickettsii.", [["Rickettsia rickettsii", "DISEASE", 26, 47], ["Rickettsia rickettsii", "ORGANISM", 26, 47], ["Rickettsia rickettsii", "SPECIES", 26, 47], ["Rickettsia rickettsii", "SPECIES", 26, 47], ["The causative organism", "PROBLEM", 0, 22], ["Rickettsia rickettsii", "PROBLEM", 26, 47], ["causative organism", "OBSERVATION", 4, 22], ["Rickettsia rickettsii", "OBSERVATION", 26, 47]]], ["RMSF is associated with retinal or cutaneous hemorrhages, epistaxis, melena, hematuria, and other clinical findings.", [["retinal", "ANATOMY", 24, 31], ["cutaneous", "ANATOMY", 35, 44], ["RMSF", "DISEASE", 0, 4], ["retinal or cutaneous hemorrhages", "DISEASE", 24, 56], ["epistaxis", "DISEASE", 58, 67], ["melena", "DISEASE", 69, 75], ["hematuria", "DISEASE", 77, 86], ["retinal", "MULTI-TISSUE_STRUCTURE", 24, 31], ["cutaneous", "ORGANISM_SUBDIVISION", 35, 44], ["melena", "PATHOLOGICAL_FORMATION", 69, 75], ["RMSF", "PROBLEM", 0, 4], ["retinal or cutaneous hemorrhages", "PROBLEM", 24, 56], ["epistaxis", "PROBLEM", 58, 67], ["melena", "PROBLEM", 69, 75], ["hematuria", "PROBLEM", 77, 86], ["other clinical findings", "PROBLEM", 92, 115], ["associated with", "UNCERTAINTY", 8, 23], ["retinal", "ANATOMY", 24, 31], ["cutaneous", "ANATOMY", 35, 44], ["hemorrhages", "OBSERVATION", 45, 56], ["epistaxis", "OBSERVATION", 58, 67], ["melena", "OBSERVATION", 69, 75], ["hematuria", "OBSERVATION", 77, 86]]], ["The organism is eliminated from dogs after infection, and chronic carrier states have not been reported.", [["infection", "DISEASE", 43, 52], ["dogs", "ORGANISM", 32, 36], ["dogs", "SPECIES", 32, 36], ["The organism", "PROBLEM", 0, 12], ["infection", "PROBLEM", 43, 52], ["chronic carrier states", "PROBLEM", 58, 80], ["infection", "OBSERVATION", 43, 52], ["chronic", "OBSERVATION_MODIFIER", 58, 65]]], ["The consensus of the panel is that healthy blood donors do not need to be screened for RMSF, because infected dogs are acutely ill and no asymptomatic carrier state is known to exist.Feline DiseasesVectorborne Diseases-Testing Recommended.", [["blood", "ANATOMY", 43, 48], ["RMSF", "DISEASE", 87, 91], ["acutely ill", "DISEASE", 119, 130], ["Feline DiseasesVectorborne Diseases", "DISEASE", 183, 218], ["blood", "ORGANISM_SUBSTANCE", 43, 48], ["donors", "ORGANISM", 49, 55], ["dogs", "ORGANISM", 110, 114], ["dogs", "SPECIES", 110, 114], ["healthy blood donors", "PROBLEM", 35, 55], ["RMSF", "PROBLEM", 87, 91], ["infected dogs", "PROBLEM", 101, 114], ["acutely ill", "PROBLEM", 119, 130], ["asymptomatic carrier state", "PROBLEM", 138, 164], ["Feline DiseasesVectorborne Diseases", "PROBLEM", 183, 218]]], ["Hemoplasmosis: Hemobartonella felis, a hemotrophic organism known to produce anemia in infected cats, recently has been reclassified to the genus Mycoplasma.", [["Hemoplasmosis", "DISEASE", 0, 13], ["Hemobartonella felis", "DISEASE", 15, 35], ["anemia", "DISEASE", 77, 83], ["Mycoplasma", "DISEASE", 146, 156], ["Hemobartonella felis", "ORGANISM", 15, 35], ["cats", "ORGANISM", 96, 100], ["Hemobartonella felis", "SPECIES", 15, 35], ["cats", "SPECIES", 96, 100], ["Hemobartonella felis", "SPECIES", 15, 35], ["Hemobartonella felis", "PROBLEM", 15, 35], ["a hemotrophic organism", "PROBLEM", 37, 59], ["anemia in infected cats", "PROBLEM", 77, 100], ["the genus Mycoplasma", "PROBLEM", 136, 156], ["anemia", "OBSERVATION", 77, 83], ["infected cats", "OBSERVATION", 87, 100], ["genus Mycoplasma", "OBSERVATION", 140, 156]]], ["Genetic studies of H felis have identified at least 2 different strains, now known as Mycoplasma haemofelis (Ohio or large form) and Candidatus Mycoplasma haemominutum (California or small form).", [["Mycoplasma haemofelis", "DISEASE", 86, 107], ["Mycoplasma haemominutum", "DISEASE", 144, 167], ["H felis", "ORGANISM", 19, 26], ["Mycoplasma haemofelis", "ORGANISM", 86, 107], ["Mycoplasma haemominutum", "ORGANISM", 144, 167], ["H felis", "SPECIES", 19, 26], ["Mycoplasma haemofelis", "SPECIES", 86, 107], ["Candidatus", "SPECIES", 133, 143], ["Mycoplasma haemominutum", "SPECIES", 144, 167], ["H felis", "SPECIES", 19, 26], ["Mycoplasma haemofelis", "SPECIES", 86, 107], ["Mycoplasma haemominutum", "SPECIES", 144, 167], ["Genetic studies", "TEST", 0, 15], ["2 different strains", "PROBLEM", 52, 71], ["Mycoplasma haemofelis", "PROBLEM", 86, 107], ["Candidatus Mycoplasma haemominutum", "PROBLEM", 133, 167], ["Mycoplasma haemominutum", "OBSERVATION", 144, 167]]], ["28 Differences in pathogenicity between the 2 strains still are being defined, but it appears that M haemofelis is the more virulent organism.", [["M haemofelis", "ORGANISM", 99, 111], ["M haemofelis", "SPECIES", 99, 111], ["M haemofelis", "SPECIES", 99, 111], ["the 2 strains", "PROBLEM", 40, 53], ["M haemofelis", "PROBLEM", 99, 111], ["the more virulent organism", "PROBLEM", 115, 141], ["pathogenicity", "OBSERVATION", 18, 31]]], ["[29] [30] [31] Cats that recover from infection can remain chronic carriers.", [["infection", "DISEASE", 38, 47], ["[29] [30] [31] Cats", "SIMPLE_CHEMICAL", 0, 19], ["infection", "PROBLEM", 38, 47], ["chronic carriers", "PROBLEM", 59, 75], ["infection", "OBSERVATION", 38, 47], ["chronic", "OBSERVATION_MODIFIER", 59, 66]]], ["28, 29 Natural routes of transmission still are being determined, but fleas are a likely vector.", [["fleas", "OBSERVATION", 70, 75]]], ["In a recent study, 22.7% of cats (with a history of flea infestation) used as blood donors in the United States with a history of flea infestation was PCR positive.", [["blood", "ANATOMY", 78, 83], ["flea infestation", "DISEASE", 52, 68], ["flea infestation", "DISEASE", 130, 146], ["cats", "ORGANISM", 28, 32], ["blood", "ORGANISM_SUBSTANCE", 78, 83], ["flea", "ORGANISM", 130, 134], ["cats", "SPECIES", 28, 32], ["flea", "SPECIES", 130, 134], ["a recent study", "TEST", 3, 17], ["flea infestation", "PROBLEM", 52, 68], ["flea infestation", "PROBLEM", 130, 146], ["PCR positive", "PROBLEM", 151, 163]]], ["32 Intravenous inoculation of infected blood has been used to produce experimental infections.", [["blood", "ANATOMY", 39, 44], ["infections", "DISEASE", 83, 93], ["blood", "ORGANISM_SUBSTANCE", 39, 44], ["Intravenous inoculation", "TREATMENT", 3, 26], ["infected blood", "PROBLEM", 30, 44], ["experimental infections", "PROBLEM", 70, 93], ["infected", "OBSERVATION", 30, 38], ["experimental", "OBSERVATION_MODIFIER", 70, 82], ["infections", "OBSERVATION", 83, 93]]], ["33 No serologic assay for the disease is commercially available.", [["serologic assay", "TEST", 6, 21], ["the disease", "PROBLEM", 26, 37], ["disease", "OBSERVATION", 30, 37]]], ["Although blood smear examination for the organism on the surface of erythrocytes has been used to detect active infections, the organisms are unlikely to be apparent in the chronically infected, asymptomatic cats.", [["blood", "ANATOMY", 9, 14], ["surface", "ANATOMY", 57, 64], ["erythrocytes", "ANATOMY", 68, 80], ["infections", "DISEASE", 112, 122], ["chronically infected", "DISEASE", 173, 193], ["blood", "ORGANISM_SUBSTANCE", 9, 14], ["surface", "CELLULAR_COMPONENT", 57, 64], ["erythrocytes", "CELL", 68, 80], ["cats", "ORGANISM", 208, 212], ["erythrocytes", "CELL_TYPE", 68, 80], ["cats", "SPECIES", 208, 212], ["blood smear examination", "TEST", 9, 32], ["the organism", "PROBLEM", 37, 49], ["active infections", "PROBLEM", 105, 122], ["the organisms", "PROBLEM", 124, 137], ["active", "OBSERVATION_MODIFIER", 105, 111], ["infections", "OBSERVATION", 112, 122], ["unlikely to be", "UNCERTAINTY", 142, 156], ["chronically", "OBSERVATION_MODIFIER", 173, 184], ["infected", "OBSERVATION", 185, 193]]], ["The organisms can be detected by light microscopy or with the use of commercially available PCR assays, and microscopy or PCR-positive cats should be excluded from the donor pool.Feline DiseasesBartonellosis: Bartonella spp. are gram-negative, intraerythrocytic bacteria from the family Bartonellaceae.", [["Feline DiseasesBartonellosis", "DISEASE", 179, 207], ["Bartonella spp.", "DISEASE", 209, 224], ["cats", "ORGANISM", 135, 139], ["Feline", "ORGANISM", 179, 185], ["Bartonella spp.", "ORGANISM", 209, 224], ["Bartonella spp.", "SPECIES", 209, 224], ["Bartonella spp.", "SPECIES", 209, 224], ["light microscopy", "TEST", 33, 49], ["PCR assays", "TEST", 92, 102], ["microscopy", "TEST", 108, 118], ["PCR", "TEST", 122, 125], ["Feline DiseasesBartonellosis", "PROBLEM", 179, 207], ["Bartonella spp.", "TEST", 209, 224], ["gram", "TEST", 229, 233], ["intraerythrocytic bacteria", "PROBLEM", 244, 270], ["intraerythrocytic bacteria", "OBSERVATION", 244, 270]]], ["Cats serve as a reservoir for a number of Bartonella species, including Bartonella henselae, Bartonella clarridgeiae, and Bartonella koehlerae.", [["Bartonella species", "DISEASE", 42, 60], ["Bartonella henselae", "DISEASE", 72, 91], ["Bartonella clarridgeiae", "DISEASE", 93, 116], ["Bartonella koehlerae", "DISEASE", 122, 142], ["Bartonella species", "ORGANISM", 42, 60], ["Bartonella henselae", "ORGANISM", 72, 91], ["Bartonella clarridgeiae", "ORGANISM", 93, 116], ["Bartonella koehlerae", "ORGANISM", 122, 142], ["Bartonella henselae", "SPECIES", 72, 91], ["Bartonella clarridgeiae", "SPECIES", 93, 116], ["Bartonella koehlerae", "SPECIES", 122, 142], ["Bartonella henselae", "SPECIES", 72, 91], ["Bartonella clarridgeiae", "SPECIES", 93, 116], ["Bartonella koehlerae", "SPECIES", 122, 142], ["a reservoir", "TREATMENT", 14, 25], ["Bartonella species", "PROBLEM", 42, 60], ["Bartonella henselae", "TEST", 72, 91], ["Bartonella clarridgeiae", "TEST", 93, 116], ["Bartonella species", "OBSERVATION", 42, 60]]], ["Infected cats typically have a prolonged, asymptomatic bacteremia, but uveitis and endocarditis have been reported.", [["bacteremia", "DISEASE", 55, 65], ["uveitis", "DISEASE", 71, 78], ["endocarditis", "DISEASE", 83, 95], ["cats", "ORGANISM", 9, 13], ["cats", "SPECIES", 9, 13], ["Infected cats", "PROBLEM", 0, 13], ["a prolonged, asymptomatic bacteremia", "PROBLEM", 29, 65], ["uveitis", "PROBLEM", 71, 78], ["endocarditis", "PROBLEM", 83, 95], ["prolonged", "OBSERVATION_MODIFIER", 31, 40], ["asymptomatic", "OBSERVATION_MODIFIER", 42, 54], ["bacteremia", "OBSERVATION", 55, 65], ["uveitis", "OBSERVATION", 71, 78], ["endocarditis", "OBSERVATION", 83, 95]]], ["34, 35 Fleas can harbor the organism and are believed to be the likely vector.", [["believed to be the likely", "UNCERTAINTY", 45, 70]]], ["36 Natural transmission of B henselae by blood transfusion is likely because the organism is an intraerythrocytic bacterium, 37 but cases of bartonellosis resulting from clinical transfusion have not been reported.", [["blood", "ANATOMY", 41, 46], ["B henselae", "DISEASE", 27, 37], ["bartonellosis", "DISEASE", 141, 154], ["B henselae", "ORGANISM", 27, 37], ["blood", "ORGANISM_SUBSTANCE", 41, 46], ["B henselae", "SPECIES", 27, 37], ["B henselae", "SPECIES", 27, 37], ["B henselae", "TREATMENT", 27, 37], ["blood transfusion", "TREATMENT", 41, 58], ["the organism", "PROBLEM", 77, 89], ["an intraerythrocytic bacterium", "PROBLEM", 93, 123], ["bartonellosis", "PROBLEM", 141, 154], ["clinical transfusion", "TREATMENT", 170, 190], ["intraerythrocytic bacterium", "OBSERVATION", 96, 123]]], ["Bacteremia can be produced experimentally in cats after transmission of infected blood.", [["blood", "ANATOMY", 81, 86], ["Bacteremia", "DISEASE", 0, 10], ["cats", "ORGANISM", 45, 49], ["blood", "ORGANISM_SUBSTANCE", 81, 86], ["cats", "SPECIES", 45, 49], ["Bacteremia", "PROBLEM", 0, 10], ["infected blood", "PROBLEM", 72, 86], ["infected", "OBSERVATION", 72, 80]]], ["38 Transmission of some Bartonella species from infected cats to humans does occur, with cat scratch fever the most frequently documented B henselae-induced disease.", [["scratch fever", "DISEASE", 93, 106], ["B henselae", "DISEASE", 138, 148], ["Bartonella species", "ORGANISM", 24, 42], ["cats", "ORGANISM", 57, 61], ["humans", "ORGANISM", 65, 71], ["cat", "ORGANISM", 89, 92], ["B henselae", "ORGANISM", 138, 148], ["cats", "SPECIES", 57, 61], ["humans", "SPECIES", 65, 71], ["B henselae", "SPECIES", 138, 148], ["humans", "SPECIES", 65, 71], ["B henselae", "SPECIES", 138, 148], ["some Bartonella species", "PROBLEM", 19, 42], ["cat scratch fever", "PROBLEM", 89, 106], ["B henselae-induced disease", "PROBLEM", 138, 164], ["Bartonella species", "OBSERVATION", 24, 42], ["most frequently", "OBSERVATION_MODIFIER", 111, 126], ["henselae", "OBSERVATION", 140, 148], ["disease", "OBSERVATION", 157, 164]]], ["39 Blood culture or PCR are used to detect current infection, and serology provides evidence of previous or current infection.", [["Blood culture", "ANATOMY", 3, 16], ["infection", "DISEASE", 51, 60], ["infection", "DISEASE", 116, 125], ["Blood culture", "TEST", 3, 16], ["PCR", "TEST", 20, 23], ["current infection", "PROBLEM", 43, 60], ["serology", "TEST", 66, 74], ["current infection", "PROBLEM", 108, 125], ["infection", "OBSERVATION", 51, 60], ["infection", "OBSERVATION", 116, 125]]], ["One study in the United States and western Canada showed a seroprevalence for B henselae of 27.9% in 628 pet cats, with regional variability.", [["B henselae", "DISEASE", 78, 88], ["B henselae", "ORGANISM", 78, 88], ["cats", "ORGANISM", 109, 113], ["B henselae", "SPECIES", 78, 88], ["cats", "SPECIES", 109, 113], ["B henselae", "SPECIES", 78, 88], ["One study", "TEST", 0, 9], ["B henselae", "TEST", 78, 88], ["pet cats", "TEST", 105, 113], ["regional variability", "OBSERVATION", 120, 140]]], ["40 Another study showed that B henselae and B clarridgeiae bacteremia was found in up to 50% of the domestic and feral cat populations in regions where fleas were endemic.", [["B henselae", "DISEASE", 29, 39], ["bacteremia", "DISEASE", 59, 69], ["B henselae", "ORGANISM", 29, 39], ["B clarridgeiae", "ORGANISM", 44, 58], ["cat", "ORGANISM", 119, 122], ["B henselae", "SPECIES", 29, 39], ["B clarridgeiae", "SPECIES", 44, 58], ["B henselae", "SPECIES", 29, 39], ["B clarridgeiae", "SPECIES", 44, 58], ["feral cat", "SPECIES", 113, 122], ["Another study", "TEST", 3, 16], ["B henselae", "PROBLEM", 29, 39], ["B clarridgeiae bacteremia", "PROBLEM", 44, 69], ["fleas", "PROBLEM", 152, 157], ["henselae", "OBSERVATION", 31, 39], ["bacteremia", "OBSERVATION", 59, 69], ["feral cat populations", "OBSERVATION", 113, 134]]], ["41 However, B henselae infection was only documented by PCR assay in 2 of 117 (1.7%) community source cats used as blood donors in the United States.", [["blood", "ANATOMY", 115, 120], ["B henselae infection", "DISEASE", 12, 32], ["B henselae", "ORGANISM", 12, 22], ["cats", "ORGANISM", 102, 106], ["blood", "ORGANISM_SUBSTANCE", 115, 120], ["B henselae", "SPECIES", 12, 22], ["B henselae", "SPECIES", 12, 22], ["B henselae infection", "PROBLEM", 12, 32], ["PCR assay", "TEST", 56, 65], ["henselae", "OBSERVATION_MODIFIER", 14, 22], ["infection", "OBSERVATION", 23, 32]]], ["32 Serologic cross-reactivity among B henselae and B clarridgeiae and B koehlerae does not always occur, but blood culture and PCR are capable of detecting all Bartonella species.", [["blood", "ANATOMY", 109, 114], ["B henselae", "ORGANISM", 36, 46], ["B clarridgeiae", "ORGANISM", 51, 65], ["B koehlerae", "ORGANISM", 70, 81], ["blood", "ORGANISM_SUBSTANCE", 109, 114], ["B henselae", "SPECIES", 36, 46], ["B clarridgeiae", "SPECIES", 51, 65], ["B koehlerae", "SPECIES", 70, 81], ["B henselae", "SPECIES", 36, 46], ["B clarridgeiae", "SPECIES", 51, 65], ["B koehlerae", "SPECIES", 70, 81], ["Serologic cross-reactivity", "TEST", 3, 29], ["B henselae and B clarridgeiae and B koehlerae", "TEST", 36, 81], ["blood culture", "TEST", 109, 122], ["PCR", "TEST", 127, 130], ["all Bartonella species", "PROBLEM", 156, 178], ["henselae", "OBSERVATION", 38, 46], ["Bartonella species", "OBSERVATION", 160, 178]]], ["Although sensitive, blood culture can take up to 4-6 weeks to perform, and bacterial isolates require molecular characterization such as PCR or DNA sequencing to confirm their identity.", [["blood culture", "ANATOMY", 20, 33], ["blood", "ORGANISM_SUBSTANCE", 20, 25], ["DNA", "CELLULAR_COMPONENT", 144, 147], ["blood culture", "TEST", 20, 33], ["bacterial isolates", "PROBLEM", 75, 93], ["molecular characterization", "TEST", 102, 128], ["PCR", "TEST", 137, 140], ["DNA sequencing", "TEST", 144, 158]]], ["Treatment does not consistently lead to elimination of the organism.", [["Treatment", "TREATMENT", 0, 9], ["the organism", "PROBLEM", 55, 67]]], ["42 The panel was divided on screening recommendation for Bartonella.", [["The panel", "TEST", 3, 12], ["screening recommendation", "TEST", 28, 52], ["Bartonella", "PROBLEM", 57, 67]]], ["All authors felt it would be ideal to strive for a Bartonella-free donor pool, but several factors, including the potential pathogenicity and epidemiology of feline bartonellosis, led to a division of the panel on whether or not to categorize feline bartonellosis in the recommended or conditional group.", [["feline bartonellosis", "DISEASE", 158, 178], ["bartonellosis", "DISEASE", 250, 263], ["feline", "ORGANISM", 158, 164], ["feline", "ORGANISM", 243, 249], ["feline", "SPECIES", 158, 164], ["feline", "SPECIES", 243, 249], ["a Bartonella", "PROBLEM", 49, 61], ["feline bartonellosis", "PROBLEM", 158, 178]]], ["Four of 7 authors recommended routine screening of feline blood donors, with seropositive, PCRpositive or blood culture-positive cats excluded from donation.", [["blood", "ANATOMY", 58, 63], ["blood", "ANATOMY", 106, 111], ["feline", "ORGANISM", 51, 57], ["blood donors", "ORGANISM_SUBSTANCE", 58, 70], ["blood", "ORGANISM_SUBSTANCE", 106, 111], ["cats", "ORGANISM", 129, 133], ["routine screening", "TEST", 30, 47], ["feline blood donors", "TEST", 51, 70], ["seropositive", "TEST", 77, 89], ["blood culture", "TEST", 106, 119]]], ["Three of 7 authors felt that the lack of current in-formation on the pathogenicity of the organism and the possibility of a high prevalence of pre-existing infections in some areas warranted a conditional recommendation.Non-Vectorborne Diseases-Testing Recommended.", [["infections", "DISEASE", 156, 166], ["the organism", "PROBLEM", 86, 98], ["pre-existing infections", "PROBLEM", 143, 166], ["Non-Vectorborne Diseases", "PROBLEM", 220, 244], ["infections", "OBSERVATION", 156, 166], ["Diseases", "OBSERVATION", 236, 244]]], ["FeLV Infection:FeLV is an oncornavirus that causes a variety of neoplastic and nonneoplastic diseases in cats.", [["neoplastic", "ANATOMY", 64, 74], ["nonneoplastic", "ANATOMY", 79, 92], ["FeLV Infection", "DISEASE", 0, 14], ["neoplastic and nonneoplastic diseases", "DISEASE", 64, 101], ["FeLV", "ORGANISM", 0, 4], ["FeLV", "ORGANISM", 15, 19], ["neoplastic", "CANCER", 64, 74], ["nonneoplastic", "CANCER", 79, 92], ["cats", "ORGANISM", 105, 109], ["cats", "SPECIES", 105, 109], ["FeLV Infection", "PROBLEM", 0, 14], ["FeLV", "PROBLEM", 15, 19], ["an oncornavirus", "PROBLEM", 23, 38], ["neoplastic and nonneoplastic diseases in cats", "PROBLEM", 64, 109], ["Infection", "OBSERVATION", 5, 14], ["FeLV", "OBSERVATION", 15, 19], ["variety", "OBSERVATION_MODIFIER", 53, 60], ["neoplastic", "OBSERVATION_MODIFIER", 64, 74], ["nonneoplastic", "OBSERVATION_MODIFIER", 79, 92], ["diseases", "OBSERVATION", 93, 101]]], ["Transmission of the virus occurs primarily through saliva, but the virus is present in the blood and can be transmitted by blood transfusion.", [["blood", "ANATOMY", 91, 96], ["blood", "ANATOMY", 123, 128], ["saliva", "ORGANISM_SUBSTANCE", 51, 57], ["blood", "ORGANISM_SUBSTANCE", 91, 96], ["blood", "ORGANISM_SUBSTANCE", 123, 128], ["the virus", "PROBLEM", 16, 25], ["the virus", "PROBLEM", 63, 72], ["blood transfusion", "TREATMENT", 123, 140], ["virus", "OBSERVATION", 20, 25], ["virus", "OBSERVATION", 67, 72], ["blood", "ANATOMY", 91, 96]]], ["43 Testing of donor cats for the FeLV antigen by ELISA is recommended, and all seropositive cats should be excluded from blood donation.", [["blood", "ANATOMY", 121, 126], ["cats", "ORGANISM", 20, 24], ["FeLV", "ORGANISM", 33, 37], ["cats", "ORGANISM", 92, 96], ["blood", "ORGANISM_SUBSTANCE", 121, 126], ["FeLV antigen", "PROTEIN", 33, 45], ["cats", "SPECIES", 20, 24], ["cats", "SPECIES", 92, 96], ["FeLV", "SPECIES", 33, 37], ["donor cats", "TREATMENT", 14, 24], ["the FeLV antigen", "TEST", 29, 45], ["ELISA", "TEST", 49, 54], ["all seropositive cats", "TREATMENT", 75, 96], ["blood donation", "TEST", 121, 135]]], ["Free-roaming cats have constant potential exposure and should be excluded from blood donor programs.Non-Vectorborne Diseases-Testing Recommended.", [["blood", "ANATOMY", 79, 84], ["cats", "ORGANISM", 13, 17], ["blood", "ORGANISM_SUBSTANCE", 79, 84], ["cats", "SPECIES", 13, 17], ["blood donor programs", "TREATMENT", 79, 99], ["Non-Vectorborne Diseases", "PROBLEM", 100, 124], ["Diseases", "OBSERVATION", 116, 124]]], ["FeLV Infection:Feline Immunodeficiency Virus Infection: The feline immunodeficiency virus (FIV) is a lentivirus transmitted by exposure to the virus in saliva or blood.", [["saliva", "ANATOMY", 152, 158], ["blood", "ANATOMY", 162, 167], ["FeLV Infection", "DISEASE", 0, 14], ["Feline Immunodeficiency Virus Infection", "DISEASE", 15, 54], ["feline immunodeficiency virus (FIV)", "DISEASE", 60, 95], ["FeLV", "ORGANISM", 0, 4], ["Feline Immunodeficiency Virus", "ORGANISM", 15, 44], ["feline immunodeficiency virus", "ORGANISM", 60, 89], ["FIV", "ORGANISM", 91, 94], ["lentivirus", "ORGANISM", 101, 111], ["saliva", "ORGANISM_SUBSTANCE", 152, 158], ["blood", "ORGANISM_SUBSTANCE", 162, 167], ["feline immunodeficiency virus", "SPECIES", 60, 89], ["Feline Immunodeficiency Virus", "SPECIES", 15, 44], ["feline immunodeficiency virus", "SPECIES", 60, 89], ["FIV", "SPECIES", 91, 94], ["lentivirus", "SPECIES", 101, 111], ["FeLV Infection", "PROBLEM", 0, 14], ["Feline Immunodeficiency Virus Infection", "PROBLEM", 15, 54], ["The feline immunodeficiency virus", "PROBLEM", 56, 89], ["the virus in saliva", "PROBLEM", 139, 158], ["Infection", "OBSERVATION", 5, 14], ["Feline Immunodeficiency Virus", "OBSERVATION", 15, 44]]], ["44 Testing of donor cats for FIV-specific antibodies by ELISA is recommended, and all seropositive cats should be excluded.", [["cats", "ORGANISM", 20, 24], ["FIV", "ORGANISM", 29, 32], ["cats", "ORGANISM", 99, 103], ["FIV-specific antibodies", "PROTEIN", 29, 52], ["cats", "SPECIES", 20, 24], ["cats", "SPECIES", 99, 103], ["FIV", "SPECIES", 29, 32], ["donor cats", "TEST", 14, 24], ["FIV-specific antibodies", "TEST", 29, 52], ["ELISA", "TEST", 56, 61], ["all seropositive cats", "TREATMENT", 82, 103]]], ["Cats vaccinated against FIV also will be seropositive, and other serological or PCR tests that definitively discriminate between vaccinated and nonvaccinated FIV-positive cats are not available.", [["Cats", "ORGANISM", 0, 4], ["FIV", "ORGANISM", 24, 27], ["FIV", "ORGANISM", 158, 161], ["cats", "ORGANISM", 171, 175], ["cats", "SPECIES", 171, 175], ["FIV", "SPECIES", 24, 27], ["FIV", "SPECIES", 158, 161], ["FIV", "PROBLEM", 24, 27], ["seropositive", "PROBLEM", 41, 53], ["other serological", "TEST", 59, 76], ["PCR tests", "TEST", 80, 89], ["nonvaccinated FIV", "TEST", 144, 161]]], ["45, 46 It is recommended therefore that all seropositive cats, including vaccinated cats, be excluded from the donor pool.", [["cats", "ORGANISM", 57, 61], ["cats", "ORGANISM", 84, 88], ["cats", "SPECIES", 57, 61], ["cats", "SPECIES", 84, 88], ["all seropositive cats", "TREATMENT", 40, 61], ["vaccinated cats", "TREATMENT", 73, 88]]], ["Free-roaming cats should also be excluded from donor programs.Non-Vectorborne Diseases-Testing Recommended.", [["cats", "ORGANISM", 13, 17], ["cats", "SPECIES", 13, 17], ["Free-roaming cats", "TREATMENT", 0, 17], ["Non-Vectorborne Diseases", "PROBLEM", 62, 86], ["Diseases", "OBSERVATION", 78, 86]]], ["FeLV Infection:Vectorborne Diseases-Conditional Testing.", [["FeLV Infection", "DISEASE", 0, 14], ["FeLV", "ORGANISM", 0, 4], ["FeLV Infection", "PROBLEM", 0, 14], ["Vectorborne Diseases", "PROBLEM", 15, 35], ["Infection", "OBSERVATION", 5, 14]]], ["Cytauxzoonosis: Cytauxzoon felis is a tickborne organism in the order Piroplasmida and family Theileriidae.", [["Cytauxzoonosis", "CHEMICAL", 0, 14], ["Cytauxzoon felis", "DISEASE", 16, 32], ["Cytauxzoon felis", "ORGANISM", 16, 32], ["Cytauxzoon felis", "SPECIES", 16, 32], ["Cytauxzoon felis", "SPECIES", 16, 32], ["Cytauxzoon felis", "PROBLEM", 16, 32]]], ["The organism infects erythrocytes and can be transmitted experimentally via blood.", [["erythrocytes", "ANATOMY", 21, 33], ["blood", "ANATOMY", 76, 81], ["erythrocytes", "CELL", 21, 33], ["blood", "ORGANISM_SUBSTANCE", 76, 81], ["erythrocytes", "CELL_TYPE", 21, 33], ["The organism infects erythrocytes", "PROBLEM", 0, 33], ["infects erythrocytes", "OBSERVATION", 13, 33]]], ["47 The fatal form of the disease develops after tick transmission of the organism or after experimental administration of infected tissue homogenates.", [["tissue homogenates", "ANATOMY", 131, 149], ["tissue homogenates", "TISSUE", 131, 149], ["the disease", "PROBLEM", 21, 32], ["tick transmission of the organism", "PROBLEM", 48, 81], ["infected tissue homogenates", "PROBLEM", 122, 149], ["fatal", "OBSERVATION_MODIFIER", 7, 12], ["disease", "OBSERVATION", 25, 32], ["infected tissue homogenates", "OBSERVATION", 122, 149]]], ["In naturally occurring disease, the majority of infected cats develop severe anemia and die within 5 days.", [["anemia", "DISEASE", 77, 83], ["cats", "ORGANISM", 57, 61], ["cats", "SPECIES", 57, 61], ["naturally occurring disease", "PROBLEM", 3, 30], ["infected cats", "PROBLEM", 48, 61], ["severe anemia", "PROBLEM", 70, 83], ["infected", "OBSERVATION_MODIFIER", 48, 56], ["severe", "OBSERVATION_MODIFIER", 70, 76], ["anemia", "OBSERVATION", 77, 83]]], ["A chronic carrier state has been identified in Arkansas and Tennessee.", [["A chronic carrier state", "PROBLEM", 0, 23], ["chronic", "OBSERVATION_MODIFIER", 2, 9]]], ["48 No commercially available serologic or PCR test is available for C felis, and blood smears must be examined for the signet-shaped piroplasm in erythrocytes.", [["blood", "ANATOMY", 81, 86], ["piroplasm", "ANATOMY", 133, 142], ["erythrocytes", "ANATOMY", 146, 158], ["C felis", "ORGANISM", 68, 75], ["blood", "ORGANISM_SUBSTANCE", 81, 86], ["piroplasm", "CANCER", 133, 142], ["erythrocytes", "CELL", 146, 158], ["erythrocytes", "CELL_TYPE", 146, 158], ["C felis", "SPECIES", 68, 75], ["C felis", "SPECIES", 68, 75], ["PCR test", "TEST", 42, 50], ["C felis", "PROBLEM", 68, 75], ["blood smears", "TEST", 81, 93], ["the signet-shaped piroplasm in erythrocytes", "PROBLEM", 115, 158], ["shaped", "OBSERVATION_MODIFIER", 126, 132], ["piroplasm", "OBSERVATION", 133, 142], ["erythrocytes", "ANATOMY", 146, 158]]], ["Because the majority of infected cats are ill and the carrier state is geographically limited, the disease is considered of low priority when screening clinically healthy cats as potential blood donors.", [["blood", "ANATOMY", 189, 194], ["cats", "ORGANISM", 33, 37], ["cats", "ORGANISM", 171, 175], ["blood donors", "ORGANISM_SUBSTANCE", 189, 201], ["cats", "SPECIES", 33, 37], ["cats", "SPECIES", 171, 175], ["infected cats", "PROBLEM", 24, 37], ["the disease", "PROBLEM", 95, 106], ["blood donors", "TEST", 189, 201], ["majority", "OBSERVATION_MODIFIER", 12, 20], ["infected", "OBSERVATION", 24, 32], ["disease", "OBSERVATION", 99, 106]]], ["Use of indoor cats and appropriate ectoparasite prophylaxis are advised to avoid this disease in donor animals.Non-Vectorborne Diseases-Testing Recommended.", [["cats", "ORGANISM", 14, 18], ["cats", "SPECIES", 14, 18], ["indoor cats", "TREATMENT", 7, 18], ["appropriate ectoparasite prophylaxis", "TREATMENT", 23, 59], ["this disease in donor animals", "PROBLEM", 81, 110], ["Non-Vectorborne Diseases", "PROBLEM", 111, 135], ["Diseases", "OBSERVATION", 127, 135]]], ["FeLV Infection:Ehrlichiosis, Anaplasmosis, Neorickettsiosis: An E canis-like infection and A phagocytophilum infections of cats have been described, with PCR amplification of the organism from blood.", [["blood", "ANATOMY", 193, 198], ["FeLV Infection", "DISEASE", 0, 14], ["Ehrlichiosis", "DISEASE", 15, 27], ["Neorickettsiosis", "CHEMICAL", 43, 59], ["E canis-like infection", "DISEASE", 64, 86], ["A phagocytophilum infections", "DISEASE", 91, 119], ["FeLV", "ORGANISM", 0, 4], ["E canis", "ORGANISM", 64, 71], ["A phagocytophilum", "ORGANISM", 91, 108], ["cats", "ORGANISM", 123, 127], ["blood", "ORGANISM_SUBSTANCE", 193, 198], ["E canis", "SPECIES", 64, 71], ["A phagocytophilum", "SPECIES", 91, 108], ["cats", "SPECIES", 123, 127], ["E canis", "SPECIES", 64, 71], ["A phagocytophilum", "SPECIES", 91, 108], ["FeLV Infection", "PROBLEM", 0, 14], ["Ehrlichiosis", "PROBLEM", 15, 27], ["Anaplasmosis", "PROBLEM", 29, 41], ["Neorickettsiosis", "PROBLEM", 43, 59], ["An E canis", "PROBLEM", 61, 71], ["infection", "PROBLEM", 77, 86], ["A phagocytophilum infections of cats", "PROBLEM", 91, 127], ["PCR amplification of the organism from blood", "PROBLEM", 154, 198], ["Infection", "OBSERVATION", 5, 14], ["Ehrlichiosis", "OBSERVATION", 15, 27], ["Anaplasmosis", "OBSERVATION", 29, 41], ["canis", "OBSERVATION", 66, 71], ["infection", "OBSERVATION", 77, 86], ["phagocytophilum infections", "OBSERVATION", 93, 119]]], ["[49] [50] [51] In 1 study with healthy blood donor cats, DNA from these genera could not be detected.", [["blood", "ANATOMY", 39, 44], ["blood", "ORGANISM_SUBSTANCE", 39, 44], ["cats", "ORGANISM", 51, 55], ["DNA", "CELLULAR_COMPONENT", 57, 60], ["cats", "SPECIES", 51, 55], ["1 study", "TEST", 18, 25], ["healthy blood donor cats", "TREATMENT", 31, 55], ["DNA from these genera", "PROBLEM", 57, 78]]], ["32 Neorickettisa risticii can infect experimentally inoculated cats but has not been grown or amplified from naturally exposed cats.", [["Neorickettisa risticii", "ORGANISM", 3, 25], ["cats", "ORGANISM", 63, 67], ["cats", "ORGANISM", 127, 131], ["Neorickettisa risticii", "SPECIES", 3, 25], ["cats", "SPECIES", 63, 67], ["cats", "SPECIES", 127, 131], ["Neorickettisa risticii", "SPECIES", 3, 25]]], ["52 Screening for these organisms in healthy cats to be used as blood donors is not routinely recommended at this time, but veterinarians in areas where known infections with these agents have occurred should consider testing of their blood donors.Non-Vectorborne Diseases-Testing Recommended.", [["blood", "ANATOMY", 63, 68], ["blood", "ANATOMY", 234, 239], ["infections", "DISEASE", 158, 168], ["cats", "ORGANISM", 44, 48], ["blood", "ORGANISM_SUBSTANCE", 63, 68], ["blood", "ORGANISM_SUBSTANCE", 234, 239], ["donors", "ORGANISM", 240, 246], ["cats", "SPECIES", 44, 48], ["these organisms in healthy cats", "PROBLEM", 17, 48], ["blood donors", "TEST", 63, 75], ["known infections", "PROBLEM", 152, 168], ["these agents", "TREATMENT", 174, 186], ["their blood donors", "TEST", 228, 246], ["Non-Vectorborne Diseases", "PROBLEM", 247, 271], ["infections", "OBSERVATION", 158, 168]]], ["FeLV Infection:Other Diseases-Testing Not Recommended.", [["FeLV Infection", "DISEASE", 0, 14], ["FeLV", "ORGANISM", 0, 4], ["FeLV Infection", "PROBLEM", 0, 14], ["Other Diseases", "PROBLEM", 15, 29], ["Infection", "OBSERVATION", 5, 14]]], ["Feline Infectious Peritonitis: Several enteric coronaviruses occur in cats.", [["Infectious Peritonitis", "DISEASE", 7, 29], ["enteric coronaviruses", "DISEASE", 39, 60], ["Feline", "ORGANISM", 0, 6], ["coronaviruses", "ORGANISM", 47, 60], ["cats", "ORGANISM", 70, 74], ["cats", "SPECIES", 70, 74], ["Feline Infectious Peritonitis", "PROBLEM", 0, 29], ["Several enteric coronaviruses", "PROBLEM", 31, 60], ["Infectious", "OBSERVATION_MODIFIER", 7, 17], ["Peritonitis", "OBSERVATION", 18, 29], ["Several", "OBSERVATION_MODIFIER", 31, 38], ["enteric coronaviruses", "OBSERVATION_MODIFIER", 39, 60]]], ["Feline infectious peritonitis is a terminal disease of cats caused by a mutant form of feline enteric coronavirus.", [["Feline infectious peritonitis", "DISEASE", 0, 29], ["feline enteric coronavirus", "DISEASE", 87, 113], ["Feline", "ORGANISM", 0, 6], ["cats", "ORGANISM", 55, 59], ["feline enteric coronavirus", "ORGANISM", 87, 113], ["cats", "SPECIES", 55, 59], ["feline enteric coronavirus", "SPECIES", 87, 113], ["feline enteric coronavirus", "SPECIES", 87, 113], ["Feline infectious peritonitis", "PROBLEM", 0, 29], ["a terminal disease of cats", "PROBLEM", 33, 59], ["feline enteric coronavirus", "PROBLEM", 87, 113], ["infectious", "OBSERVATION_MODIFIER", 7, 17], ["peritonitis", "OBSERVATION", 18, 29], ["terminal", "OBSERVATION_MODIFIER", 35, 43], ["disease", "OBSERVATION", 44, 51], ["feline enteric coronavirus", "OBSERVATION", 87, 113]]], ["Documentation of clinical transmission of the disease by blood transfusion does not exist at this time.", [["blood", "ANATOMY", 57, 62], ["blood", "ORGANISM_SUBSTANCE", 57, 62], ["the disease", "PROBLEM", 42, 53], ["blood transfusion", "TEST", 57, 74], ["disease", "OBSERVATION", 46, 53]]], ["Screening of blood donor cats with serology or reverse transcriptase (RT)-PCR is not recommended, because healthy cats can have antibody titers against the enteric coronavirus and can also be RT-PCR positive.", [["blood", "ANATOMY", 13, 18], ["enteric coronavirus", "DISEASE", 156, 175], ["blood", "ORGANISM_SUBSTANCE", 13, 18], ["cats", "ORGANISM", 25, 29], ["cats", "ORGANISM", 114, 118], ["enteric coronavirus", "ORGANISM", 156, 175], ["reverse transcriptase", "PROTEIN", 47, 68], ["cats", "SPECIES", 25, 29], ["cats", "SPECIES", 114, 118], ["enteric coronavirus", "SPECIES", 156, 175], ["blood donor cats", "TEST", 13, 29], ["serology", "TEST", 35, 43], ["reverse transcriptase", "TREATMENT", 47, 68], ["(RT)-PCR", "TEST", 69, 77], ["antibody titers", "PROBLEM", 128, 143], ["the enteric coronavirus", "PROBLEM", 152, 175], ["RT-PCR", "TEST", 192, 198], ["enteric coronavirus", "ANATOMY", 156, 175]]], ["The consensus of the panel was not to screen for coronavirus antibodies or RNA in clinically healthy cats being considered as blood donors.Non-Vectorborne Diseases-Testing Recommended.", [["blood", "ANATOMY", 126, 131], ["coronavirus", "ORGANISM", 49, 60], ["cats", "ORGANISM", 101, 105], ["blood", "ORGANISM_SUBSTANCE", 126, 131], ["coronavirus antibodies", "PROTEIN", 49, 71], ["coronavirus", "SPECIES", 49, 60], ["the panel", "TEST", 17, 26], ["coronavirus antibodies", "PROBLEM", 49, 71], ["RNA", "PROBLEM", 75, 78], ["blood donors", "TEST", 126, 138], ["Non-Vectorborne Diseases", "PROBLEM", 139, 163], ["Diseases", "OBSERVATION", 155, 163]]], ["FeLV Infection:Toxoplasmosis: Cats are the definitive host for Toxoplasma gondii, an intracellular coccidian parasite.", [["intracellular", "ANATOMY", 85, 98], ["FeLV Infection", "DISEASE", 0, 14], ["Toxoplasmosis", "DISEASE", 15, 28], ["Toxoplasma gondii", "DISEASE", 63, 80], ["FeLV", "ORGANISM", 0, 4], ["Cats", "ORGANISM", 30, 34], ["Toxoplasma gondii", "ORGANISM", 63, 80], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 85, 98], ["Toxoplasma gondii", "SPECIES", 63, 80], ["Toxoplasma gondii", "SPECIES", 63, 80], ["FeLV Infection", "PROBLEM", 0, 14], ["Toxoplasmosis", "PROBLEM", 15, 28], ["Toxoplasma gondii", "PROBLEM", 63, 80], ["an intracellular coccidian parasite", "PROBLEM", 82, 117], ["Infection", "OBSERVATION", 5, 14], ["Toxoplasmosis", "OBSERVATION", 15, 28], ["coccidian parasite", "OBSERVATION", 99, 117]]], ["Toxoplasma oocyts are excreted in feces, whereas tachyzoites and bradyzoites are found in tissues.", [["feces", "ANATOMY", 34, 39], ["tachyzoites", "ANATOMY", 49, 60], ["bradyzoites", "ANATOMY", 65, 76], ["tissues", "ANATOMY", 90, 97], ["Toxoplasma oocyts", "ORGANISM", 0, 17], ["feces", "ORGANISM_SUBSTANCE", 34, 39], ["tachyzoites", "ORGANISM_SUBSTANCE", 49, 60], ["bradyzoites", "CELL", 65, 76], ["tissues", "TISSUE", 90, 97], ["Toxoplasma", "SPECIES", 0, 10], ["Toxoplasma oocyts", "TEST", 0, 17], ["tachyzoites", "PROBLEM", 49, 60], ["bradyzoites", "PROBLEM", 65, 76], ["excreted", "OBSERVATION_MODIFIER", 22, 30], ["feces", "OBSERVATION_MODIFIER", 34, 39]]], ["Transmission occurs by ingestion of infected tissues or ingestion of oocyst-contaminated food or water.", [["tissues", "ANATOMY", 45, 52], ["tissues", "TISSUE", 45, 52], ["infected tissues", "PROBLEM", 36, 52], ["oocyst", "PROBLEM", 69, 75], ["infected", "OBSERVATION", 36, 44]]], ["Although T gondii antigens and DNA have been detected in healthy cats by PCR assay, transmission by blood transfusion has not been documented.", [["blood", "ANATOMY", 100, 105], ["T gondii antigens", "GENE_OR_GENE_PRODUCT", 9, 26], ["DNA", "CELLULAR_COMPONENT", 31, 34], ["cats", "ORGANISM", 65, 69], ["blood", "ORGANISM_SUBSTANCE", 100, 105], ["T gondii antigens", "PROTEIN", 9, 26], ["T gondii", "SPECIES", 9, 17], ["cats", "SPECIES", 65, 69], ["T gondii", "SPECIES", 9, 17], ["T gondii antigens", "TEST", 9, 26], ["DNA", "PROBLEM", 31, 34], ["PCR assay", "TEST", 73, 82], ["blood transfusion", "TEST", 100, 117]]], ["53 For purposes of blood safety, the consensus of the panel is that there is no indication for screening healthy potential donor cats for T gondii antigens, antibodies, or DNA.General RecommendationsTables 1 and 2 indicate those tests that are highly recommended for the screening of blood donors and tests that should be considered.", [["blood", "ANATOMY", 19, 24], ["blood", "ANATOMY", 284, 289], ["blood", "ORGANISM_SUBSTANCE", 19, 24], ["cats", "ORGANISM", 129, 133], ["T gondii antigens", "GENE_OR_GENE_PRODUCT", 138, 155], ["DNA", "CELLULAR_COMPONENT", 172, 175], ["blood", "ORGANISM_SUBSTANCE", 284, 289], ["T gondii antigens", "PROTEIN", 138, 155], ["antibodies", "PROTEIN", 157, 167], ["T gondii", "SPECIES", 138, 146], ["T gondii", "SPECIES", 138, 146], ["blood safety", "TEST", 19, 31], ["donor cats", "TEST", 123, 133], ["T gondii antigens", "TEST", 138, 155], ["antibodies", "PROBLEM", 157, 167], ["DNA", "PROBLEM", 172, 175], ["those tests", "TEST", 223, 234], ["blood donors", "TEST", 284, 296], ["tests", "TEST", 301, 306], ["no indication for", "UNCERTAINTY", 77, 94]]], ["Note that some of the diseases are restricted to certain geographic regions or have higher prevalence in certain breeds.General RecommendationsThe consensus panel hopes that its findings will lead to re-evaluation of the current infectious disease screening process for potential dog and cat donors.", [["dog", "ORGANISM", 280, 283], ["cat", "ORGANISM", 288, 291], ["donors", "ORGANISM", 292, 298], ["dog", "SPECIES", 280, 283], ["dog", "SPECIES", 280, 283], ["the diseases", "PROBLEM", 18, 30], ["diseases", "OBSERVATION", 22, 30], ["higher", "OBSERVATION_MODIFIER", 84, 90], ["certain breeds", "OBSERVATION", 105, 119], ["infectious", "OBSERVATION", 229, 239]]], ["Diagnostic laboratories should reexamine their donor screening panels, offering assays for those diseases that are of most concern in bloodborne disease transmission.Management TechniquesThe panel agreed on several management techniques designed to decrease the risk of disease transmission via blood transfusion. or tetracycline, are not acceptable in lieu of testing for blood donors.", [["blood", "ANATOMY", 295, 300], ["blood", "ANATOMY", 373, 378], ["bloodborne disease transmission", "DISEASE", 134, 165], ["tetracycline", "CHEMICAL", 317, 329], ["tetracycline", "CHEMICAL", 317, 329], ["blood", "ORGANISM_SUBSTANCE", 295, 300], ["tetracycline", "SIMPLE_CHEMICAL", 317, 329], ["blood", "ORGANISM_SUBSTANCE", 373, 378], ["Diagnostic laboratories", "TEST", 0, 23], ["their donor screening panels", "TEST", 41, 69], ["assays", "TEST", 80, 86], ["those diseases", "PROBLEM", 91, 105], ["bloodborne disease transmission", "PROBLEM", 134, 165], ["The panel", "TEST", 187, 196], ["several management techniques", "TREATMENT", 207, 236], ["disease transmission", "PROBLEM", 270, 290], ["blood transfusion", "TREATMENT", 295, 312], ["tetracycline", "TREATMENT", 317, 329], ["testing", "TEST", 361, 368], ["blood donors", "TEST", 373, 385], ["disease", "OBSERVATION", 270, 277]]], ["Heartworm and ectoparasite prophylactics are acceptable for blood donors.", [["blood", "ANATOMY", 60, 65], ["blood", "ORGANISM_SUBSTANCE", 60, 65], ["Heartworm", "TEST", 0, 9], ["ectoparasite prophylactics", "TREATMENT", 14, 40], ["blood donors", "PROBLEM", 60, 72]]], ["Initial clinicopathologic screening of the donor is advised (CBC, serum chemistries, urinalysis, and fecal examination).", [["serum", "ANATOMY", 66, 71], ["fecal", "ANATOMY", 101, 106], ["serum", "ORGANISM_SUBSTANCE", 66, 71], ["fecal", "ORGANISM_SUBDIVISION", 101, 106], ["Initial clinicopathologic screening", "TEST", 0, 35], ["CBC", "TEST", 61, 64], ["serum chemistries", "TEST", 66, 83], ["urinalysis", "TEST", 85, 95], ["fecal examination", "TEST", 101, 118], ["fecal", "ANATOMY", 101, 106]]], ["Determination of PCV is advised before each collection to ensure blood products with adequate red blood cells for transfusion and to protect the donor from anemia secondary to repeated donations.Blood Collection Procedure Recommendations1.", [["blood", "ANATOMY", 65, 70], ["red blood cells", "ANATOMY", 94, 109], ["Blood", "ANATOMY", 195, 200], ["anemia", "DISEASE", 156, 162], ["blood", "ORGANISM_SUBSTANCE", 65, 70], ["red blood cells", "CELL", 94, 109], ["Blood", "ORGANISM_SUBSTANCE", 195, 200], ["red blood cells", "CELL_TYPE", 94, 109], ["PCV", "TREATMENT", 17, 20], ["blood products", "TREATMENT", 65, 79], ["adequate red blood cells", "TREATMENT", 85, 109], ["transfusion", "TREATMENT", 114, 125], ["the donor", "PROBLEM", 141, 150], ["anemia", "PROBLEM", 156, 162], ["repeated donations", "TREATMENT", 176, 194], ["PCV", "OBSERVATION", 17, 20], ["anemia", "OBSERVATION", 156, 162]]], ["All blood for transfusion should be collected in an aseptic manner.", [["blood", "ANATOMY", 4, 9], ["blood", "ORGANISM_SUBSTANCE", 4, 9], ["transfusion", "TREATMENT", 14, 25]]], ["Before administration, the label of the blood product should be examined for the following: expiration date, donor species, product type, blood type.", [["blood", "ANATOMY", 40, 45], ["blood", "ANATOMY", 138, 143], ["blood", "ORGANISM_SUBSTANCE", 40, 45], ["blood", "ORGANISM_SUBSTANCE", 138, 143], ["the blood product", "TREATMENT", 36, 53], ["donor species", "PROBLEM", 109, 122]]], ["Before administration, the blood products should be visually inspected.", [["blood", "ANATOMY", 27, 32], ["blood", "ORGANISM_SUBSTANCE", 27, 32], ["the blood products", "TREATMENT", 23, 41]]], ["Bacterial contamination should be suspected if bag segments appear much lighter in color than the bag itself, the red blood cell mass appears purple, a zone of hemolysis is observed just above the red cell mass, clots are visible, or the plasma or supernatant fluid is murky, purple, brown or red.", [["red blood cell", "ANATOMY", 114, 128], ["red cell", "ANATOMY", 197, 205], ["clots", "ANATOMY", 212, 217], ["plasma", "ANATOMY", 238, 244], ["supernatant fluid", "ANATOMY", 248, 265], ["hemolysis", "DISEASE", 160, 169], ["red blood cell", "CELL", 114, 128], ["red cell", "CELL", 197, 205], ["clots", "ORGANISM_SUBSTANCE", 212, 217], ["plasma", "ORGANISM_SUBSTANCE", 238, 244], ["Bacterial contamination", "PROBLEM", 0, 23], ["bag segments", "PROBLEM", 47, 59], ["the bag", "TREATMENT", 94, 101], ["the red blood cell mass", "PROBLEM", 110, 133], ["purple", "PROBLEM", 142, 148], ["a zone of hemolysis", "PROBLEM", 150, 169], ["the red cell mass", "PROBLEM", 193, 210], ["clots", "PROBLEM", 212, 217], ["the plasma or supernatant fluid", "TEST", 234, 265], ["purple", "PROBLEM", 276, 282], ["red", "PROBLEM", 293, 296], ["contamination", "OBSERVATION", 10, 23], ["much lighter", "OBSERVATION_MODIFIER", 67, 79], ["red blood", "ANATOMY", 114, 123], ["cell mass", "OBSERVATION", 124, 133], ["purple", "OBSERVATION_MODIFIER", 142, 148], ["zone", "OBSERVATION_MODIFIER", 152, 156], ["hemolysis", "OBSERVATION", 160, 169], ["red cell", "OBSERVATION", 197, 205], ["mass", "OBSERVATION", 206, 210], ["clots", "OBSERVATION", 212, 217], ["supernatant", "OBSERVATION_MODIFIER", 248, 259], ["fluid", "OBSERVATION", 260, 265], ["murky", "OBSERVATION_MODIFIER", 269, 274], ["purple", "OBSERVATION_MODIFIER", 276, 282], ["brown", "OBSERVATION_MODIFIER", 284, 289], ["red", "OBSERVATION", 293, 296]]], ["In the presence of any of these findings, culture should be performed to determine whether contamination has occurred.", [["culture", "TEST", 42, 49], ["contamination", "PROBLEM", 91, 104]]], ["If the unit appears abnormal, it should not be administered.", [["abnormal", "PROBLEM", 20, 28], ["abnormal", "OBSERVATION", 20, 28]]], ["Currently, veterinarians cannot rely on screening of individual units for infectious disease because of the turnaround time and costs of available tests.", [["infectious disease", "DISEASE", 74, 92], ["infectious disease", "PROBLEM", 74, 92], ["available tests", "TEST", 137, 152]]], ["However, this model should be considered the gold standard, and we should continue to encourage industry to develop this technology.", [["this technology", "TREATMENT", 116, 131]]], ["An aliquot of plasma should be stored from each donated unit of blood.", [["plasma", "ANATOMY", 14, 20], ["blood", "ANATOMY", 64, 69], ["plasma", "ORGANISM_SUBSTANCE", 14, 20], ["blood", "ORGANISM_SUBSTANCE", 64, 69], ["An aliquot of plasma", "TREATMENT", 0, 20]]], ["This practice would allow retrospective testing in cases of suspected transfusion-associated disease transmission.Records1.", [["retrospective testing", "TEST", 26, 47], ["associated disease transmission", "PROBLEM", 82, 113], ["disease", "OBSERVATION", 93, 100]]], ["Records should be kept on all transfusions, documenting both the donor unit used and the recipient given the transfusion.", [["all transfusions", "TREATMENT", 26, 42], ["the donor unit", "TREATMENT", 61, 75], ["the recipient", "TREATMENT", 85, 98], ["the transfusion", "TREATMENT", 105, 120]]], ["A standardized transfusion form can be helpful.", [["A standardized transfusion", "TREATMENT", 0, 26]]], ["Appropriate records must be kept so that all recipients receiving blood from a given donor can be easily contacted should that donor be found to carry an infectious disease agent.", [["blood", "ANATOMY", 66, 71], ["recipients", "ORGANISM", 45, 55], ["blood", "ORGANISM_SUBSTANCE", 66, 71], ["an infectious disease agent", "PROBLEM", 151, 178], ["infectious", "OBSERVATION", 154, 164]]], ["Consent forms for owners of patients receiving transfusions should be considered.", [["patients", "ORGANISM", 28, 36], ["patients", "SPECIES", 28, 36], ["transfusions", "TREATMENT", 47, 59]]], ["These forms should provide information to the owner detailing the risks of transfusions and should indicate that blood banks and veterinarians cannot guarantee a disease-free product.SummaryThousands of blood transfusions are performed each year on dogs and cats, and the demand for blood products continues to grow.", [["blood", "ANATOMY", 113, 118], ["blood", "ANATOMY", 203, 208], ["blood", "ANATOMY", 283, 288], ["blood", "ORGANISM_SUBSTANCE", 113, 118], ["blood", "ORGANISM_SUBSTANCE", 203, 208], ["dogs", "ORGANISM", 249, 253], ["cats", "ORGANISM", 258, 262], ["blood", "ORGANISM_SUBSTANCE", 283, 288], ["dogs", "SPECIES", 249, 253], ["cats", "SPECIES", 258, 262], ["transfusions", "TREATMENT", 75, 87], ["blood banks", "TEST", 113, 124], ["a disease-free product", "PROBLEM", 160, 182], ["blood transfusions", "TREATMENT", 203, 221], ["cats", "TREATMENT", 258, 262], ["blood products", "TREATMENT", 283, 297]]], ["Risks associated with transfusions include the risk of disease transmission.", [["transfusions", "TREATMENT", 22, 34], ["disease transmission", "PROBLEM", 55, 75], ["disease", "OBSERVATION", 55, 62]]], ["Appropriate screening of blood donors for bloodborne infectious disease agents should be performed to lessen this risk.", [["blood", "ANATOMY", 25, 30], ["bloodborne infectious disease", "DISEASE", 42, 71], ["blood", "ORGANISM_SUBSTANCE", 25, 30], ["blood donors", "TREATMENT", 25, 37], ["bloodborne infectious disease agents", "TREATMENT", 42, 78]]], ["Geographic restrictions of disease, breed predilection, and documentation of actual disease transmission by transfusion all are factors that might need to be considered when making a decision on what screening program to use.", [["disease", "PROBLEM", 27, 34], ["breed predilection", "PROBLEM", 36, 54], ["actual disease transmission", "PROBLEM", 77, 104], ["transfusion", "TREATMENT", 108, 119], ["disease", "OBSERVATION", 27, 34]]], ["In addition, factors involving general health care and management of blood donors should be employed to further ensure blood safety.SummaryFootnote a Canine Snap 3DX Test, IDEXX Laboratories Inc, One IDEXX Drive, Westbrook, ME", [["blood", "ANATOMY", 69, 74], ["blood", "ANATOMY", 119, 124], ["blood", "ORGANISM_SUBSTANCE", 69, 74], ["blood", "ORGANISM_SUBSTANCE", 119, 124], ["general health care", "TREATMENT", 31, 50], ["management of blood donors", "TREATMENT", 55, 81], ["blood safety", "TEST", 119, 131]]]], "0e50da92e79541b109103e9de56811e35a8475b0": [["Diagnostic Methodology of Pulmonary ComplicationsIdeally, any respiratory/pulmonary complication observed after HSCT must be evaluated following a predetermined institutional protocol (Lucena et al. 2014) , which should include:Diagnostic Methodology of Pulmonary Complications1.", [["Pulmonary", "ANATOMY", 26, 35], ["respiratory", "ANATOMY", 62, 73], ["pulmonary", "ANATOMY", 74, 83], ["Pulmonary", "ANATOMY", 254, 263], ["respiratory/pulmonary complication", "DISEASE", 62, 96], ["Pulmonary", "ORGAN", 26, 35], ["pulmonary", "ORGAN", 74, 83], ["any respiratory/pulmonary complication", "PROBLEM", 58, 96], ["HSCT", "TREATMENT", 112, 116], ["a predetermined institutional protocol", "TREATMENT", 145, 183], ["Pulmonary Complications", "PROBLEM", 254, 277], ["Pulmonary", "ANATOMY", 26, 35], ["pulmonary", "ANATOMY", 74, 83], ["complication", "OBSERVATION", 84, 96], ["Pulmonary", "ANATOMY", 254, 263], ["Complications", "OBSERVATION", 264, 277]]], ["Noninvasive tests: Blood samples for culture and antigen determination, sputum culture, nasopharyngeal swabs testing CMV, respiratory syncytial virus (RSV), Legionella, Pneumocystis jirovecii (PJ), parainfluenza virus (PIV), adenovirus (ADV), as well as urinary antigen tests and chest x-ray.", [["Blood samples", "ANATOMY", 19, 32], ["sputum", "ANATOMY", 72, 78], ["nasopharyngeal swabs", "ANATOMY", 88, 108], ["urinary", "ANATOMY", 254, 261], ["respiratory syncytial virus", "DISEASE", 122, 149], ["Pneumocystis jirovecii (PJ), parainfluenza virus", "DISEASE", 169, 217], ["Blood samples", "ORGANISM_SUBSTANCE", 19, 32], ["nasopharyngeal swabs", "MULTI-TISSUE_STRUCTURE", 88, 108], ["CMV", "ORGANISM", 117, 120], ["respiratory syncytial virus", "ORGANISM", 122, 149], ["RSV", "ORGANISM", 151, 154], ["Pneumocystis jirovecii", "ORGANISM", 169, 191], ["PJ", "ORGANISM", 193, 195], ["parainfluenza virus", "ORGANISM", 198, 217], ["PIV", "ORGANISM", 219, 222], ["adenovirus", "ORGANISM", 225, 235], ["urinary antigen", "GENE_OR_GENE_PRODUCT", 254, 269], ["respiratory syncytial virus", "SPECIES", 122, 149], ["Pneumocystis jirovecii", "SPECIES", 169, 191], ["parainfluenza virus", "SPECIES", 198, 217], ["CMV", "SPECIES", 117, 120], ["respiratory syncytial virus", "SPECIES", 122, 149], ["RSV", "SPECIES", 151, 154], ["Pneumocystis jirovecii", "SPECIES", 169, 191], ["parainfluenza virus", "SPECIES", 198, 217], ["PIV", "SPECIES", 219, 222], ["adenovirus", "SPECIES", 225, 235], ["ADV", "SPECIES", 237, 240], ["Noninvasive tests", "TEST", 0, 17], ["Blood samples", "TEST", 19, 32], ["culture", "TEST", 37, 44], ["antigen determination", "TEST", 49, 70], ["sputum culture", "TEST", 72, 86], ["nasopharyngeal swabs testing", "TEST", 88, 116], ["CMV", "TEST", 117, 120], ["respiratory syncytial virus", "PROBLEM", 122, 149], ["RSV", "TEST", 151, 154], ["Legionella", "PROBLEM", 157, 167], ["Pneumocystis jirovecii", "PROBLEM", 169, 191], ["parainfluenza virus", "PROBLEM", 198, 217], ["adenovirus", "PROBLEM", 225, 235], ["urinary antigen tests", "TEST", 254, 275], ["chest x-ray", "TEST", 280, 291], ["nasopharyngeal", "ANATOMY", 88, 102], ["respiratory syncytial", "ANATOMY", 122, 143], ["Pneumocystis jirovecii", "OBSERVATION", 169, 191], ["parainfluenza virus", "OBSERVATION", 198, 217], ["urinary", "ANATOMY", 254, 261], ["chest", "ANATOMY", 280, 285]]], ["If negative \u2192 empirical treatment (variable behavior; some centers start empirical treatment before the BAL, but many others start the treatment after BAL).", [["empirical treatment", "TREATMENT", 14, 33], ["variable behavior", "PROBLEM", 35, 52], ["empirical treatment", "TREATMENT", 73, 92], ["the BAL", "TEST", 100, 107], ["the treatment", "TREATMENT", 131, 144]]], ["If no response in a maximum of 2-3 days (or if galactomannan (GM) +) \u2192 (a) High-resolution chest-computed tomography (HRCTPulmonary Edema Due to Fluid OverloadDespite not being included in most classifications of pulmonary complications after HSCT, pulmonary edema (PE) as a consequence of a fluid overload (FO) is extremely frequent (Rond\u00f3n et al. 2017Clinical ManifestationsCharacterized by development around day +20 after HSCT of fever and nonproductive cough, dyspnea, tachypnea, hypoxemia, rales, and diffuse alveolar or interstitial infiltrates on x-rays or CT scans.DiagnosisAll of the following must be present for accepting the IPS diagnosis:PathogenesisThe pathophysiology of IPS is complex.", [["pulmonary", "ANATOMY", 213, 222], ["pulmonary", "ANATOMY", 249, 258], ["fluid", "ANATOMY", 292, 297], ["alveolar", "ANATOMY", 515, 523], ["interstitial infiltrates", "ANATOMY", 527, 551], ["GM", "CHEMICAL", 62, 64], ["Edema", "DISEASE", 132, 137], ["pulmonary complications", "DISEASE", 213, 236], ["pulmonary edema", "DISEASE", 249, 264], ["PE", "DISEASE", 266, 268], ["fluid overload", "DISEASE", 292, 306], ["fever", "DISEASE", 434, 439], ["cough", "DISEASE", 458, 463], ["dyspnea", "DISEASE", 465, 472], ["tachypnea", "DISEASE", 474, 483], ["hypoxemia", "DISEASE", 485, 494], ["IPS", "DISEASE", 687, 690], ["pulmonary", "ORGAN", 213, 222], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 249, 264], ["alveolar", "MULTI-TISSUE_STRUCTURE", 515, 523], ["galactomannan", "TEST", 47, 60], ["computed tomography", "TEST", 97, 116], ["HRCTPulmonary Edema", "PROBLEM", 118, 137], ["Fluid OverloadDespite", "PROBLEM", 145, 166], ["pulmonary complications", "PROBLEM", 213, 236], ["HSCT", "PROBLEM", 243, 247], ["pulmonary edema", "PROBLEM", 249, 264], ["PE", "PROBLEM", 266, 268], ["a fluid overload", "PROBLEM", 290, 306], ["fever", "PROBLEM", 434, 439], ["nonproductive cough", "PROBLEM", 444, 463], ["dyspnea", "PROBLEM", 465, 472], ["tachypnea", "PROBLEM", 474, 483], ["hypoxemia", "PROBLEM", 485, 494], ["rales", "PROBLEM", 496, 501], ["diffuse alveolar or interstitial infiltrates", "PROBLEM", 507, 551], ["x-rays", "TEST", 555, 561], ["CT scans", "TEST", 565, 573], ["chest", "ANATOMY", 91, 96], ["Edema", "OBSERVATION", 132, 137], ["Fluid", "OBSERVATION", 145, 150], ["pulmonary", "ANATOMY", 213, 222], ["complications", "OBSERVATION", 223, 236], ["pulmonary", "ANATOMY", 249, 258], ["edema", "OBSERVATION", 259, 264], ["PE", "OBSERVATION", 266, 268], ["fluid overload", "OBSERVATION", 292, 306], ["nonproductive", "OBSERVATION_MODIFIER", 444, 457], ["cough", "OBSERVATION", 458, 463], ["hypoxemia", "OBSERVATION", 485, 494], ["rales", "OBSERVATION", 496, 501], ["diffuse", "OBSERVATION_MODIFIER", 507, 514], ["alveolar", "ANATOMY_MODIFIER", 515, 523], ["interstitial", "ANATOMY_MODIFIER", 527, 539], ["infiltrates", "OBSERVATION", 540, 551], ["IPS", "ANATOMY", 687, 690]]], ["Data generated using experimental models support that IPS is a process in which the lung is susceptible to two distinct but interrelated pathways of immune-mediated injury: a T-cell axis and an inflammatory cytokine axis.", [["lung", "ANATOMY", 84, 88], ["T-cell", "ANATOMY", 175, 181], ["lung", "ORGAN", 84, 88], ["T-cell", "CELL", 175, 181], ["inflammatory cytokine", "PROTEIN", 194, 215], ["experimental models support", "TREATMENT", 21, 48], ["immune-mediated injury", "PROBLEM", 149, 171], ["an inflammatory cytokine axis", "PROBLEM", 191, 220], ["lung", "ANATOMY", 84, 88], ["injury", "OBSERVATION", 165, 171], ["inflammatory", "OBSERVATION_MODIFIER", 194, 206], ["cytokine axis", "OBSERVATION", 207, 220]]], ["These distinct but related pathways of inflammation culminate in the recruitment of immune cells to the lung leading to tissue damage and dysfunction (Cooke and Yanik 2016) Incidence -The strict methodology required to establish IPS diagnosis and the increased use of RIC have reduced its incidence of 20% to 25% observed 20 years ago (at that time IPS was called idiopathic pneumonia) -This reduction runs in parallel of the improvement in the diagnostic methodologies to detect infectious pathogens.", [["immune cells", "ANATOMY", 84, 96], ["lung", "ANATOMY", 104, 108], ["tissue", "ANATOMY", 120, 126], ["inflammation", "DISEASE", 39, 51], ["tissue damage", "DISEASE", 120, 133], ["idiopathic pneumonia", "DISEASE", 364, 384], ["immune cells", "CELL", 84, 96], ["lung", "ORGAN", 104, 108], ["tissue", "TISSUE", 120, 126], ["immune cells", "CELL_TYPE", 84, 96], ["inflammation", "PROBLEM", 39, 51], ["immune cells", "PROBLEM", 84, 96], ["tissue damage", "PROBLEM", 120, 133], ["dysfunction", "PROBLEM", 138, 149], ["IPS diagnosis", "TEST", 229, 242], ["RIC", "TREATMENT", 268, 271], ["idiopathic pneumonia", "PROBLEM", 364, 384], ["the diagnostic methodologies", "TEST", 441, 469], ["infectious pathogens", "PROBLEM", 480, 500], ["inflammation", "OBSERVATION", 39, 51], ["recruitment", "OBSERVATION_MODIFIER", 69, 80], ["immune cells", "OBSERVATION", 84, 96], ["lung", "ANATOMY", 104, 108], ["tissue", "ANATOMY", 120, 126], ["damage", "OBSERVATION", 127, 133], ["increased", "OBSERVATION_MODIFIER", 251, 260], ["pneumonia", "OBSERVATION", 375, 384], ["infectious", "OBSERVATION_MODIFIER", 480, 490]]], ["However, the frequent absence of response to the specific treatment against a detected pathogen suggests that the true incidence of IPS may be underestimated -Nowadays: <10% of allo-HSCT (8% after MAC; 2% after RIC) Timing -Within first 120 days after BMT, usually observed between days +18 and +21 (20 years ago: around days +40 to +50) -Late IPS can be observed but they are exceptional (Thompson et al. 2017) Risk factors (from Cooke and Yanik 2016) Older age / Karnofsky index <90 / higher interval diagnosis-HSCT MAC or TBI (\u226512 Gy) / HLA disparity / GVHD prophylaxis with MTX Acute GVHD/previous viral infection / other malignancies than leukemiaTreatment and PrognosisSupportive measures -Supplemental O 2 therapy -Mechanical ventilation (invasive or not [high-flow nasal O 2 , CPAP]) -Empiric broad-spectrum antimicrobials -Strict control of fluids balance/hemofiltration Specific treatment As mentioned, lung injury in IPS can occur through two pathways, the TNF-alfa/LPS dependent and IL6/IL17 dependent (Cooke and Yanik 2016) ; consequently, treatment options are focused in these directions \u2022 Methyl-PDN \u2264 2 mg/kg/d; if not clear response, consider as soon as possible:Treatment and Prognosis\u2022 Anti-TNF\u03b1: Etanercept 0.4 mg/kg twice weekly (maximum of 8 doses) + systemic steroids (2 mg/ kg/d).", [["malignancies", "ANATOMY", 626, 638], ["lung", "ANATOMY", 913, 917], ["IPS", "DISEASE", 132, 135], ["TBI", "DISEASE", 525, 528], ["GVHD", "DISEASE", 556, 560], ["MTX", "CHEMICAL", 578, 581], ["GVHD", "DISEASE", 588, 592], ["viral infection", "DISEASE", 602, 617], ["malignancies", "DISEASE", 626, 638], ["leukemiaTreatment", "DISEASE", 644, 661], ["lung injury", "DISEASE", 913, 924], ["LPS", "CHEMICAL", 977, 980], ["Methyl-PDN", "CHEMICAL", 1105, 1115], ["Etanercept", "CHEMICAL", 1217, 1227], ["steroids", "CHEMICAL", 1283, 1291], ["MTX", "CHEMICAL", 578, 581], ["O 2", "CHEMICAL", 709, 712], ["O 2", "CHEMICAL", 779, 782], ["Methyl-PDN", "CHEMICAL", 1105, 1115], ["steroids", "CHEMICAL", 1283, 1291], ["MTX", "SIMPLE_CHEMICAL", 578, 581], ["malignancies", "CANCER", 626, 638], ["lung", "ORGAN", 913, 917], ["TNF-alfa", "GENE_OR_GENE_PRODUCT", 968, 976], ["LPS", "SIMPLE_CHEMICAL", 977, 980], ["IL6", "GENE_OR_GENE_PRODUCT", 995, 998], ["IL17", "GENE_OR_GENE_PRODUCT", 999, 1003], ["Methyl-PDN", "SIMPLE_CHEMICAL", 1105, 1115], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 1211, 1215], ["Etanercept", "SIMPLE_CHEMICAL", 1217, 1227], ["TNF", "PROTEIN", 968, 971], ["IL6", "PROTEIN", 995, 998], ["IL17", "PROTEIN", 999, 1003], ["TNF", "PROTEIN", 1211, 1214], ["the specific treatment", "TREATMENT", 45, 67], ["a detected pathogen", "PROBLEM", 76, 95], ["allo-HSCT", "TREATMENT", 177, 186], ["MAC", "TEST", 197, 200], ["Karnofsky index", "TEST", 465, 480], ["HSCT MAC", "PROBLEM", 513, 521], ["TBI", "PROBLEM", 525, 528], ["HLA disparity", "PROBLEM", 540, 553], ["GVHD prophylaxis", "TREATMENT", 556, 572], ["MTX", "TREATMENT", 578, 581], ["Acute GVHD", "PROBLEM", 582, 592], ["previous viral infection", "PROBLEM", 593, 617], ["other malignancies", "PROBLEM", 620, 638], ["leukemiaTreatment", "TREATMENT", 644, 661], ["PrognosisSupportive measures", "TREATMENT", 666, 694], ["Supplemental O 2 therapy", "TREATMENT", 696, 720], ["Mechanical ventilation", "TREATMENT", 722, 744], ["high-flow nasal O 2", "TREATMENT", 763, 782], ["CPAP", "TREATMENT", 785, 789], ["Empiric broad-spectrum antimicrobials", "TREATMENT", 793, 830], ["fluids balance", "TREATMENT", 850, 864], ["hemofiltration", "TREATMENT", 865, 879], ["Specific treatment", "TREATMENT", 880, 898], ["lung injury in IPS", "PROBLEM", 913, 931], ["the TNF-alfa/LPS dependent", "TREATMENT", 964, 990], ["Methyl-PDN \u2264", "TREATMENT", 1105, 1117], ["Anti-TNF", "TREATMENT", 1206, 1214], ["Etanercept", "TREATMENT", 1217, 1227], ["systemic steroids", "TREATMENT", 1274, 1291], ["GVHD", "OBSERVATION", 556, 560], ["GVHD", "OBSERVATION", 588, 592], ["viral", "OBSERVATION_MODIFIER", 602, 607], ["infection", "OBSERVATION", 608, 617], ["lung", "ANATOMY", 913, 917], ["injury", "OBSERVATION", 918, 924]]], ["The randomized study of etanercept + steroids vs. steroids + placebo was terminated prematurely due to slow accrual.", [["etanercept", "CHEMICAL", 24, 34], ["steroids", "CHEMICAL", 37, 45], ["steroids", "CHEMICAL", 50, 58], ["steroids", "CHEMICAL", 37, 45], ["steroids", "CHEMICAL", 50, 58], ["etanercept + steroids", "SIMPLE_CHEMICAL", 24, 45], ["steroids", "SIMPLE_CHEMICAL", 50, 58], ["The randomized study", "TEST", 0, 20], ["etanercept + steroids", "TREATMENT", 24, 45], ["steroids", "TREATMENT", 50, 58], ["placebo", "TREATMENT", 61, 68], ["slow accrual", "PROBLEM", 103, 115]]], ["In the limited number of patients examined, there were no differences in response rates (\u224860%) at day +28.", [["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33], ["response rates", "TEST", 73, 87], ["no", "UNCERTAINTY", 55, 57]]], ["In a phase II trial in children, the CR rate was 71% and 1 y survival was 63% .", [["children", "ORGANISM", 23, 31], ["children", "SPECIES", 23, 31], ["the CR rate", "TEST", 33, 44]]], ["This combination has also been shown to be effective in exceptional cases of late IPS with a 42% of CR and a 2 y survival of 62% among responders (Thompson et al. 2017Diffuse Alveolar Hemorrhage (DAH)Diffuse alveolar hemorrhage (DAH) is a relevant cause of acute respiratory failure that occurs in 2-14% of recipients, with similar incidence in both auto-and allo-HSCT recipients (Afessa et al. 2002a) .Diffuse Alveolar Hemorrhage (DAH)DAH is probably a consequence of damage to the alveolar capillary basement membrane (see Chap.", [["alveolar", "ANATOMY", 208, 216], ["respiratory", "ANATOMY", 263, 274], ["alveolar capillary basement membrane", "ANATOMY", 483, 519], ["Alveolar Hemorrhage", "DISEASE", 175, 194], ["DAH", "DISEASE", 196, 199], ["Diffuse alveolar hemorrhage", "DISEASE", 200, 227], ["DAH", "DISEASE", 229, 232], ["respiratory failure", "DISEASE", 263, 282], ["Alveolar Hemorrhage", "DISEASE", 411, 430], ["DAH", "DISEASE", 432, 435], ["DAH", "DISEASE", 436, 439], ["alveolar", "MULTI-TISSUE_STRUCTURE", 208, 216], ["recipients", "ORGANISM", 307, 317], ["alveolar capillary", "TISSUE", 483, 501], ["basement membrane", "CELLULAR_COMPONENT", 502, 519], ["late IPS", "PROBLEM", 77, 85], ["CR", "TEST", 100, 102], ["Diffuse Alveolar Hemorrhage", "PROBLEM", 167, 194], ["DAH", "PROBLEM", 196, 199], ["Diffuse alveolar hemorrhage", "PROBLEM", 200, 227], ["DAH", "PROBLEM", 229, 232], ["acute respiratory failure", "PROBLEM", 257, 282], ["allo-HSCT recipients", "TREATMENT", 359, 379], ["Diffuse Alveolar Hemorrhage (DAH)DAH", "PROBLEM", 403, 439], ["damage to the alveolar capillary basement membrane", "PROBLEM", 469, 519], ["shown to be", "UNCERTAINTY", 31, 42], ["effective", "OBSERVATION_MODIFIER", 43, 52], ["Alveolar", "ANATOMY_MODIFIER", 175, 183], ["Hemorrhage", "OBSERVATION", 184, 194], ["DAH", "OBSERVATION_MODIFIER", 196, 199], ["Diffuse", "OBSERVATION_MODIFIER", 200, 207], ["alveolar", "ANATOMY_MODIFIER", 208, 216], ["hemorrhage", "OBSERVATION", 217, 227], ["relevant cause of", "UNCERTAINTY", 239, 256], ["acute", "OBSERVATION_MODIFIER", 257, 262], ["respiratory failure", "OBSERVATION", 263, 282], ["Alveolar", "ANATOMY_MODIFIER", 411, 419], ["Hemorrhage", "OBSERVATION", 420, 430], ["probably a consequence of", "UNCERTAINTY", 443, 468], ["damage", "OBSERVATION", 469, 475], ["alveolar", "ANATOMY_MODIFIER", 483, 491], ["capillary", "ANATOMY_MODIFIER", 492, 501], ["basement", "ANATOMY_MODIFIER", 502, 510]]], ["It is difficult to differentiate a true DAH from the alveolar hemorrhage associated with an infection (Majhail et al. 2006 ).Clinical manifestationsUsually observed within the first month after HSCT (a median of 23 days), often during the pre-engraftment phase; however, later onset is encountered in up to 42% of cases The clinical manifestations are those of all IPS.", [["alveolar", "ANATOMY", 53, 61], ["DAH", "DISEASE", 40, 43], ["alveolar hemorrhage", "DISEASE", 53, 72], ["infection", "DISEASE", 92, 101], ["alveolar", "ORGAN", 53, 61], ["a true DAH", "PROBLEM", 33, 43], ["the alveolar hemorrhage", "PROBLEM", 49, 72], ["an infection", "PROBLEM", 89, 101], ["Clinical manifestations", "PROBLEM", 125, 148], ["all IPS", "TREATMENT", 361, 368], ["true", "OBSERVATION_MODIFIER", 35, 39], ["DAH", "OBSERVATION", 40, 43], ["alveolar", "ANATOMY", 53, 61], ["hemorrhage", "OBSERVATION", 62, 72], ["infection", "OBSERVATION", 92, 101]]], ["Hemoptysis is exceptional Diagnosis Based on BAL: Same criteria as IPS plus a differential characteristic; the progressive bloodier return of BAL fluid aliquots, in at least three segmental bronchi, indicating the presence of blood in the alveoli (or 20% hemosiderin-laden macrophage, although their absence does not exclude the diagnosis as it can take 72 h to appear).", [["BAL fluid", "ANATOMY", 142, 151], ["bronchi", "ANATOMY", 190, 197], ["blood", "ANATOMY", 226, 231], ["alveoli", "ANATOMY", 239, 246], ["hemosiderin-laden macrophage", "ANATOMY", 255, 283], ["Hemoptysis", "DISEASE", 0, 10], ["bronchi", "MULTI-TISSUE_STRUCTURE", 190, 197], ["blood", "ORGANISM_SUBSTANCE", 226, 231], ["alveoli", "MULTI-TISSUE_STRUCTURE", 239, 246], ["hemosiderin", "SIMPLE_CHEMICAL", 255, 266], ["macrophage", "CELL", 273, 283], ["Hemoptysis", "PROBLEM", 0, 10], ["the progressive bloodier return of BAL fluid aliquots", "PROBLEM", 107, 160], ["blood in the alveoli", "PROBLEM", 226, 246], ["20% hemosiderin-laden macrophage", "PROBLEM", 251, 283], ["progressive", "OBSERVATION_MODIFIER", 111, 122], ["bloodier", "OBSERVATION_MODIFIER", 123, 131], ["BAL fluid aliquots", "OBSERVATION", 142, 160], ["segmental", "ANATOMY_MODIFIER", 180, 189], ["bronchi", "ANATOMY", 190, 197], ["blood", "OBSERVATION", 226, 231], ["alveoli", "ANATOMY", 239, 246], ["laden macrophage", "OBSERVATION", 267, 283]]], ["Note: DAH can have infectious or noninfectious etiologies (Majhail et al. 2006 ) Risk factors -Higher incidence after TBI and high-dose CY -Similar incidence among MAC and RIC -There is no correlation with the platelet counts Differential diagnosis with -Classic IPS: Very difficult, only by means of BAL.", [["platelet", "ANATOMY", 210, 218], ["DAH", "DISEASE", 6, 9], ["TBI", "DISEASE", 118, 121], ["CY", "CHEMICAL", 136, 138], ["platelet", "CELL", 210, 218], ["DAH", "PROBLEM", 6, 9], ["noninfectious etiologies", "PROBLEM", 33, 57], ["TBI", "TEST", 118, 121], ["high-dose CY", "TREATMENT", 126, 138], ["the platelet counts", "TEST", 206, 225], ["BAL", "TEST", 301, 304], ["DAH", "OBSERVATION", 6, 9], ["infectious", "OBSERVATION_MODIFIER", 19, 29], ["noninfectious", "OBSERVATION_MODIFIER", 33, 46]]], ["IPS usually appears after the engraftment, predominates in allo-HSCT, does not respond to steroids, and progresses to fibrosis in 85% of cases (only 15% on DAH).", [["steroids", "CHEMICAL", 90, 98], ["fibrosis", "DISEASE", 118, 126], ["DAH", "DISEASE", 156, 159], ["steroids", "CHEMICAL", 90, 98], ["the engraftment", "TREATMENT", 26, 41], ["allo-HSCT", "TREATMENT", 59, 68], ["steroids", "TREATMENT", 90, 98], ["fibrosis", "PROBLEM", 118, 126], ["DAH", "PROBLEM", 156, 159], ["engraftment", "OBSERVATION", 30, 41], ["fibrosis", "OBSERVATION", 118, 126]]], ["Note: Noninfectious DAH falls under the \"diagnostic umbrella\" of IPS (Panoskaltsis-Mortari et al. 2011) -PERDS: Almost impossible except for LBA progressively bloodier -Pulmonary hemorrhage: By FOB, no blood is seen in DAH -DAH associated with infection: Impossible without detection of the pathogen (Majhail et al. 2006)Treatment and Prognosis of DAHTreatment -Although systematically treated with high doses of methyl-PDN (250-500 mg q6h \u00d7 5 days, followed by tapered dosage over 2-4 weeks) and aminocaproic acid (ACA), the overall response to this treatment is disappointing (Rathi et al. 2015 ) -A recent study seems to show that the best treatment is to use low steroid doses (\u2264250 mg/d) \u00b1 ACA (Rathi et al. 2015 ) -Factor VIIa addition does not appear to improve the results obtained with PDN (Elinoff et al. 2014 ) -Try to avoid mechanical ventilation by means of CPAP Prognosis -Poor: Overall mortality as high as 85% by day 100 (Rathi et al. 2015) -Less than 15% of patients die as a direct consequence of DAH, but the frequent evolution to MOF increases mortality to >60% (30% in auto and 70% in allo-HSCT) (Afessa et al. 2002b ) -DAH that appear early after allo-HSCT (32% early vs. 70% late) or after auto-HSCT have a better prognosis (Afessa et al. 2002b; Majhail et al. 2006) The same as cGVHD but specifically involving the lung (Cooke et al. 2017) .", [["Pulmonary", "ANATOMY", 169, 178], ["blood", "ANATOMY", 202, 207], ["lung", "ANATOMY", 1339, 1343], ["DAH", "DISEASE", 20, 23], ["Pulmonary hemorrhage", "DISEASE", 169, 189], ["DAH", "DISEASE", 219, 222], ["DAH", "DISEASE", 224, 227], ["infection", "DISEASE", 244, 253], ["methyl-PDN", "CHEMICAL", 413, 423], ["aminocaproic acid", "CHEMICAL", 497, 514], ["ACA", "CHEMICAL", 516, 519], ["steroid", "CHEMICAL", 667, 674], ["PDN", "DISEASE", 795, 798], ["DAH", "DISEASE", 1015, 1018], ["MOF", "DISEASE", 1050, 1053], ["DAH", "DISEASE", 1141, 1144], ["cGVHD", "DISEASE", 1302, 1307], ["methyl-PDN", "CHEMICAL", 413, 423], ["aminocaproic acid", "CHEMICAL", 497, 514], ["steroid", "CHEMICAL", 667, 674], ["blood", "ORGANISM_SUBSTANCE", 202, 207], ["methyl-PDN", "SIMPLE_CHEMICAL", 413, 423], ["aminocaproic acid", "SIMPLE_CHEMICAL", 497, 514], ["ACA", "SIMPLE_CHEMICAL", 516, 519], ["steroid", "SIMPLE_CHEMICAL", 667, 674], ["Factor VIIa", "GENE_OR_GENE_PRODUCT", 721, 732], ["patients", "ORGANISM", 975, 983], ["lung", "ORGAN", 1339, 1343], ["Factor VIIa", "PROTEIN", 721, 732], ["patients", "SPECIES", 975, 983], ["Noninfectious DAH falls", "PROBLEM", 6, 29], ["IPS", "PROBLEM", 65, 68], ["LBA progressively bloodier", "PROBLEM", 141, 167], ["Pulmonary hemorrhage", "PROBLEM", 169, 189], ["blood", "PROBLEM", 202, 207], ["DAH", "PROBLEM", 219, 222], ["DAH", "PROBLEM", 224, 227], ["infection", "PROBLEM", 244, 253], ["the pathogen", "PROBLEM", 287, 299], ["DAHTreatment", "TREATMENT", 348, 360], ["methyl-PDN", "TREATMENT", 413, 423], ["aminocaproic acid (ACA)", "TREATMENT", 497, 520], ["this treatment", "TREATMENT", 546, 560], ["A recent study", "TEST", 600, 614], ["low steroid doses", "TREATMENT", 663, 680], ["ACA (Rathi et", "TREATMENT", 695, 708], ["Factor VIIa", "TREATMENT", 721, 732], ["mechanical ventilation", "TREATMENT", 836, 858], ["CPAP", "TREATMENT", 871, 875], ["DAH", "PROBLEM", 1015, 1018], ["MOF increases mortality", "PROBLEM", 1050, 1073], ["auto", "TEST", 1090, 1094], ["allo-HSCT", "TREATMENT", 1106, 1115], ["DAH", "PROBLEM", 1141, 1144], ["allo-HSCT", "TREATMENT", 1169, 1178], ["Noninfectious", "OBSERVATION_MODIFIER", 6, 19], ["DAH", "OBSERVATION", 20, 23], ["Pulmonary", "ANATOMY", 169, 178], ["hemorrhage", "OBSERVATION", 179, 189], ["DAH", "OBSERVATION", 219, 222], ["DAH", "OBSERVATION", 224, 227], ["infection", "OBSERVATION", 244, 253], ["DAH", "OBSERVATION", 1015, 1018], ["cGVHD", "OBSERVATION", 1302, 1307], ["lung", "ANATOMY", 1339, 1343]]], ["Its course may be aggravated by respiratory infections, viral infections, and gastroesophageal reflux Timing and incidence -Average starting period: 12 (3-24) months -Incidence: 3% at 2 years in the longest series (Arora et al. 2016) ; 11% in a prospective study (Bergeron et al. 2018 ) Clinical manifestations -Variable clinical course, usually insidious onset with progressive deterioration.", [["respiratory", "ANATOMY", 32, 43], ["gastroesophageal", "ANATOMY", 78, 94], ["respiratory infections", "DISEASE", 32, 54], ["viral infections", "DISEASE", 56, 72], ["gastroesophageal reflux", "DISEASE", 78, 101], ["respiratory infections", "PROBLEM", 32, 54], ["viral infections", "PROBLEM", 56, 72], ["gastroesophageal reflux Timing", "PROBLEM", 78, 108], ["a prospective study", "TEST", 243, 262], ["progressive deterioration", "PROBLEM", 367, 392], ["may be", "UNCERTAINTY", 11, 17], ["respiratory", "ANATOMY", 32, 43], ["infections", "OBSERVATION", 44, 54], ["viral", "OBSERVATION_MODIFIER", 56, 61], ["infections", "OBSERVATION", 62, 72], ["gastroesophageal", "ANATOMY", 78, 94], ["reflux", "OBSERVATION", 95, 101], ["progressive", "OBSERVATION_MODIFIER", 367, 378], ["deterioration", "OBSERVATION", 379, 392]]], ["Sometimes can present as an acute, fulminating course -Progressive breathlessness, nonproductive cough, and wheezing, although some asymptomatic cases are only detected by PFTs. -It is necessary to carry out PFT every 3 m in the first year after HSCT for an early detection a -In >75% of the BOS, there are chronic GVHD in other locations (continued)Late-Onset Noninfectious Pulmonary Complications (LONIPC)In addition to late-onset IPS mentioned before and some other exceptional complications (thromboembolisms, pneumomediastinum), there are two forms of chronic pulmonary dysfunction commonly observed in patients surviving more than 100 days after allo-HSCT.", [["Pulmonary", "ANATOMY", 375, 384], ["pulmonary", "ANATOMY", 565, 574], ["breathlessness", "DISEASE", 67, 81], ["cough", "DISEASE", 97, 102], ["wheezing", "DISEASE", 108, 116], ["BOS", "DISEASE", 292, 295], ["GVHD", "DISEASE", 315, 319], ["Noninfectious Pulmonary Complications", "DISEASE", 361, 398], ["IPS", "DISEASE", 433, 436], ["thromboembolisms", "DISEASE", 496, 512], ["pneumomediastinum", "DISEASE", 514, 531], ["chronic pulmonary dysfunction", "DISEASE", 557, 586], ["Pulmonary", "ORGAN", 375, 384], ["pulmonary", "ORGAN", 565, 574], ["patients", "ORGANISM", 608, 616], ["patients", "SPECIES", 608, 616], ["Progressive breathlessness", "PROBLEM", 55, 81], ["nonproductive cough", "PROBLEM", 83, 102], ["wheezing", "PROBLEM", 108, 116], ["some asymptomatic cases", "PROBLEM", 127, 150], ["an early detection", "TEST", 255, 273], ["chronic GVHD in other locations", "PROBLEM", 307, 338], ["late-onset IPS", "TREATMENT", 422, 436], ["some other exceptional complications", "PROBLEM", 458, 494], ["thromboembolisms", "PROBLEM", 496, 512], ["pneumomediastinum", "PROBLEM", 514, 531], ["chronic pulmonary dysfunction", "PROBLEM", 557, 586], ["allo-HSCT", "TREATMENT", 652, 661], ["acute", "OBSERVATION_MODIFIER", 28, 33], ["Progressive", "OBSERVATION_MODIFIER", 55, 66], ["breathlessness", "OBSERVATION", 67, 81], ["nonproductive", "OBSERVATION_MODIFIER", 83, 96], ["cough", "OBSERVATION", 97, 102], ["chronic", "OBSERVATION_MODIFIER", 307, 314], ["GVHD", "OBSERVATION", 315, 319], ["Onset", "OBSERVATION_MODIFIER", 355, 360], ["Noninfectious", "OBSERVATION_MODIFIER", 361, 374], ["Pulmonary", "ANATOMY", 375, 384], ["Complications", "OBSERVATION", 385, 398], ["exceptional", "OBSERVATION_MODIFIER", 469, 480], ["complications", "OBSERVATION", 481, 494], ["pneumomediastinum", "OBSERVATION", 514, 531], ["chronic", "OBSERVATION_MODIFIER", 557, 564], ["pulmonary", "ANATOMY", 565, 574], ["dysfunction", "OBSERVATION", 575, 586]]], ["One is an obstructive lung disease (bronchiolitis obliterans syndrome, BOS) and the other a restrictive lung disease (cryptogenetic organizing pneumonia, COP).Late-Onset Noninfectious Pulmonary Complications (LONIPC)A recent prospective study showed that among 198 patients included after day +100, the cumulative incidence of LONIPC is 20%, and that of BOS is 11% at 3 years among allo-HSCT recipients (Bergeron et al. 2018) .", [["lung", "ANATOMY", 22, 26], ["lung", "ANATOMY", 104, 108], ["Pulmonary", "ANATOMY", 184, 193], ["obstructive lung disease", "DISEASE", 10, 34], ["bronchiolitis obliterans syndrome", "DISEASE", 36, 69], ["BOS", "DISEASE", 71, 74], ["lung disease", "DISEASE", 104, 116], ["pneumonia", "DISEASE", 143, 152], ["COP", "DISEASE", 154, 157], ["Noninfectious Pulmonary Complications", "DISEASE", 170, 207], ["LONIPC", "DISEASE", 327, 333], ["BOS", "DISEASE", 354, 357], ["lung", "ORGAN", 22, 26], ["lung", "ORGAN", 104, 108], ["Pulmonary", "ORGAN", 184, 193], ["patients", "ORGANISM", 265, 273], ["patients", "SPECIES", 265, 273], ["an obstructive lung disease", "PROBLEM", 7, 34], ["bronchiolitis obliterans syndrome", "PROBLEM", 36, 69], ["a restrictive lung disease", "PROBLEM", 90, 116], ["cryptogenetic organizing pneumonia", "PROBLEM", 118, 152], ["Late-Onset Noninfectious Pulmonary Complications", "PROBLEM", 159, 207], ["A recent prospective study", "TEST", 216, 242], ["LONIPC", "TEST", 327, 333], ["allo-HSCT recipients", "TREATMENT", 382, 402], ["obstructive", "OBSERVATION_MODIFIER", 10, 21], ["lung", "ANATOMY", 22, 26], ["disease", "OBSERVATION", 27, 34], ["bronchiolitis obliterans", "OBSERVATION", 36, 60], ["restrictive", "OBSERVATION_MODIFIER", 92, 103], ["lung", "ANATOMY", 104, 108], ["disease", "OBSERVATION", 109, 116], ["cryptogenetic", "OBSERVATION_MODIFIER", 118, 131], ["organizing", "OBSERVATION_MODIFIER", 132, 142], ["pneumonia", "OBSERVATION", 143, 152], ["Onset", "OBSERVATION_MODIFIER", 164, 169], ["Noninfectious", "OBSERVATION_MODIFIER", 170, 183], ["Pulmonary", "ANATOMY", 184, 193], ["Complications", "OBSERVATION", 194, 207], ["20%", "OBSERVATION_MODIFIER", 337, 340]]], ["Another study shows the impact of these complications on 5-year survival (28% with vs. 87% w/o LONIPC) (Nishio et al. 2009 ).Bronchiolitis Obliterans Syndrome (BOS)Pathogenesis, timing, incidence, clinical manifestations, diagnosis, and radiology of BOS are shown in Table 52 .2.", [["Bronchiolitis Obliterans Syndrome", "DISEASE", 125, 158], ["BOS", "DISEASE", 160, 163], ["BOS", "DISEASE", 250, 253], ["Another study", "TEST", 0, 13], ["these complications", "PROBLEM", 34, 53], ["Bronchiolitis Obliterans Syndrome", "PROBLEM", 125, 158], ["radiology of BOS", "TEST", 237, 253], ["complications", "OBSERVATION", 40, 53], ["Obliterans", "OBSERVATION", 139, 149]]], ["Treatment and prognosis of BOS are included in Table 52 .3.Cryptogenetic Organizing Pneumonia (COP)Formerly called BOOP (bronchiolitis obliterans with organizational pneumonia).", [["BOS", "DISEASE", 27, 30], ["Pneumonia", "DISEASE", 84, 93], ["BOOP", "DISEASE", 115, 119], ["bronchiolitis obliterans", "DISEASE", 121, 145], ["pneumonia", "DISEASE", 166, 175], ["Treatment", "TREATMENT", 0, 9], ["Cryptogenetic Organizing Pneumonia (COP)", "PROBLEM", 59, 99], ["BOOP (bronchiolitis obliterans", "PROBLEM", 115, 145], ["organizational pneumonia", "PROBLEM", 151, 175], ["Organizing", "OBSERVATION_MODIFIER", 73, 83], ["Pneumonia", "OBSERVATION", 84, 93], ["BOOP", "OBSERVATION", 115, 119], ["bronchiolitis obliterans", "OBSERVATION", 121, 145], ["organizational", "OBSERVATION_MODIFIER", 151, 165], ["pneumonia", "OBSERVATION", 166, 175]]], ["COP is a LONIPC of that is associated with restrictive pulmonary dysfunction.", [["pulmonary", "ANATOMY", 55, 64], ["pulmonary dysfunction", "DISEASE", 55, 76], ["pulmonary", "ORGAN", 55, 64], ["restrictive pulmonary dysfunction", "PROBLEM", 43, 76], ["associated with", "UNCERTAINTY", 27, 42], ["restrictive", "OBSERVATION_MODIFIER", 43, 54], ["pulmonary", "ANATOMY", 55, 64], ["dysfunction", "OBSERVATION", 65, 76]]], ["Reportedly, the incidence of COP among HSCT recipients is increasing due to the use of transbronchial biopsies as diagnostic tool.", [["transbronchial", "ANATOMY", 87, 101], ["COP", "DISEASE", 29, 32], ["transbronchial biopsies", "MULTI-TISSUE_STRUCTURE", 87, 110], ["COP among HSCT recipients", "TREATMENT", 29, 54], ["transbronchial biopsies", "TEST", 87, 110], ["diagnostic tool", "TEST", 114, 129], ["COP", "OBSERVATION_MODIFIER", 29, 32], ["transbronchial", "ANATOMY", 87, 101]]], ["The greatest diagnostic challenge is the differentiation of COP from BOS (see Table 52 .4) (Yoshihara et al. 2007; Cooke et al. 2017 ).", [["BOS", "DISEASE", 69, 72], ["greatest", "OBSERVATION_MODIFIER", 4, 12]]], ["(Chien et al. 2010; Uhlving et al. 2012) -Clinical manifestation (may be asymptomatic and only detected on PFT) + -Absence of active infection (demonstrated by BAL) + -Chronic GVHD in other locations b + -Obstructive alteration with air entrapment (FEV1 < 75% NV or > 10% decrease; ratio FEV1/FVC ratio < 0.7; residual volume > 120%) with nonsignificant bronchodilator test and a decreased DLCO + -Compatible radiology (see below)Cryptogenetic Organizing Pneumonia (COP)\u2022 Definitive: Histologic confirmation by thoracotomy, VATS, or transbronchial biopsy c Radiology -Chest x-ray: Normal or with signs of hyperinflation -CT scan: Radiological pattern of constrictive bronchiolitis with aerial entrapment, attenuation in mosaic, bronchiectasis and bronchial wall thickening, characteristic air trapping at exhalation DLCO transfer capacity of CO, FEV1 maximum expiratory volume in the first second, FVC forced vital capacity, VATS video-assisted thoracoscopic surgery a Some experts consider that a 10% decrease in the FEV1 basal after HSCT should make you suspect in BOS diagnosis b If the lung is the only organ with cGVHD, a biopsy is needed to confirm the diagnosis (NIH criteria) c Rarely transbronchial biopsy is used (low sensitivity and low predictive value) to establish a diagnosis that is eminently clinical.", [["bronchial wall", "ANATOMY", 747, 761], ["lung", "ANATOMY", 1090, 1094], ["organ", "ANATOMY", 1107, 1112], ["infection", "DISEASE", 133, 142], ["GVHD", "DISEASE", 176, 180], ["air entrapment", "DISEASE", 233, 247], ["Pneumonia", "DISEASE", 455, 464], ["constrictive bronchiolitis", "DISEASE", 654, 680], ["aerial entrapment", "DISEASE", 686, 703], ["bronchiectasis", "DISEASE", 728, 742], ["BOS", "DISEASE", 1067, 1070], ["cGVHD", "DISEASE", 1118, 1123], ["CO", "CHEMICAL", 842, 844], ["lung", "ORGAN", 1090, 1094], ["organ", "ORGAN", 1107, 1112], ["asymptomatic", "PROBLEM", 73, 85], ["PFT", "TEST", 107, 110], ["active infection", "PROBLEM", 126, 142], ["BAL", "TEST", 160, 163], ["Chronic GVHD in other locations", "PROBLEM", 168, 199], ["Obstructive alteration", "PROBLEM", 205, 227], ["air entrapment", "PROBLEM", 233, 247], ["FEV1", "TEST", 249, 253], ["NV", "TEST", 260, 262], ["ratio", "TEST", 282, 287], ["FEV1", "TEST", 288, 292], ["FVC ratio", "TEST", 293, 302], ["residual volume", "TEST", 310, 325], ["nonsignificant bronchodilator test", "TEST", 339, 373], ["a decreased DLCO", "PROBLEM", 378, 394], ["Cryptogenetic Organizing Pneumonia", "PROBLEM", 430, 464], ["Histologic confirmation", "TEST", 484, 507], ["thoracotomy", "TREATMENT", 511, 522], ["VATS", "TREATMENT", 524, 528], ["transbronchial biopsy", "TEST", 533, 554], ["Chest x-ray", "TEST", 568, 579], ["hyperinflation", "PROBLEM", 605, 619], ["CT scan", "TEST", 621, 628], ["constrictive bronchiolitis", "PROBLEM", 654, 680], ["aerial entrapment", "PROBLEM", 686, 703], ["attenuation in mosaic", "PROBLEM", 705, 726], ["bronchiectasis", "PROBLEM", 728, 742], ["bronchial wall thickening", "PROBLEM", 747, 772], ["characteristic air trapping", "PROBLEM", 774, 801], ["exhalation DLCO", "TEST", 805, 820], ["CO", "TEST", 842, 844], ["FEV1 maximum expiratory volume", "TEST", 846, 876], ["VATS video-assisted thoracoscopic surgery", "TREATMENT", 925, 966], ["a 10% decrease in the FEV1 basal", "TREATMENT", 996, 1028], ["a biopsy", "TEST", 1125, 1133], ["Rarely transbronchial biopsy", "TEST", 1186, 1214], ["active", "OBSERVATION_MODIFIER", 126, 132], ["infection", "OBSERVATION", 133, 142], ["Chronic", "OBSERVATION_MODIFIER", 168, 175], ["GVHD", "OBSERVATION", 176, 180], ["Obstructive", "OBSERVATION", 205, 216], ["air entrapment", "OBSERVATION", 233, 247], ["Pneumonia", "OBSERVATION", 455, 464], ["thoracotomy", "OBSERVATION", 511, 522], ["VATS", "ANATOMY", 524, 528], ["transbronchial", "ANATOMY", 533, 547], ["Chest", "ANATOMY", 568, 573], ["Normal", "OBSERVATION", 581, 587], ["hyperinflation", "OBSERVATION", 605, 619], ["constrictive", "OBSERVATION_MODIFIER", 654, 666], ["bronchiolitis", "OBSERVATION", 667, 680], ["aerial entrapment", "OBSERVATION", 686, 703], ["attenuation", "OBSERVATION_MODIFIER", 705, 716], ["mosaic", "OBSERVATION_MODIFIER", 720, 726], ["bronchiectasis", "OBSERVATION", 728, 742], ["bronchial", "ANATOMY", 747, 756], ["wall", "ANATOMY_MODIFIER", 757, 761], ["thickening", "OBSERVATION", 762, 772], ["air trapping", "OBSERVATION", 789, 801], ["expiratory volume", "OBSERVATION", 859, 876], ["lung", "ANATOMY", 1090, 1094], ["cGVHD", "OBSERVATION", 1118, 1123]]], ["If histology is available, the term bronchiolitis obliterans can be used; if not available, the process is referred to as BOS Anti-infectious prophylaxis If hypogammaglobulinemia: IVIg Treatment of gastroesophageal reflux Respiratory physiotherapy Specific treatment \u2022 Prednisone: 1-1.5 mg/kg/day, transient and unsatisfactory response in most cases.", [["gastroesophageal", "ANATOMY", 198, 214], ["bronchiolitis obliterans", "DISEASE", 36, 60], ["hypogammaglobulinemia", "DISEASE", 157, 178], ["gastroesophageal reflux", "DISEASE", 198, 221], ["Prednisone", "CHEMICAL", 269, 279], ["Prednisone", "CHEMICAL", 269, 279], ["gastroesophageal", "ORGAN", 198, 214], ["Prednisone", "SIMPLE_CHEMICAL", 269, 279], ["histology", "TEST", 3, 12], ["the term bronchiolitis obliterans", "PROBLEM", 27, 60], ["BOS Anti-infectious prophylaxis", "TREATMENT", 122, 153], ["hypogammaglobulinemia", "PROBLEM", 157, 178], ["IVIg", "TREATMENT", 180, 184], ["gastroesophageal reflux Respiratory physiotherapy", "TREATMENT", 198, 247], ["Prednisone", "TREATMENT", 269, 279], ["bronchiolitis", "OBSERVATION", 36, 49], ["hypogammaglobulinemia", "OBSERVATION", 157, 178], ["gastroesophageal", "ANATOMY", 198, 214]]], ["The addition of CSA, azathioprine, ATG, or photopheresis has few advantages \u2022 Budesonide/inhaled formoterol has been shown to be transiently effective in 60% of the patients (Bergeron et al. 2015) \u2022 Etanercept/infliximab: Effective in some cases (Yanik et al. 2012) \u2022 FAM combination therapy: Effective in disease stabilization a :Cryptogenetic Organizing Pneumonia (COP)-Fluticasone inhaled 440 mcg c/12 h (adult), 220 mcg in children + -Azithromycin 250 mg/d (adults), 5 mg/kg/d (children) b + -Montelukast 10 mg orally at night (adults), 5 mg (children) Two weeks before FAM increase (or start) PDN to 1 mg/kg/d, then decrease 0.25 mg/kg/d \u00d7 week (Williams et al. 2015) \u2022 In BOS controlled but with a severe residual respiratory insufficiency, lung transplantation may be considered after a few years (Cheng et al. 2014 ) Prognosis -TRM is very high; 32% (18-57%) at 2 years of HSCT almost always get associated with progressive respiratory failure and opportunistic infections -SRV around 65% (4%-80%) at 2 years a Fluticasone theoretically decreases the inflammatory pulmonary component; azithromycin reduces IL-8 levels and neutrophilia; and montelukast is an antagonist of the leukotriene receptors (bronchodilator) b However, the ALLOZITHRO randomized trial has shown that early administration of azithromycin resulted in worse airflow decline-free survival than did placebo; the value of these findings is limited by early termination of the trial (Bergeron et al. 2017)Key Points\u2022 Lung injury occurs frequently following HSCT and significantly contributes to morbidity and mortality in the immediate post transplant period and in the months and years that follow.", [["respiratory", "ANATOMY", 720, 731], ["lung", "ANATOMY", 747, 751], ["respiratory", "ANATOMY", 932, 943], ["pulmonary", "ANATOMY", 1072, 1081], ["Lung", "ANATOMY", 1491, 1495], ["CSA", "CHEMICAL", 16, 19], ["azathioprine", "CHEMICAL", 21, 33], ["ATG", "CHEMICAL", 35, 38], ["Budesonide", "CHEMICAL", 78, 88], ["formoterol", "CHEMICAL", 97, 107], ["Etanercept", "CHEMICAL", 199, 209], ["infliximab", "CHEMICAL", 210, 220], ["FAM", "CHEMICAL", 268, 271], ["Pneumonia", "DISEASE", 356, 365], ["Fluticasone", "CHEMICAL", 372, 383], ["Azithromycin", "CHEMICAL", 439, 451], ["Montelukast", "CHEMICAL", 497, 508], ["FAM", "CHEMICAL", 574, 577], ["BOS", "DISEASE", 678, 681], ["respiratory insufficiency", "DISEASE", 720, 745], ["respiratory failure", "DISEASE", 932, 951], ["opportunistic infections", "DISEASE", 956, 980], ["SRV", "DISEASE", 982, 985], ["Fluticasone", "CHEMICAL", 1019, 1030], ["azithromycin", "CHEMICAL", 1093, 1105], ["neutrophilia", "DISEASE", 1130, 1142], ["montelukast", "CHEMICAL", 1148, 1159], ["leukotriene", "CHEMICAL", 1184, 1195], ["azithromycin", "CHEMICAL", 1305, 1317], ["Lung injury", "DISEASE", 1491, 1502], ["azathioprine", "CHEMICAL", 21, 33], ["Budesonide", "CHEMICAL", 78, 88], ["formoterol", "CHEMICAL", 97, 107], ["Azithromycin", "CHEMICAL", 439, 451], ["Fluticasone", "CHEMICAL", 1019, 1030], ["azithromycin", "CHEMICAL", 1093, 1105], ["montelukast", "CHEMICAL", 1148, 1159], ["azithromycin", "CHEMICAL", 1305, 1317], ["CSA", "SIMPLE_CHEMICAL", 16, 19], ["azathioprine", "SIMPLE_CHEMICAL", 21, 33], ["ATG", "SIMPLE_CHEMICAL", 35, 38], ["Budesonide", "SIMPLE_CHEMICAL", 78, 88], ["formoterol", "SIMPLE_CHEMICAL", 97, 107], ["patients", "ORGANISM", 165, 173], ["Etanercept", "SIMPLE_CHEMICAL", 199, 209], ["infliximab", "SIMPLE_CHEMICAL", 210, 220], ["FAM", "SIMPLE_CHEMICAL", 268, 271], ["children", "ORGANISM", 427, 435], ["Azithromycin", "SIMPLE_CHEMICAL", 439, 451], ["children", "ORGANISM", 482, 490], ["b + -Montelukast", "SIMPLE_CHEMICAL", 492, 508], ["children", "ORGANISM", 547, 555], ["FAM", "SIMPLE_CHEMICAL", 574, 577], ["lung", "ORGAN", 747, 751], ["Fluticasone", "SIMPLE_CHEMICAL", 1019, 1030], ["pulmonary", "ORGAN", 1072, 1081], ["azithromycin", "SIMPLE_CHEMICAL", 1093, 1105], ["IL-8", "GENE_OR_GENE_PRODUCT", 1114, 1118], ["montelukast", "SIMPLE_CHEMICAL", 1148, 1159], ["leukotriene receptors", "GENE_OR_GENE_PRODUCT", 1184, 1205], ["azithromycin", "SIMPLE_CHEMICAL", 1305, 1317], ["Lung", "ORGAN", 1491, 1495], ["IL-8", "PROTEIN", 1114, 1118], ["leukotriene receptors", "PROTEIN", 1184, 1205], ["patients", "SPECIES", 165, 173], ["children", "SPECIES", 427, 435], ["children", "SPECIES", 482, 490], ["children", "SPECIES", 547, 555], ["CSA", "TREATMENT", 16, 19], ["azathioprine", "TREATMENT", 21, 33], ["ATG", "TREATMENT", 35, 38], ["photopheresis", "TREATMENT", 43, 56], ["Budesonide", "TREATMENT", 78, 88], ["inhaled formoterol", "TREATMENT", 89, 107], ["the patients (Bergeron et al.", "TREATMENT", 161, 190], ["Etanercept/infliximab", "TREATMENT", 199, 220], ["FAM combination therapy", "TREATMENT", 268, 291], ["Cryptogenetic Organizing Pneumonia (COP)", "TREATMENT", 331, 371], ["Fluticasone inhaled", "TREATMENT", 372, 391], ["Azithromycin", "TREATMENT", 439, 451], ["Montelukast", "TREATMENT", 497, 508], ["PDN", "TREATMENT", 598, 601], ["a severe residual respiratory insufficiency", "PROBLEM", 702, 745], ["lung transplantation", "TREATMENT", 747, 767], ["Prognosis", "TEST", 825, 834], ["TRM", "TEST", 836, 839], ["HSCT", "TEST", 881, 885], ["progressive respiratory failure", "PROBLEM", 920, 951], ["opportunistic infections", "PROBLEM", 956, 980], ["SRV", "TEST", 982, 985], ["a Fluticasone", "TREATMENT", 1017, 1030], ["the inflammatory pulmonary component", "PROBLEM", 1055, 1091], ["azithromycin reduces IL", "TREATMENT", 1093, 1116], ["neutrophilia", "PROBLEM", 1130, 1142], ["montelukast", "TREATMENT", 1148, 1159], ["the leukotriene receptors", "TREATMENT", 1180, 1205], ["bronchodilator)", "TREATMENT", 1207, 1222], ["the ALLOZITHRO randomized trial", "TREATMENT", 1234, 1265], ["azithromycin", "TREATMENT", 1305, 1317], ["worse airflow decline", "PROBLEM", 1330, 1351], ["Lung injury", "PROBLEM", 1491, 1502], ["morbidity", "PROBLEM", 1569, 1578], ["Pneumonia", "OBSERVATION", 356, 365], ["severe", "OBSERVATION_MODIFIER", 704, 710], ["residual", "OBSERVATION_MODIFIER", 711, 719], ["respiratory insufficiency", "OBSERVATION", 720, 745], ["lung", "ANATOMY", 747, 751], ["transplantation", "OBSERVATION", 752, 767], ["progressive", "OBSERVATION_MODIFIER", 920, 931], ["respiratory failure", "OBSERVATION", 932, 951], ["opportunistic", "OBSERVATION_MODIFIER", 956, 969], ["infections", "OBSERVATION", 970, 980], ["inflammatory", "OBSERVATION_MODIFIER", 1059, 1071], ["pulmonary", "ANATOMY", 1072, 1081], ["component", "OBSERVATION_MODIFIER", 1082, 1091], ["neutrophilia", "OBSERVATION", 1130, 1142], ["Lung", "ANATOMY", 1491, 1495], ["injury", "OBSERVATION", 1496, 1502]]], ["It can be observed in 25-55% of recipients. \u2022 Noninfectious lung injury following HSCT may be mediated by either immune or nonimmune mechanisms and could represent up to the 50% of noninfectious mortality after allo-HSCT.Key Points\u2022 Most relevant noninfectious early pulmonary complications are pulmonary edema by fluid overflow, idiopathic pneumonia syndrome, and diffuse alveolar hemorrhage, a vascular endothelial syndrome. \u2022 The most relevant late-onset noninfectious pulmonary complications are bronchiolitis obliterans and cryptogenetic organizing pneumonia. \u2022 All of them have specific diagnostic criteria, management, treatment, and prognosis.", [["lung", "ANATOMY", 60, 64], ["pulmonary", "ANATOMY", 267, 276], ["pulmonary", "ANATOMY", 295, 304], ["fluid", "ANATOMY", 314, 319], ["alveolar", "ANATOMY", 373, 381], ["vascular endothelial", "ANATOMY", 396, 416], ["pulmonary", "ANATOMY", 472, 481], ["lung injury", "DISEASE", 60, 71], ["pulmonary edema", "DISEASE", 295, 310], ["idiopathic pneumonia syndrome", "DISEASE", 330, 359], ["alveolar hemorrhage", "DISEASE", 373, 392], ["vascular endothelial syndrome", "DISEASE", 396, 425], ["pulmonary complications", "DISEASE", 472, 495], ["bronchiolitis obliterans", "DISEASE", 500, 524], ["pneumonia", "DISEASE", 554, 563], ["recipients", "ORGANISM", 32, 42], ["lung", "ORGAN", 60, 64], ["pulmonary", "ORGAN", 267, 276], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 295, 310], ["fluid", "ORGANISM_SUBSTANCE", 314, 319], ["alveolar", "MULTI-TISSUE_STRUCTURE", 373, 381], ["vascular endothelial", "TISSUE", 396, 416], ["pulmonary", "ORGAN", 472, 481], ["Noninfectious lung injury", "PROBLEM", 46, 71], ["HSCT", "TREATMENT", 82, 86], ["nonimmune mechanisms", "PROBLEM", 123, 143], ["allo-HSCT", "TREATMENT", 211, 220], ["Most relevant noninfectious early pulmonary complications", "PROBLEM", 233, 290], ["pulmonary edema", "PROBLEM", 295, 310], ["fluid overflow", "PROBLEM", 314, 328], ["idiopathic pneumonia syndrome", "PROBLEM", 330, 359], ["diffuse alveolar hemorrhage", "PROBLEM", 365, 392], ["a vascular endothelial syndrome", "PROBLEM", 394, 425], ["onset noninfectious pulmonary complications", "PROBLEM", 452, 495], ["bronchiolitis obliterans", "PROBLEM", 500, 524], ["cryptogenetic organizing pneumonia", "PROBLEM", 529, 563], ["treatment", "TREATMENT", 626, 635], ["Noninfectious", "OBSERVATION_MODIFIER", 46, 59], ["lung", "ANATOMY", 60, 64], ["injury", "OBSERVATION", 65, 71], ["noninfectious", "OBSERVATION", 181, 194], ["Most relevant", "UNCERTAINTY", 233, 246], ["noninfectious", "OBSERVATION_MODIFIER", 247, 260], ["early", "OBSERVATION_MODIFIER", 261, 266], ["pulmonary", "ANATOMY", 267, 276], ["complications", "OBSERVATION", 277, 290], ["pulmonary", "ANATOMY", 295, 304], ["edema", "OBSERVATION", 305, 310], ["fluid overflow", "OBSERVATION", 314, 328], ["idiopathic", "OBSERVATION_MODIFIER", 330, 340], ["pneumonia", "OBSERVATION", 341, 350], ["diffuse", "OBSERVATION_MODIFIER", 365, 372], ["alveolar", "ANATOMY_MODIFIER", 373, 381], ["hemorrhage", "OBSERVATION", 382, 392], ["vascular endothelial syndrome", "OBSERVATION", 396, 425], ["most relevant", "OBSERVATION_MODIFIER", 433, 446], ["late", "OBSERVATION_MODIFIER", 447, 451], ["onset", "OBSERVATION_MODIFIER", 452, 457], ["noninfectious", "OBSERVATION_MODIFIER", 458, 471], ["pulmonary", "ANATOMY", 472, 481], ["complications", "OBSERVATION", 482, 495], ["bronchiolitis obliterans", "OBSERVATION", 500, 524], ["cryptogenetic", "OBSERVATION_MODIFIER", 529, 542], ["organizing", "OBSERVATION_MODIFIER", 543, 553], ["pneumonia", "OBSERVATION", 554, 563]]]], "3e7ca9c330f1dbf7effa9cb25c3c4cd96ce23e43": [["condition, such as cardiovascular diseases, hypertension and diabetes.", [["cardiovascular", "ANATOMY", 19, 33], ["cardiovascular diseases", "DISEASE", 19, 42], ["hypertension", "DISEASE", 44, 56], ["diabetes", "DISEASE", 61, 69], ["cardiovascular diseases", "PROBLEM", 19, 42], ["hypertension", "PROBLEM", 44, 56], ["diabetes", "PROBLEM", 61, 69], ["cardiovascular", "ANATOMY", 19, 33], ["diseases", "OBSERVATION", 34, 42], ["hypertension", "OBSERVATION", 44, 56], ["diabetes", "OBSERVATION", 61, 69]]], ["8 Apart from the existing systemic co-morbidities, which weaken the immune system, many factors make the geriatric population more vulnerable to SARS-CoV-2 infection.", [["immune system", "ANATOMY", 68, 81], ["SARS", "DISEASE", 145, 149], ["infection", "DISEASE", 156, 165], ["SARS-CoV-2", "ORGANISM", 145, 155], ["SARS-CoV", "SPECIES", 145, 153], ["the existing systemic co-morbidities", "PROBLEM", 13, 49], ["the geriatric population", "PROBLEM", 101, 125], ["SARS", "PROBLEM", 145, 149], ["CoV-2 infection", "PROBLEM", 150, 165], ["systemic", "OBSERVATION_MODIFIER", 26, 34], ["co-morbidities", "OBSERVATION", 35, 49], ["infection", "OBSERVATION", 156, 165]]], ["9 With the geriatric population expected to reach around 1200 million by 2025, understanding the elements that make them susceptible to SARS-CoV-2 is critical.", [["SARS", "DISEASE", 136, 140], ["SARS-CoV-2", "ORGANISM", 136, 146], ["SARS-CoV", "SPECIES", 136, 144]]], ["10 There is an impending need to formulate specific guidelines/protocols for managing the older adults in the backdrop of COVID-19, considering the physiological, psychological and treatment needs of geriatric patients, which are unique.", [["patients", "ORGANISM", 210, 218], ["patients", "SPECIES", 210, 218], ["COVID", "TEST", 122, 127]]], ["This paper aims to develop a stepwise protocol for the dental management of geriatric patients.| RECOMMENDATI ON S FOR DENTAL MANAG EMENT OF G ERIATRI C PATIENTS IN THE WAK E OF COVID -19For effective screening, diagnosis and management of geriatric patients against the COVID outbreak, we propose \"five basic steps,\" as described below: (Table 1) .", [["patients", "ORGANISM", 86, 94], ["patients", "ORGANISM", 250, 258], ["patients", "SPECIES", 86, 94], ["patients", "SPECIES", 250, 258], ["a stepwise protocol", "TREATMENT", 27, 46], ["the dental management", "TREATMENT", 51, 72], ["management", "TREATMENT", 226, 236]]], ["These steps are initiated through telephone, text monitoring or video calls even before the patient arrives.| Step -1: Documenting personal details and chief complaintIn the beginning, it is mandatory to record the demographic details such as the name, hospital record number, age, gender, postal address, marital status and other personal information before the actual examination.", [["patient", "ORGANISM", 92, 99], ["patient", "SPECIES", 92, 99], ["text monitoring", "TEST", 45, 60], ["the actual examination", "TEST", 359, 381]]], ["The patient's residential address aids the clinician to take appropriate steps should the patient be from a COVID hotspot.", [["patient", "ORGANISM", 4, 11], ["patient", "ORGANISM", 90, 97], ["patient", "SPECIES", 4, 11], ["patient", "SPECIES", 90, 97]]], ["It may also help assess the socioeconomic status as it determines the patient's psychological and general well-being.", [["patient", "ORGANISM", 70, 77], ["patient", "SPECIES", 70, 77]]], ["Older adults in developed countries tend to stay in institutionalised settings like nursing homes, making them vulnerable to infection.", [["infection", "DISEASE", 125, 134], ["infection", "PROBLEM", 125, 134], ["infection", "OBSERVATION", 125, 134]]], ["It may be preferable to obtain the details over telephone or email, to avoid long appointments and unnecessary exposure.| Step -1: Documenting personal details and chief complaintMany countries acknowledge that the SARS-CoV-2 casualties are much higher than reported, should the fatalities outside the hospital be taken into account.", [["SARS", "DISEASE", 215, 219], ["SARS-CoV", "ORGANISM", 215, 223], ["the SARS", "TEST", 211, 219]]], ["According to a published report by the London School of Economics, about 42 to 57% of deaths related to COVID-19 occurred in nursing homes across five developed countries in Europe (Belgium (42%), France (45%), Italy (53%), Ireland (54%) and Spain (57%).", [["deaths", "DISEASE", 86, 92], ["COVID", "DISEASE", 104, 109], ["COVID", "TEST", 104, 109], ["Spain", "TEST", 242, 247]]], ["11 The patient's recent travel history must be noted within the district or outside the state or country.", [["patient", "ORGANISM", 7, 14], ["patient", "SPECIES", 7, 14]]], ["Those who have resided or travelled through a COVID hotspot may have to follow simple quarantine norms or get tested.", [["COVID hotspot", "DNA", 46, 59]]], ["Based on the information gathered, an appointment could be scheduled at the earliest in case of an emergency.| Step 2: Recording dental, medical and drug historyAfter obtaining the demographic details, the patient's dental, medical and drug history must be recorded.", [["patient", "ORGANISM", 206, 213], ["patient", "SPECIES", 206, 213]]], ["Any preexisting medical condition, including the treatment regimen and the route of drug administration, has to be known.", [["Any preexisting medical condition", "PROBLEM", 0, 33], ["the treatment regimen", "TREATMENT", 45, 66], ["drug administration", "TREATMENT", 84, 103]]], ["Medication known to interfere with dental procedure or produce side effects must be noted.| Step 2: Recording dental, medical and drug historyAvailable evidence suggests that ageing individuals with underlying medical disorders are more susceptible to SARS-CoV-2 infection than healthy individuals.", [["medical disorders", "DISEASE", 210, 227], ["SARS-CoV-2 infection", "DISEASE", 252, 272], ["SARS-CoV-2", "ORGANISM", 252, 262], ["SARS-CoV", "SPECIES", 252, 260], ["Medication", "TREATMENT", 0, 10], ["dental procedure", "TREATMENT", 35, 51], ["side effects", "PROBLEM", 63, 75], ["underlying medical disorders", "PROBLEM", 199, 227], ["SARS", "PROBLEM", 252, 256], ["2 infection", "PROBLEM", 261, 272]]], ["12 Thus, older adults at higher risk to contract SARS-CoV-2 infection include those with diabetes, asthma, immunocompromised state, chronic renal ailments requiring dialysis and individuals with liver dysfunction.", [["renal", "ANATOMY", 140, 145], ["liver", "ANATOMY", 195, 200], ["SARS-CoV-2 infection", "DISEASE", 49, 69], ["diabetes", "DISEASE", 89, 97], ["asthma", "DISEASE", 99, 105], ["chronic renal ailments", "DISEASE", 132, 154], ["liver dysfunction", "DISEASE", 195, 212], ["adults", "ORGANISM", 15, 21], ["SARS-CoV-2", "ORGANISM", 49, 59], ["renal", "ORGAN", 140, 145], ["liver", "ORGAN", 195, 200], ["CoV-2", "SPECIES", 54, 59], ["SARS", "PROBLEM", 49, 53], ["CoV-2 infection", "PROBLEM", 54, 69], ["diabetes", "PROBLEM", 89, 97], ["asthma", "PROBLEM", 99, 105], ["immunocompromised state", "PROBLEM", 107, 130], ["chronic renal ailments", "PROBLEM", 132, 154], ["dialysis", "TREATMENT", 165, 173], ["liver dysfunction", "PROBLEM", 195, 212], ["asthma", "OBSERVATION", 99, 105], ["immunocompromised", "OBSERVATION", 107, 124], ["chronic", "OBSERVATION_MODIFIER", 132, 139], ["renal", "ANATOMY", 140, 145], ["ailments", "OBSERVATION", 146, 154], ["liver", "ANATOMY", 195, 200], ["dysfunction", "OBSERVATION", 201, 212]]], ["Additionally, individuals with pulmonary and cardiac conditions such as chronic obstructive pulmonary disease (COPD), emphysema and chronic bronchitis, idiopathic pulmonary fibrosis and cystic fibrosis, coronary artery diseases, congenital heart disease, cardiomyopathies, and pulmonary hypertension are also at a higher risk of acquiring SARS-CoV-2 infection.| Step 2: Recording dental, medical and drug historyYang et al (2020) 13 assessed the prevalence of co-morbidities in SARS-CoV-2 infected patients and concluded that the risk is greater among individuals with hypertension, diabetes, cardiovascular and respiratory disorders in decreasing order.", [["pulmonary", "ANATOMY", 31, 40], ["cardiac", "ANATOMY", 45, 52], ["pulmonary", "ANATOMY", 92, 101], ["pulmonary", "ANATOMY", 163, 172], ["cystic", "ANATOMY", 186, 192], ["coronary artery", "ANATOMY", 203, 218], ["heart", "ANATOMY", 240, 245], ["pulmonary", "ANATOMY", 277, 286], ["cardiovascular", "ANATOMY", 593, 607], ["respiratory", "ANATOMY", 612, 623], ["pulmonary and cardiac conditions", "DISEASE", 31, 63], ["chronic obstructive pulmonary disease", "DISEASE", 72, 109], ["COPD", "DISEASE", 111, 115], ["emphysema", "DISEASE", 118, 127], ["chronic bronchitis", "DISEASE", 132, 150], ["idiopathic pulmonary fibrosis", "DISEASE", 152, 181], ["cystic fibrosis", "DISEASE", 186, 201], ["coronary artery diseases", "DISEASE", 203, 227], ["congenital heart disease", "DISEASE", 229, 253], ["cardiomyopathies", "DISEASE", 255, 271], ["pulmonary hypertension", "DISEASE", 277, 299], ["SARS-CoV-2 infection", "DISEASE", 339, 359], ["co-morbidities", "DISEASE", 460, 474], ["SARS-CoV-2 infected", "DISEASE", 478, 497], ["hypertension", "DISEASE", 569, 581], ["diabetes", "DISEASE", 583, 591], ["cardiovascular and respiratory disorders", "DISEASE", 593, 633], ["pulmonary", "ORGAN", 31, 40], ["pulmonary", "ORGAN", 92, 101], ["pulmonary", "ORGAN", 163, 172], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 203, 218], ["heart", "ORGAN", 240, 245], ["pulmonary", "ORGAN", 277, 286], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 339, 349], ["SARS-CoV-2", "ORGANISM", 478, 488], ["patients", "ORGANISM", 498, 506], ["patients", "SPECIES", 498, 506], ["SARS-CoV", "SPECIES", 478, 486], ["pulmonary and cardiac conditions", "PROBLEM", 31, 63], ["chronic obstructive pulmonary disease", "PROBLEM", 72, 109], ["COPD)", "PROBLEM", 111, 116], ["emphysema", "PROBLEM", 118, 127], ["chronic bronchitis", "PROBLEM", 132, 150], ["idiopathic pulmonary fibrosis", "PROBLEM", 152, 181], ["cystic fibrosis", "PROBLEM", 186, 201], ["coronary artery diseases", "PROBLEM", 203, 227], ["congenital heart disease", "PROBLEM", 229, 253], ["cardiomyopathies", "PROBLEM", 255, 271], ["pulmonary hypertension", "PROBLEM", 277, 299], ["acquiring SARS", "PROBLEM", 329, 343], ["CoV-2 infection", "PROBLEM", 344, 359], ["hypertension", "PROBLEM", 569, 581], ["diabetes", "PROBLEM", 583, 591], ["cardiovascular and respiratory disorders", "PROBLEM", 593, 633], ["pulmonary", "ANATOMY", 31, 40], ["cardiac", "ANATOMY", 45, 52], ["conditions", "OBSERVATION", 53, 63], ["chronic", "OBSERVATION_MODIFIER", 72, 79], ["obstructive", "OBSERVATION_MODIFIER", 80, 91], ["pulmonary", "ANATOMY", 92, 101], ["disease", "OBSERVATION", 102, 109], ["COPD", "OBSERVATION", 111, 115], ["emphysema", "OBSERVATION", 118, 127], ["chronic", "OBSERVATION_MODIFIER", 132, 139], ["bronchitis", "OBSERVATION", 140, 150], ["idiopathic", "OBSERVATION_MODIFIER", 152, 162], ["pulmonary", "ANATOMY", 163, 172], ["fibrosis", "OBSERVATION", 173, 181], ["cystic", "OBSERVATION_MODIFIER", 186, 192], ["fibrosis", "OBSERVATION", 193, 201], ["coronary artery", "ANATOMY", 203, 218], ["diseases", "OBSERVATION", 219, 227], ["heart", "ANATOMY", 240, 245], ["disease", "OBSERVATION", 246, 253], ["cardiomyopathies", "OBSERVATION", 255, 271], ["pulmonary", "ANATOMY", 277, 286], ["hypertension", "OBSERVATION", 287, 299], ["infection", "OBSERVATION", 350, 359], ["hypertension", "OBSERVATION", 569, 581], ["diabetes", "OBSERVATION", 583, 591], ["respiratory disorders", "OBSERVATION", 612, 633]]], ["In addition to these co-morbidities, ageing patients undergoing chemotherapy, radiotherapy, prolonged corticosteroid therapy and organ transplantation are risk-prone for SARS-CoV-2 infection due to their suppressed immune status.| Step 2: Recording dental, medical and drug historyDocumentation of these systemic co-morbidities should help the healthcare provider obtain medical clearance, timely schedule appointments and prescribe the right medication before planning treatment.", [["organ", "ANATOMY", 129, 134], ["SARS-CoV-2 infection", "DISEASE", 170, 190], ["patients", "ORGANISM", 44, 52], ["organ", "ORGAN", 129, 134], ["SARS-CoV-2", "ORGANISM", 170, 180], ["patients", "SPECIES", 44, 52], ["these co-morbidities", "PROBLEM", 15, 35], ["chemotherapy", "TREATMENT", 64, 76], ["radiotherapy", "TREATMENT", 78, 90], ["prolonged corticosteroid therapy", "TREATMENT", 92, 124], ["organ transplantation", "TREATMENT", 129, 150], ["SARS", "PROBLEM", 170, 174], ["CoV", "PROBLEM", 175, 178], ["2 infection", "PROBLEM", 179, 190], ["these systemic co-morbidities", "PROBLEM", 298, 327], ["the right medication", "TREATMENT", 433, 453], ["planning treatment", "TREATMENT", 461, 479], ["co-morbidities", "OBSERVATION", 21, 35]]], ["The details obtained should be seen in the context of factors that increase geriatric patients' vulnerability to SARS-CoV-2 infection.", [["SARS", "DISEASE", 113, 117], ["infection", "DISEASE", 124, 133], ["patients", "ORGANISM", 86, 94], ["SARS-CoV-2", "ORGANISM", 113, 123], ["patients", "SPECIES", 86, 94], ["SARS-CoV", "SPECIES", 113, 121], ["SARS", "PROBLEM", 113, 117], ["CoV-2 infection", "PROBLEM", 118, 133], ["infection", "OBSERVATION", 124, 133]]], ["These factors are presented along with a risk analysis scoring chart in Table 2 .| Step 2: Recording dental, medical and drug historyTA B L E 1 Overview of the 5 steps for dental management of geriatric patients in the wake of COVID-19| Step 2: Recording dental, medical and drug historySteps Description| Step 2: Recording dental, medical and drug historyStep 1 Documenting personal details and chief complaint| Step 2: Recording dental, medical and drug historyStep 2 Recording Dental, Medical and Drug History| Step 2: Recording dental, medical and drug historyStep 3 Evaluation for specific clinical manifestations of SARS-CoV-2 Infection| Step 2: Recording dental, medical and drug historyStep 4 Treatment Planning based on the chief complaint and urgency| Step 2: Recording dental, medical and drug historyStep 5 Recommendations-before, during and after dental treatment Note: Steps 1-4 to be performed through telephone/video conferencing and then verified on arrival at the clinic| Physiological factorsAgeing is a significant risk factor that has an enormous effect on the overall functioning of the immune system and an individuals' healing capacity.", [["immune system", "ANATOMY", 1109, 1122], ["SARS", "DISEASE", 622, 626], ["patients", "ORGANISM", 203, 211], ["immune system", "ANATOMICAL_SYSTEM", 1109, 1122], ["Physiological factors", "PROTEIN", 990, 1011], ["patients", "SPECIES", 203, 211], ["dental management", "TREATMENT", 172, 189], ["Evaluation", "TEST", 571, 581], ["SARS", "PROBLEM", 622, 626], ["urgency", "PROBLEM", 753, 760], ["Physiological factors", "PROBLEM", 990, 1011], ["a significant risk factor", "PROBLEM", 1021, 1046], ["an individuals' healing capacity", "PROBLEM", 1127, 1159], ["significant", "OBSERVATION_MODIFIER", 1023, 1034], ["enormous", "OBSERVATION_MODIFIER", 1059, 1067], ["healing", "OBSERVATION_MODIFIER", 1143, 1150], ["capacity", "OBSERVATION_MODIFIER", 1151, 1159]]], ["Studies have documented a reduction with age in the production of B and T cells in bone marrow and thymus, along with the diminished function of mature lymphocytes in secondary lymphoid tissues.", [["B", "ANATOMY", 66, 67], ["T cells", "ANATOMY", 72, 79], ["bone marrow", "ANATOMY", 83, 94], ["thymus", "ANATOMY", 99, 105], ["lymphocytes", "ANATOMY", 152, 163], ["lymphoid tissues", "ANATOMY", 177, 193], ["B", "CELL", 66, 67], ["T cells", "CELL", 72, 79], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 83, 94], ["thymus", "ORGAN", 99, 105], ["lymphocytes", "CELL", 152, 163], ["secondary lymphoid tissues", "TISSUE", 167, 193], ["B and T cells", "CELL_TYPE", 66, 79], ["mature lymphocytes", "CELL_TYPE", 145, 163], ["Studies", "TEST", 0, 7], ["the diminished function of mature lymphocytes in secondary lymphoid tissues", "PROBLEM", 118, 193], ["reduction", "OBSERVATION_MODIFIER", 26, 35], ["bone marrow", "ANATOMY", 83, 94], ["thymus", "ANATOMY", 99, 105], ["diminished", "OBSERVATION_MODIFIER", 122, 132], ["mature lymphocytes", "OBSERVATION", 145, 163], ["secondary lymphoid tissues", "OBSERVATION", 167, 193]]], ["14 A lowered immune response, compounded by poor nutrition among the older adults', makes them vulnerable in responding to a microbial challenge, unlike the young.", [["A lowered immune response", "PROBLEM", 3, 28], ["a microbial challenge", "TREATMENT", 123, 144], ["immune response", "OBSERVATION", 13, 28]]], ["15 A crucial aspect of geriatric oral health care is to be aware of impaired healing capacity and reduced immunity while managing COVID positive adults.| Physiological factorsThe age-associated physiologic changes in the oral cavity that predispose geriatric patients to viral infections include thinning epithelium, enabling easier passage of viral particles into the host cells.| Physiological factorsThe healing capacity of oral tissues is also impaired due to reduced collagen turnover rate, loss of elastin and adipose tissue in the submucosa, an increase in the fibrous stroma and degenerative changes in the collagen.", [["oral", "ANATOMY", 33, 37], ["oral cavity", "ANATOMY", 221, 232], ["epithelium", "ANATOMY", 305, 315], ["cells", "ANATOMY", 374, 379], ["oral tissues", "ANATOMY", 427, 439], ["adipose tissue", "ANATOMY", 516, 530], ["submucosa", "ANATOMY", 538, 547], ["fibrous stroma", "ANATOMY", 568, 582], ["viral infections", "DISEASE", 271, 287], ["oral", "ORGANISM_SUBDIVISION", 33, 37], ["oral cavity", "ORGAN", 221, 232], ["patients", "ORGANISM", 259, 267], ["epithelium", "TISSUE", 305, 315], ["cells", "CELL", 374, 379], ["oral tissues", "TISSUE", 427, 439], ["collagen", "GENE_OR_GENE_PRODUCT", 472, 480], ["elastin", "GENE_OR_GENE_PRODUCT", 504, 511], ["adipose tissue", "TISSUE", 516, 530], ["submucosa", "MULTI-TISSUE_STRUCTURE", 538, 547], ["fibrous stroma", "TISSUE", 568, 582], ["collagen", "GENE_OR_GENE_PRODUCT", 615, 623], ["Physiological factors", "PROTEIN", 154, 175], ["host cells", "CELL_TYPE", 369, 379], ["Physiological factors", "PROTEIN", 382, 403], ["collagen", "PROTEIN", 472, 480], ["elastin", "PROTEIN", 504, 511], ["collagen", "PROTEIN", 615, 623], ["patients", "SPECIES", 259, 267], ["impaired healing capacity", "PROBLEM", 68, 93], ["Physiological factors", "PROBLEM", 154, 175], ["physiologic changes in the oral cavity", "PROBLEM", 194, 232], ["viral infections", "PROBLEM", 271, 287], ["thinning epithelium", "PROBLEM", 296, 315], ["Physiological factors", "PROBLEM", 382, 403], ["The healing capacity of oral tissues", "PROBLEM", 403, 439], ["reduced collagen turnover rate", "PROBLEM", 464, 494], ["loss of elastin and adipose tissue in the submucosa", "PROBLEM", 496, 547], ["the fibrous stroma", "PROBLEM", 564, 582], ["degenerative changes in the collagen", "PROBLEM", 587, 623], ["physiologic", "OBSERVATION_MODIFIER", 194, 205], ["changes", "OBSERVATION", 206, 213], ["oral cavity", "ANATOMY", 221, 232], ["viral", "OBSERVATION_MODIFIER", 271, 276], ["infections", "OBSERVATION", 277, 287], ["viral particles", "OBSERVATION", 344, 359], ["host cells", "OBSERVATION", 369, 379], ["healing", "OBSERVATION_MODIFIER", 407, 414], ["capacity", "OBSERVATION_MODIFIER", 415, 423], ["oral tissues", "ANATOMY", 427, 439], ["reduced", "OBSERVATION_MODIFIER", 464, 471], ["collagen", "OBSERVATION", 472, 480], ["turnover rate", "OBSERVATION", 481, 494], ["elastin", "OBSERVATION", 504, 511], ["adipose tissue", "OBSERVATION", 516, 530], ["submucosa", "ANATOMY", 538, 547], ["increase", "OBSERVATION_MODIFIER", 552, 560], ["fibrous stroma", "OBSERVATION", 568, 582], ["degenerative", "OBSERVATION", 587, 599], ["collagen", "ANATOMY", 615, 623]]], ["The reduced epithelial thickness contributes to the onset of burning sensations, ulceration and bleeding from gums among geriatric patients.", [["epithelial", "ANATOMY", 12, 22], ["burning sensations", "DISEASE", 61, 79], ["ulceration", "DISEASE", 81, 91], ["bleeding", "DISEASE", 96, 104], ["epithelial", "TISSUE", 12, 22], ["gums", "ORGANISM_SUBDIVISION", 110, 114], ["patients", "ORGANISM", 131, 139], ["patients", "SPECIES", 131, 139], ["The reduced epithelial thickness", "PROBLEM", 0, 32], ["burning sensations", "PROBLEM", 61, 79], ["ulceration", "PROBLEM", 81, 91], ["bleeding from gums", "PROBLEM", 96, 114], ["reduced", "OBSERVATION_MODIFIER", 4, 11], ["epithelial thickness", "OBSERVATION", 12, 32], ["onset", "OBSERVATION_MODIFIER", 52, 57], ["burning sensations", "OBSERVATION", 61, 79], ["ulceration", "OBSERVATION", 81, 91], ["bleeding", "OBSERVATION", 96, 104]]], ["Oral care specialists have to be aware of the condition of the oral epithelium before preparing the patient for preprocedural mouth rinses with high alcohol content.| Physiological factorsIt is well-known that ageing influences the flow rate and composition of saliva, and alters the taste sensation by affecting the ionic channels and receptors of the gustatory cells.", [["Oral", "ANATOMY", 0, 4], ["oral epithelium", "ANATOMY", 63, 78], ["mouth", "ANATOMY", 126, 131], ["gustatory cells", "ANATOMY", 353, 368], ["alcohol", "CHEMICAL", 149, 156], ["alcohol", "CHEMICAL", 149, 156], ["oral epithelium", "TISSUE", 63, 78], ["patient", "ORGANISM", 100, 107], ["alcohol", "SIMPLE_CHEMICAL", 149, 156], ["saliva", "ORGANISM_SUBSTANCE", 261, 267], ["gustatory cells", "CELL", 353, 368], ["Physiological factors", "PROTEIN", 167, 188], ["ionic channels", "PROTEIN", 317, 331], ["gustatory cells", "CELL_TYPE", 353, 368], ["patient", "SPECIES", 100, 107], ["preprocedural mouth rinses", "TREATMENT", 112, 138], ["Physiological factors", "PROBLEM", 167, 188], ["the flow rate", "TEST", 228, 241], ["gustatory cells", "OBSERVATION", 353, 368]]], ["16 Reduced salivary flow impairs saliva's flushing action and increases the risk of plaque formation.", [["salivary", "ANATOMY", 11, 19], ["plaque", "ANATOMY", 84, 90], ["plaque", "DISEASE", 84, 90], ["salivary", "ORGAN", 11, 19], ["saliva", "ORGANISM_SUBSTANCE", 33, 39], ["plaque", "PATHOLOGICAL_FORMATION", 84, 90], ["Reduced salivary flow impairs", "PROBLEM", 3, 32], ["saliva's flushing action", "TREATMENT", 33, 57], ["plaque formation", "PROBLEM", 84, 100], ["Reduced", "OBSERVATION_MODIFIER", 3, 10], ["salivary flow", "OBSERVATION", 11, 24], ["plaque", "OBSERVATION", 84, 90]]], ["This predisposes the geriatric patients to the risk of bacterial and viral infection.", [["bacterial and viral infection", "DISEASE", 55, 84], ["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39], ["bacterial and viral infection", "PROBLEM", 55, 84], ["bacterial", "OBSERVATION", 55, 64], ["viral", "OBSERVATION_MODIFIER", 69, 74], ["infection", "OBSERVATION", 75, 84]]], ["Besides the reduced salivary rate associated with the ageing adult population, saliva has a lower protein and salivary immunoglobulin content.", [["salivary", "ANATOMY", 20, 28], ["salivary", "ANATOMY", 110, 118], ["salivary", "ORGAN", 20, 28], ["saliva", "ORGANISM_SUBSTANCE", 79, 85], ["salivary", "ORGANISM_SUBSTANCE", 110, 118], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 119, 133], ["immunoglobulin", "PROTEIN", 119, 133], ["the reduced salivary rate", "PROBLEM", 8, 33], ["a lower protein and salivary immunoglobulin content", "PROBLEM", 90, 141], ["reduced", "OBSERVATION_MODIFIER", 12, 19]]], ["17 Thus, it is necessary to assess the salivary flow rate among older adults, which is reduced due to medications, hormonal changes and depression.| ObesityObesity, identified as one of the significant epidemics, has been identified as a novel and independent risk factor of SARS-CoV-2 infection.", [["salivary", "ANATOMY", 39, 47], ["depression", "DISEASE", 136, 146], ["ObesityObesity", "DISEASE", 149, 163], ["SARS-CoV-2 infection", "DISEASE", 275, 295], ["salivary", "ORGAN", 39, 47], ["SARS-CoV-2", "ORGANISM", 275, 285], ["SARS-CoV-2", "SPECIES", 275, 285], ["medications", "TREATMENT", 102, 113], ["hormonal changes", "PROBLEM", 115, 131], ["depression", "PROBLEM", 136, 146], ["ObesityObesity", "PROBLEM", 149, 163], ["SARS", "PROBLEM", 275, 279], ["CoV-2 infection", "PROBLEM", 280, 295], ["significant", "OBSERVATION_MODIFIER", 190, 201], ["epidemics", "OBSERVATION", 202, 211], ["infection", "OBSERVATION", 286, 295]]], ["18 Obesity is known to lower immunity and cause severe impairment of organ and tissue function.", [["organ", "ANATOMY", 69, 74], ["tissue", "ANATOMY", 79, 85], ["Obesity", "DISEASE", 3, 10], ["impairment of organ and tissue function", "DISEASE", 55, 94], ["organ", "ORGAN", 69, 74], ["tissue", "TISSUE", 79, 85], ["Obesity", "PROBLEM", 3, 10], ["severe impairment of organ and tissue function", "PROBLEM", 48, 94], ["Obesity", "OBSERVATION", 3, 10], ["lower immunity", "OBSERVATION_MODIFIER", 23, 37], ["severe", "OBSERVATION_MODIFIER", 48, 54], ["impairment", "OBSERVATION", 55, 65], ["organ", "ANATOMY", 69, 74], ["tissue function", "OBSERVATION", 79, 94]]], ["It creates multiple systemic complications involving the heart, type-2 diabetes, cancers, osteoarthritis and psychological disturbance.", [["heart", "ANATOMY", 57, 62], ["cancers", "ANATOMY", 81, 88], ["type-2 diabetes", "DISEASE", 64, 79], ["cancers", "DISEASE", 81, 88], ["osteoarthritis", "DISEASE", 90, 104], ["psychological disturbance", "DISEASE", 109, 134], ["heart", "ORGAN", 57, 62], ["cancers", "CANCER", 81, 88], ["multiple systemic complications involving the heart", "PROBLEM", 11, 62], ["type-2 diabetes", "PROBLEM", 64, 79], ["cancers", "PROBLEM", 81, 88], ["osteoarthritis", "PROBLEM", 90, 104], ["psychological disturbance", "PROBLEM", 109, 134], ["multiple", "OBSERVATION_MODIFIER", 11, 19], ["systemic", "OBSERVATION_MODIFIER", 20, 28], ["complications", "OBSERVATION", 29, 42], ["heart", "ANATOMY", 57, 62], ["diabetes", "OBSERVATION", 71, 79], ["cancers", "OBSERVATION", 81, 88], ["osteoarthritis", "OBSERVATION", 90, 104]]], ["19 Most of the complications linked to obesity are due to increased oxidative stress and the release of adipokines.", [["obesity", "DISEASE", 39, 46], ["adipokines", "GENE_OR_GENE_PRODUCT", 104, 114], ["adipokines", "PROTEIN", 104, 114], ["the complications", "PROBLEM", 11, 28], ["obesity", "PROBLEM", 39, 46], ["increased oxidative stress", "PROBLEM", 58, 84], ["the release of adipokines", "TREATMENT", 89, 114], ["obesity", "OBSERVATION", 39, 46], ["oxidative stress", "OBSERVATION", 68, 84]]], ["Obesity interferes with the respiratory function by decreasing the lung volume, particularly the expiratory reserve volume and functional residual capacity.", [["respiratory", "ANATOMY", 28, 39], ["lung", "ANATOMY", 67, 71], ["Obesity", "DISEASE", 0, 7], ["lung", "ORGAN", 67, 71], ["Obesity", "PROBLEM", 0, 7], ["the respiratory function", "PROBLEM", 24, 48], ["decreasing the lung volume", "PROBLEM", 52, 78], ["the expiratory reserve volume", "TEST", 93, 122], ["functional residual capacity", "PROBLEM", 127, 155], ["respiratory function", "OBSERVATION", 28, 48], ["decreasing", "OBSERVATION_MODIFIER", 52, 62], ["lung", "ANATOMY", 67, 71], ["volume", "OBSERVATION", 72, 78], ["expiratory", "OBSERVATION", 97, 107], ["reserve volume", "OBSERVATION", 108, 122], ["functional", "OBSERVATION", 127, 137], ["residual capacity", "OBSERVATION", 138, 155]]], ["19 The weak respiratory move-| Poor oral hygienePoor oral hygiene status is considered to be a major risk factor for acquiring viral infections.", [["oral", "ANATOMY", 36, 40], ["oral", "ANATOMY", 53, 57], ["viral infections", "DISEASE", 127, 143], ["oral", "ORGANISM_SUBDIVISION", 36, 40], ["oral", "ORGANISM_SUBDIVISION", 53, 57], ["a major risk factor", "PROBLEM", 93, 112], ["acquiring viral infections", "PROBLEM", 117, 143], ["weak", "OBSERVATION_MODIFIER", 7, 11], ["respiratory move", "OBSERVATION", 12, 28], ["infections", "OBSERVATION", 133, 143]]], ["Lack of manual dexterity and overdependency among older people hampers regular oral hygiene maintenance.", [["oral", "ANATOMY", 79, 83], ["overdependency", "DISEASE", 29, 43], ["people", "ORGANISM", 56, 62], ["oral", "ORGANISM_SUBDIVISION", 79, 83], ["people", "SPECIES", 56, 62], ["manual dexterity", "PROBLEM", 8, 24], ["manual dexterity", "OBSERVATION", 8, 24]]], ["22 In a large cohort of older adults, the prevalence of TA B L E 2 Risk analysis chart increase to assess the vulnerability of geriatric patients to SARS-CoV-2 infection Any dermal lesions or intra oral lesions of inexplicable nature in last 14 d?| Poor oral hygiene7| Poor oral hygieneAny neurological symptoms like headache and seizures for inexplicable reasons in last 14 d? 8 Has the patient been diagnosed with and seeking treatment for hypertension? 9 Has the patient been diagnosed with and seeking treatment for diabetes? 10 Has the patient been diagnosed with and undergoing treatment for cardiovascular problems? 11 Has the patient been diagnosed with and undergoing treatment for respiratory problems?", [["dermal lesions", "ANATOMY", 174, 188], ["oral lesions", "ANATOMY", 198, 210], ["oral", "ANATOMY", 254, 258], ["oral", "ANATOMY", 274, 278], ["neurological", "ANATOMY", 290, 302], ["cardiovascular", "ANATOMY", 598, 612], ["respiratory", "ANATOMY", 691, 702], ["SARS", "DISEASE", 149, 153], ["infection", "DISEASE", 160, 169], ["neurological symptoms", "DISEASE", 290, 311], ["headache", "DISEASE", 317, 325], ["seizures", "DISEASE", 330, 338], ["hypertension", "DISEASE", 442, 454], ["diabetes", "DISEASE", 520, 528], ["cardiovascular problems", "DISEASE", 598, 621], ["respiratory problems", "DISEASE", 691, 711], ["patients", "ORGANISM", 137, 145], ["SARS-CoV-2", "ORGANISM", 149, 159], ["dermal lesions", "PATHOLOGICAL_FORMATION", 174, 188], ["oral lesions", "PATHOLOGICAL_FORMATION", 198, 210], ["oral", "ORGANISM_SUBDIVISION", 254, 258], ["oral", "ORGANISM_SUBDIVISION", 274, 278], ["patient", "ORGANISM", 388, 395], ["patient", "ORGANISM", 466, 473], ["patient", "ORGANISM", 541, 548], ["patient", "ORGANISM", 634, 641], ["patients", "SPECIES", 137, 145], ["patient", "SPECIES", 388, 395], ["patient", "SPECIES", 466, 473], ["patient", "SPECIES", 541, 548], ["patient", "SPECIES", 634, 641], ["TA B L E", "TREATMENT", 56, 64], ["SARS", "PROBLEM", 149, 153], ["CoV-2 infection", "PROBLEM", 154, 169], ["Any dermal lesions", "PROBLEM", 170, 188], ["intra oral lesions", "PROBLEM", 192, 210], ["Any neurological symptoms", "PROBLEM", 286, 311], ["headache", "PROBLEM", 317, 325], ["seizures", "PROBLEM", 330, 338], ["hypertension", "PROBLEM", 442, 454], ["diabetes", "PROBLEM", 520, 528], ["treatment", "TREATMENT", 584, 593], ["cardiovascular problems", "PROBLEM", 598, 621], ["treatment", "TREATMENT", 677, 686], ["respiratory problems", "PROBLEM", 691, 711], ["large", "OBSERVATION_MODIFIER", 8, 13], ["infection", "OBSERVATION", 160, 169], ["dermal", "ANATOMY", 174, 180], ["lesions", "OBSERVATION", 181, 188], ["intra", "OBSERVATION_MODIFIER", 192, 197], ["oral", "OBSERVATION_MODIFIER", 198, 202], ["lesions", "OBSERVATION", 203, 210], ["hypertension", "OBSERVATION", 442, 454]]], ["Does the patient complain of dry mouth/eyes? 16 Does the patient reside in an assisted institution/old age home? dental caries among the dentate elderly was 22%, with 20% of the 75-to 84-year-olds presenting active root decay.", [["mouth", "ANATOMY", 33, 38], ["eyes", "ANATOMY", 39, 43], ["root", "ANATOMY", 215, 219], ["dry mouth", "DISEASE", 29, 38], ["dental caries", "DISEASE", 113, 126], ["patient", "ORGANISM", 9, 16], ["mouth", "ORGANISM_SUBDIVISION", 33, 38], ["eyes", "ORGAN", 39, 43], ["patient", "ORGANISM", 57, 64], ["root", "ORGAN", 215, 219], ["patient", "SPECIES", 9, 16], ["patient", "SPECIES", 57, 64], ["dry mouth/eyes", "PROBLEM", 29, 43], ["dental caries", "PROBLEM", 113, 126], ["mouth", "ANATOMY", 33, 38], ["eyes", "ANATOMY", 39, 43], ["active", "OBSERVATION_MODIFIER", 208, 214], ["root decay", "OBSERVATION", 215, 225]]], ["23 Accumulation of bacterial plaque with periodontally compromised teeth is the most frequent finding among the ageing adults.", [["plaque", "ANATOMY", 29, 35], ["teeth", "ANATOMY", 67, 72], ["bacterial plaque", "DISEASE", 19, 35], ["bacterial plaque", "PATHOLOGICAL_FORMATION", 19, 35], ["teeth", "ORGAN", 67, 72], ["adults", "ORGANISM", 119, 125], ["bacterial plaque", "PROBLEM", 19, 35], ["periodontally compromised teeth", "PROBLEM", 41, 72], ["bacterial", "OBSERVATION_MODIFIER", 19, 28], ["plaque", "OBSERVATION", 29, 35], ["periodontally compromised teeth", "OBSERVATION", 41, 72]]], ["24 When oral hygiene continues to remain poor, loss of teeth and edentulism occurs.| Poor oral hygieneIncidentally, tooth loss has been shown to have a positive relationship with mortality from all causes 25 and to the reduced quality of life impairment.", [["oral", "ANATOMY", 8, 12], ["teeth", "ANATOMY", 55, 60], ["oral", "ANATOMY", 90, 94], ["tooth", "ANATOMY", 116, 121], ["loss of teeth", "DISEASE", 47, 60], ["edentulism", "DISEASE", 65, 75], ["tooth loss", "DISEASE", 116, 126], ["oral", "ORGANISM_SUBDIVISION", 8, 12], ["teeth", "ORGAN", 55, 60], ["oral", "ORGANISM_SUBDIVISION", 90, 94], ["tooth", "ORGAN", 116, 121], ["oral hygiene", "TREATMENT", 8, 20], ["loss of teeth", "PROBLEM", 47, 60], ["edentulism", "PROBLEM", 65, 75], ["tooth loss", "PROBLEM", 116, 126], ["life impairment", "PROBLEM", 238, 253], ["teeth", "ANATOMY", 55, 60], ["edentulism", "OBSERVATION", 65, 75], ["tooth loss", "OBSERVATION", 116, 126], ["positive", "OBSERVATION", 152, 160]]], ["26 Geriatric patients with poor oral health are an independent in-hospital mortality predictor.", [["oral", "ANATOMY", 32, 36], ["patients", "ORGANISM", 13, 21], ["oral", "ORGANISM_SUBDIVISION", 32, 36], ["patients", "SPECIES", 13, 21]]], ["27 It has been demonstrated that angiotensin-converting enzyme 2 (ACE2) receptors are the primary sites for SARS-CoV-2 entry into the host cells.", [["cells", "ANATOMY", 139, 144], ["angiotensin", "CHEMICAL", 33, 44], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 33, 64], ["ACE2", "GENE_OR_GENE_PRODUCT", 66, 70], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 108, 118], ["host cells", "CELL", 134, 144], ["angiotensin-converting enzyme 2 (ACE2) receptors", "PROTEIN", 33, 81], ["host cells", "CELL_TYPE", 134, 144], ["angiotensin-converting enzyme", "TEST", 33, 62], ["SARS", "TEST", 108, 112], ["CoV", "TEST", 113, 116], ["host cells", "OBSERVATION", 134, 144]]], ["The spike (S) protein of SARS-CoV-2 recognises the host cell receptors and fuses with the cell membranes before gaining admission in oral mucosa, tongue and salivary glands.", [["cell", "ANATOMY", 56, 60], ["cell membranes", "ANATOMY", 90, 104], ["oral mucosa", "ANATOMY", 133, 144], ["tongue", "ANATOMY", 146, 152], ["salivary glands", "ANATOMY", 157, 172], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 25, 35], ["host cell", "CELL", 51, 60], ["cell membranes", "CELLULAR_COMPONENT", 90, 104], ["oral mucosa", "MULTI-TISSUE_STRUCTURE", 133, 144], ["tongue", "ORGAN", 146, 152], ["salivary glands", "ORGAN", 157, 172], ["spike (S) protein", "PROTEIN", 4, 21], ["SARS-CoV-2", "PROTEIN", 25, 35], ["host cell receptors", "PROTEIN", 51, 70], ["SARS-CoV", "SPECIES", 25, 33], ["The spike (S) protein", "TEST", 0, 21], ["SARS", "TEST", 25, 29], ["CoV", "TEST", 30, 33], ["the cell membranes", "TREATMENT", 86, 104], ["host cell receptors", "OBSERVATION", 51, 70], ["cell membranes", "OBSERVATION", 90, 104], ["oral mucosa", "ANATOMY", 133, 144], ["tongue", "ANATOMY", 146, 152], ["salivary glands", "ANATOMY", 157, 172]]], ["28 Individuals infected with SARS-CoV-2 have higher viral loads in the saliva, oropharynx, nasal passages and upper respiratory tract.", [["saliva", "ANATOMY", 71, 77], ["oropharynx", "ANATOMY", 79, 89], ["nasal passages", "ANATOMY", 91, 105], ["upper respiratory tract", "ANATOMY", 110, 133], ["SARS", "DISEASE", 29, 33], ["SARS-CoV-2", "ORGANISM", 29, 39], ["saliva", "ORGANISM_SUBSTANCE", 71, 77], ["oropharynx", "ORGAN", 79, 89], ["nasal", "ORGANISM_SUBDIVISION", 91, 96], ["upper respiratory", "ORGANISM_SUBDIVISION", 110, 127], ["tract", "ORGANISM_SUBDIVISION", 128, 133], ["SARS-CoV", "SPECIES", 29, 37], ["SARS", "PROBLEM", 29, 33], ["CoV", "TEST", 34, 37], ["higher viral loads in the saliva, oropharynx, nasal passages and upper respiratory tract", "PROBLEM", 45, 133], ["viral loads", "OBSERVATION", 52, 63], ["saliva", "ANATOMY", 71, 77], ["oropharynx", "ANATOMY", 79, 89], ["nasal passages", "ANATOMY", 91, 105], ["upper", "ANATOMY_MODIFIER", 110, 115], ["respiratory tract", "ANATOMY", 116, 133]]], ["29 Poor oral hygiene can increase the risk of pneumonia, acute respiratory distress syndrome, sepsis, septic shock and death in COVID positive geriatric patients.", [["oral", "ANATOMY", 8, 12], ["respiratory", "ANATOMY", 63, 74], ["pneumonia", "DISEASE", 46, 55], ["acute respiratory distress syndrome", "DISEASE", 57, 92], ["sepsis", "DISEASE", 94, 100], ["septic shock", "DISEASE", 102, 114], ["death", "DISEASE", 119, 124], ["oral", "ORGANISM_SUBDIVISION", 8, 12], ["patients", "ORGANISM", 153, 161], ["patients", "SPECIES", 153, 161], ["pneumonia", "PROBLEM", 46, 55], ["acute respiratory distress syndrome", "PROBLEM", 57, 92], ["sepsis", "PROBLEM", 94, 100], ["septic shock", "PROBLEM", 102, 114], ["death", "PROBLEM", 119, 124], ["pneumonia", "OBSERVATION", 46, 55], ["acute", "OBSERVATION_MODIFIER", 57, 62], ["respiratory distress syndrome", "OBSERVATION", 63, 92], ["sepsis", "OBSERVATION", 94, 100], ["septic shock", "OBSERVATION", 102, 114]]], ["30 It is found that the neutrophil to lymphocyte ratio at an early stage of COVID-19 predicts patients who are likely to develop critical illness.", [["neutrophil", "ANATOMY", 24, 34], ["lymphocyte", "ANATOMY", 38, 48], ["neutrophil", "CELL", 24, 34], ["lymphocyte", "CELL", 38, 48], ["patients", "ORGANISM", 94, 102], ["patients", "SPECIES", 94, 102], ["the neutrophil", "TEST", 20, 34], ["lymphocyte ratio", "TEST", 38, 54], ["critical illness", "PROBLEM", 129, 145], ["likely to", "UNCERTAINTY", 111, 120], ["illness", "OBSERVATION", 138, 145]]], ["31 Patients in ICU exhibit an exceptionally high bacterial load.", [["Patients", "ORGANISM", 3, 11], ["Patients", "SPECIES", 3, 11], ["an exceptionally high bacterial load", "PROBLEM", 27, 63], ["high bacterial load", "OBSERVATION", 44, 63]]], ["Thus, it is obligatory to check the modifiable risk factors such as diet, poor oral hygiene and overall glycemic control.", [["oral", "ANATOMY", 79, 83], ["oral", "ORGANISM_SUBDIVISION", 79, 83], ["the modifiable risk factors", "PROBLEM", 32, 59]]], ["The oral cavity's viral load should be lowered by adopting effective oral and throat hygiene, and by seeking professional dental care.", [["oral cavity", "ANATOMY", 4, 15], ["oral", "ANATOMY", 69, 73], ["throat", "ANATOMY", 78, 84], ["oral cavity", "MULTI-TISSUE_STRUCTURE", 4, 15], ["oral", "ORGANISM_SUBDIVISION", 69, 73], ["throat", "ORGANISM_SUBDIVISION", 78, 84], ["The oral cavity's viral load", "TREATMENT", 0, 28], ["oral cavity", "ANATOMY", 4, 15], ["viral load", "OBSERVATION", 18, 28], ["throat", "ANATOMY", 78, 84]]], ["32| Step 3: Evaluate for specific clinical manifestations of SARS-CoV-2 infectionApart from obtaining the necessary personal, medical, and drug history, and performing the risk analysis, dentists need to look for any signs and symptoms related to SARS-CoV-2 infection.", [["SARS-CoV-2 infection", "DISEASE", 61, 81], ["SARS", "DISEASE", 247, 251], ["infection", "DISEASE", 258, 267], ["SARS-CoV-2", "ORGANISM", 247, 257], ["SARS-CoV-2", "SPECIES", 61, 71], ["SARS-CoV", "SPECIES", 247, 255], ["SARS", "PROBLEM", 61, 65], ["CoV", "PROBLEM", 66, 69], ["2 infection", "PROBLEM", 70, 81], ["the risk analysis", "TEST", 168, 185], ["any signs and symptoms", "PROBLEM", 213, 235], ["SARS", "PROBLEM", 247, 251], ["CoV", "PROBLEM", 252, 255], ["2 infection", "PROBLEM", 256, 267], ["SARS", "OBSERVATION", 61, 65], ["infection", "OBSERVATION", 72, 81], ["infection", "OBSERVATION", 258, 267]]], ["33 It is vital to recognise potential carriers and test suspected patients before undertaking any dental procedure.| Step 3: Evaluate for specific clinical manifestations of SARS-CoV-2 infectionAs per the WHO bulletin, the common symptoms of SARS- and causing potential death.", [["SARS", "DISEASE", 174, 178], ["SARS", "DISEASE", 242, 246], ["death", "DISEASE", 270, 275], ["patients", "ORGANISM", 66, 74], ["patients", "SPECIES", 66, 74], ["SARS-CoV", "SPECIES", 174, 182], ["any dental procedure", "TREATMENT", 94, 114], ["SARS", "PROBLEM", 174, 178], ["CoV", "PROBLEM", 179, 182], ["2 infectionAs", "PROBLEM", 183, 196], ["the common symptoms", "PROBLEM", 219, 238], ["SARS", "PROBLEM", 242, 246], ["potential death", "PROBLEM", 260, 275], ["SARS", "OBSERVATION", 174, 178]]], ["38 There have been reports which state that SARS-CoV-2 infection can also cause inflammation of the brain and indirectly cause neurological damage and neurodegenerative changes such as Alzheimer's and Parkinson's.", [["brain", "ANATOMY", 100, 105], ["neurological", "ANATOMY", 127, 139], ["infection", "DISEASE", 55, 64], ["inflammation of the brain", "DISEASE", 80, 105], ["neurological damage", "DISEASE", 127, 146], ["Alzheimer's and Parkinson's", "DISEASE", 185, 212], ["SARS-CoV-2", "ORGANISM", 44, 54], ["brain", "ORGAN", 100, 105], ["SARS-CoV-2", "SPECIES", 44, 54], ["SARS", "PROBLEM", 44, 48], ["CoV-2 infection", "PROBLEM", 49, 64], ["inflammation of the brain", "PROBLEM", 80, 105], ["neurological damage", "PROBLEM", 127, 146], ["neurodegenerative changes", "PROBLEM", 151, 176], ["Alzheimer's", "PROBLEM", 185, 196], ["Parkinson's", "PROBLEM", 201, 212], ["infection", "OBSERVATION", 55, 64], ["inflammation", "OBSERVATION", 80, 92], ["brain", "ANATOMY", 100, 105], ["damage", "OBSERVATION", 140, 146], ["neurodegenerative", "OBSERVATION", 151, 168]]], ["[39] [40] [41] Incidentally, cutaneous lesions related to SARS-CoV-2 and referred to as COVID toes, have been reported.", [["cutaneous lesions", "ANATOMY", 29, 46], ["SARS", "DISEASE", 58, 62], ["[39] [40] [41", "SIMPLE_CHEMICAL", 0, 13], ["cutaneous lesions", "CANCER", 29, 46], ["SARS-CoV", "SPECIES", 58, 66], ["Incidentally, cutaneous lesions", "PROBLEM", 15, 46], ["SARS", "PROBLEM", 58, 62], ["CoV", "TEST", 63, 66], ["cutaneous", "ANATOMY", 29, 38], ["lesions", "OBSERVATION", 39, 46], ["toes", "ANATOMY", 94, 98]]], ["42 With geriatric patients having a weak immune response, dermatological manifestations may offer some clues during screening.", [["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26], ["a weak immune response", "PROBLEM", 34, 56], ["dermatological manifestations", "PROBLEM", 58, 87], ["screening", "TEST", 116, 125]]], ["A recent report highlighted an irregular oral ulcer, suspected to be the inaugural oral symptom for SARS-CoV-2.", [["oral ulcer", "ANATOMY", 41, 51], ["oral", "ANATOMY", 83, 87], ["ulcer", "DISEASE", 46, 51], ["SARS", "DISEASE", 100, 104], ["oral", "ORGANISM_SUBDIVISION", 41, 45], ["ulcer", "PATHOLOGICAL_FORMATION", 46, 51], ["oral", "ORGANISM_SUBDIVISION", 83, 87], ["SARS-CoV", "SPECIES", 100, 108], ["an irregular oral ulcer", "PROBLEM", 28, 51], ["the inaugural oral symptom", "PROBLEM", 69, 95], ["SARS", "PROBLEM", 100, 104], ["irregular", "OBSERVATION_MODIFIER", 31, 40], ["oral", "ANATOMY", 41, 45], ["ulcer", "OBSERVATION", 46, 51], ["suspected to be", "UNCERTAINTY", 53, 68]]], ["43 However, this needs to be observed in a larger cohort of patients before confirmation.| Step 3: Evaluate for specific clinical manifestations of SARS-CoV-2 infectionIn light of these developments, it is prudent to screen all the patients for SARS-CoV-2.", [["SARS", "DISEASE", 148, 152], ["SARS", "DISEASE", 245, 249], ["patients", "ORGANISM", 60, 68], ["patients", "ORGANISM", 232, 240], ["SARS-CoV-2", "ORGANISM", 245, 255], ["patients", "SPECIES", 60, 68], ["patients", "SPECIES", 232, 240], ["SARS-CoV", "SPECIES", 245, 253], ["SARS", "PROBLEM", 148, 152], ["CoV", "PROBLEM", 153, 156], ["SARS", "PROBLEM", 245, 249], ["CoV", "TEST", 250, 253], ["SARS", "OBSERVATION", 148, 152]]], ["If any of the signs and symptoms are noted, the dental team must refrain from carrying out any dental treatment, unless it is an emergency.", [["the signs and symptoms", "PROBLEM", 10, 32], ["any dental treatment", "TREATMENT", 91, 111]]], ["While the dentist has to record a detailed clinical history, noting the telltale signs and symptoms associated with SARS-CoV-2 infection, it is also important to note that the mere presence of these manifestations may not confirm that the patient is COVID-19 positive.", [["SARS-CoV-2 infection", "DISEASE", 116, 136], ["SARS-CoV-2", "ORGANISM", 116, 126], ["patient", "ORGANISM", 239, 246], ["patient", "SPECIES", 239, 246], ["SARS-CoV", "SPECIES", 116, 124], ["the telltale signs", "PROBLEM", 68, 86], ["symptoms", "PROBLEM", 91, 99], ["SARS", "PROBLEM", 116, 120], ["CoV-2 infection", "PROBLEM", 121, 136], ["COVID", "TEST", 250, 255], ["infection", "OBSERVATION", 127, 136]]], ["Some of these may present as| Step 4: Treatment schedule based on priorityIt is essential to categorise the treatment needs into, not important and not urgent (elective); important but not very urgent; important and urgent (emergency).", [["Treatment schedule", "TREATMENT", 38, 56]]], ["Optimum planning would help to minimise dental visits and the overall duration of the dental treatment (Table 3) .", [["the dental treatment", "TREATMENT", 82, 102]]], ["It is vital to prioritise emergency and urgent treatment to ensure that geriatric patients stay indoors unless the situation demands professional intervention.", [["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90], ["urgent treatment", "TREATMENT", 40, 56], ["professional intervention", "TREATMENT", 133, 158]]], ["These are as follows:| Step 4: Treatment schedule based on priority\u2022 Patients requiring emergency dental procedures but have no fever or symptoms consistent with COVID-19 infection should be seen in a dental operatory with appropriate protocols (Step 5) and PPE in place.| Step 4: Treatment schedule based on priority\u2022 Patients requiring urgent/emergency treatment, having fever associated with dental conditions like a periapical abscess/periodontal abscess, intraoral swelling, and no other signs or symptoms of COVID-19 infection should be seen in a dental operatory.| Step 4: Treatment schedule based on priorityWear appropriate PPE, as recommended in Table 4 , under infection control recommendations.| Step 4: Treatment schedule based on priority\u2022 Patients requiring urgent/emergency treatment who exhibit signs and symptoms of SARS-CoV-2 infection should be referred for medical consultation and treatment.", [["periapical", "ANATOMY", 420, 430], ["periodontal", "ANATOMY", 439, 450], ["intraoral", "ANATOMY", 460, 469], ["fever", "DISEASE", 128, 133], ["COVID-19", "CHEMICAL", 162, 170], ["infection", "DISEASE", 171, 180], ["fever", "DISEASE", 373, 378], ["periapical abscess", "DISEASE", 420, 438], ["periodontal abscess", "DISEASE", 439, 458], ["intraoral swelling", "DISEASE", 460, 478], ["COVID", "DISEASE", 514, 519], ["infection", "DISEASE", 523, 532], ["infection", "DISEASE", 672, 681], ["SARS-CoV-2 infection", "DISEASE", 834, 854], ["Patients", "ORGANISM", 69, 77], ["Patients", "ORGANISM", 319, 327], ["periapical abscess", "PATHOLOGICAL_FORMATION", 420, 438], ["periodontal abscess", "PATHOLOGICAL_FORMATION", 439, 458], ["Patients", "ORGANISM", 754, 762], ["Patients", "SPECIES", 69, 77], ["Patients", "SPECIES", 319, 327], ["Patients", "SPECIES", 754, 762], ["SARS-CoV", "SPECIES", 834, 842], ["Treatment schedule", "TREATMENT", 31, 49], ["emergency dental procedures", "TREATMENT", 88, 115], ["fever", "PROBLEM", 128, 133], ["symptoms", "PROBLEM", 137, 145], ["COVID-19 infection", "PROBLEM", 162, 180], ["a dental operatory", "TEST", 199, 217], ["appropriate protocols", "TREATMENT", 223, 244], ["Treatment schedule", "TREATMENT", 281, 299], ["urgent/emergency treatment", "TREATMENT", 338, 364], ["fever", "PROBLEM", 373, 378], ["dental conditions", "PROBLEM", 395, 412], ["a periapical abscess", "PROBLEM", 418, 438], ["periodontal abscess", "PROBLEM", 439, 458], ["intraoral swelling", "PROBLEM", 460, 478], ["other signs or symptoms", "PROBLEM", 487, 510], ["COVID-19 infection", "PROBLEM", 514, 532], ["Treatment schedule", "TREATMENT", 580, 598], ["priorityWear appropriate PPE", "TREATMENT", 608, 636], ["Treatment schedule", "TREATMENT", 716, 734], ["urgent/emergency treatment", "TREATMENT", 773, 799], ["signs", "PROBLEM", 812, 817], ["symptoms", "PROBLEM", 822, 830], ["SARS", "PROBLEM", 834, 838], ["CoV-2 infection", "PROBLEM", 839, 854], ["medical consultation", "TEST", 878, 898], ["treatment", "TREATMENT", 903, 912], ["infection", "OBSERVATION", 171, 180], ["periapical", "ANATOMY", 420, 430], ["abscess", "OBSERVATION", 431, 438], ["periodontal", "ANATOMY", 439, 450], ["abscess", "OBSERVATION", 451, 458], ["intraoral", "ANATOMY", 460, 469], ["swelling", "OBSERVATION", 470, 478], ["no", "UNCERTAINTY", 484, 486], ["infection", "OBSERVATION", 523, 532], ["infection", "OBSERVATION", 672, 681]]], ["Emergency treatment is limited to the prescription of antibiotics and analgesics.", [["Emergency treatment", "TREATMENT", 0, 19], ["antibiotics", "TREATMENT", 54, 65], ["analgesics", "TREATMENT", 70, 80]]], ["It is recommended that the dentists give sufficient time for patients to recover from the infection before attending to their treatment needs.| Step 4: Treatment schedule based on priorityHowever, for geriatric patients who test positive for COVID-19, emergency treatment could be provided, even if they are in the acute phase of the disease after following the guidelines highlighted in Step 5.", [["infection", "DISEASE", 90, 99], ["patients", "ORGANISM", 61, 69], ["patients", "ORGANISM", 211, 219], ["patients", "SPECIES", 61, 69], ["patients", "SPECIES", 211, 219], ["the infection", "PROBLEM", 86, 99], ["Treatment schedule", "TREATMENT", 152, 170], ["COVID", "TEST", 242, 247], ["emergency treatment", "TREATMENT", 252, 271], ["the disease", "PROBLEM", 330, 341], ["infection", "OBSERVATION", 90, 99], ["acute", "OBSERVATION_MODIFIER", 315, 320], ["disease", "OBSERVATION", 334, 341]]], ["It is crucial to amend the protocol for patients residing in assisted institutions/nursing homes who might find it difficult to visit the dental office.", [["patients", "ORGANISM", 40, 48], ["patients", "SPECIES", 40, 48]]], ["This amendment might be inevitable in some cases if these areas have been sealed off as a containment zone or due to the non-availability of healthcare workers/staff to bring them to the dental office.", [["sealed", "OBSERVATION", 74, 80]]], ["Under these circumstances, community dental health coordinators should consider arranging a mobile dental infrastructure at their disposal to provide on-site treatment, taking necessary precautions.", [["a mobile dental infrastructure", "TREATMENT", 90, 120], ["site treatment", "TREATMENT", 153, 167], ["necessary precautions", "TREATMENT", 176, 197]]], ["This approach is undoubtedly advantageous as it assures optimal geriatric dental care to non-ambulatory patients who are relatively safe in their residence and minimises community transmission among the inmates at the institution.", [["patients", "ORGANISM", 104, 112], ["patients", "SPECIES", 104, 112]]], ["It is recommended that appropriate PPE be worn and the mobile dental unit be sanitised before and after the procedure.|Step 5: Recommended guidelines before, during and after dental treatment| Recommendations before dental treatmentIt is of utmost importance to comply with infection control protocols in the dental clinic to prevent the risk of healthcare-associated infections.", [["infection", "DISEASE", 274, 283], ["infections", "DISEASE", 368, 378], ["appropriate PPE", "TREATMENT", 23, 38], ["the procedure", "TREATMENT", 104, 117], ["dental treatment", "TREATMENT", 216, 232], ["infection control protocols", "TREATMENT", 274, 301], ["healthcare-associated infections", "PROBLEM", 346, 378], ["infections", "OBSERVATION", 368, 378]]], ["45 The infection control protocol should be adopted immediately the patient enters the dental clinic and continues through to completion of the procedure and the patient's departure.", [["infection", "DISEASE", 7, 16], ["patient", "ORGANISM", 68, 75], ["patient", "ORGANISM", 162, 169], ["patient", "SPECIES", 68, 75], ["patient", "SPECIES", 162, 169], ["The infection control protocol", "TREATMENT", 3, 33], ["the procedure", "TREATMENT", 140, 153], ["infection", "OBSERVATION", 7, 16]]], ["There is an agreement among the health professionals that the transmission of SARS-CoV-2 is mainly through large respiratory droplets and secretions, with a droplet particle size ranging from >5 to 10 \u03bcm in diameter.", [["respiratory droplets", "ANATOMY", 113, 133], ["secretions", "ANATOMY", 138, 148], ["SARS", "DISEASE", 78, 82], ["SARS-CoV-2", "ORGANISM", 78, 88], ["SARS", "PROBLEM", 78, 82], ["CoV", "TEST", 83, 86], ["large respiratory droplets", "PROBLEM", 107, 133], ["secretions", "PROBLEM", 138, 148], ["a droplet particle size", "TEST", 155, 178], ["large", "OBSERVATION_MODIFIER", 107, 112], ["respiratory droplets", "OBSERVATION", 113, 133], ["secretions", "OBSERVATION", 138, 148], ["droplet particle", "OBSERVATION_MODIFIER", 157, 173], ["size", "OBSERVATION_MODIFIER", 174, 178], [">5 to 10 \u03bcm", "OBSERVATION_MODIFIER", 192, 203]]], ["Particles < 5 \u03bcm in diameter, are referred to as the droplet nuclei.", [["droplet nuclei", "ANATOMY", 53, 67], ["nuclei", "CELLULAR_COMPONENT", 61, 67], ["Particles", "TEST", 0, 9], ["droplet nuclei", "OBSERVATION", 53, 67]]], ["46 It is best to assign selected days/timings for geriatric patients in a| Recommendations before dental treatmentweek to reduce the waiting time and reduce their contact with other patients.", [["patients", "ORGANISM", 60, 68], ["patients", "ORGANISM", 182, 190], ["patients", "SPECIES", 60, 68], ["patients", "SPECIES", 182, 190], ["dental treatmentweek", "TREATMENT", 98, 118]]], ["Before examining the patient, the dental assistants have to record the patient's body temperature, using a non-contact forehead thermometer, or with cameras having infrared thermal sensors. \u2022 Disposal of tissues and handkerchiefs into a garbage bin immediately after use.| Recommendations before dental treatment\u2022 Hand hygiene tips, after cough and sneeze.| Recommendations before dental treatmentThe availability of alcohol-based hand rubs (containing 60%-95% alcohol) and touchless receptacles for disposal at healthcare facility entrances, waiting rooms and patient check-ins are the general dental clinic requirements.", [["body", "ANATOMY", 81, 85], ["forehead", "ANATOMY", 119, 127], ["tissues", "ANATOMY", 204, 211], ["hand", "ANATOMY", 431, 435], ["cough", "DISEASE", 339, 344], ["alcohol", "CHEMICAL", 417, 424], ["alcohol", "CHEMICAL", 461, 468], ["alcohol", "CHEMICAL", 417, 424], ["alcohol", "CHEMICAL", 461, 468], ["patient", "ORGANISM", 21, 28], ["patient", "ORGANISM", 71, 78], ["body", "ORGANISM_SUBDIVISION", 81, 85], ["forehead", "ORGANISM_SUBDIVISION", 119, 127], ["tissues", "TISSUE", 204, 211], ["alcohol", "SIMPLE_CHEMICAL", 417, 424], ["alcohol", "SIMPLE_CHEMICAL", 461, 468], ["patient", "ORGANISM", 561, 568], ["patient", "SPECIES", 21, 28], ["patient", "SPECIES", 71, 78], ["patient", "SPECIES", 561, 568], ["a non-contact forehead thermometer", "TREATMENT", 105, 139], ["infrared thermal sensors", "TREATMENT", 164, 188], ["dental treatment", "TREATMENT", 296, 312], ["Hand hygiene tips", "TREATMENT", 314, 331], ["cough", "PROBLEM", 339, 344], ["dental treatment", "TREATMENT", 381, 397], ["patient check", "TEST", 561, 574], ["tissues", "ANATOMY", 204, 211], ["hygiene", "OBSERVATION", 319, 326], ["tips", "OBSERVATION_MODIFIER", 327, 331]]], ["It may be essential to let the patient know before entering the dental clinic that they would have to take their shoes or footwear off and sanitise their hands and feet with soap and water or alcohol-based sanitisers.| Recommendations before dental treatmentGeriatric patients frequently arrive with an assistant/helper.", [["alcohol", "CHEMICAL", 192, 199], ["alcohol", "CHEMICAL", 192, 199], ["patient", "ORGANISM", 31, 38], ["hands", "ORGANISM_SUBDIVISION", 154, 159], ["feet", "ORGANISM_SUBDIVISION", 164, 168], ["alcohol", "SIMPLE_CHEMICAL", 192, 199], ["patients", "ORGANISM", 268, 276], ["patient", "SPECIES", 31, 38], ["patients", "SPECIES", 268, 276], ["soap", "TREATMENT", 174, 178], ["dental treatment", "TREATMENT", 242, 258], ["feet", "ANATOMY", 164, 168]]], ["It is advisable to have only the patient enter the clinical operating area.| Recommendations before dental treatmentHowever, if the entry of the assistant/helper cannot be avoided, this person has to be thoroughly screened for COVID-19 signs and symptoms before entering.", [["patient", "ORGANISM", 33, 40], ["patient", "SPECIES", 33, 40], ["person", "SPECIES", 186, 192], ["dental treatment", "TREATMENT", 100, 116], ["COVID", "TEST", 227, 232], ["symptoms", "PROBLEM", 246, 254]]], ["Patients with special needs requiring wheelchairs and crutches have to be sanitised before entering the dental operatory.| Recommendations before dental treatmentDentists and dental auxiliary personnel must be trained to wear and remove the PPEs appropriately to prevent the spread of infection.", [["infection", "DISEASE", 285, 294], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["wheelchairs", "TREATMENT", 38, 49], ["crutches", "TREATMENT", 54, 62], ["dental treatment", "TREATMENT", 146, 162], ["the PPEs", "TREATMENT", 237, 245], ["infection", "PROBLEM", 285, 294], ["infection", "OBSERVATION", 285, 294]]], ["It is also essential to change the mask when soiled or worn.", [["the mask", "TREATMENT", 31, 39]]], ["47 It is critical to avoid touching the mask, or any inanimate objects with bare hands, as the transmission of the COVID-19 virus can occur either by direct contact with an infected person or indirect contact with objects in the immediate environment used by the infected person.| Recommendations before dental treatmentUtmost precaution must be taken not to touch the eye and nose when working in the dental clinic and to use a face shield and head cap while interacting with patients.", [["eye", "ANATOMY", 369, 372], ["head cap", "ANATOMY", 445, 453], ["COVID-19 virus", "ORGANISM", 115, 129], ["eye", "ORGAN", 369, 372], ["nose", "ORGAN", 377, 381], ["head", "ORGANISM_SUBDIVISION", 445, 449], ["patients", "ORGANISM", 477, 485], ["person", "SPECIES", 182, 188], ["person", "SPECIES", 272, 278], ["patients", "SPECIES", 477, 485], ["COVID-19 virus", "SPECIES", 115, 129], ["the mask", "TREATMENT", 36, 44], ["the COVID-19 virus", "PROBLEM", 111, 129], ["dental treatment", "TREATMENT", 304, 320], ["Utmost precaution", "TREATMENT", 320, 337], ["a face shield", "TREATMENT", 427, 440], ["eye", "ANATOMY", 369, 372], ["nose", "ANATOMY", 377, 381]]], ["The patient waiting area, screening zone, door and knob of the entrance must be frequently cleaned with an alcohol-based spray.| Recommendation during the dental procedureDue to the inherent risks that dentists and dental assistants are exposed to, in form of droplet, splatter, contact and aerosols, the Occupational Safety and Health Act (OSHA) have placed dentistry in the high-risk occupation category.", [["alcohol", "CHEMICAL", 107, 114], ["alcohol", "CHEMICAL", 107, 114], ["patient", "ORGANISM", 4, 11], ["alcohol", "SIMPLE_CHEMICAL", 107, 114], ["patient", "SPECIES", 4, 11], ["screening zone", "TEST", 26, 40]]], ["32 Under the current circumstances, four-handed dental practice is best recommended as it ensures increased efficiency of treatment and reduced contact time with the patient.", [["patient", "ORGANISM", 166, 173], ["patient", "SPECIES", 166, 173], ["treatment", "TREATMENT", 122, 131], ["increased", "OBSERVATION_MODIFIER", 98, 107], ["efficiency", "OBSERVATION_MODIFIER", 108, 118]]], ["Four-handed dental practice helps to provide better patient care, reduces stress and fatigue of both the operator and the assistant, and maximises the dental team's productivity.| Recommendation during the dental procedureAerosol generation, which is a common occurrence in the dental clinic, increases the vulnerability to SARS-CoV-2 infection.", [["fatigue", "DISEASE", 85, 92], ["SARS", "DISEASE", 324, 328], ["infection", "DISEASE", 335, 344], ["patient", "ORGANISM", 52, 59], ["SARS-CoV-2", "ORGANISM", 324, 334], ["patient", "SPECIES", 52, 59], ["SARS-CoV-2", "SPECIES", 324, 334], ["stress and fatigue", "PROBLEM", 74, 92], ["the dental procedure", "TREATMENT", 202, 222], ["SARS", "PROBLEM", 324, 328], ["CoV-2 infection", "PROBLEM", 329, 344], ["infection", "OBSERVATION", 335, 344]]], ["Airborne transmission facilitates microbes' viability in the air for more extended periods and their transmission over distances greater than 1 m.", [["air", "ANATOMY", 61, 64]]], ["48 Verity et al, 49 reported that viral loads in nasopharyngeal swabs from a group of patients with severe COVID-19 were 60 times higher than the viral loads among patients with a mild form of the disease.", [["nasopharyngeal swabs", "ANATOMY", 49, 69], ["nasopharyngeal swabs", "MULTI-TISSUE_STRUCTURE", 49, 69], ["patients", "ORGANISM", 86, 94], ["patients", "ORGANISM", 164, 172], ["patients", "SPECIES", 86, 94], ["patients", "SPECIES", 164, 172], ["viral loads in nasopharyngeal swabs", "PROBLEM", 34, 69], ["severe COVID", "PROBLEM", 100, 112], ["the disease", "PROBLEM", 193, 204], ["viral loads", "OBSERVATION", 34, 45], ["nasopharyngeal", "ANATOMY", 49, 63], ["viral loads", "OBSERVATION", 146, 157], ["mild", "OBSERVATION_MODIFIER", 180, 184], ["disease", "OBSERVATION", 197, 204]]], ["If such patients, with viral particles confined to the nasopharynx, were to be treated in a dental setting, and the procedure involved the generation of aerosols, other people would have increased susceptibility due to aerosol production.| Recommendation during the dental procedureDentists have to incorporate necessary modifications in their operatory to minimise aerosol production and prevent disease TA B L E 4 Online resources and guidelines: Before, during and after dental treatment transmission from emitted particles.", [["nasopharynx", "ANATOMY", 55, 66], ["patients", "ORGANISM", 8, 16], ["nasopharynx", "ORGAN", 55, 66], ["people", "ORGANISM", 169, 175], ["patients", "SPECIES", 8, 16], ["people", "SPECIES", 169, 175], ["viral particles", "PROBLEM", 23, 38], ["the procedure", "TREATMENT", 112, 125], ["the generation of aerosols", "TREATMENT", 135, 161], ["increased susceptibility", "PROBLEM", 187, 211], ["aerosol production", "PROBLEM", 219, 237], ["the dental procedureDentists", "TREATMENT", 262, 290], ["aerosol production", "TREATMENT", 366, 384], ["dental treatment transmission", "TREATMENT", 474, 503], ["nasopharynx", "ANATOMY", 55, 66]]], ["A critical step to reduce the salivary viral load is by enforcing the practice of preprocedural rinse with Povidone-Iodine (PVP-I) in patients.", [["salivary", "ANATOMY", 30, 38], ["Povidone-Iodine", "CHEMICAL", 107, 122], ["PVP-I", "CHEMICAL", 124, 129], ["Povidone-Iodine", "CHEMICAL", 107, 122], ["PVP-I", "CHEMICAL", 124, 129], ["salivary", "ORGAN", 30, 38], ["Povidone-Iodine", "SIMPLE_CHEMICAL", 107, 122], ["PVP-I", "SIMPLE_CHEMICAL", 124, 129], ["patients", "ORGANISM", 134, 142], ["patients", "SPECIES", 134, 142], ["A critical step", "TREATMENT", 0, 15], ["the salivary viral load", "PROBLEM", 26, 49], ["preprocedural rinse", "TREATMENT", 82, 101], ["Povidone", "TREATMENT", 107, 115], ["Iodine (PVP-I", "TREATMENT", 116, 129]]], ["50, 51 Studies have shown that SARS-CoV and MERS-CoV were highly susceptible to PVP-I mouth rinse.", [["PVP-I", "CHEMICAL", 80, 85], ["PVP", "CHEMICAL", 80, 83], ["SARS-CoV", "ORGANISM", 31, 39], ["MERS-CoV", "ORGANISM", 44, 52], ["SARS-CoV", "SPECIES", 31, 39], ["MERS-CoV", "SPECIES", 44, 52], ["SARS", "PROBLEM", 31, 35], ["CoV", "TEST", 36, 39], ["MERS", "PROBLEM", 44, 48], ["CoV", "PROBLEM", 49, 52], ["PVP", "TREATMENT", 80, 83], ["SARS", "OBSERVATION", 31, 35]]], ["Therefore, preprocedural mouth rinses with 0.2% povidone-iodine might reduce the load of SARS-CoV-2 in saliva.", [["mouth", "ANATOMY", 25, 30], ["povidone-iodine", "CHEMICAL", 48, 63], ["SARS", "DISEASE", 89, 93], ["povidone-iodine", "CHEMICAL", 48, 63], ["povidone-iodine", "SIMPLE_CHEMICAL", 48, 63], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 89, 99], ["saliva", "ORGANISM_SUBSTANCE", 103, 109], ["preprocedural mouth rinses", "TREATMENT", 11, 37], ["0.2% povidone", "TREATMENT", 43, 56], ["iodine", "TREATMENT", 57, 63], ["SARS", "PROBLEM", 89, 93], ["CoV", "TEST", 94, 97]]], ["[52] [53] [54] Alternatively, the use of 0.5%-1% hydrogen peroxide mouth rinses has demonstrated non-specific virucidal activity against coronaviruses.", [["hydrogen peroxide", "CHEMICAL", 49, 66], ["hydrogen peroxide", "CHEMICAL", 49, 66], ["[52] [53] [54]", "SIMPLE_CHEMICAL", 0, 14], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 49, 66], ["coronaviruses", "ORGANISM", 137, 150], ["1% hydrogen peroxide mouth rinses", "TREATMENT", 46, 79], ["non-specific virucidal activity", "PROBLEM", 97, 128], ["coronaviruses", "PROBLEM", 137, 150], ["non-specific", "OBSERVATION_MODIFIER", 97, 109], ["virucidal activity", "OBSERVATION", 110, 128]]], ["However, one has to use hydrogen peroxide judiciously in geriatric patients.", [["hydrogen peroxide", "CHEMICAL", 24, 41], ["hydrogen peroxide", "CHEMICAL", 24, 41], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 24, 41], ["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 67, 75], ["hydrogen peroxide", "TREATMENT", 24, 41]]], ["Hydrogen peroxide is a highly caustic and a reactive substance, which can damage oral soft tissues when used in high concentrations and for a prolonged duration.", [["oral soft tissues", "ANATOMY", 81, 98], ["Hydrogen peroxide", "CHEMICAL", 0, 17], ["Hydrogen peroxide", "CHEMICAL", 0, 17], ["Hydrogen peroxide", "SIMPLE_CHEMICAL", 0, 17], ["oral soft tissues", "TISSUE", 81, 98], ["Hydrogen peroxide", "TREATMENT", 0, 17], ["a reactive substance", "PROBLEM", 42, 62], ["highly caustic", "OBSERVATION_MODIFIER", 23, 37], ["reactive", "OBSERVATION_MODIFIER", 44, 52], ["substance", "OBSERVATION", 53, 62], ["soft tissues", "ANATOMY", 86, 98], ["high concentrations", "OBSERVATION_MODIFIER", 112, 131]]], ["55 It is necessary to minimise intraoral imaging as patients tend to elicit a gag or cough reflex.", [["cough", "DISEASE", 85, 90], ["patients", "ORGANISM", 52, 60], ["gag", "GENE_OR_GENE_PRODUCT", 78, 81], ["patients", "SPECIES", 52, 60], ["intraoral imaging", "TEST", 31, 48], ["a gag or cough reflex", "PROBLEM", 76, 97]]], ["When intraoral imaging is mandated, sensors should have a double barrier to prevent perforation and cross-contamination.", [["perforation", "DISEASE", 84, 95], ["intraoral imaging", "TEST", 5, 22], ["a double barrier", "TREATMENT", 56, 72], ["perforation", "PROBLEM", 84, 95], ["cross-contamination", "PROBLEM", 100, 119], ["perforation", "OBSERVATION", 84, 95]]], ["56 Latex finger cots used in conjunction with the standard plastic sheaths covering direct digital radiography (DDR) sensors may effectively prevent cross-contamination than plastic sheaths alone.", [["Latex finger cots", "TEST", 3, 20], ["the standard plastic sheaths", "TREATMENT", 46, 74], ["direct digital radiography", "TEST", 84, 110]]], ["However, dentists are recommended to use extraoral imaging, such as panoramic radiography or cone-beam computed tomography (CBCT).", [["extraoral imaging", "TEST", 41, 58], ["panoramic radiography", "TEST", 68, 89], ["cone-beam computed tomography (CBCT", "TEST", 93, 128]]], ["It is also necessary to disinfect the radiograph holders and machine heads after each patient.| Recommendation during the dental procedureStudies have shown that sonic and ultrasonic scalers have a higher particle transmission incidence, followed by air polishing, air/ water syringes and high-speed handpieces.", [["patient", "ORGANISM", 86, 93], ["patient", "SPECIES", 86, 93], ["the radiograph holders", "TREATMENT", 34, 56], ["the dental procedureStudies", "TEST", 118, 145], ["sonic and ultrasonic scalers", "PROBLEM", 162, 190], ["air polishing", "TREATMENT", 250, 263], ["air/ water syringes", "TREATMENT", 265, 284], ["high-speed handpieces", "TREATMENT", 289, 310]]], ["57 Ideally, the aerosol-generating procedures are planned for the last appointment of the day.", [["the aerosol-generating procedures", "TREATMENT", 12, 45]]], ["As per WHO (2020) and OSHA recommendations, the patients should be transferred to a safer room with negative pressure ventilation and with 12 air changes/hour \"ACH\" or 160 L/s/patient.", [["patients", "ORGANISM", 48, 56], ["patient", "ORGANISM", 176, 183], ["patients", "SPECIES", 48, 56], ["patient", "SPECIES", 176, 183], ["negative pressure ventilation", "TREATMENT", 100, 129]]], ["60 The same protocol is recommended for emergency treatment of geriatric patients who test positive for COVID-19.", [["patients", "ORGANISM", 73, 81], ["patients", "SPECIES", 73, 81], ["COVID", "TEST", 104, 109]]], ["It is strongly recommended that an anti-retraction dental handpiece is used with specially designed anti-retractive valves or other anti-reflux designs as a preventive measure for cross-infection.", [["an anti-retraction dental handpiece", "TREATMENT", 32, 67], ["anti-retractive valves", "TREATMENT", 100, 122], ["other anti-reflux designs", "TREATMENT", 126, 151], ["cross-infection", "PROBLEM", 180, 195]]], ["61, 62 When indicated, dentists must place rubber dams to minimise splatter generation and aspiration of viral particles from the oral cavity to nasopharynx.", [["oral cavity", "ANATOMY", 130, 141], ["nasopharynx", "ANATOMY", 145, 156], ["oral cavity", "ORGAN", 130, 141], ["nasopharynx", "ORGAN", 145, 156], ["rubber dams", "TREATMENT", 43, 54], ["splatter generation", "TREATMENT", 67, 86], ["aspiration of viral particles", "PROBLEM", 91, 120], ["aspiration", "OBSERVATION", 91, 101], ["viral particles", "OBSERVATION", 105, 120], ["oral cavity", "ANATOMY", 130, 141], ["nasopharynx", "ANATOMY", 145, 156]]], ["It is also necessary to use high volume evacuators (HVE) while performing any dental procedure.| Recommendation during the dental procedureAdequate care must be taken to minimise injury during ex-| Recommendations after the dental procedureClear post-operative instructions should be given to the patient.| Recommendations after the dental procedureThe dentist must ensure that the prescribed medication is not contraindicated or interferes with the current medication.", [["patient", "ORGANISM", 297, 304], ["patient", "SPECIES", 297, 304], ["high volume evacuators", "TREATMENT", 28, 50], ["any dental procedure", "TREATMENT", 74, 94], ["the dental procedure", "TREATMENT", 119, 139], ["injury", "PROBLEM", 179, 185], ["the dental procedure", "TREATMENT", 220, 240], ["the dental procedure", "TREATMENT", 329, 349], ["the prescribed medication", "TREATMENT", 378, 403], ["the current medication", "TREATMENT", 446, 468]]], ["There are some concerns related to the use of NSAIDs, as there may be a slated adverse effect noted when used in patients with acute viral respiratory infections, including COVID-19.", [["respiratory", "ANATOMY", 139, 150], ["viral respiratory infections", "DISEASE", 133, 161], ["NSAIDs", "SIMPLE_CHEMICAL", 46, 52], ["patients", "ORGANISM", 113, 121], ["patients", "SPECIES", 113, 121], ["NSAIDs", "TREATMENT", 46, 52], ["a slated adverse effect", "PROBLEM", 70, 93], ["acute viral respiratory infections", "PROBLEM", 127, 161], ["COVID", "TEST", 173, 178], ["acute", "OBSERVATION_MODIFIER", 127, 132], ["viral", "OBSERVATION_MODIFIER", 133, 138], ["respiratory infections", "OBSERVATION", 139, 161]]], ["63 However, WHO has confirmed that there is no evidence of severe adverse events in patients with COVID-19 due to the use of NSAIDs.", [["NSAIDs", "CHEMICAL", 125, 131], ["patients", "ORGANISM", 84, 92], ["NSAIDs", "SIMPLE_CHEMICAL", 125, 131], ["patients", "SPECIES", 84, 92], ["severe adverse events", "PROBLEM", 59, 80], ["COVID", "TEST", 98, 103], ["NSAIDs", "TREATMENT", 125, 131], ["no evidence of", "UNCERTAINTY", 44, 58], ["severe", "OBSERVATION_MODIFIER", 59, 65]]], ["64 The dental team must emphasise the importance of maintaining oral hygiene to the patient as a part of post-operative instructions.", [["oral", "ANATOMY", 64, 68], ["oral", "ORGANISM_SUBDIVISION", 64, 68], ["patient", "ORGANISM", 84, 91], ["patient", "SPECIES", 84, 91], ["oral hygiene", "TREATMENT", 64, 76]]], ["It is advisable to have a counsellor as a part of the dental team to address mental health issues and other apprehensions during the site visits mentioned in Step 4.| Recommendations after the dental procedureThe \"OSHA Guidelines on preparing the workplace for COVID-19\" and \"Environmental protection agency approved COVID-19 chemical disinfectants\" are listed in Table 4 .", [["COVID", "CHEMICAL", 317, 322], ["mental health issues", "PROBLEM", 77, 97], ["the dental procedure", "TREATMENT", 189, 209], ["COVID", "TEST", 261, 266]]], ["The dental team should disinfect the impression tray with or without impression materials, casts and temporary dentures appropriately before sending them to the laboratory.", [["impression materials", "PROBLEM", 69, 89], ["casts and temporary dentures", "TREATMENT", 91, 119]]], ["The dental team could indicate the COVID status of the patient to the laboratory for further precautions at their end.| Recommendations after the dental procedureDisposal of the biomedical waste generated in the clinic is a necessary procedure and should be performed according to established protocols.", [["patient", "ORGANISM", 55, 62], ["patient", "SPECIES", 55, 62], ["further precautions", "TREATMENT", 85, 104], ["a necessary procedure", "TREATMENT", 222, 243]]], ["45 The existing knowledge on COVID-19 is currently limited as researchers around the globe are intensifying their efforts to develop an effective vaccine.", [["COVID", "TEST", 29, 34], ["an effective vaccine", "TREATMENT", 133, 153], ["globe", "ANATOMY", 85, 90]]], ["It has been reported that SARS-CoV-2 may remain viable in aerosol and survive for up to 3 days on inanimate surfaces at room temperature, with a higher preference for humid conditions.", [["SARS-CoV-2", "ORGANISM", 26, 36], ["SARS", "PROBLEM", 26, 30]]], ["45, 49 With most of the dental procedures generating a significant amount of aerosol, dentistry is classified as one of the most high-risk jobs amidst the pandemic.", [["the dental procedures", "TREATMENT", 20, 41], ["significant", "OBSERVATION_MODIFIER", 55, 66], ["amount", "OBSERVATION_MODIFIER", 67, 73]]], ["Disinfecting the inanimate surfaces using chemicals recently approved for COVID-19, and maintaining a dry environment to prevent the virus's spread is critical.| SUMMARYThe outbreak of the SARS-CoV-2 pandemic is a global concern that poses a severe threat to human health, well-being and survival.", [["COVID-19", "CHEMICAL", 74, 82], ["SARS-CoV-2 pandemic", "DISEASE", 189, 208], ["SARS-CoV-2", "ORGANISM", 189, 199], ["human", "ORGANISM", 259, 264], ["CoV-2 pandemic", "SPECIES", 194, 208], ["human", "SPECIES", 259, 264], ["SARS-CoV-2", "SPECIES", 189, 199], ["human", "SPECIES", 259, 264], ["chemicals", "TREATMENT", 42, 51], ["COVID", "TEST", 74, 79], ["a dry environment", "TREATMENT", 100, 117], ["the virus's spread", "PROBLEM", 129, 147], ["the SARS", "PROBLEM", 185, 193], ["virus", "OBSERVATION", 133, 138], ["severe", "OBSERVATION_MODIFIER", 242, 248]]], ["The SARS-CoV-2 pandemic has resulted in a higher mortality rate among the elder/geriatric age group.", [["SARS", "DISEASE", 4, 8], ["SARS-CoV-2", "ORGANISM", 4, 14], ["The SARS", "TEST", 0, 8], ["a higher mortality rate", "PROBLEM", 40, 63]]], ["Addressing the unique needs of geriatric patients who present with co-morbid conditions is critical to reducing mortality and preventing the spread of SARS-CoV-2 infection.", [["SARS-CoV-2 infection", "DISEASE", 151, 171], ["patients", "ORGANISM", 41, 49], ["SARS-CoV-2", "ORGANISM", 151, 161], ["patients", "SPECIES", 41, 49], ["SARS-CoV-2", "SPECIES", 151, 161], ["co-morbid conditions", "PROBLEM", 67, 87], ["SARS", "PROBLEM", 151, 155], ["CoV-2 infection", "PROBLEM", 156, 171], ["infection", "OBSERVATION", 162, 171]]], ["In this paper, we have proposed generic protocols and stepwise guidelines for the effective management of geriatric patients in a dental setting.", [["patients", "ORGANISM", 116, 124], ["patients", "SPECIES", 116, 124], ["generic protocols", "TREATMENT", 32, 49], ["stepwise guidelines", "TREATMENT", 54, 73], ["the effective management", "TREATMENT", 78, 102], ["geriatric patients", "TREATMENT", 106, 124]]], ["Universal guidelines to specifically meet the challenges of geriatric patients in the dental setting ensure the health of vulnerable sections of the society and the well-being of the community at large.", [["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 70, 78]]]]}